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Abstract  
Background 
 
Non adherence to medication in myocardial infarction patients ranges from 13-60% 
(Garavalia et al, 2009).  Consistent use of secondary prevention medication after a 
coronary event is associated with lower adjusted mortality and higher survival rates 
compared with patients who are not compliant (Newby et al, 2006).  Strategies to tackle 
the burden of non adherence could involve pharmacy care and services including 
Medication Use Review and the New Medicine Service with a motivational interview as 
part of the counselling session of a community pharmacist.  
 
Objective 
 
To investigate the feasibility and potential impact of a pharmacy care intervention 
involving motivational interviews and referral to the community pharmacy services, 
amongst patients with acute coronary syndrome, on adherence to medication and on 
health outcomes. 
 
Methods 
This thesis reports a prospective, intervention, controlled feasibility/pilot study.  Seventy 
one patients discharged from a London Heart Attack Centre following acute treatment for 
a coronary event were enrolled and followed up for six months.  Thirty two pharmacies in 
London were allocated into intervention or control sites. The intervention was delivered 
by community pharmacists face-to-face in the pharmacy, or by telephone as part of the 
New Medicine Service or a Medication Use Review.  The consultation included a 15-20 
minute motivational interviewing session aimed at improving protective cardiovascular 
medicine adherence.  As this was a feasibility study, measures of uptake, workability and 
acceptability were gathered from all stakeholders.  A measure of fidelity to the 
intervention was also performed.  The primary outcome measure was adherence to 
secondary prevention medication using a self report adherence measure.  Secondary 
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clinical outcomes included blood pressure and LDL-C.  Data collection of outcome 
measures took place at baseline, 3 months and 6 months.  An intention-to-treat analysis 
was conducted for the outcome measures.   
Results  
 
Given a small sample size, the feasibility study was not powered to measure clinical 
outcomes.  However, at 3 and 6 months there was a statistically significant difference in 
adherence between the intervention group and the control group (P= 0.026), (P=0.004) 
respectively.  In addition, there was a statistically significant relationship between the 
level of adherence at 3 months and beliefs regarding medicines (P=0.028).  Patients who 
reported better adherence expressed positive beliefs regarding the necessity of taking 
their medicines.  However, given the small sample size, no statistically significant 
outcome difference in terms of recorded blood pressure and LDL-C was observed over 
the six months of the study.  
   
Conclusion  
The feasibility, acceptability and potentially positive clinical outcome of the intervention 
was demonstrated, along with a high level of patient acceptability.  It had a significant 
impact on cardiovascular medicine taking adherence.  But these findings must be 
interpreted with caution.  The intervention should be tested in a larger trial to ascertain its 
full clinical utility.   
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Chapter One:                                                                           Introduction and Background            
 
This chapter will discuss the epidemiology of cardiovascular disease around the world 
including the context of epidemiological transition.  It will provide an overview of 
cardiovascular disease and its risk factors.  There will be a particular focus on coronary 
heart disease, which is the disease studied in this thesis, and its prevention and 
management.  The chapter will explore the role of medicines in secondary prevention, 
and include a discussion on adherence, reasons for non-adherence, measurement of 
adherence and strategies, in particular, behavioural approaches (motivational 
interviewing) in addressing non-adherence.   
 
 
 
1.1-Introduction  
Cardiovascular diseases (CVDs) account for more than 17 million deaths globally each 
year (30% of all deaths); a figure which is expected to grow to 23.6 million by 2030 
(Wong et al, 2014).  The WHO projections suggest that non communicable diseases will 
be responsible for a significantly increased number of deaths in the next decade; with the 
greatest increases in the WHO regions of Africa, South-East Asia and the Eastern 
Mediterranean (WHO, 2015).  It is also noteworthy that many deaths occur in people 
under 70 years of age, in the more productive period of life.  The WHO believes that 
population based strategies, lifestyle changes and encouraging people to adhere to their 
medicines and regimens may be effective for both people with established disease and for 
those at high risk of developing disease (WHO, 2015).  
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1.2-Recognition of the importance of cardiovascular prevention worldwide 
Since the 1920s cardiovascular disease has been identified as a significant cause of death 
worldwide.  Articles from the 1930s and 1940s suggested hypertension, cholesterol, poor 
nutrition, obesity, smoking, physical inactivity, and psychosocial stress as important 
factors contributing to heart disease, but they at that time did not provide strong evidence 
to support this assertion (Mensah and Brown, 2007).   
 
A rising prevalence of CVD was similarly noted in the 1930s and 1940s in the USA 
(Fuster and Kelly, 2010).  This lead to the establishment of the Framingham Heart Study 
under the direction of the National Heart Institute (now known as the National Heart, 
Lung, and Blood Institute or NHLBI) (www.framinghamheartstudy.org).  The 
Framingham Heart Study became a joint project of the National Heart, Lung and Blood 
Institute and Boston University.  The aim was to identify the common factors that 
contribute to cardiovascular diseases, and it focused on participants whom did not yet 
have obvious cardiac diseases.  The study recruited 5,209 men and women ages between 
30- 62 from the town Framingham, Massachusetts.  In the period between 1948 and 2003 
participants and their generations (children and grandchildren) were enrolled and 
followed-up.  The Framingham heart study led to identification of the major risk factors 
for cardiovascular diseases; high blood pressure, high blood cholesterol, smoking, 
obesity, diabetes, and physical inactivity as well as providing information on the effects 
of related factors such as blood triglyceride and HDL cholesterol levels, age, gender, and 
psychosocial issues (Fuster and Kelly, 2010).  From this time the concept of CVD risk 
factors has become an essential part of the modern medicine and has led to the 
identification and development of effective treatment and preventive strategies in clinical 
practice. 
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Another important epidemiology study was the Seven Countries Study in 1958 to 
establish if there was a relationship between hypercholesterolemia and coronary heart 
disease (Keys, 1980).  The study included 16 cohorts, in seven countries, in four regions 
of the world (United States, Northern Europe, Southern Europe, and Japan).  In total, 
12,763 men, 40-59 years of age, were enrolled between 1958 and 1964 and followed for 
15 years in a prospective design (Keys, 1980).  The study demonstrated that 
hypercholesterolemia increases cardiovascular risk both at the population level, 
individual level and in different cultures.  The researchers recommended a healthy diet, 
avoiding obesity and promotion of physical activity, which all became major aspects for 
prevention of cardiovascular disease.  
 
After World War II there was a notable rise in coronary heart disease (CHD) in Western 
countries, although in some countries a decline in rates of disease was observed in the 
following decades (Keil, 2005).  In the 1980s and 1990s, the WHO MONICA 
(Monitoring trends and determinants in cardiovascular disease) project was conducted to 
assess trends and determinants of cardiovascular mortality, incidence and case fatality.  
Altogether some 13 million people from 21 countries in Western Europe and also Russia, 
Iceland, Canada, China and Australia were monitored over a 10 year period. 166,000 
myocardial infarction patients were registered and more than 300,000 men and women 
were recruited and monitored for their cardiovascular risk factors and other health data.  
The study also gathered data on mortality, morbidity, coronary care and population-based 
risk factor surveillance.  The findings provided information for disease treatment and 
prevention of CVD in developed countries.  The MONICA study also showed that other 
factors (in addition to established risk factors of cardiovascular disease: obesity, smoking, 
blood pressure and cholesterol) such as unrest, poverty and social and economic change 
could have an effect on contribution to the incidence of heart disease, a role that was not 
valued at that time.  The study produced mass data for cardiovascular diseases around the 
world and remains the largest cardiology study.   
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Other important epidemiological studies can be found in the Table 1.1 below.  It is 
beyond the scope of this chapter to describe all the epidemiological studies conducted 
over the last decades.  Nevertheless, cardiovascular epidemiological studies conducted 
over the past 70 years have made important contributions to our knowledge of disease 
distribution, and highlighted the importance of risk factors and subclinical disease in 
predicting cardiovascular events. This has led to the development of methods for 
estimating the individual's 'global' risk of CHD and CVD.  This information has been 
used to guide the initiation and intensity of preventive therapies (Wong, 2014).   
  
Table 1.1 Major global and national epidemiological studies of cardiovascular disease 
adapted from (Wong, 2014) 
Study Year 
commenced 
Location Population studied 
The Minnesota 
Businessmen study 
1946 Minnesota, USA 281 men aged <55 years 
INTERHEART 1999 Global 15,152 patients with MI and 14,820 
age-matched and sex-matched 
control individuals 
The PURE study 2002 17 countries 153,996 adults aged 35–70 years 
The Ni–Hon–San study 1965 Japan; Hawaii, USA; 
San Francisco, CA, 
USA 
20,000 Japanese men aged 45–69 
years 
The Whitehall and 
Whitehall II studies 
1967 and 
1985 
UK 18,403 male civil servants aged 40–
64 years, and 10,314 male and 
female civil servants aged 35–55 
years 
The Rejkavik study and 
AGES 
1968 and 
2003 
Iceland 9,141 and 2,499 men aged 34–79 
years 
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The PROCAM study 1979 Germany 4,043 men and 1,333 women aged 
50–65 years 
The CARDIA study 1984 Four communities in 
the USA 
5,115 African American and white 
men and women aged 18–30 years 
ARIC 1987 Four communities in 
the USA 
15,792 African American and 
white men and women aged 45–64 
years 
The Strong Heart study 1989 13 American Indian 
tribes in the USA 
4,549 Native American men and 
women aged 45–75 years 
The Cardiovascular 
Health study 
1989 Four communities in 
the USA 
5,888 African American and white 
men and women aged 65–102 years 
The Jackson Heart study 2000 Jackson, MS, USA 5,302 African American men and 
women aged 21–94 years 
MESA 2000 Six communities in 
the USA 
6,814 African American, Chinese, 
Hispanic, and white men and 
women aged 45–80 years 
The Hispanic Community 
Health study/Study of 
Latinos 
2006 Four communities in 
the USA 
15,079 Hispanic men and women 
aged 18–72 years 
 
The epidemiology of cardiovascular disease facts and application to the UK 
  
Despite the significant decline in mortality in the UK, CVD has a tremendous burden on 
health and costs. Both primary and secondary prevention measures are considered 
necessary to reduce both the burden of CVD and inequalities in CVD mortality and 
prevalence (Bhatnagar et al, 2015).  In 2012 cardiovascular disease was the most 
common cause of death in the UK for women (28% of all female deaths), but not for 
men, where cancer was the most common cause of death (32% of all male deaths) 
(Bhatnagar et al, 2015).    Mortality from CVD varies widely throughout the UK, with 
the highest age-standardised CVD death rates in Scotland (347/100 000) and the North of 
England (320/ 100 000 in the North West).  Prevalence of coronary heart disease is also 
highest in the North of England (4.5% in the North East) and Scotland (4.3%).  Men have 
a greater risk of myocardial infarction than women.   
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Around 73,000 deaths in the UK each year are attributed to coronary heart disease and 
there are an estimated 2.3 million people living with the condition, who need secondary 
prevention medication (NHS, 2014).  Prescriptions and surgical interventions for CVD 
have substantially increased over the last two decades.  The National Health Service in 
England spent around £6.8 billion on CVD in 2012/2013, the majority of which came 
from spending in secondary care (Bhatnagar et al, 2015).    
 
1.3-Epidemiological transition 
At the beginning of the 20th century, cardiovascular disease was responsible for fewer 
than 10% of all deaths worldwide.  Today, that figure is about 30%, with 82% of the 
burden now occurring in developing countries (Gaziano et al, 2011).   Gaziano, 2005 and 
Gaziano et al, 2011 (Please see Appendix 1) argue that social and economic transition in 
the world had a major impact on cardiovascular disease prevalence worldwide.  This 
transition has lead to a shift in the cause of death from infectious diseases and 
malnutrition before 1900 to CVD and cancer currently in most high income countries.  
Increases in wealth that lead to better availability of food, improved sanitation,  and 
access to vaccines and antibiotics, contributed to increased lifespan and a greater 
incidence of CVD.  As the average lifespan increased beyond 50 years; mortality from 
CVD in particular and other non communicable diseases exceeded mortality from 
malnutrition and infectious diseases.  The predominant form of CVD is coronary heart 
disease, but ischemic stroke also emerges as a significant cause of mortality and 
morbidity. 
 
In the age of delayed degenerative diseases, age-adjusted CVD mortality tends to decline 
because of widespread primary and secondary prevention efforts such as smoking 
cessation programs and effective blood pressure control, acute hospital management, and 
technological advances such as the availability of bypass surgery (Gaziano et al, 2011).  
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However, congestive heart failure prevalence increases because of the improved survival 
of those with ischemic heart disease.  New trends suggest that many developed countries 
could be entering a fifth as-yet-unnamed phase of the epidemiological transition, 
characterized by an epidemic of obesity and diabetes prevalence.  This trend is not unique 
to developed countries, however, according to recent WHO data, there are about 1.1 
billion overweight adults in the world, with 115 million of them known to be living with 
obesity related problems in the developing world (Gaziano et al, 2011), (WHO, 2015). 
The so called “epidemiological transition” is taking place because of the rapid aging of 
the developing world’s populations, progressive urbanization and socioeconomic 
transformation, and changed dietary habits (Jabbour et al, 2012), (Gaziano et al, 2011).   
 
Governments in the Eastern Mediterranean Region (EMR) are not believed to have 
placed a sufficiently high priority on addressing the high and rising prevalence of non-
communicable diseases, with variations in policies between countries and overall weak 
implementation (Rahim et al, 2014).  In the next two decades it is anticipated that the 
EMR will be overwhelmed by stroke, heart disease and diabetes (Jabbour et al, 2012) 
(please see Appendix 2).  However, some EMR countries have recognised this escalating 
risk and started to look for solutions to decrease the CVD burden.  Examples of these 
solutions are the Abu Dhabi Cardiovascular Program, “Weqaya” (Hajat et al, 2010) and 
the Isfahan Healthy Heart Program in the Islamic Republic of Iran (Sarrafzadegan et al, 
2009). 
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1.4-Early onset of cardiovascular diseases 
Established cardiovascular diseases are often witnessed in middle-aged or elderly men 
and women.  However, if focusing on atherosclerosis, risk factors in adulthood for CVD 
have been correlated with increasing severity of asymptomatic coronary and aortic 
atherosclerosis in young people. Thus, the process is believed to start at an early age, 
through adolescence and early adulthood (Berenson, 2001; Zieske et al, 2002; Sternby et 
al, 1999; Tell and Vellar, 1988) suggesting that cardiovascular disease prevention and 
promotion of healthy lifestyles should commence in childhood.  
 
1.5-Potential for prevention 
Four stages of prevention can be identified, corresponding to different phases in the 
development of disease (Alwan, 1997), (Donovan et al, 2015). Stage one ‘primordial 
prevention’ aims to avoid the emergence and establishment of the social, economic and 
cultural patterns of living that are known to contribute to an increased risk of disease.  
For Non Communicable Diseases (NCDs) primordial prevention should include national 
policies on food and nutrition, comprehensive programmes to discourage smoking and 
promotion of regular physical activity.  It addresses broad health determinants rather than 
preventing personal exposure to risk factors, which is the goal of primary prevention.    
Stage two ‘primary prevention’ seeks to prevent the onset of specific diseases via risk 
reduction. The purpose of primary prevention is to limit the incidence of disease by 
focusing on known causes and risk factors, e.g. efforts to discourage unhealthy eating 
habits, reduce obesity, promote physical activity and reduce smoking.  It involves two 
strategies that are often complementary.  It can focus on the whole population, with the 
aim of reducing average risk (population strategy) or on people at high risk as a result of 
particular exposures.   
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Stage three ‘secondary prevention’, aims to cure patients and/or reduce the more serious 
consequences of disease through early diagnosis and treatment.  It comprises the 
measures available to individuals and populations for early detection and prompt and 
effective intervention.  It is directed at the period between onset of disease and the normal 
time of diagnosis, and aims to reduce the prevalence of disease.   
Stage four ‘tertiary prevention’, is aimed at reducing the progress or complications of 
established disease and is an important aspect of therapeutic and rehabilitation medicine. 
It consists of measures intended to reduce impairment and disability, to minimise 
suffering caused by departure from good health and to promote patient adjustment to 
incurable conditions.  The key goal for tertiary prevention is to enhance quality of life.   
 
1.6-Benefits of screening for cardiovascular risk 
Many people are unaware of their cardio-vascular risk status. Opportunistic and other 
forms of screening by health care providers are therefore, a potentially useful means of 
detecting risk factors, such as raised blood pressure, abnormal blood lipids and blood 
glucose (WHO, MONICA study, 2005).  The predicted risk of an individual can be a 
useful guide for making clinical decisions on the intensity of preventive interventions; 
when dietary advice should be strict and specific, when suggestions for physical activity 
should be intensified and individualized, and when and which drugs should be prescribed 
to control risk factors.  Such a risk stratification approach is particularly suitable to 
settings with limited resources, where saving the greatest number of lives at lowest cost 
becomes necessary (WHO report, 2002).  A systematic review (Sheridan et al, 2010) 
assessed the effect of providing CHD risk information to adults and identified 20 articles 
including 14 randomized controlled studies. The review showed that CHD risk 
information alone or with accompanying education, could increase the accuracy of 
perceived risk and probably increase intent to start therapy among individuals at 
moderate to high risk (Sheridan et al, 2010).  
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Sheridan et al, (2010) also found that providing risk information at only one point in time 
seemed ineffective, and that repeated instances of counselling were needed to achieve 
small but significant reductions in predicted CHD risk (absolute differences, −0.2% to 
−2% over 10 years in studies using risk estimates derived from Framingham equations).  
 
Opportunistic comprehensive CVD risk assessment in primary care for all adults over 40 
years, who have no history of CVD or diabetes, and who are not already on treatment for 
blood pressure or lipids, has been advocated (Joint British Society, 2014).  Younger 
adults (under 40 years) with a family history of premature atherosclerotic disease should 
also have their cardiovascular risk factors measured (Joint British Society, 2014).  
Moreover, the American Heart Association’s 2014 guidelines (Goff et al, 2014)  
recommend risk factor assessment in adults at age 20 years and that all adults at age 40 
years or above should know their absolute risk of developing CHD; and 10-year CVD 
risk should be used as the basis for recommendations to reduce the risk (Goff et al, 2014).  
Risk assessment should include ethnicity, smoking habit history, family history of CVD 
and measurements of weight, waist circumference, blood pressure, lipids (total 
cholesterol and high-density lipoprotein (HDL) cholesterol) and glucose (Goff et al, 
2014).  The American Heart Association guidelines also recommend recording the pulse 
rate and rhythm to screen for atrial fibrillation (Goff et al, 2014).  Once all risk factors 
have been identified cardiovascular risk charts or calculators should be used to estimate 
the total risk of developing CVD over the following 10 years.  A total CVD risk of over 
20% over 10 years is defined as high-risk.  People with moderate-to-high risk are more 
likely to be compliant with lifestyle changes and preventative medication if given 
information about their individual cardiovascular risk (Sheridan et al, 2010).  There are 
several risk calculators available to estimate both 10-year risk and lifetime risk of CVD, 
such as the JBS 3 risk assessment tool (Joint British Society, 2014) and the QRISK2 
(www.qrisk.org) calculator.  
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The National Institute for Health and Clinical Excellence (NICE) 2014 does not 
recommend any particular risk calculator.  However, calculators which are based on the 
Framingham risk equation may overestimate risk in UK populations.  This may be as 
much as 5% for UK men.  There are other coronary heart disease-cardiovascular disease 
risk calculators (please refer to Appendix 3). 
 
1.7-Role of medications in primary and secondary prevention of cardiac diseases 
 
Major advances have been made in understanding the pathogenesis of cardiovascular 
diseases. For example in coronary syndromes (unstable angina, myocardial infarction, 
and coronary death) recognition that rupture of plaques, leading to coronary thrombosis, 
accounts for most acute coronary syndromes and that the risk of plaque rupture and its 
consequences can be substantially reduced by medical intervention (Grundy, 1999), 
(Kumar and Cannon, 2009).  Thus preventive medical therapies are now available to 
reduce risk factors for disease, before it becomes clinically manifest and appropriate 
selection of patients for aggressive primary prevention emerges as a crucial issue (Kumar 
and Cannon, 2009).  Both NICE, 2014 and JBS3, 2014 clinical guidelines recommend 
pharmacological therapy for individuals with high lifetime CVD and with high 10-year 
CVD risk, in whom lifestyle changes alone are considered insufficient by the physician 
and person concerned.  These therapies include the following: statins are recommended 
as they are highly effective at reducing CVD events with evidence of benefit to LDL-C 
levels <2 mmol/L.  Statins are safe, with trial evidence showing no effects on non-
cardiovascular mortality. Pharmacological treatment for patients with hypertension 
should follow current NICE guidance (CG127) treatment algorithm.   
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For secondary prevention all patients post-myocardial infarction NICE, (2014) 
recommendations include: indefinite antiplatelet therapy with low dose aspirin (75–100 
mg).  In patients with true aspirin intolerance, clopidogrel 75 mg should be considered as 
an alternative.  More potent antiplatelet agents (such as prasugrel or ticagrelor) are 
recommended as dual antiplatelet therapy in combination with aspirin in patients with 
acute coronary syndromes.  Dual antiplatelet therapy is recommended for up to 12 
months post-MI with a minimum of 1 month for patients also receiving a bare metal stent 
and 6 months for patients also receiving a drug eluting stent.  Lipid lowering therapy 
should include intensive statin therapy which is recommended in all patients following 
myocardial infarction, in the absence of a contraindication or intolerance, irrespective of 
initial cholesterol values.  Thus statins should be prescribed with a ‘lower is better’ 
approach to achieve values of at least <2.5 mmol/L for non-HDL-C (equivalent to <1.8 
mmol/L for LDL-C).  In addition, β-blockers, ACE inhibitors/ARBs, aldosterone 
antagonists post-MI are recommended in line with existing NICE guidance.  
 
 
Adherence to medicines regimens in patients with cardiovascular diseases 
 
Evidence on rates of non-adherence to cardiovascular medicine 
 
There is considerable evidence that adherence to prescribed medicines for secondary 
prevention of cardiovascular disease is sub–optimal and that this adversely impacts on 
clinical outcomes.  Despite the importance of secondary prevention, non-adherence rates 
for myocardial infarction patients ranges from 13-60% for prescribed, evidence-based 
medicines (Garavalia et al, 2009).  The main concern is not with compliance alone (and 
the wastage of medicines) but also the implications of discontinuation and the lack of 
clinical benefit and possible serious consequences.  
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Furthermore, studies conducted in the USA and the UK show that approximately one 
fourth of cardiac patients do not fill their cardiac medications (Jackevicius et al, 2002) 
(Jackevicius et al, 2008) (Carter et al, 2003).   Jackevicius et al, 2002 showed that only 
40% of patents were still taking statins 2 years after hospitalization for acute coronary 
syndrome, adherence was even lower for patients taking statins for chronic coronary 
disease.  A second study by Jackevicius et al, 2008 showed that among patients 
discharged, after being hospitalized for acute myocardial infarction, 24% did not fill their 
cardiac medications by day 7 of discharge.   
 
Studies examining long term adherence to primary and secondary prevention 
cardiovascular medication show that persistence also remains poor.  Both Chapman et al, 
2005 and Glader et al, 2010 give evidence that adherence to cardiovascular medication 
declines sharply following treatment initiation.  Chapman et al, 2005 looked at patterns 
of adherence with concomitant antihypertensive and lipid-lowering
 
therapy and found 
that the percentage of patients’ adherent to both medications declined sharply following 
treatment initiation,
 with 44.7% of patients’ adherent at 3 months and 35.8% at 12 
months, respectively.  Glader et al, 2010 found that persistence declines with secondary 
prevention medication in the 24 months after ischemic stroke as shown in figure 1.1. 
 
Figure 1.1 Persistence to secondary prevention medication after ischemic stroke  
 
Adapted from Glader EL, Sjölander M, Eriksson M, et al. (2010) Persistent use of secondary preventive 
drugs declines rapidly during the first 2 years after stroke,  Stroke; 41(2):397-401. 
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Discontinuation rates of secondary prevention medication after a myocardial infarction in 
practice follow the pattern shown in the figure 1.2 (Akincigil, et al, 2007).  Nevertheless, 
it is important to also take into consideration physicians, stopping or changing medicines 
during the course of treatment, because this would not be related to non-adherence.  Thus 
after a myocardial infarction NICE, 2014 guidelines recommend that aspirin plus a 
second antiplatelet drug is usually advised for up to 12 months after  a myocardial 
infarction.  
Figure 1.2 Discontinuation rates of secondary prevention medication after a myocardial 
infarction (Akincigil, et al, 2007). 
Adapted from Akincigil A, Bowblis JR, Levin C et al. (2007) Long-Term Adherence to Evidence Based 
Secondary Prevention Therapies after Acute Myocardial Infarction, J Gen Intern Med; 23(2):115–21. 
 
 
In summary, this suggests that many patients initiating primary and secondary therapy 
may receive no or limited benefit from the medication because of premature 
discontinuation. 
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Effect of non-adherence to medication on the outcomes of cardiovascular diseases 
 
Consistent use of secondary prevention medication after a coronary event is associated 
with lower adjusted mortality and higher survival rates compared with patients who are 
not compliant (Newby et al, 2006).  Blackburn et al, (2005) investigated the association 
between cardiovascular morbidity and non adherence to statin therapy in a study 
involving 1056 patients and found that patients in the adherent group were half as likely 
to experience a subsequent myocardial infarction as the patients in the non adherent 
group.  A similar finding was reported by McGinnis et al, (2009) in a study in which 
2201 patients were followed regarding their adherence to statin therapy.  McGinnis et al, 
(2009) found that risk of any-cause death was lower among patients who were adherent 
compared with non adherent patients.  In a further study, Gehi et al, (2007) followed 
1015 outpatients with established coronary heart disease; non adherent participants were 
more likely than adherent participants to develop cardiovascular events during 3.9 years 
of follow-up.  
 
Furthermore, medications like aspirin and clopidogrel if stopped early can lead to short 
term consequences for instance rehospitalisation and even increased risk of death 
(Garavalia et al, 2009).  In the Prospective Registry Evaluating Myocardial Infarction 
Event Recovery (PREMIER) 16% of patients were reported to have ceased their 
clopidogrel 30 days after their Percutaneous Coronary Intervention procedure (PCI) 
(Spertus et al, 2006).   The mortality rate over the next 11 months of those who stopped 
thienopyridine therapy was 7.5% compared with 0.7% in those still taking clopidogrel 30 
days after PCI.  This represented a significant increase in risk of event rates (hazard ratio 
9.02, 95% CI 1.3 to 60.6) (Spertus et al, 2006).  Thus, there is considerable evidence of 
the effect of non-adherence on coronary heart disease outcomes, suggesting that 
interventions to improve adherence may be effective in improving treatment outcomes, 
evidence is summarised in the tables 1.2 and 1.3.   
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1.8-Medication-Taking Behaviour-Definitions 
A. Definitions   
The World Health Organization in 2003 framed a definition for adherence that includes 
health-related behaviours that extend beyond taking prescribed medications.  Examples 
of these behaviours are seeking medical attention, filling prescriptions, taking medication 
appropriately and attending follow-up appointments.  Different terms are used regarding 
medication-taking behaviours, including: compliance, adherence and concordance.  
Compliance has been defined as ‘the extent to which the patient’s behaviour matches the 
prescriber’s recommendations.’  However, its use is declining as it implies lack of patient 
involvement; this approach has negative connotations and allows for the interpretation of 
non-adherence as deviant behaviour (Horne, 2005).  In addition, compliance suggests that 
the patient is passively following the doctor’s orders and that the treatment plan is not 
based on a therapeutic alliance or contract established between the patient and the 
physician (Osterberg, and Blaschke, 2005). 
 
Adherence has been defined as ‘The extent to which the patient’s behaviour matches 
agreed recommendations from the prescriber.’  It has been adopted by many as an 
alternative term to compliance, in an attempt to emphasise that the patient is free to 
decide whether to adhere to the doctor’s recommendations and that failure to do so 
should not be a reason to blame the patient; adherence develops the definition of 
compliance by emphasising the need for agreement (Horne, 2005).  Thus adherence shifts 
the balance between professional and patient to suggest there should be agreement 
between professional and patient about the prescriber’s recommendation (NICE, 2009).  
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The WHO adopted the following definition of adherence to long-term therapy ‘The 
extent to which a person’s behaviour – taking medication, following a diet, and/or 
executing lifestyle changes, corresponds with agreed recommendations from a health care 
provider.’ (WHO, 2003), adherence, now commonly replaces compliance as a preferred 
term (Horne, 2005).    
Concordance is a term that is used in the United Kingdom. Concordance was first 
introduced by a joint working group assembled by the Royal Pharmaceutical Society of 
Great Britain in 1995.  The ‘concordance’ construct recognized the need for patients and 
health care providers to cooperate in the definition of a mutually agreed treatment 
programme, acknowledging that patients and providers may have differing views 
(Virjens et al, 2012).  Its definition has changed over time from one which focused on the 
consultation process, in which doctor and patient agree therapeutic decisions that 
incorporate their respective views, to a wider concept which stretches from prescribing 
communication to patient support in medicine taking.  Concordance is sometimes used, 
incorrectly, as a synonym for adherence (Horne, 2005).  Thus the term concordance has 
infrequently, and not always appropriately, replaced the terms compliance or adherence.   
Compliance and adherence share the property of being quantifiable parameters, which 
detail when doses are taken and how much drug each dose provides, while concordance 
implies a certain meeting of the minds/perspectives of carers/caregivers and patients 
regarding a treatment plan suitable for a course of pharmacotherapy, during which the 
patients and/or carers/caregivers bear the responsibility for correct administration of the 
medicine(s) (Virjens et al, 2012).  
Persistence describes the duration of continuation with therapy (Elliot et al, 2008), non 
persistence referring to patients stopping their medication earlier than the prescriber’s 
recommendation.    
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Furthermore, medication non-adherence may occur at different points in a patient’s 
decision-making process. 
 
It may occur at the start of therapy, if a patient receives the 
initial prescription but does not fill it (primary non-adherence), or it may occur after 
therapy has started if the patient fails to follow the instructions or fails to refill the 
prescription (secondary non-adherence) (Jackevicius et al, 2008).  
Adherence will be used in this thesis as a term for medication taking behaviour as 
concluded by expert panels and consultation groups (Horne, 2005; Virjens et al, 2012).   
 
Intentional and unintentional non-adherence 
Non-adherence to medications has been identified as intentional or unintentional.  
Unintentional non-adherence arises from capacity and resource limitations that prevent 
patients from implementing their decisions to follow treatment recommendations as a 
consequence of individual restrictions and their environment characteristics (Horne, 
2005).  Examples of unintentional non-adherence include poor recall or difficulties in 
understanding the instructions, problems with using the treatment, inability to pay for the 
treatment, or simply forgetting to take it (NICE, 2009).  Intentional non-adherence arises 
from the beliefs, attitudes and expectations that influence patients’ motivation to begin 
and persist with the treatment regimen (Horne, 2005).  Addressing non-adherence is not 
about getting patients to take more medicines.  It starts with an understanding of patients’ 
perspectives of medicines and the reasons why they may not want or are unable to use 
them (NICE, 2009).  It is important to distinguish between these two types of non-
adherence because research has shown the underlying causes of these two types of non-
adherence are different (Clifford et al, 2010).  
 
Understanding the reasons behind non-adherence may be helpful in designing appropriate 
interventions.  Interventions addressing unintentional non-adherence may need to focus 
on simplifying the regimen, reminding patients to take their medication, and supporting  
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patients in making the intake of medication part of their daily routine (Hugtenburg et al, 
2013).  On the other hand patients with intentional non-adherence may become doubtful 
about their medication because of side effects and other disadvantages, such as drug 
dependency, or reduced long-term efficacy (Hugtenburg et al, 2013).   In addition, using 
certain medication can be stigmatizing or remind patients that they are ill.  These factors 
may contribute to a lack of motivation to use the necessary medication. Therefore, 
interventions such as increasing knowledge about the disease and its treatment and 
addressing patient concerns or fears about potential side effects may provide solutions for 
intentional non-adherence (Hugtenburg et al, 2013).  However, research also indicates 
that there may be more to unintentional non-adherence than pure forgetfulness, patients 
reporting intentional versus unintentional non-adherence have been found to be similar to 
one another in terms of their adherence-related knowledge and motivation (Gadkari and 
McHorney, 2012).  Unintentional non-adherence has also been recently linked to 
perceived need for medications, medication concerns, and beliefs about treatment 
efficacy, which suggests that interventions focusing on patients’ medication beliefs may 
be required to address both intentional and unintentional non-adherence (Gadkari and 
McHorney 2012).  Thus the two types of non adherence could be overlapping and there is 
a need to adapt a patient centred approach that encourages informed adherence (NICE, 2009). 
 
B. Measurements of adherence  
The difficulties of valid and reliable measurements have been the focus of much 
discussion and research.  Many different approaches have been taken to the measurement 
of adherence. There is currently no ‘gold standard’ measure of adherence (Vik et al., 
2004; Horne et al, 2005). Interpreting studies comparing the performance of various 
adherence measures is therefore difficult because different studies have used different 
methods.  Each of the available methods has certain flaws which limit the accuracy 
(Horne et al, 2005).   
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Adherence measures have been distinguished as direct and indirect measurements, each 
method has advantages and disadvantages (Osterberg, and Blaschke, 2005), (more details 
can be found in Appendix 4).   
Direct methods  
Direct methods include observing people taking medication, or the measurement of 
medicine, metabolites, or biological markers in the blood (Please see Appendix 4).  
Although objective and accurate, direct adherence measures are often impractical or too 
expensive (Osterberg, and Blaschke, 2005).  Direct measures are considered by some to 
be more reliable and accurate than indirect measures.  However, they are labour-intensive 
and costly and also if patients are being observed, they might tend to change behaviour 
and this can give a false impression of adherence (Osterberg, and Blaschke, 2005).   
Biological Assays 
Biological assays are part of direct methods and measure the concentration of a drug, its 
metabolites, or tracer compounds in the blood or urine of a patient.  These are invasive, 
costly, patients are aware that they are been tested so maybe more inclined to adhere.   
Therefore, biological assays are not a good measure of normal adherence patterns.  A 
number of factors can affect the results like physiological differences, food interactions 
(Vik et al, 2004). 
Pill Counts  
This is often considered as a straightforward approach to the measurement of adherence.  
Pill counts are a simple method involving counting the number of pills remaining in a 
container (Williams et al, 2012).  Pill counts may not provide an accurate reflection of 
medication taking behaviour and they may be manipulated by people if they are aware 
that the pills are being counted (e.g., pill dumping). Thus, they do not necessarily mean 
that medication has been taken at the correct time (Glynn et al, 2011). 
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Pill counts have been described as an “objective” measure of adherence, because they 
don’t rely on subject’s self-report (Glynn et al, 2011), (Williams et al, 2012).  Moreover, 
pill count based adherence measures may provide an estimate of adherence on average 
over a given period of time. Consecutive days without medication and other variations in 
the pattern of medication use are not captured by this method (Williams et al, 2012).  
When relying on the patient to bring medication to a scheduled visit or when making a 
scheduled home visit, there is the possibility that the patient will dispose of surplus pills 
to avoid the discovery of non-adherence.  Further, even in the most well-intentioned of 
circumstances, it is possible that pills stored elsewhere may inadvertently not be included 
in the count, leading to an over estimation of adherence (Williams et al, 2012).  
Electronic Monitoring  
There are a number of electronic monitors capable of recording the time of opening 
bottles, dispensing drops (e.g. eye drops) or activating a canister (e.g. metered dose 
inhaler for asthma) that can give a measure of adherence (Jimmy and Jose, 2011).  Most 
commonly used, is the Medication Event Monitoring System (MEMS).  This is a 
container that has an electronic chip in the lid that records the time of each opening 
(Garfield et al, 2011).  Electronic monitoring methods have greatly advanced in recent 
years and allow recordings of the timing and frequency of accessing the container.  
However, they are expensive, and there is no guarantee that opening of the medication 
container is followed by ingestion of the correct dose.  Thus, opening or emptying of 
containers does not necessarily reflect what the patient has taken. These devices may 
therefore be considered as measures of variables indicative of adherence rather than 
absolute measures of medication use (Garfield et al, 2011).   It could also be argued that 
placing an electronic cap to measure adherence is an intervention in itself, which will 
influence medication-taking behaviour (a Hawthorne effect) as people are aware that they 
are being monitored, rather than provide a measure reflective of normal behaviour (Glynn 
et al, 2011).   
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Furthermore, MEMS is also not suitable for all formulations and medications.  It may be 
more useful for a single solid dosage medication being delivered and monitored as part of 
a clinical trial than multiple drug use in routine primary care (Garfield et al, 2011).   
Advantages of MEMS include measurement of adherence in real time, tracking the 
timing of missed doses, avoidance of error due to recall or memory associated with self-
report, evaluating medication dose response and the ability to identify patterns of 
adherence behaviour that would be difficult to detect with other types of measures (e.g. 
self-report, pharmacy refill) (Williams et al, 2012). Disadvantages associated with 
electronic monitoring include, in addition to their high cost, the possibility of 
malfunction, possible interference with routine adherence activities, inability to confirm 
ingestion of the medication, inconsistent use of the electronic monitoring device, and the 
need to censor data (Williams et al, 2012).  Despite these disadvantages electronic 
monitoring data has been considered the reference standard when validating other 
measures of adherence (Pearson et al, 2007), (Garfield et al, 2012). 
 
Pharmacy Records and Prescription Claims  
Prescribing data, such as the rate of prescription refills or cessation of refills 
(discontinuation rate) can often be obtained through pharmacies, but require a closed-
pharmacy system to be accurate (Glynn et al, 2011).  Also, they cannot be regarded as 
equivalent to measures of the ingestion of medication.  Interpretation of pharmacy refill 
data relies heavily on the assumption that the pharmacy record is complete, 
comprehensive, exclusive and accurate. So long as these assumptions hold true, 
pharmacy refill data can be an effective method to measure medication adherence 
(Williams et al, 2012).  However, pharmacy refills, whilst possibly a prerequisite for 
adherence, cannot provide assurances or detail on what medications are taken, and when 
and how (Williams et al, 2012). 
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Self report adherence measures 
In clinical practice there is a need to measure adherence in a cheap and relatively 
unobtrusive way which can be used routinely (Garfield et al, 2011).  There is also a need 
to distinguish between intentional and unintentional non-adherence, which have different 
underlying causes and therefore require different interventions; self report is the only 
measure which is able to meet these criteria (Garfield et al, 2011).  Self report has been 
considered the method of choice for clinical use (Garfield et al, 2011).   NICE guidelines 
have identified that whilst other types of measures are useful for clinical trials of new 
drugs, self report is an appropriate tool for clinical practice (NICE, 2009). However, 
patients are known to overestimate their level of adherence (Horne, 2005).  Therefore, 
self report method is often combined with other methods used to achieve a valid measure 
of adherence.  Nevertheless, triangulation of self report adherence measure with other 
methods of measuring adherence may not be practical for regular clinical use (Garfield et 
al, 2011).  In addition, recent reviews have shown that self report has moderate 
correlation with electronic monitoring, although self reported adherence levels are higher 
than adherence levels derived from MEMS (Garfield et al, 2011).   
 
Self-report measures can be classified into patient-kept diaries, patient interviews and 
questionnaires.  Self-reported adherence measures range from highly specific inquiries 
concerning the number of medication doses people have taken (or missed) to general 
estimates of how much or how often medication was taken as prescribed, which may be 
anchored by a specified period of time (Williams et al, 2012).  Similarly diverse, the 
methods for administering these measures include individual structured interviews, 
computer delivered assessments, paper and pencil measurement, Short Message Service 
(SMS) text prompts, voice response systems, and web-based data collection (Williams et 
al, 2012).   
 
42 
 
Chapter One:                                                                        Introduction and Background            
 
Patient Estimates of Adherence 
Direct questioning of patients to assess adherence can be an effective method.  Patients 
who admit to non adherence have been found to be accurate in their self-assessment.  
However, patients who claim adherence may be underreporting their non adherence to 
avoid caregiver disapproval (Vik et al. 2004).   
Patient diaries and Surveys 
Diaries in which patients record details of medicines-taking might provide relevant 
information but may also be viewed as an intervention which influences their medication-
taking behaviours (because the patient is completing the diaries and taking the medication 
concomitantly) (Fairman et al, 2000).  Thus, their validity as a measurement tool might 
be questionable.  
A large number of self report measures have been used to measure adherence, few are 
summarised briefly below (Lam and Fresco, 2015): 
Hill-Bone Compliance Scale (Hill-Bone) 
As a measure of reviewing patient’s medication-taking behaviour and barriers to 
adherence, Hill-Bone has limited generalizability since it targets patients with 
antihypertensive medication only. This scale has been suggested as suitable for use in 
studies specific for hypertension in a predominantly black population (Lam and Fresco, 
2015). 
Eight-Item Morisky Medication Adherence Scale (MMAS-8) 
Morisky et al. developed this 8-item MMAS (MMAS-8) in 2008. The first seven items 
are Yes/No responses while the last item is a 5-point Likert response.  The additional 
items (additional to the MMAS-4) focus on medication-taking behaviours, especially 
related to underuse, such as forgetfulness, so barriers to adherence can be identified more 
clearly. 
43 
 
Chapter One:                                                                        Introduction and Background            
 
93% sensitivity and 53% specificity were reported while validating in “a sample of low 
income minority patients treated for hypertension”. It is probably the most commonly 
used self-report measure for adherence to medication (Lam and Fresco, 2015).  The 
Morisky Scale will be discussed further in chapter 4 of this thesis. 
The Self-Efficacy for Appropriate Medication Use Scale (SEAMS) 
The SEAMS is a 13-item, 3-point Likert-type scale focusing on self-efficacy in chronic 
disease management while measuring barriers to medication adherence. It may be 
difficult to carry out at the point of care because of its length.  However, this scale has 
been validated in various chronic conditions.  Reliability of this scale was measured by 
its internal consistency, coefficient alpha reliability at 0.89 and 0.88, on low and high 
literacy populations, respectively (Lam and Fresco, 2015).  
Medication Adherence Report Scale (MARS) 
MARS assesses both beliefs and barriers to medication adherence.  It consists of 10 
questions with a simple scoring to evaluate patient’s adherence behaviour, attitude 
towards medication, and general disease control during the past week.  It was designed 
and first validated for patients with schizophrenia (Lam and Fresco, 2015).   
Diagnostic Adherence to Medication Scale (the DAMS) 
Garfield et al, 2012 developed a theory based adherence scale (the DAMS) and 
established its content and preliminary construct validity.  The DAMS is a relatively new 
and short self-report measure (consists of 6 questions).  The DAMS was developed for 
routine monitoring of adherence in clinical practice.  The authors concluded that it was 
acceptable to patients taking single or multiple medication and valid when tested against 
other adherence measures.  Adherence ratings of the DAMS were significantly associated 
with levels of self reported adherence on all other measures Spearman Rho 0.348-0.719, 
(p < 0.01) (Garfield et al, 2012). 
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Self report measures have the advantage of being simple and inexpensive, quick and easy 
to administer, and able to identify those who are non adherent (as it is likely those 
reporting non-adherence are being truthful).  Self-reporting can also gather social, 
situational and behavioural factors including revealing patterns of medicine use and what 
leads to non-compliance (NICE, 2009).  In addition, to the problem of self-report over-
estimating adherence, other disadvantages include inaccurate self-reporting as a 
consequence of poor recall, social desirability bias and errors in self-observation.  The 
timeframe of the adherence recollection may also affect the accuracy of recall.  Wording 
of questions, how this is expressed, and the skills of the interviewer may influence the 
accuracy of the response.  However, being non-judgmental, e,g, by giving a preamble 
before adherence questions, and asking about specific behaviours may improve the 
validity of responses (NICE, 2009).  
 
 
In conclusion, a perfect measure of adherence does not exist and therefore, when 
choosing a suitable measure researchers balance reliability, practicality and cost 
effectiveness of the chosen method; in addition a multi measure approach could also be a 
current solution (Lam and Fresco, 2015).  
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Reasons for non- adherence to cardiac medication 
The World Health Organization (2003) categorized potential reasons for medication non 
adherence into 5 broad groupings listed in the table below, these factors are summarised 
and described below: 
Table 1.4 Reasons for medication non adherence cited in (Ho et al, 2009) and cited in 
(WHO, 2003).  
 
Health system factors 
These are structural or operational factors of health care system that may create barriers 
to adherence. These may include, poorly developed health services, inadequate or non-
existent reimbursement by health insurance plans, poor medication distribution systems, 
lack of knowledge and training for health care providers on managing chronic diseases, 
overworked health care providers, lack of incentives and feedback on performance, short 
consultations, weak capacity of the system to educate patients and provide follow-up, 
inability to establish community support and self-management capacity, and lack of 
knowledge on adherence and of effective interventions for improving it (WHO, 2003). 
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Condition-related factors 
Condition-related factors reflect particular illness-related demands faced by the patient. 
Some strong determinants of adherence are those related to the severity of symptoms, 
level of disability (physical, psychological, social and vocational), rate of progression and 
severity of the disease, and the availability of effective treatments (WHO, 2003).  Their 
impact depends on how they influence patients’ risk perception, the importance of 
following treatment, and the priority placed on adherence. Co-morbidities, such as 
depression (in diabetes or HIV/AIDS), and drug and alcohol abuse, are important 
modifiers of adherence behaviour (WHO, 2003). 
Patient-related factors  
Patient-related factors represent the resources, knowledge, attitudes, beliefs, perceptions 
and expectations of the patient, patients’ knowledge and beliefs about their illness, 
motivation to manage it, confidence (self-efficacy) in their ability to engage in illness-
management behaviours, and expectations regarding the outcome of treatment (WHO, 
2003). 
Therapy-related factors  
There are many therapy-related factors that affect adherence. Most notable are those 
related to the complexity of the medical regimen, duration of treatment, previous 
treatment failures, frequent changes in treatment, the immediacy of beneficial effects, 
side-effects, and the availability of medical support to deal with them (WHO, 2003). 
Socioeconomic factors 
Socioeconomic factors that may contribute, include poor socioeconomic status, poverty, 
illiteracy, low level of education, unemployment, lack of effective social support 
networks, unstable living conditions, long distance from treatment centre, high cost of 
transport, high cost of medication, changing  
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environmental situations, culture and lay beliefs about illness and treatment, and family 
dysfunction (WHO, 2003).  
Many studies have examined factors associated with non-adherence and discontinuation 
of medication for cardiovascular disease (Sonali et al, 2005) (Gazmararian et al, 2006) 
and have reported association of poorer existence of adherence with the following 
factors: age, gender (female), marital status (unmarried), low education and health 
literacy.  Other studies also investigating barriers to medication adherence in CVD have 
reported factors such as side effects of the cardiac medication (Garavalia et al, 2009), 
(Fried et al, 2011), regimen complexity (Melloni et al, 2009), economic factors and payer 
policies in which patients were unable to afford expensive cardiac medicines (Doshi et al, 
2009).  Clinicians should be aware that reasons may vary between patients (Garavalia et 
al, 2009) and that adherence interventions should be tailored to the needs of the patient in 
order to achieve maximum impact (WHO, 2003). 
 
 
1.9- Strategies to tackle non adherence  
Strategies and interventions to tackle non-adherence to cardiac medication are numerous 
and can be related to areas as shown previously of patient, healthcare practitioner and 
health system.  In this thesis three strategies will be studied these include pharmacy care, 
communication between health providers that could aim to tackle both factors of 
healthcare practitioner and health system and behavioural interventions that could aim to 
address patient related factors such as knowledge and motivation.  These three strategies 
will be examined with the potential of been utilised in a study to improve adherence to 
cardiovascular medication.  The following sections will show evidence of effectiveness 
of these three strategies.  
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 1-Pharmacy care 
Effects of hospital pharmacist interventions on outcomes of cardiovascular disease  
The addition of a pharmacist to a multidisciplinary team to improve outcomes of 
cardiovascular diseases has been addressed in a number of studies and in several diseases 
including dyslipidemia, heart failure and hypertension.  Traywick et al, 2003 in a 
retrospective cohort study examined the effect of the addition of a pharmacist to the 
interdisciplinary medical team for management of dyslipidaemia.  There were two 
groups; the pharmacist group was associated with a significant reduction in mean low-
density lipoprotein (LDL, 18.5%) compared to the cohort that did not have a pharmacist 
as the primary manager of dyslipidemia (LDL, 6.5%, P=0.049).  Moreover, Gattis et al, 
(1999) developed an intervention evaluated in a randomized trial, to assess the role of a 
pharmacist as a member of the multidisciplinary heart failure team, in this trial 
pharmacists optimized ACE inhibitors doses, the study found that all cause mortality and 
heart failure events were significantly lower in the pharmacist group compared with the 
control group (4 vs 16; P = .005).  Bogden et al, 1998 in a randomised control trial 
randomised Hawaiian hypertensive patients, who failed to meet the national standard 
blood pressure goals into an intervention group that had a pharmacist as part of the team 
and a control group with no pharmacist.  The percentages of patients achieving national 
goals in the intervention and control arms were 55% and 20% respectively (p <0.001). 
Effects of community pharmacist interventions on outcomes of cardiovascular disease    
There are presently approaching 12,000 community pharmacies in England and there are 
around 30,000 community pharmacists (Colin-Thome et al, 2016).  Pharmacists are 
trained in therapeutics and are trained to deal with patients.  They are skilled to identify 
and address patients’ problems with medicines including adherence (Holland et al, 2007).  
Furthermore, the role of community pharmacists within the UK is changing to include 
supporting patients in managing medicines to achieve optimal clinical outcomes (Jaffray 
et al, 2007).  Therefore they are a resource to support patients who have a chronic disease 
in regards to their medication.   
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A systematic review (Watson et al, 1998) of community pharmacist interventions in 
CHD provides; evidence of benefits of pharmacists’ interventions in improvements in 
blood pressure, cholesterol, anticoagulation control, and smoking cessation rates.  Several 
randomised control trials conducted in the UK (Goodyer and Miskelly, 1992, 
Blenkinsopp et al, 2000, Jaffray et al, 2007, Holland et al, 2007) have evaluated the role 
of community pharmacists in improving outcomes of cardiovascular diseases and 
increasing adherence for patients with hypertension, heart failure and coronary heart 
diseases.  In addition, local initiatives such as the Community Pharmacy Future (CPF) 
project collaboration between Boots UK, The Co-operative Pharmacy, Lloyds Pharmacy 
and Rowlands Pharmacy have highlighted the potential value of extended pharmaceutical 
care (Colin-Thome et al, 2016), in which community pharmacists screened and identified 
patients with undiagnosed chronic obstructive pulmonary disease. Pharmacists in this 
project (CPF) made significant improvements to medicines adherence and quality of life 
for older patients on multiple medicines, leading to better medicines optimisation.  
However, further research in the UK is needed to evaluate and promote the role of 
community pharmacists as new extended roles are proposed, all with their challenges.  
Pharmacy care as a strategy to tackle non adherence to cardiovascular medication, will be 
researched in detail in a systematic review discussed in chapter two of this thesis.   
 
2-Communication of health care professionals across the primary-secondary care 
interface     
Evidence has shown that when patients move between care providers the risk of 
miscommunication between health providers and unintended changes to medicines 
remain a significant problem.  In 2010 a UK audit across 50 acute trusts involving over 
8600 patients found that when medicines were checked after admission most patients had 
at least one omitted drug or wrong dose (Dodds, 2010). 
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Earlier UK studies suggest that between 30 and 70% of patients have either an error or an 
unintentional change to their medicines when their care is transferred (NPSA, 2007).  
More recent studies reveal that this problem also exists in other countries.  For example a 
study in Australia (Belleli et al, 2013) showed that only 55% of the discharge summaries 
of patients are received by GPs before the first post-discharge visit.  Moreover, a review 
in USA (Kripalani et al, 2007) involving 73 studies showed that direct communication 
between hospital and primary care physicians occurs infrequently (3%-20%) and the 
availability of a discharge summary at the first post discharge visit is low (12%-34%) and 
remains poor at 4 weeks (51%-77%). Thus deficits in communication and information 
transfer at hospital discharge are common and may adversely affect patient care.  In 2012 
the Royal Pharmaceutical Society (RPS) published a report “Keeping patients safe when 
they transfer between care providers” the report was based on an early adopter 
programme encouraging organizations to adapt a multidisciplinary approach.  The 
programme aimed to improve the transfer of information about medicines and included a 
series of workshops involving clinicians, front-line staff, practitioners, community 
pharmacists, patients and managers. 
 
Some of the core recommendations of the RPS report include: (1) IT systems in hospitals 
and general practice should ensure that their systems are able to effectively transfer the 
recommended core content of records for medicines (2) all community pharmacies 
should have an NHS.net website address to enable secure communications between 
secondary and primary care (3) the most effective ways of signposting patients treated in 
secondary care to the post discharge Medicines Use Review Service and New Medicine 
Service offered by community pharmacists should be shared nationally to ensure that 
patients are able to optimise their outcomes from medicines.  There are examples of good 
communication practices such as a recent project in 2014 “PharmOutcome” which is an 
example of a referral technology developed between hospital and community pharmacies.  
This project endorsed by the Local Pharmaceutical Committee in North East and North  
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Cumbria is an Academic Health Science Network project.  This involves a web-based 
application and a secure method of data transfer to all community pharmacies in the area.  
In addition, there are numerous pilots of collaborations between hospital and primary 
care to facilitate and improve medicines management over the interface and these are 
taking place in several areas around the UK (The Pharmaceutical Journal, 2004).  
Therefore, it is important to establish a link between hospital pharmacists and community 
pharmacists as part of a continuation of patient care; because miscommunications across 
the primary/secondary care interface have been numerous and many studies as mentioned 
earlier have shown how this has had a negative impact on patient care.  Thus in order to 
work efficiently; community pharmacies need to have links with pharmacies in secondary 
and tertiary care and also with other members of the primary health care team 
(www.dhsspsni.gov.uk/makingitbetter04_sect3.pdf). 
 
Communication of health providers with patients  
Good communication between healthcare professionals and patients is needed for 
involvement of patients in decisions about medicines and for supporting adherence 
(NICE, 2009).  NICE, 2009 guidelines on adherence provide recommendations to 
healthcare professionals, to help patients adhere to their medicines.  These involve urging 
healthcare professionals to adapt their consultation style to the needs of patients, establish 
effective ways of communication with each patient individually and encourage patients to 
be involved and ask questions about their conditions.  Over the years, much has been 
published in the literature on this important topic (Fong et al, 2010).  In one study 
Garavalia et al, (2011) the researchers recognised traditional views of adherence where 
the patient is viewed as a passive recipient of instructions rather than an active decision 
maker and developed a tool for communication between cardiac patients and clinicians 
(Medicine Discussion Questions- MedDQ).  Garavalia et al, 2011 suggested that this tool 
can be easily used by community pharmacists to help identify patients at risk of non-  
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adherence to cardiac medication.  However, the authors reported that more research is 
needed before expanding the MedDQ’s application in clinical settings.  
3- Behavioural interventions to improve adherence    
 
Evidence from meta-analyses of different interventions (including behavioural 
interventions) to improve adherence 
 
Improving adherence to cardiac medication in clinical practice remains modest and 
challenging (Ho et al, 2009).  This statement is based on evidence from numerous meta-
analyses.  A meta–analysis by Schroeder, 2005 determined the effectiveness of 
interventions aiming to increase adherence to blood pressure lowering medication.  Thirty 
eight studies testing 58 different adherence interventions on 15,519 patients were 
included in the meta-analysis.  The interventions included the following; education of 
caregivers and patients (e.g. health education) in six studies but education alone seemed 
unsuccessful, only one of six studies improved adherence.  Simplification of dosage 
regimens was used in nine studies and seven of these trials showed improvement in 
adherence with a relative small increase in adherence of 8% to 19%.  Complex health and 
organizational interventions, including interventions in combination, increased adherence 
in eight of the eighteen studies with an increase of 5%-41%.  Motivational strategies 
including patient motivation and support were successful in 10 out of 24 of the studies 
reviewed, with an increase in adherence up to 23% (Schroeder, 2005).  The meta-analysis 
concluded that simplification of dosing regimens appeared to be the most promising 
intervention to increase adherence to blood pressure–lowering medication and that the 
evidence of the effect of motivational and more complex interventions was mixed and 
inconclusive (Schroeder, 2005). 
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A second meta-analysis by Peterson (2003), evaluated 484 articles and studied multiple 
interventions, including; behavioural, educational, combined interventions and 
interventions   including mail reminders, this analysis concluded that; the data from these 
studies are  not homogeneous hence  conclusions were difficult to be derived.  The meta-
analysis revealed an increase of 4-11 % in adherence and concluded that no single 
strategy appeared to be best. 
 
Evidence from meta-analyses of behavioural interventions to improve adherence 
 
Despite the challenges to improve adherence reported above, there is strong evidence that 
behavioural and motivational strategies could be effective after all (Roter et al, 1998), 
(Easthall et al, 2013).  Older evidence such as a meta-analysis (Roter et al, 1998), of 
adherence-enhancing interventions demonstrated that comprehensive interventions, 
combining cognitive, behavioural, and affective motivational components, were more 
effective than single-focused interventions including information alone.  In addition, 
more recent evidence from meta-analysis of 26 RCTs (Easthall et al, 2013) supported the 
use of motivational interviewing and other cognitive-based behaviour change techniques 
as interventions to improve medication adherence.   Much of health care today involves 
helping patients manage conditions whose outcomes can be greatly influenced by 
behaviour change.  Patient related factors are a determinant of adherence behaviour as 
discussed in earlier sections of this chapter, the patient’s perceived value of adhering, 
with the patient’s intrinsic motivation could be targeted along with providing education to 
increase knowledge of the medications (WHO, 2003).  Motivational strategies and 
behavioural support are becoming increasingly more common to use in healthcare 
settings to promote behavioural change.  Therefore, a behavioural approach to enhance 
adherence is selected to be investigated with a focus on motivational interviewing. 
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The coming sections will provide a discussion of the theory of motivational interviewing, 
followed by evidence of its application and use to improve adherence, by different 
healthcare professionals including pharmacists: 
Motivational interviewing  
Motivational interviewing refers to a counselling approach in part developed by clinical 
psychologists Professor William R Miller and Professor Stephen Rollnick.  The concept 
of motivational interviewing evolved from experience in the treatment of problem 
drinkers and was first described by Miller (1983) in an article published in Behavioural 
Psychotherapy.  These fundamental concepts and approaches were later elaborated by 
Miller and Rollnick (1991) in a more detailed description of clinical procedures (Miller et 
al, 1991).  In 2004 Miller further described motivational interviews as “a way of being 
with people which is also directive in seeking to move the person toward change by 
selectively evoking and strengthening the patient’s own reasons for change”.  
Motivational interviewing is a client-centred, directive style of counselling.  Clinical 
trials have established motivational interviews as an efficacious method for facilitating 
behaviour change as well as increasing adherence to treatment.  This method is intended 
for use particularly when patient motivation and adherence are important for treatment to 
be effective (Bisono et al, 2006).   
 
Numerous studies have shown that motivational interviewing has been successfully used 
to improve adherence to medication in diseases such as chronic illnesses like diabetes, 
psychiatric disorders, HIV and asthma (Smith et al, 1997), (Kemp et al, 1998), (Daley et 
al, 1998), (Dilorio et al, 2003), (Rosen et al, 2002), (Schmaling et al, 2001) (Miller, 
2004).  Moreover, research has shown that even one session of motivational interviewing 
at early stages of treatment can improve adherence and outcomes of many diseases 
(Miller, 2000).  Regarding time, the application of such techniques to practice requires 
little additional time and can be very effective.   
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A skilled provider can use motivational interviewing for 5–10 minutes per session per 
patient and achieve desirable outcomes (Possidente et al, 2006).  Motivational 
interviewing is based on four key principles (Bisono et al, 2006), these principles are 
outlined in figure 1.3 and then further described below; 
 Figure 1.3 Description of Motivational Interviewing Principles (Bisono et al, 2006) 
Adapted from Bisono A.M, Manuel J K, Forcehimes A.A, (2006) Promoting Treatment Adherence 
Through Motivational Interviewing05-O’Donohue-(V-5).qxd 6/9/2006 10:39 AM Page 71. 
 
1. Express empathy: expressing empathy involves actively listening to the patient and 
conveying an understanding of the patient’s perspective, without judging, criticizing, or 
blaming.  In motivational interviewing, ambivalence about change is regarded as normal 
and a part of the change process; therefore empathic listening is used to understand and 
accurately reflect this ambivalence (Miller, 2004), (Bisono et al, 2006).  
2. Develop discrepancy: a goal in motivational interviewing is for patients to see a 
discrepancy between their personal goals and their present behaviour.  The objective is 
for the practitioner to direct the discussion in such a way that the patients perceive this 
discrepancy and the reasons to change their behaviour without pressure from the 
practitioner (Bisono et al, 2006).  
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3. Roll with resistance: avoiding pushing against resistance to change is a third principle. 
Rather than arguing with a patient who is resistant to change, practitioners roll with this 
resistance. Arguing in favour of a certain position with the patient, for instance, arguing 
to persuade patients to take medications will likely result in defensiveness on his or her 
part, a decreased desire to take the medication, and lower medication compliance.  
Practitioners can roll with resistance by reflecting or rephrasing the patient’s arguments 
against change (Bisono et al, 2006). 
 4. Support self-efficacy: self-efficacy, a person’s confidence in his or her ability to 
achieve a specific goal, is an important predictor of a successful treatment outcome.  If a 
practitioner believes that the patient is able to change his or her behaviour and expresses 
this support, the patient may feel empowered by the idea that change is possible (Miller, 
2004), (Bisono et al, 2006). Motivational interviewing has been contrasted with 
traditional pharmacist consultations as demonstrated in the figure 1.4 below: 
Figure 1.4 Comparison of Motivational Interviewing with a traditional pharmacist 
consultation –Possidente et al, 2005. 
Adapted from Possidente C.J, Bucci K. K and  Mcclain W.J (2005) Motivational interviewing: A tool to 
improve medication adherence? Am J Health-Syst Pharm.; 2005; 62:1311-4. 
Traditional pharmacist consultation Motivational interviewing 
Practitioner is an expert and assumes that the 
patient needs more knowledge, provides advice 
and anticipates that patient will follow the 
instructions. 
A partnership is developed between 
practitioner and patient, to reach an 
informed decision.  Patient decides own 
care. 
Information is given to patient by practitioner. To develop discrepancy practitioner 
provides patient with information.  
Practitioner dictates healthcare behaviour. Behaviour is negotiated between 
practitioner and patient to reach an 
agreement. 
The aim is to motivate the patient.  The aim is to elicit commitment to 
change behaviour. 
Practitioner convinces patient to change 
behaviour.  
Practitioner understands, in addition 
accepts patient’s behaviour.  
Practitioner expects respect.  Practitioner must earn respect. 
Practitioner saves patient.  Patient saves self.  
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Evidence of use of motivational interviewing in cardiovascular diseases by healthcare 
professionals other than pharmacists  
Research suggests that it is possible to train healthcare professionals to offer motivational 
interviewing (The Health Foundation, 2011) the section below shows evidence of 
motivational interviewing delivered by healthcare professionals other than pharmacists to 
improve adherence to medications in cardiovascular disease:  
A review in 2011 by Thompson et al, examined motivational interviewing delivered by 
nurses, as a method for improving modifiable coronary heart disease risk factors.  The 
review included one systematic review, three literature reviews of motivational 
interviewing, four meta-analyses and five primary studies of motivational interviewing 
pertaining to cardiovascular health.  This review suggested with strong evidence that 
motivational interviewing is an effective behavioural approach and that it focuses on 
eliciting the individual’s own intrinsic motivation for change of behaviour that offers a 
promise in improving cardiovascular health status.  
 
Randomised control trials such as Hardcastle et al, 2013 evaluated, in a primary –care 
setting, the effectiveness of a six-month low-intensity motivational interviewing 
intervention in maintaining reductions in CVD risk factors at 12 months post-
intervention.  This included five face-to-face motivational interviewing session delivered 
(by a physical activity specialist and a registered dietician) to 203 patients, compared to 
132 patients in the control group who received standard information. The intervention 
included patient-centred, tailored counselling sessions which incorporated principles and 
strategies from motivational interviewing. Consistent with the underpinning ‘spirit’ of 
motivational interviewing, personal motives to change cardiovascular risk factors were 
identified by the patient and not imposed by the practitioner.  Outcome measures 
included; risk factors for cardiovascular disease; body mass index, bodyweight, blood 
pressure, cholesterol and physical activity.   
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The results revealed significant differences between the two groups for cholesterol and 
walking.  Obese and hypercholesterolemic patients exhibited significant improvements in 
body mass index and cholesterol respectively.  However, post-intervention improvements 
in other health-related outcomes including blood pressure and weight were not 
maintained.  Based on these findings, the study recommended that future interventions 
should be conducted in a primary care setting to target patients with high risk of CVD.  
Training on motivational interviewing in Hardcastle et al, 2013 included two 4 hours 
training sessions and the consultations were audio-recorded.  Another recent RCT 
included a USA study Palacio et al, (2015) in ethnic minorities’ patients after a coronary 
stent placement, 452 patients were randomised to receive either four motivational 
interviewing telephone calls over a 12 month period or a one-time mailed DVD video 
containing educational information on antiplatelets medication.  The consultation was 
delivered by nurses trained on motivational interviewing in a 3 day workshop.  The 
intervention aimed to elicit individual values, preferences, arguments for change, and 
reasons for past failures and to empower patients to resolve ambivalence and develop a 
behaviour modification plan.  The nurses succeeded to establish rapport with patients, 
and used open-ended questions.  The results showed statistically significant results on 
adherence to antiplatelet therapy; measured by both self report Morisky scale and by 
prescription refills (P = 0.01).  
   
Evidence of use of motivational interviewing in cardiovascular diseases by pharmacists 
For motivational interviewing in CVDs delivered by pharmacists, only four studies were 
found, it is worth to mention that these studies were not published before the design of 
this pilot study.  Three trials were published in scientific journals (Binaso et al, 2012), 
(Hedegaard et al, 2014), (Pringle et al, 2014) and one trial (still recruiting patients) was 
published on ClinicalTrials.gov (NCT02102503). 
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These studies were conducted in countries other than the UK and they implemented 
varying approaches on using motivational interviewing including consultation timings 
and modes of delivery.  Two involved community pharmacists delivering the intervention 
in a community pharmacy setting (Binaso et al, 2012), (Pringle et al, 2014) and two 
employed hospital pharmacists in a hospital clinic setting (Hedegaard et al, 2014), 
(NCT02102503).  Three of these studies are RCTs (Binaso et al, 2012), (Hedegaard et al, 
2014), (NCT02102503) and one is a quasi-experimental (Pringle et al, 2014). These 
studies are summarised in the following section: 
 
Binaso et al, 2012 in an RCT recruited 10 community pharmacy sites across the United 
States and enrolled 216 patients with diabetes.  During a 6 month period pharmacists 
delivered a behavioural intervention to improve patient adherence to diabetes medication 
therapy.  The intervention consisted of structured communication sessions using 
motivational interviewing techniques to facilitate discussions with patients; in a quick, 
simple, interactive, and patient-centred way. The interventions were developed to be 
easily incorporated into community pharmacy workflow.  Patients in the intervention 
group showed a 6% increase in adherence compared with previous 180 days pre-
intervention and a 28% increase in adherence compared with control group.   
 
In Denmark; Hedegaard et al, 2014 conducted an intervention that focused on 
pharmacists’ medication review and a motivational interviewing consultation.  This study 
included 211 patients randomised after a stroke/TIA.  The intervention was divided into a 
30-minutes face-to-face patient interview, to support adherence and lifestyle changes and 
3 follow-up telephone calls that lasted for 6 months.  The aim of the interview was to 
help the patients’ identify goals in relation to their medication/disease and to facilitate 
behaviour change by exploring ambivalence and by mobilizing the patients’ intrinsic 
values for behaviour change. 
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To assist the pharmacist in adhering to a standardized approach, an interview guide was 
developed. The primary outcome was adherence, measured by prescription refills.  
Results showed that despite patients been satisfied with the service and reported 
increased knowledge about the medications; no statistically significant differences were 
found for adherence and persistence to specific thrombopreventive agents.  The authors 
attribute the absence of an intervention effect, to the unintentional use of some elements 
of the intervention in the control group (i.e. contamination).   
 
 
A large-scale community pharmacy study was conducted in Pennsylvania –USA (Pringle 
et al, 2014).  The design of the study was quasi-experimental in which the control group 
received standard care from a community pharmacist which comprised information on 
medication during refills, whilst the intervention group additionally were offered a brief 
screen that indicates a patient risk of non-adherence, followed by a pharmacist-led brief 
intervention provided to patients at elevated risk.  The brief interventions were 
pharmacist-led; two-to-five-minute conversations using motivational interviewing 
principles with a focus on exploring and resolving a patient's ambivalence and centred on 
motivational processes within the individual that facilitated change.  This study involved 
283 pharmacists in the intervention group delivering the brief intervention to 29,042 
patients with chronic diseases compared to 295 control group pharmacists and 30,454 
patients.  The intervention significantly improved medication adherence for all classes of 
medication under study, ranging from 4.8% difference in adherence for oral diabetes 
medicine to 3.1% for beta blockers measured by prescription refills.   
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In Pringle et al, (2014) the authors reported that the project was implemented under real-
world conditions, with very limited extra funding to community pharmacies.  
Furthermore, the brief intervention was stably integrated into the standard workflow 
process without affecting the normal pharmacy operation or requiring additional staffing.  
In this large study pharmacists’ training and also assessment of proficiency of the skills 
were mentioned.   However, the study was not a randomised control trial, where 
measures such a randomisation, concealment and blinding were employed.  This can raise 
concerns with internal validity and also the possibility of convincingly demonstrating a 
causal link between the intervention and observed outcomes.  Finally, a recently 
commenced Swedish randomised control trial registered on ClinicalTrials.gov 
(NCT02102503), is investigating if an intervention can improve patients' medication 
adherence.  The intervention will involve a medication review and a motivational 
interviewing counselling session, delivered by hospital pharmacists, at three months post-
discharge and a follow-up phone call two weeks later for patients on secondary 
prevention medication after a myocardial infarction.  The primary outcome will include 
targets of LDL-C and secondary outcomes are adherence to secondary prevention 
medication and blood pressure control.  The trial, currently recruiting, aims to recruit 585 
patients and is estimated to be completed in 2018.  The authors were contacted by the 
PhD student (researcher) for preliminary results, but the authors reported that no results 
are available.  
 
In conclusion, from the evidence described above, there is evidence that motivational 
interviewing interventions can be effectively delivered by pharmacists, to improve 
adherence to medication, in the cardiovascular population.  However, the evidence is still 
limited.  Therefore, there is a need for multi-centred randomised controlled trials that 
could provide conclusive evidence about the impact of motivational interviewing on 
adherence to cardiovascular medications across different settings, ethnicity, age and 
socio- demographic populations.   
End of Chapter One 
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Overview of the thesis 
 
1- Background literature on cardiovascular diseases and the importance of adherence 
to medication to improve outcomes, this was reviewed in chapter one. 
  
2- Examine previous evidence and review literature to identify trials examining 
pharmacy services with an aim to improve adherence and clinical outcomes to 
cardiovascular diseases.  This was by conducting a systematic literature review in 
chapter two.  
 
3- Review the evidence to identify pharmacy services and pharmacy roles in the UK. 
To be able to design an intervention, which can be incorporated into community 
pharmacy this was studied in chapter three.   
 
4- Employ conclusions from previous and existing evidence of pharmacy services to 
design a pilot feasibility study that can be incorporated into UK community 
pharmacy services.  This was designed in chapter four.  
 
5-  Chapters five and six will show results of the feasibility study and chapter seven 
will include a discussion of the results.  
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Chapter Two 
Pharmacy Care and Adherence to Primary and Secondary Prevention 
Cardiovascular Medication- A systematic review of studies 
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2.1-Introduction 
As discussed in chapter 1, adherence has been defined as the ‘active, voluntary, and 
collaborative involvement of the patient in a mutually acceptable course of behaviour to 
produce a therapeutic result’ (Ho et al, 2009).  Non-adherence to medications has been 
documented to occur in >60% of patients with cardiovascular disease (Baroletti et al, 
2010).  Primary non adherence (not initially filling the prescription) leads to a significant 
increase in 1-year mortality after hospitalization for myocardial infarction (Jackevicius et 
al, 2008).  Secondary non-adherence (failure to follow the instructions or to refill the 
prescription) has been shown to increase mortality, hospitalisations and costs (Baroletti et 
al, 2010).  Therefore, it is crucial to promote adherence to improve outcomes in these 
groups of patients.  Evidence-based data have demonstrated that pharmacists deliver 
clinical services that improve cost effective quality of care in patients with cardiovascular 
diseases (Giberson et al, 2013).  It is estimated that poor adherence costs US$100 billion 
annually in the USA (Vermeire et al, 2005) and the cost of unwanted medications 
exceeds £100 million annually in the UK (Clifford et al, 2010).   
 
Pharmacists are believed to have an increasingly important role in improving adherence. 
This role can be achieved through services in hospitals (example, medicines 
reconciliation and monitoring) and in the community (in the UK: Medication Usage 
Reviews and the New Medicine Service; in the USA: Medication Therapy Management 
(MTM); in Australia and Canada: MedsCheck program).  Moreover, pharmacists have 
reduced healthcare costs by minimizing adverse clinical events (hospitalisations, 
emergency room visits, etc) and reduced outpatient visits (Giberson et al, 2013).  
Advanced patient care services, delivered by pharmacists, decrease drug-related 
morbidity and mortality (Giberson et al, 2013).  Therefore, it is accepted that pharmacists 
are well placed to support patients with their medication use.  This review aimed to 
explore existing evidence on if and how healthcare delivery could be improved through 
the use of pharmacist-delivered patient care with a focus on cardiovascular diseases. 
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Research question: can pharmacy care improve adherence to primary and secondary 
cardiovascular medication? 
2.2-Aim and Objectives  
To determine if pharmacy service intervention can lead to enhanced adherence to primary 
and secondary cardiovascular medication and improve outcomes of cardiovascular 
diseases.  
 To establish if there is an effect of pharmacy service intervention, on improving 
adherence to medications and outcomes of cardiovascular diseases. 
 To identify types of interventions found to be effective in clinical trials in 
improving adherence to cardiovascular medication that could be implemented in 
practice. 
 
 
2.3-Materials and Methods  
Search strategy and data resources  
A systematic search of articles published in peer reviewed healthcare-related journals was 
performed.  The literature was systematically searched in order to identify articles 
describing and evaluating pharmacist delivered interventions to improve outcomes and 
adherence measures to cardiovascular medication.  Data bases Pubmed central UK, 
Pubmed, Cochrane Library, CINAHL, PsycINFO, EMBASE, International 
Pharmaceutical Abstracts and Google Scholar were searched for the period from 
01/01/1990 to 19/11/2013  (please refer to Figure 2.1- Study selection chart below).  The 
review commenced with three main key words: pharmacy care, adherence and 
cardiovascular disease.  These were included in the databases searched, first without 
search restriction and second with search restrictions to randomised control trials, the 
specified period and English language.  
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The following key words were used (pharmacy care, adherence, cardiovascular disease or 
diseases), (pharmacy care, compliance, cardiovascular disease), (pharmaceutical care, 
adherence, cardiovascular disease), (pharmacists, cardiac disease, adherence), 
(adherence, pharmacists, cardiovascular disease) and (adherence, pharmacist 
interventions, cardiovascular disease).  In addition, search terms related to the type of 
diseases (adherence, pharmacists, hypertension or hyperlipidemia, or diabetes, or 
coronary heart disease, or heart failure).  Following this search the other key words were 
generated from MeSH (medical subject heading) terms in PubMed and term mapping 
database EMBASE.  Key words not listed as MeSH or Map Terms were searched as 
phrases using the free text search mode.  A further list of search terms was generated by 
referring to a key review, Cutrona et al, 2010, which studied modes of delivery for 
interventions to improve cardiovascular medication adherence.  The reference list of 
relevant papers was also searched in order to identify any additional studies.  Duplicate 
articles were removed if they were found in the different databases.  Two articles 
published study protocols, therefore the authors were contacted for the results.  
 
 
Selection criteria 
The articles were selected through screening of titles and abstracts.  The criteria for 
relevant studies were: randomised control trials; interventions aiming to enhance 
adherence to cardiovascular medications; trials evaluating clinical outcomes of 
cardiovascular diseases in which adherence was the secondary outcome; studies delivered 
in hospital or community settings and studies in English language. 
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Data extraction 
Electronic data bases were searched to identify studies that matched the inclusion criteria.   
After application of the key words the databases yield the following number of articles; 
Pub Med (n=174), Pub Med Central UK (n=13), Cochrane library (n=619), Google 
scholar (n=1850), CINAHL plus (n=230), PsycINFO (n=414), International 
Pharmaceutical Abstracts (n=0), EMBASE (n=795).  The search gave a total number of 
4095 citations.  The titles and/or abstracts of these articles were reviewed and 111 full 
text articles matched the inclusion criteria and were retrieved either electronically or on 
paper copy for assessment; 39 articles were identified.  The reference lists of the relevant 
39 articles were also searched and an additional 3 articles were found.  Therefore, a total 
of 42 randomised controlled trials were included in this review (Figure 2.1 Study 
selection chart below).  In total, 69 articles were excluded for the following reasons: did 
not study adherence (n=22), no adherence measurement (n=6), not a randomised control 
trial (n=5), Studies including stroke (n=3) assessed adherence aids (n=2), drug related 
problems (n=4), guideline optimization (n=2), assessed a clinic (n=2), other health 
practitioners (n=2), risk factor reduction (n=3), not cardiac (n=4), no pharmacists (n=3), 
optimisation of medicine ( n=2), article in Spanish (n= 5), article in Japanese (n=1), use 
of the medication and not adherence (n=2), no clear randomisation (n=1).  Only full texts 
of randomised controlled trials were included in this review. 
 
Process of data extraction 
A table of details of each intervention was developed and it included a full description of 
the nature of each intervention and its duration.  The interventions were compared for 
differences and similarities and then the main categories were established. They were 
categorised according to the mode of delivery.  A further table was developed for 
adherence measures then similar measures were grouped.  Further variables assessed 
were arranged in tables to enable analysis. These included setting, patient groups, 
outcome measures and study design (Please refer to appendix 5-9).  
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Figure 2.1 Study selection chart  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Databases 
searched                     
 
No of 
articles  
Pub Med   
PubMed 
central  UK     
174 
13 
Cochrane 
library   
619 
Google scholar 1850 
Cinhal plus 230 
Psyc Info 414 
International -
Pharmaceutical 
Abstracts 
Embase  
 
0 
 
795 
Total 4095 
articles 
Records screened 
(n =3819   ) 
Additional records 
identified through other 
sources 
(n = 3) 
Records identified through 
database searching 
(n = 4095 articles   ) 
 
 
 
Records after duplicates removed 
(n = 3819  ) 
Records excluded 
(n = 3708  ) 
Full-text articles excluded, with reasons 
(n =69   ) 
Reason  No. 
No adherence  22 
No adherence measurement  6 
Not a randomised control trial 
Studies including stroke                              
5 
3
 
Assessed adherence aids  2 
Drug related problems  4 
Guideline optimization  2 
Assessed a clinic 2 
Other health practitioners  2 
Risk factor reduction  3 
Not cardiac 4 
No pharmacists  3 
Optimization of medicine  2 
Spanish article  5 
Japanese article 1 
Use of the medication and not 
adherence  
2 
No clear randomisation  1 
Total excluded articles  69 
 
 
Full-text articles assessed 
for eligibility 
(n = 111  ) 
 
 
Studies included in 
qualitative synthesis 
(n = 42 ) 
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2.4-Results  
The 42 studies that met the inclusion criteria were conducted in different countries USA 
(18 articles), UK (3), Australia (3), Canada (4), UAE (2), Netherland (2), Belgium (2), 
Thailand (2), Northern Ireland (1), Portugal (1), Brazil (1), Spain (1), Jordan (1) and 
China (1). 
 
Study Design  
All the 42 trials included in this review were randomised controlled trials 27 trials 
randomised patients into intervention and control groups (Lee et al, 2006), (Bouvy et al, 
2003),(Morgado et al, 2011) , (Yunsheng et al, 2010),(Carter et al, 2008), (Mazroui et al, 
2009),( Hunt etal,2007), ( Holland et al, 2007), (Peterson et al, 2004), (Murray et al, 
2007), (Phumipamorn et al, 2008),  (Sookaneknun  et al, 2004), (Taylor et al, 2003), 
(Jaffray et al, 2007), (Odegard et al ,2005), (Mehos et al, 2000) ,(Park et al, 1996) 
,(Obreli-Neto et al, 2011), (Lopez et al, 2006), (Faulkner et al, 2000) ,( Calvert et al, 
2012), (Zhao et al, 2012) , (Planas et al, 2009), (Eussen et al, 2010), (Jarab et 
al,2012),(Alsabbagh et al, 2012), (Ho et al,2014).  Six trials randomised pharmacies to 
avoid contamination between the intervention and control groups (Zillich et al, 2005) 
,(Svarstad et al, 2009), (Aslani  et al, 2010), ( Lau et al, 2010), (Blenkinsopp et al, 2000), 
(Mehuys, 2011).  Two trials randomised at clinic level to minimize contamination at 
physician level (Carter et al, 2008),(Carter et al, 2009).  Moreover, two trials (Villeneuve 
et al, 2010), (Heisler et al, 2012) randomized clusters.  Villeneuve et al, 2010 randomised 
clusters including both physicians and community pharmacists.  Heisler et al, 2012 
conducted a cluster randomised effectiveness study in which primary care teams within 
sites were randomised.  On the other hand one trial (Vrijens et al, 2006) randomized two 
districts in Belgium into usual care and a supportive intervention program and one trial 
(Edworthy et al, 2007) randomised cardiologists and accordingly assigned patients to 
either arm.   
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Finally, three trials were designed as prospective randomised controlled pilot studies 
(Gwadry-Sridhar et al, 2005), (Varma et al, 1999), (Evans et al, 2010); all the three trials 
randomised patients. 
 
Patient/Disease groups  
Of the 42 trials that met the inclusion criteria 17 were conducted in patients with 
hypertension (Lee et al, 2006), (Morgado et al, 2011) ,(Carter et al, 2008), (Hunt et al, 
2008), (Zillich et al, 2005) ,(Svarstad et al, 2009),( Lau et al, 2010) (Sookaneknun  et al, 
2004) ,(Taylor et al, 2003), (Blenkinsopp et al, 2000) ,(Mehos et al, 2000) ,(Park et al, 
1996) ,(Obreli-Neto et al, 2011) ,( Calvert et al, 2012) ,(Carter et al, 2009), ( Zhao et al, 
2012) ,(Planas et al, 2009), 10 in patients with diabetes  (Mazroui et al, 2009), 
(Phumipamorn et al, 2008) ,(Taylor et al, 2003), (Odegard et al ,2005), (Mehuys, 2011) , 
(Obreli-Neto et al, 2011), (Planas et al, 2009), (Evans et al, 2010), (Heisler et 
al,2012),(Jarab etal,2012), 7 in patients with dyslipidemia (Lee et al, 2006), (Villeneuve 
et al  , 2010), (Aslani  et al, 2010) ,(Vrijens et al, 2006),(Taylor et al, 2003), (Evans et al, 
2010) , (Eussen et al, 2010) , 7 in patients with heart failure (Bouvy et al, 2003),( Holland 
et al, 2007),(Sadik, 2005),(Gwadry-Sridhar et al, 2005),(Murray et al, 2007),(Varma et 
al, 1999), (Lopez et al, 2006) and 9 in patients with coronary heart disease (Yunsheng et 
al, 2010),(Peterson et al, 2004), (Jaffray et al, 2007,(Edworthy et al, 2007), (Faulkner et 
al, 2000), (Calvert , 2012), (Evans et al, 2010),(Alsabbagh et al, 2012),(Ho et al, 2014).  
One trial (Lee et al, 2006) studied patients with hypertension and dyslipidemia; another 
trial (Taylor et al, 2003) studied patients with hypertension, dyslipidemia, diabetes and 
patients on anticoagulation therapy.  Furthermore, two trials (obreli-Neto et al, 2011), 
(Planas et al, 2009) included patients with hypertension and diabetes and finally, one trial 
(Evans et al, 2010) studied patient populations for primary and secondary prevention 
(hypertension, diabetes, dyslipidemia and coronary heart disease).    
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Overview of goals of interventions and primary/secondary outcomes  
In 19 trials (Lee et al, 2006), (Bouvy et al, 2003), (Yunsheng et al, 2010), (Sadik, 2005), 
(Peterson et al, 2004), (Gwadry-Sridhar et al, 2005), (Murray et al, 2007), (Aslani et al, 
2010) ,( Lau et al, 2010), (Vrijens et al, 2006),  (Blenkinsopp et al, 2000), (Obreli-Neto 
et al, 2011), (Calvert et al, 2012), ( Zhao et al, 2012), (Planas et al, 2009), (Eussen et al, 
2010), (Alsabbagh et al, 2012), (Ho et al,2014),(Faulkner et al, 2000) the aim of the 
intervention was to enhance adherence to cardiovascular medication and adherence was 
the primary outcome.  The remaining interventions measured adherence as a secondary 
outcome; the primary aims being to improve blood pressure control and management of 
hypertension (Morgado et al, 2011), (Carter et al, 2008), (Hunt et al, 2008), (Zillich et al, 
2005),(Svarstad et al, 2009), (Sookaneknun  et al, 2004) ,(Mehos et al, 2000), (Park et al, 
1996) ,(Carter et al, 2009),(Planas et al, 2009),  (Heisler et al,2012),  to improve 
glycaemic control and quality of care for diabetic patients (Mazroui et al, 2009), 
(Phumipamorn et al, 2008), (Odegard et al ,2005), (Mehuys, 2011), (Jarab etal,2012) and 
to improve clinical outcomes in heart failure patients (Holland et al, 2007), (Sadik, 2005) 
,(Varma et al, 1999), (Lopez et al, 2006).  Other secondary outcomes included reduction 
in multiple cardiovascular risk factors (Taylor et al, 2003), (Evans et al, 2010), to 
improve use of guidelines for secondary prevention medication in patients with CHD 
(Jaffray et al, 2007), (Edworthy et al, 2007) and the achievement of target lipid levels and 
lipid control (Villeneuve et al, 2010).  
 
Setting   
In fifteen studies the principal setting for the intervention was a community pharmacy 
(Bouvy et al, 2003), (Zillich et al, 2005), (Villeneuve et al  , 2010), (Murray et al, 2007), 
(Svarstad et al, 2009), (Aslani  et al, 2010), ( Lau et al, 2010), ,(Vrijens et al, 2006),  
(Sookaneknun  et al, 2004), (Jaffray et al, 2007), (Blenkinsopp et al, 2000), (Park et al, 
1996) ,(Mehuys, 2011), (Planas et al, 2009), (Eussen et al, 2010); in 14 studies the 
interventions were in hospital (Lee et al, 2006), (Morgado et al, 2011),  
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(Yunsheng et al, 2010), (Mazroui et al, 2009), (Sadik, 2005), (Gwadry-Sridhar et al, 
2005), (Phumipamorn et al, 2008), (Edworthy et al, 2007), (Varma et al, 1999), (Lopez et 
al, 2006) ,( Zhao et al, 2012),(Faulkner et al, 2000) ,(Alsabbagh et al, 2012), (Ho et 
al,2014) and in 9 studies (Carter et al, 2009), (Hunt etal,2007) ,(Taylor et al, 2003), 
(Odegard et al ,2005) ,(Mehos et al, 2000), (Obreli-Neto et al, 2011), (Carter et al, 2008), 
(Evans et al, 2010), (Heisler et al, 2012) the setting was a clinic or primary care practice.  
In two trials (Holland et al, 2007), (Peterson et al, 2004) the intervention setting was the 
patient’s home and in one trial (Calvert et al, 2012) the intervention was delivered in a 
hospital and community pharmacist setting. 
 
2.5-Details of the intervention 
In accordance with the eligibility criteria, all interventions were conducted by a 
pharmacist.  All interventions were complex and included multiple components.  
However, they are described here according to the principal component of the 
intervention.  Categorization followed the studied trials’ description of their interventions 
and also the researcher’s own judgment.  Interventions were classified into categories 
these included: patient education by pharmacist, collaborative care, communication 
between primary and secondary care, combined interventions and use of electronic 
devices.  
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Patient education 
Education by a pharmacist was delivered face to face, by telephone or by a home visit. 
 
Face-to-face patient education 
Pharmacists provided education face to face with a patient in 21 trials.  This followed a 
pre-specified structure in seven trials (Lee et al, 2006), (Bouvy et al , 2003), (Morgado et 
al, 2010), (Mazroui et al , 2009) (Blenkinsopp et al , 2000), (Varma et al, 1999),  (Eussen 
et al, 2010).  In addition, the consultation focused on the disease and prescribed 
medications  (Lee et al  , 2006),  (Al Mazroui et al  , 2009), (Sadik et al, 2005), (Alsani et 
al, 2010), (Murray et al, 2007), (Mehuys et al, 2011), (Taylor et al, 2003),  
(Phumipamorn et al, 2008) , (Varma et al, 1999),  (Odegard et al, 2005),  (Park et al, 
1996), (Planas et al, 2009) , (Evans et al, 2010).  Patient education also included 
discussions on medication-related problems (Aslani  et al, 2010) , (Sookaneknun  et al, 
2004), (Odegard et al, 2005),  (Planas et al, 2009), lifestyle changes (Morgado et al  , 
2010), (Phumipamorn et al, 2008) , (Sookaneknun  et al, 2004), (Taylor et al, 2003), 
(Jaffray et al, 2007), (Mehuys et al, 2011), (Planas et al, 2009), (Evans et al, 2010) and 
reinforcement  of adherence (Bouvy et al , 2003), (Morgado et al  , 2010), (Sookaneknun  
et al, 2004), (Jaffray et al, 2007), (Blenkinsopp et al  , 2000), (Eussen et al, 2010).  
 
 
Patient education by telephone contact 
Telephone counselling was the principal intervention in four trials, three of which 
(Yunsheng et al, 2010), (Jarab et al, 2012), (Faulkner et al, 2000) included an initial 
inpatient consultation by a pharmacist regarding the patient’s medications, prior to 
discharge.  This was followed by structured telephone counselling by the pharmacist to 
reinforce the information.  In the fourth trial (Alsabbagh et al, 2012) there was no 
inpatient consultation prior to the telephone calls.  All subjects in the intervention group 
received education and counselling on medication adherence.  The next call took place 
within 1–2 weeks or when needed to support medication adherence. 
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Home visits by pharmacists 
In two trials (Holland et al, 2007), (Peterson et al, 2004) the intervention was delivered in 
home visits by a pharmacist.  These included education on the disease, lifestyle issues 
and compliance with therapy.  Recommendations were also made to physicians and local 
pharmacies for adherence aids. 
 
 
 
Motivational interviews 
 
In one trial (Heisler et al, 2012) adherence counselling and medication management was 
delivered by clinical pharmacists trained in behavioural counselling approaches 
(motivational interviewing). Details of training, application and implementation were 
provided to ensure principles of motivational interviews were followed.  A ‘road map’ 
was provided for the pharmacists and there was also an assessment to check reliability of 
the technique. However, the aim in this study was to improve blood pressure control by 
intensifying medication and improving adherence. In this study adherence was a 
secondary outcome, the primary outcome measure being systolic blood pressure. The 
primary care teams (primary care providers; physicians, pharmacists and nurses) were 
randomised to evaluate the real-world effectiveness of pharmacy-team interactions rather 
than just the efficacy of pharmacist interactions with patients.  Two further trials (Lau et 
al, 2010), (Jarab et al, 2012) mentioned motivational interviewing, but gave no details on 
how this component was implemented as part of the intervention and no assurance of the 
reliability of the technique.   
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Collaboration between healthcare professionals 
Collaborative care  
In seven trials (Carter et al, 2008), (Hunt et al, 2008), (Villeneuve et al, 2010), (Gwadry-
Sridhar et al, 2005), (Edworthy et al, 2007), (Obreli- Neto et al, 2011), (Carter et al, 
2009) the intervention involved collaboration between pharmacists and physicians or 
nurses, in a multidisciplinary approach.  Five (Carter et al, 2008), (Hunt et al, 2008), 
(Villeneuve et al, 2010), (Obreli- Neto et al, 2011), (Carter et al, 2009) of these trials, 
addressed suboptimal regimens and poor adherence to medication through these 
collaborations.  The other two trials (Gwadry-Sridhar et al, 2005), (Edworthy et al, 2007) 
included joint intensive multidisciplinary team programmes that provided counselling on 
medications, videos and printed material to promote adherence. 
 
 
Communication between primary and secondary care 
One trial (Calvert et al, 2012) evaluated the effect of facilitated communication between 
hospital and community pharmacists on medication adherence.  The intervention group 
received enhanced in-hospital counselling, communication of discharge medications to 
community pharmacists and physicians, and ongoing assessment of adherence by 
community pharmacists. 
 
Combined intervention 
One trial (Ho et al, 2014) described as a multifaceted intervention that lasted for 1 year 
following discharge, comprised the following: pharmacist-led medication reconciliation 
7–10 days after discharge and at 1 month via an in-person clinic visit or telephone call; 
pharmacists provided the patient’s primary care clinician and/or cardiologist with their 
contact details for questions or clarifications; and two types of voice messaging 
(educational and medication refill reminder calls).  The medication refill calls were 
synchronised to when a medication refill was due.   
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In a second trial (Lau et al, 2010) the participants received a number of interventions 
from the pharmacist which included the following: patient education and motivational 
interviewing; electronic blood pressure home monitors; home medicine review, dose 
administration aid and patient medication profile; refill reminders by SMS, telephone or 
mail. 
 
 
Use of electronic devices 
Four trials (Zilich et al, 2005), (Virijens et al, 2006), (Svarstad et al, 2009),( Mehos et al, 
2000)  used electronic devices as the main intervention.  In two trials (Zilich et al, 2005) , 
( Mehos et al, 2000) patients were provided with a fully automated self blood pressure 
monitor and were told to perform two blood pressure measurements each morning.   In 
one trial (Svarstad et al, 2009) patients were given a toolkit which included a blood 
pressure tracker and a pedometer.  In another trial (Virijens et al, 2006) patients were 
instructed on how to use a Medication Event Monitoring System (MEMS; medication 
bottles that contain a microelectronic chip that registers the date and time of every bottle 
opening).  Patients and a pharmacist jointly reviewed the electronically compiled dosing 
history, educational reminders and a beep card that reminded the patient of the dosing 
time. 
 
 
 
Additional components 
 
 
Additional components to the above interventions included written information (Zillich et 
al, 2005) (Faulkner et al, 2000), (Heisler et al,2012), (Morgado et al, 2011),(Svarstad et 
al, 2009), (Sookaneknun  et al, 2004), (Taylor et al, 2003), (Blenkinsopp et al, 
2000),(Mehos et al, 2000) ,(Park et al, 1996), (Evans et al, 2010), (Mazroui et al, 2009), 
(Phumipamorn et al, 2008), (Holland et al, 2007), (Sadik, 2005), (Murray et al, 2007), 
(Varma et al, 1999), (Yunsheng et al, 2010), (Jaffray et al, 2007), (Jarab et al,2012),    
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,providing patients with a diary, (Sookaneknun  et al, 2004),(Sadik, 2005), (Varma et al, 
1999) a pocket medication card (Calvert et al, 2012), educational material (Heisler et 
al,2012),( Calvert et al, 2012),education regarding the disease (Zillich et al, 2005),(Hunt 
etal,2007), (Mehos et al, 2000) educational group activities, (Obreli-Neto et al, 2011) 
recommending lifestyle change, (Villeneuve et al , 2010), recommendations to 
physicians, (Zillich et al, 2005), (Carter et al, 2008), (Svarstad et al, 2009), (Carter et al, 
2009), (Yunsheng et al, 2010), (Edworthy et al, 2007), telephone calls (Blenkinsopp et 
al, 2000),(Mehos et al, 2000), (Carter et al, 2009), (Evans et al, 2010), (Odegard et al 
,2005), (Lopez et al, 2006), home visits,  (Sookaneknun  et al, 2004) home medicine 
review ( Lau et al, 2010), pill box (Zillich et al, 2005), (Svarstad et al, 2009), (Yunsheng 
et al, 2010), (Calvert , 2012), (Ho et al, 2014) blisters, (Lee et al, 2006) electronic blood 
pressure home monitoring, (Heisler et al,2012), (Lau et al, 2010) and visual props and 
media videos (Gwadry-Sridhar et al, 2005), (Edworthy et al, 2007). 
 
Intervention duration 
 
The interventions were delivered on a weekly basis (Zillich et al, 2005), (Faulkner et al, 
2000), (Heisler et al, 2012), (Odegard et al, 2005), (Jarab et al, 2012), (Holland et al, 
2007), (Yunsheng et al, 2010), (Calvert et al, 2012),(Alsabbagh et al, 2012) , monthly 
basis (Obreli-Neto et al, 2011), (Lee et al, 2006),(Morgado et al, 2011), (Carter et al, 
2008),(Sookaneknun et al, 2004), (Blenkinsopp et al, 2000), (Mehos et al, 2000), (Park et 
al, 1996),(Carter et al, 2009), (Zhao et al, 2012), (Planas et al, 2009), (Evans et al, 2010), 
(Al Mazroui et al, 2009), (Phumipamorn et al, 2008), (Villeneuve et al, 2010), (Aslani et 
al, 2010), (Virjens et al, 2006), (Eussen et al, 2010), (Bouvy et al, 2003), (Murray et al, 
2007), (Varma et al, 1999), (Lopez et al, 2006), (Peterson et al, 2004), (Edworthy et al, 
2007), (Ho et al, 2014), at each prescription refill (Svarstad et al, 2009),(Mehuys et al, 
2011), (Sadik et al, 2005), arranged during the physician visit (Taylor et al, 2003), 
(Planas et al, 2009), according to pharmacist-determined patient need (Hunt et al, 2008), 
(Jaffray et al, 2007) or once over 2 days (Gwadry-Sridhar et al, 2005).  
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2.6-Assessment of outcomes 
Measurement of adherence  
Diverse indirect measures of adherence were used in the trials.  These included 
prescription refills, MEMS, pill counts and self reported adherence scaled questionnaires: 
Medication Adherence Report Scale and Morisky Scale.  Patients’ self-reported 
adherence alone or in combination with other methods of measurement was widely used 
in the 42 trials.  Thirty-two trials measured adherence by a single approach and 10 trials 
combined two adherence measures please refer to (Table 2.1 below). To distinguish 
adherence from non-adherence, consumption or refilling 80% of the prescribed 
medication doses was the widely accepted threshold among the trials (Obreli-Neto et al, 
2011),(Faulkner et al, 2000),(Heisler et al, 2012), (Lee etal, 2006),(Sookaneknun et al, 
2004),(Taylor et al, 2003),(Park et al, 1996),(Evans et al, 2010),(Villeneuve et al, 
2010),(Bouvy et al, 2003), (Gwadry-Sridhar et al , 2005),(Varma et al, 1999).  
Table 2.1 Measurement of adherence  
Indirect measures of adherence; from the 42 trials 32 trials measured adherence by a 
single adherence measure, 10 trials combined two adherence measures.   
 
 
  
Single adherence measurement  Number of trials  
Refill data Ten trials 
(Heisler et al, 2012), (Mehos et al, 2000), (Planas 
et al, 2009), (Evans et al, 2010), (Villeneuve et al, 2010), 
(Eussen et al, 2010), (Yunsheng et al, 2010),(Alsabbagh et al, 
2012), (Ho et al, 2014), (Sookaneknun et al, 2004)
 
Self report questionnaires Seven trials
(Taylor et al, 2003),(Almazroui et al, 2009),
 
(Odegard et al, 2005), (Sadik et al, 2005),(Peterson et al, 2004), 
(Jaffray et al, 2007), (Edworthy et al, 2007)
 
Morisky scaled questionnaire Six trials (
Zillich et al, 2005),(Morgado et al, 2011), (Hunt 
et al, 2008), (Carter et al, 2009), (Zhao et al, 2012), (Jarab et al, 
2012)
 
Pill counts Five trials 
(Lee et al, 2006), (Park et al, 1996),(Carter et al, 
2008),(Phumipamorn et al, 2008), (Lopez et al, 2006) 
MEMS (Medication Event Monitoring 
System) 
Two trials 
(Virjens et al, 2006), (Bouvy et al, 2003)
 
The Horne’s Medication Adherence Two trials
(Holland et al, 2007), (Aslani et al, 2010)
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Report Scale (MARS)  
Combination of adherence measurement   
Refill data combined with self reported 
questionnaires 
Four trials 
(Svarstad et al, 2009), (Mehuys et al, 2011), 
(Murray et al, 2007), (Varma et al, 1999)
 
Refill data combined with the Morisky 
scale 
Two trials 
(Obreli-Neto et al, 2011), (Calvert et al, 2012)
 
Refill data combined with MEMS One trial 
(Gwadry-Sridhar et al, 2005)
 
Refill data combined with MARS One trial 
(Blenkinsopp et al, 2000)
 
Refill data combined with pill counts One trial 
(Faulkner et al, 2000)
 
Morisky Scale in addition to two scales 
originally developed in Australia the 
Tools for Adherence Behaviour 
Screening (TABS) and the medication 
refill data (MedsIndex score). 
One trial 
(Lau et al, 2010)
 
 
 
For the Morisky scale, Morgado et al, 2010, Carter et al, 2009 and Calvert et al, 2012 
used a 5 item scale derived from the 4 item scale. Hunt et al, 2008, Zilich et al, 2005, 
Zhao et al, 2012, Lau et al, 2010 and Jarab et al, 2012 all used the 4 item scale.  
Moreover, Obreli-Neto, 2011 used the 4 item Morisky -Green test translated into 
Portuguese.  
 
Impact of interventions on adherence 
The review aimed to assess the effect of pharmacist service intervention on adherence.  
Twenty six trials (Lee et al, 2006), (Morgado et al, 2011) ,(Carter et al, 2008), (Zillich et 
al, 2005) ,(Svarstad et al, 2009), ( Lau et al, 2010) ,(Sookaneknun  et al, 2004) ,(Taylor et 
al, 2003), (Blenkinsopp et al, 2000) ,(Park et al, 1996) ,(Obreli-Neto et al, 2011), 
(Calvert et al, 2012), (Zhao et al, 2012), (Mazroui et al, 2009), (Phumipamorn et al, 
2008),(Vrijens et al, 2006) ,(Eussen et al, 2010) , (Bouvy et al, 2003), (Sadik, 
2005),(Murray et al, 2007),(Varma et al, 1999), (Lopez et al, 2006) (Edworthy et al, 
2007), (Faulkner et al, 2000),(Jarab et al, 2012),(Ho et al,2014) showed a statistically 
significant improvement in adherence to cardiovascular medication.  Across the 42 
studies a statistically significant improvement in adherence of up to 35% was reported.  
The results indicate that face-to-face patient education by a pharmacist improved 
adherence in 15/21 studies, suggesting education could have a significant effect on 
adherence (refer to Table 2.2 below). 
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Electronic devices showed success in enhancing adherence in three of four studies.  
These included the integration of a home automatic blood pressure monitor, the use of 
electronic reminders (beep card) and an electronic blood pressure tracker.  In all these 
trials pharmacists also provided tailored educational services and patient follow-up.  One 
study (Heisler et al, 2012) examined the use of motivational interviews by pharmacists, 
although it did not show significant results.  Details on the training of the pharmacists and 
the delivery and content of motivational interviews were provided.  The authors report 
that high rates of treatment intensification and medication changes occurred in the control 
group, leading to improvements in the studied outcomes among the controls.  
 
 
Telephone calls with patient education and advice improved adherence in two of the four 
trials that examined this type of intervention.  Two other trials (Lau et al, 2010), (Ho et 
al, 2014) tested a combination of interventions to improve adherence, which also 
included medication refill reminders by telephone, and showed significant results.  Three 
of the seven interventions that evaluated a collaborative care approach to improve 
adherence had statistically significant results.  One trial (Calvert et al, 2012) examined 
the impact of communication between hospital and community pharmacies and showed 
significant results on adherence.  Home visits by pharmacists did not show significant 
results in improving adherence to cardiovascular medication.   In one trial (Holland et al, 
2007) some possible reasons were provided by the authors.  These reasons include; that 
the intervention was brief and/or may have been too late in the disease course to evoke a 
change in behaviour.  Also the pharmacists were not specialists in the disease studied. 
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Table 2.2 Interventions and their mode of delivery  
    
Intervention  Trials Result on 
adherence 
Result on 
outcomes 
1-Patient 
education by 
pharmacist 
Lee et al  , 2006,  Bouvy et al , 2003, Morgado et al  
, 2010, Al Mazroui et al  , 2009, Sadik et al, 2005, 
Alsani et al  , 2010, Murray et al, 2007, Mehuys et 
al, 2011, Taylor et al  , 2003, Jaffray et al, 2007, 
Blenkinsopp et al  , 2000, Sookaneknun et al  , 2004, 
Phumipamorn et al, 2008 , Varma et al, 1999,  
Odegard et al, 2005,  Park et al, 1996,  Lopez et al, 
2006,  Zhao et al  , 2011,  Planas et al, 2009 , Evans 
et al, 2010,  Eussen et al, 2010 
15 trials 
(21) 
 significant  
16 trials  
(21) 
significant 
2-Telephone 
contact 
Yunsheng et al, 2010,  Faulkner et al, 2000, Jarab et 
al, 2012, Alsabbagh et al, 2012  
2(4) trials  
significant  
 
2 (3) trials  
significant  
 
3-Use of 
electronic 
device 
 Zilich et al , 2005 (SMBP), Svarstad et al , 2009 
(pedometer, blood pressure tracker), Virijens et al, 
2006* (Beep card), Mehos et al  , 2000 (SMBP) 
3(4) trials  
significant 
 
3 (3) trials  
significant 
4-Home visit Holland et al, 2007,  Peterson et al , 2004 
 
0 (2) trials  
non 
significant 
1 (2) trials  
significant 
5-
Collaborative 
care 
Carter et al  , 2008, Hunt et al  , 2008, Villeneuve et 
al, 2010, Gwadry-Sridhar et al  , 2005, Edworthy et 
al, 2007, Obreli Neto et al  ,  2011, Carter et al  , 
2009. 
3(7) trials  
significant  
 
4 (7) trials  
significant 
 
6-
Motivational 
interviews 
Heisler et al, 2012 1(1) trials  
non 
significant  
 
0 (1) trials  
non 
significant 
 
7Communica
ti-on between 
primary and 
secondary 
care 
Calvert et al, 2012*  
 
 
 
1(1) trials  
significant 
 
 
 
0 (0) trials   
 
Combined 
interventions  
Ho et al, 2014 , Lau et al, 2010 
 
2(2) trials  
significant  
 
1(2) trials  
significant  
 Notes  
Total 
 26/42 trials 
 
Total  
27/ 39trials *Trials that did not evaluate clinical outcomes. 
Statistical significance at P value 0.05. 
SBPM: self blood pressure monitor. 
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Effectiveness of interventions on outcomes of cardiovascular diseases 
 
Studied outcomes included blood pressure control, haemoglobin A1c and/or fasting 
plasma glucose, lipid profiles and low-density lipoprotein cholesterol.  Other outcomes 
were reduction in 10-year Framingham risk score, costs and quality of life, in addition to 
rehospitalisation, mortality and patient satisfaction with pharmacy services.  Thirty nine 
trials evaluated the effect of pharmacy service interventions on outcomes of the diseases.  
Twenty seven trials had statistically significant results.  The diseases studied in primary 
prevention were hypertension, diabetes and dyslipidemia.  From the 17 studies that 
studied hypertension 16/17 (Lee et al, 2006), (Morgado et al, 2011) ,(Carter et al, 2008), 
(Hunt et al, 2008), (Zillich et al, 2005) ,(Svarstad et al, 2009), ( Lau et al, 2010) 
(Sookaneknun  et al, 2004) ,(Taylor et al, 2003), (Blenkinsopp et al, 2000) ,(Mehos et al, 
2000) ,(Park et al, 1996) ,(Obreli-Neto et al, 2011),( Calvert et al, 2012) ,(Carter et al, 
2009), (Zhao et al, 2012),(Planas et al, 2009) showed significant results and improvement 
in cardiovascular risk factors. For patients with diabetes 6/10 studies (Mazroui et al, 
2009), (Taylor et al, 2003), (Mehuys, 2011) , (Obreli-Neto et al, 2011), (Planas et al, 
2009), (Jarab et al, 2012) improved glycaemia control. Of the 6 studies in patients with 
dyslipidemia four (Lee et al, 2006), (Aslani  et al, 2010) ,(Taylor et al, 2003) , (Eussen et 
al, 2010) showed improved lipid profiles (Please refer to table 2.2  above). 
 
 
The diseases studied in secondary prevention were heart failure and coronary heart 
disease.  In heart failure 4/7 trials reported significant results (Sadik, 2005), (Murray et 
al, 2007),(Varma et al, 1999), (Lopez et al, 2006) in improving clinical outcomes 
(mortality, rehospitalisation and quality of life).  In CHD, two of the eight trials (Peterson 
et al, 2004), (Faulkner et al, 2000) achieved significant results on clinical outcomes.   
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2.7-Evaluation of the interventions  
To assess the strength of the evidence a number of checklists for critical appraisal of 
randomised control trials are available.  These include Critical Appraisal Skills 
Programme (CASP) and The Scottish Intercollegiate Guidelines Network checklist 
(SIGN).  The SIGN 2012 checklist was selected to appraise the trials in this review 
because it was found easy to follow and served as a useful tool to evaluate the 
methodology of the trials.  Overall, the follow up period in the trials ranged from 3 
months (Zillich et al, 2005) to 36 months (Obreli-Neto et al, 2011); however, in the 
majority of the studies the follow up period was either 6 months or 12 months.   
 
Regarding the sample size this ranged from a small sample size of 30 patients (Faulkner 
et al, 2000) to a large sample size of 4100 patients (Heisler et al, 2012). For 
randomisation; computer generated random sequence was the most common method of 
randomisation and was used by 15 trials (Lee et al, 2006), (Morgado et al, 2011), (Bouvy 
et al, 2003), (Hunt etal,2007) ,( Holland et al, 2007), (Peterson et al, 2004), (Murray et 
al, 2007), (Svarstad et al, 2009), (Jaffray et al, 2007), (Lopez et al, 2006), (Faulkner et al, 
2000), (Calvert , 2012), ( Zhao et al, 2012) , (Planas et al, 2009), (Eussen et al, 2010).  A 
table of random numbers was used in 5 trials (Carter et al, 2008), (Mehuys, 2011), 
(Carter et al, 2009), (Heisler et al, 2012), (Evans et al, 2010) and a randomised block 
design in 6 trials (Zillich et al, 2005), (Villeneuve et al, 2010),(Ho et al, 2013 ),(Gwadry-
Sridhar et al, 2005), (Odegard et al ,2005),(Alsabbagh et al, 2012).  In 3 trials the 
randomisation was not clear (Aslani  et al, 2010), (Taylor et al, 2003),(Park et al, 1996). 
Other randomisation methods used among the trials included randomisation by a 
statistician (Yunsheng et al, 2010), restricted randomisation (Mazroui et al, 2009), 
minimisation method (Sadik, 2005),(Varma et al, 1999),(Jarab et al, 2012), sealed 
opaque envelope technique (Lau et al, 2010), drawing a number from a container 
(Phumipamorn et al, 2008), simple randomisation (Sookaneknun  et al, 2004), cluster 
randomisation (Blenkinsopp et al, 2000), coin flip (Edworthy et al, 2007),  
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deck of cards (Mehos et al, 2000) , stratified random sampling(Obreli-Neto et al, 2011) 
and an open label study randomisation of two districts (Vrijens et al, 2006).  Thus 
according to SIGN checklist for RCTs in 5/42 (Lau et al, 2010), (Edworthy et al, 2007), 
(Phumipamorn et al, 2008), (Mehos et al, 2000), (Sookaneknun et al, 2004) trials the 
randomisation method was poor and in 3/42 trials the randomisation method was not 
specified (Aslani et al, 2010), (Taylor et al, 2003), (Park et al, 1996).  Regarding an 
adequate concealment method in the 42 trials included in the review, only 11 trials 
reported the allocation concealment (Lee et al, 2006), (Morgado et al, 2011), ( Holland et 
al, 2007),( Gwadry-Sridhar et al, 2005), (Murray et al, 2007),( Lau et al, 2010) ,(Calvert , 
2012), (Zhao et al, 2012), (Evans et al, 2010), (Heisler et al, 2012), (Ho et al, 2014).  
Concealment was not clear in the remaining 31 trials.  According to SIGN guidelines this 
could lead to an overestimation of the effect of the intervention in the trials, where 
concealment was not clearly mentioned.   
 
Due to the nature of the intervention blinding was not possible in 5 trials (Lee et al, 
2006), (Zillich et al, 2005), (Vrijens et al, 2006), (Evans et al, 2010),(Alsabbagh et al, 
2012), 3 trials were single blinded (Hunt etal,2007) ,(Park et al, 1996), (Lopez et al, 
2006), blinding was not clear in 19 trials (Bouvy et al, 2003), (Yunsheng et al, 2010), 
(Mazroui et al, 2009), (Holland et al, 2007), (Villeneuve et al , 2010), (Aslani  et al, 
2010), (Sookaneknun  et al, 2004) ,(Taylor et al, 2003), (Edworthy et al, 2007), (Varma 
et al, 1999), (Odegard et al ,2005), (Mehos et al, 2000), (Mehuys, 2011), (Faulkner et al, 
2000), (Zhao et al, 2012), (Planas et al, 2009), (Heisler et al,2012),(Ho et al, 2013),(Jarab 
et al, 2012).  Blinding included outcome assessors in 7 trials  (Sadik, 2005), (Gwadry-
Sridhar et al, 2005), (Svarstad et al, 2009), (Jaffray et al, 2007), (Blenkinsopp et al, 
2000), (Carter et al, 2009), (Eussen et al, 2010) , researchers in 3 trials (Carter et al, 
2008), (Lau et al, 2010), (Obreli-Neto et al, 2011), general practitioners in 2 trials 
(Peterson et al, 2004), (Blenkinsopp et al, 2000), also in 2 trials pharmacists (Gwadry-
Sridhar et al, 2005), (Calvert et al, 2012), physicians (Gwadry-Sridhar et al, 2005),  
(Phumipamorn et al, 2008) and nurses (Phumipamorn et al, 2008), (Morgado et al, 2011)  
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and interviewers in one trial (Murray et al, 2007).  The trials that reported blinding were 
all single blinded, there were no double blinded or even triple blinded trials.  The higher 
the level of blinding the lower the risk of bias in the study; therefore, a low risk of bias 
cannot be ruled out among the trials included in this review.  In 17 trials (Lee et al, 
2006), (Morgado et al, 2011), (Carter et al, 2008), (Hunt etal,2007), (Holland et al, 
2007), (Gwadry-Sridhar et al, 2005), (Svarstad et al, 2009), (Vrijens et al, 2006), 
(Sookaneknun  et al, 2004), (Jaffray et al, 2007), (Edworthy et al, 2007),(Park et al, 
1996), (Mehuys, 2011), (Faulkner et al, 2000), (Carter et al, 2009), (Heisler et al,2012), 
(Evans et al, 2010) all patients were included in the final analysis (intention-to-treat 
analysis); intention-to-treat was not clear in 5 trials (Mazroui et al, 2009), (Zillich et al, 
2005), (Sadik, 2005), (Peterson et al, 2004), (Lopez et al, 2006).  The results were 
adjusted in one trial (Villeneuve et a, 2010), a sensitivity analysis was used in another 
(Murray et al, 2007) and generalised estimating equations in a third (Odegard et al, 
2005). All patients were included in the final analysis for the remaining of the 42 trials.  
Therefore, for less than half of the trials in this review analysis was not on an ‘intention 
to treat’ basis.   
 
According to SIGN guidelines 2012 the number of patients that drop out of a study 
should give concern if this very high.  Conventionally, a 20% drop out rate is regarded as 
acceptable.  When examining patient withdrawal rates; dropout rates among the 42 trials 
ranged from a low dropout rate below 10% in 21 trials (Lee et al, 2006), (Morgado et al, 
2011), (Carter et al, 2008), (Mazroui et al, 2009), (Zillich et al, 2005), (Holland et al, 
2007) ,(Sadik, 2005), (Svarstad et al, 2009), (Lau et al, 2010) ,(Sookaneknun  et al, 2004) 
, (Blenkinsopp et al, 2000), (Zhao et al, 2012), (Phumipamorn et al, 2008) ,(Mehuys, 
2011) , (Obreli-Neto et al, 2011), (Villeneuve et al , 2010),(Vrijens et al, 2006), (Jaffray 
et al, 2007),(Edworthy et al, 2007),(Ho et al, 2014),(Jarab et al, 2012).  
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An acceptable below 20% dropout rate in 14 trials (Taylor et al, 2003), (Mehos et al, 
2000) ,(Park et al, 1996), (Planas et al, 2009),  (Evans et al, 2010) (Odegard et al ,2005), 
(Heisler et al,2012) , (Eussen et al, 2010),(Gwadry-Sridhar et al, 2005),(Murray et al, 
2007), (Lopez et al, 2006) (Yunsheng et al, 2010),(Peterson et al, 2004), (Calvert , 2012) 
and a high dropout rate above 20% in 6 trials (Bouvy et al, 2003), (Hunt etal,2007), 
(Aslani  et al, 2010), (Varma et al, 1999) ,(Planas et al, 2009),(Alsabbagh et al, 2012). In 
one trial (Faulkner et al, 2000)  no patients were lost to follow-up.   
 
Limitations reported by the trials included; confined population and /or trial setting (Lee 
et al, 2006), (Carter et al, 2008),(Carter et al, 2009), (Mazroui et al, 2009), 
(Phumipamorn et al, 2008) ,(Taylor et al, 2003), (Obreli-Neto et al, 2011), (Taylor et al, 
2003),(Sadik, 2005),( Murray et al, 2007), (Yunsheng et al, 2010), (Evans et al, 2010), 
high patient withdrawal rate and/or limited sample size (Bouvy et al, 2003), (Hunt 
etal,2007), (Gwadry-Sridhar et al, 2005), (Aslani  et al, 2010) (Lopez et al, 2006), 
(Faulkner et al, 2000), (Calvert , 2012) ,(Planas et al, 2009), contamination (Morgado et 
al, 2011), (Sookaneknun  et al, 2004) ,(Edworthy et al, 2007), (Odegard et al ,2005), 
(Park et al, 1996), (Eussen et al, 2010) , selection bias (Zillich et al, 2005) , ( Lau et al, 
2010), (Blenkinsopp et al, 2000) ,(Planas et al, 2009),  (Heisler et al,2012),(Villeneuve et 
al, 2010), ((Vrijens et al, 2006) ,(Varma et al, 1999), (Jaffray et al, 2007), no true control 
(Zillich et al, 2005),(Peterson et al, 2004),(Svarstad et al, 2009) and measurement of 
outcomes (Peterson et al, 2004), (Mehuys, 2011),( Zhao et al, 2012).   
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The overall assessment of the trials’ was performed by rating the methodological quality 
following the criteria mentioned above.  This showed how well each study was done to 
minimise the risk of bias or confounding.  All or most of the criteria were fulfilled in 13 
trials (Lee et al, 2006), (Morgado et al, 2011) ,(Carter et al, 2008),(Svarstad et al, 2009), 
(Lau et al, 2010)  (Blenkinsopp et al, 2000) , (Heisler et al,2012), (Eussen et al, 2010) ,( 
Holland et al, 2007),(Gwadry-Sridhar et al, 2005),(Murray et al, 2007), (Jaffray et al, 
2007),(Ho et al, 2014). In 21 trials, either  not all of the criteria were fulfilled or they 
were not adequately described, but it is considered that this would be unlikely to alter the 
conclusions of these trials (Hunt et al, 2008), (Zillich et al, 2005) ,(Park et al, 1996) 
,(Obreli-Neto et al, 2011) , ( Calvert et al, 2012) ,(Carter et al, 2009), ( Zhao et al, 2012) , 
(Evans et al, 2010), (Mazroui et al, 2009), (Phumipamorn et al, 2008) ,(Odegard et al 
,2005), (Mehuys et al, 2011) , (Villeneuve et al  , 2010), (Vrijens et al, 2006), (Bouvy et 
al, 2003), (Sadik et al, 2005), (Varma et al, 1999), (Lopez et al, 2006) (Yunsheng et al, 
2010),( Edworthy et al, 2007),(Alsabbagh et al, 2012). In 8 trials, few criteria were 
fulfilled, and this may impact on the conclusions (Peterson et al, 2004), (Aslani  et al, 
2010), (Sookaneknun  et al, 2004) ,(Taylor et al, 2003), ( Mehos et al, 2000), (Faulkner 
et al, 2000),(Planas et al, 2009), (Jarab et al, 2012).  Thus, for this review, based on 
SIGN guidelines applied to forty two trials; eight trials were thought to have an altered 
conclusion because only few criteria were fulfilled (refer to Appendix 10).  Therefore, it 
is unlikely that, different conclusions would have been found or that different 
recommendations would have emerged from this review. 
 
2.8- Discussion  
This review aimed to assess the effect of pharmacist-led interventions on adherence to 
cardiovascular medications.  Forty two studies were identified, of which 26 had a 
statistically significant and positive impact on adherence.  Interpretation was complex 
due to the heterogeneity and multiplicity of the components.   
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Furthermore, it is important to distinguish between the types of non-adherence 
(intentional, unintentional) because research has shown the underlying causes of these 
two types of non adherence are very different and this is important in designing 
appropriate interventions (Clifford et al, 2010).  Thus the difference in the effect of these 
interventions could depend on the patients’ beliefs and intentions with medication taking.  
Therefore, interventions such as use of electronic devices as reminders and prompts could 
target and be effective in patients with unintentional non-adherence (Furniss et al, 2014), 
whilst interventions involving patient education and counselling may be more effective in 
patients who are intentionally non adherent.  The results show that face-to-face patient 
counselling by a pharmacist and electronic interventions could be effective in improving 
adherence.  However, these interventions also involved other components.  Evidence 
from studies of other diseases revealed that in-person pharmacist and electronic 
interventions significantly improved adherence to medication (Velligan et al, 2013), 
(Hiligsmann et al, 2013). Motivational strategies are increasingly used in healthcare to 
promote behaviour change due to the need to focus on addressing the rising prevalence of 
chronic disease. Motivational strategies and behavioural support have also been shown to 
enhance adherence to medication (Schroeder, 2005), (Viswanathan et al, 2012).  In this 
review only one trial studied the use of motivational interviews, by pharmacists, to 
improve adherence and outcomes and showed no significant results.  Furthermore, two 
trials (Lau et al, 2010), (Jarab et al, 2012) mentioned the use of motivational interviews 
in counselling session by the pharmacist, but did not give further details on the reliability 
of the technique.    
 
 
In their reviews, Thompson et al, 2011 and Dalem et al, 2012 addressed the fact that 
behavioural interventions are effective in improving adherence.   However, they did not 
focus on the pharmacists’ role.   For this reason, further evidence is needed to establish if 
and how motivational counselling in the pharmacy setting can lead to improvements in 
adherence.  A telephone call or a reminder by a pharmacist has been found to be an 
effective approach to improve medication adherence in other diseases and chronic  
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conditions (Barber et al, 2004), (Elliot et al, 2008), (Al-Jumah, 2012), (Wu et al, 2006). 
Services in the UK delivered by community pharmacists and include face to face patient 
education and telephone encounters, such as the New Medicine Service, provide strong 
evidence that a pharmacist-led approach, focusing on patients’ problems and concern can 
significantly improve adherence in particular with newly prescribed medicines (Elliot et 
al, 2014).  Furthermore, a recent UK randomised control trial (Lyons et al, 2016) of a 
pharmacist-led telephone based intervention showed statistically significant results on 
improving adherence P= 0.01.  This intervention was designed to improve medication 
adherence, in patients with diabetes and/or hyperlipidaemia, using a mail-order 
pharmacy.  The intervention involved two telephone pharmacist consultations 4-6 weeks 
apart, a written summary of the discussion with the patient and a medicines reminder 
chart; both posted to patients’ after first encounter.  The authors report that although a 
mail-order context has some unique characteristics, the intervention is transferable to 
different settings and pharmacists, due to parallels with existing large successful, national 
services such as the NMS (Lyons et al, 2016).   
 
 
In the review by Cutrona et al, 2010 which reviewed studies focusing on cardiovascular 
diseases, phone calls showed low success (38%).  In our review, four of six trials that 
evaluated this method had statistically significant results.  Therefore, the use of telephone 
calls and SMS to improve adherence could be an effective approach.  Interventions 
involving home visits by pharmacists have reported increased adherence to prescribed 
drugs in an older population (Lowe et al, 2000), (Al-Rashed et al, 2002).  Other studies, 
in contrast, which included a domiciliary assessment by a community pharmacist, have 
found no effect on adherence (Nazareth et al, 2001).   Studies in this review were not 
sufficient to provide evident conclusions.  Although interventions in a hospital setting 
had more significant results, four of these trials were conducted in military hospitals (Lee 
et al, 2006),(Zhao et al, 2012),(Al Mazroui et al, 2009),(Ho et al, 2014)  in which 
financial barriers to adherence are removed and patients’ attendance of appointments is  
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high.  Therefore, the results of these studies had limited generalisability and external 
validity.  In the review by Cutrona et al, 2010 the results demonstrate that in-person 
interventions at hospital discharge were more effective (67%) than clinic interventions 
(47%) and in-person pharmacist interventions were effective when held in a pharmacy 
(83%) and less effective in clinics (38%).  Patients’ self-reported adherence alone or in 
combination with other methods of measurement were widely used in the 42 trials.  This 
is as recommended by the National Institute of Health and Care Excellence 2009 
guidelines, which identified that while other types of measures are useful for clinical 
trials of new drugs; self-report is an appropriate tool for clinical practice.  A threshold of 
80% to determine adherence from non adherence was accepted among the trials. This 
finding is similar to other observational studies measuring adherence (Chapman et al, 
2005), (Blackburn et al, 2005), (Pittman et al, 2011), (Bramely et al, 2006).   
 
 
A study by Wu et al, 2009 showed a positive relationship between level of medication 
adherence and event-free survival in patients with heart failure.  The study found that 
patients who take 88% of their prescribed medication doses and on 88% of days take the 
correct dose experienced longer event-free survival than patients who were less adherent.   
Moreover, in an article by Ho et al, 2009 the authors reported an analysis that suggests 
that there continues to be reductions in clinical outcomes with adherence levels beyond 
80% (eg, 80–100%), which suggests that the optimal level of adherence may be higher 
than current cutoffs. While 80% is generally accepted, there are a few studies which 
examine levels of adherence against outcomes over a period of time.  ‘Can the 
interventions, in the reviewed studies, be adapted to clinical practice?’ ‘What would be 
features of an intervention to improve adherence?’ These questions should be addressed 
with caution.  The interventions were complex and time intensive as concluded in 
previous reviews (Evans et al, 2011).  In addition, a wide variety of approaches have 
been employed in the pharmacy interventions.  The interventions were conducted in 
different countries with diverse health systems which made comparison difficult.  Factors 
that could contribute to non-adherence for example living environments, 
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 access to health care, financial resources, costs of medication would differ across 
settings. Thus interventions targeting non-adherence should also differ reflecting these 
factors.  All the interventions included a range of multiple components underlining a 
belief that a single focus is less likely to be effective.  Electronic devices did improve 
adherence, however, there is the possibility of the Hawthorne effect.  Face-to-face patient 
education by a pharmacist and possibly telephone counselling can be effective.  This 
review has several limitations.  There was a marked difference between the studies in 
their methodology, adherence measurement and duration of follow-up.  Studies were 
included from 1990 to 2013.  Definition of adherence was different in the studies 
conducted in the 1990s from those conducted in the 2000s.  Moreover, some trials only 
published their methodology; therefore these trials were excluded because no results were 
available.  Descriptive, observational studies and studies published in other languages 
were also not included.  The strengths of the review were that only randomised control 
trials were included and that interventions were examined in different settings, with a 
focus on pharmacist interventions only. 
 
2.9-Conclusions  
Evidence-based data for pharmacy services remain weak, but studies have shown that 
pharmacists can have an impact through patient education and telephone counselling. 
Behavioural interventions delivered by pharmacists could have a positive effect but 
further evidence is needed.  Self-reported adherence was the most widely used measure.  
The acceptable threshold remains at 80% among the cardiac population.  Personal contact 
or counselling by a pharmacist can be an effective method in enhancing adherence, but 
the frequency of contact to make the intervention more adaptable to practice needs 
further examination.  Finally, more research is needed to evaluate the continuity of care 
in primary and secondary settings and to promote links between hospital, community 
pharmacists and other healthcare professionals. 
 
End of Chapter Two 
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Chapter three will discuss a literature search; to determine effective roles of community 
pharmacists in the UK and whether a community pharmacy intervention could be 
incorporated into these services.  This was important before designing an intervention for 
a study, to establish feasibility and workability.   
3.1-Introduction  
Over the past four decades there has been a movement for pharmacy practice away from 
its original focus on dispensing toward focus on patient care.  The role of the pharmacist 
has advanced from that of a compounder and supplier of pharmaceutical products 
towards that of a provider of services and information and ultimately that of a provider of 
patient care (WHO, 2006).  The new approach has been given the name pharmaceutical 
care.  The most generally accepted definition of this new approach is: 
“Pharmaceutical care is the responsible provision of drug therapy for the purpose of 
achieving definite outcomes that improve a patient’s quality of life”(Hepler and Strand, 
1990). 
 
 
In adopting this definition in 1998, the International Pharmaceutical Federation (FIP) 
added one significant amendment: “achieving definite outcomes that improve or maintain 
a patient’s quality of life” (WHO, 2006).  There is a worldwide increasing recognition 
that community pharmacy can make a significant contribution to public health (Pharmacy 
and Public Health Forum report 2014).  This activity has its origins in the traditional 
advisory role of the pharmacist, which declined following the establishment of the 
National Health Service (NHS) in 1948, but has more recently been promoted following 
ministerial intervention since 1981 (Anderson 2007).  
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These so-called pharmacy "extended roles" can be seen as a return to the "traditional" 
role of the community pharmacist before the introduction of the welfare state, and an 
attempt to draw the pharmacist out of the dispensary and back in touch with the public.  
“Pharmacists should move from behind the counter and start serving the public by 
providing care instead of pills only.  There is no future in the mere act of dispensing. 
That activity can and will be taken over by the internet, machines, and/or hardly trained 
technicians.  The fact that pharmacists have an academic training and act as health care 
professionals puts a burden upon them to better serve the community than they currently 
do.” (Storpirts, 2012)  
 
The role of the pharmacist and the retail of medicines 
 
The role of the pharmacist was transformed alongside the transformation in the retailing 
of medicines.  The pharmacist changed from being the maker and supplier of medicines, 
to the supplier of manufactured medicines with information about their use.  The twenty 
first century already shows the signs of providing equally radical change (Anderson 
2007).  When the scale of production of medicines evolved from individual compounding 
to industrial mass production, the distance between pharmacist and patient contact 
increased, as shown in figure 3.1:   
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Figure 3.1 The shift from patient to manufacturer (Anderson 2008) 
Adapted from Anderson S. (2008) From "Bespoke" to "Off-the-Peg": Community Pharmacists and the 
Retailing of Medicines in Great Britain 1900 to 1970 Pharmacy in History, Vol. 50, No. 2, pp. 43-69 
 
 
 
 
 
At the beginning of the twentieth century it was still common for families to rely heavily 
on home remedies made to their own formula.  People would present scraps of paper to 
the local chemist asking for a few pennies' worth of particular ingredients.  The core of 
the chemist business was counter prescribing through the formulation of the Nostrums 
(the chemists’ secret remedies).  These Nostrums continued into the 1960’s and largely 
disappeared in 1970s.  Machinery to mass-produce medicines was developed in the later 
decades of the nineteenth century.  Following the mass-marketing of the sulphonamides 
in the late 1930s the possibility of mass-producing large numbers of effective drugs 
became a reality (Anderson, 2008).  By the 1950s and 1960s wholesalers had developed 
more compact products.  By the 1970s the number of prescriptions for liquid medicines 
had greatly declined and the vast majority of drugs being prescribed were then available 
as solid dose medicines for oral use, mainly tablets and capsules (Anderson 2008). 
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Table 3.1 key events in the historical development of community pharmacy and public 
health (Anderson, 2007)  
Table adapted from Anderson S. (2007) Community pharmacy and public health in Great Britian1936 to 
2006:how a phoenix rose from the ashes J Epidemiol Community Health ;61:844–848. 
 
Year  Policy context  Pharmacy initiative  Implications for 
pharmacy 
1948 Introduction of NHS  Community 
pharmacists become 
invisible 
1970  Conference on role of 
pharmacist in health 
promotion 
1978 working party 
on future of 
community 
Pharmacy 
 
Health education an 
important role 
1981 Ministerial statement at British 
Pharmaceutical Conference 
 Future of 
community 
pharmacy in doubt 
1982 
1986 
 Ask your pharmacist 
campaign  
Pharmacy: a report to 
the Nuffield 
Foundation  
 
Launch of Health in 
the High Street 
Raised public 
awareness of the 
role of pharmacist 
Pharmacy 
considered capable 
of further 
development. 
First national 
distribution of 
health education 
leaflets 
through pharmacies 
1987 Promoting better health  
 
Programme for 
improving primary 
care 
Support for 
pharmacies to 
display health 
education 
and promotion 
material 
1989  Pharmacy Healthcare 
re launched 
First government 
funding for 
pharmacy health 
promotion scheme 
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1990 Acheson Report on 
public health 
  
1991  Barnet Health 
Scheme launched 
Training to develop 
pharmacists’ 
knowledge and 
skills 
in health promotion 
1992 Health of the Nation  Pharmaceutical care 
report 
Proposes range of 
extended roles for 
pharmacists 
1996  Pharmacy In A New 
Age 
Health promotion 
considered second 
most important 
role to be expanded 
1998 Our Healthier Nation  Related to England 
only 
Led to review of 
pharmacy-related 
evidence 
2001 Chief Medical Officer’s report 
on public health workforce 
 Identifies different 
roles in public 
health for different 
members of the 
workforce 
2002  The Right Medicine Agenda for 
modernising and 
strengthening the role 
of pharmacists to 
deliver improved 
services to the 
public and patients 
Significant 
developments in 
community based 
pharmaceutical care, 
and in the role of 
pharmacists and 
pharmacies across 
Scotland 
2003 A Vision for Pharmacy in the 
New NHS  
  
 
2004 Choosing health white paper Programme for 
improving public 
health 
Substantial 
reference to 
pharmacy 
2005 Choosing health through 
Pharmacy 
Resolution by 
Council of Royal 
Pharmaceutical 
Society 
Pharmacy’s public 
health role to be 
increased still 
Further 
2006 Our health, Our care, Our say: a 
new direction for community 
services 
 Highlighted that 
community 
pharmacies in the 
UK are easily 
accessible and their 
location in the heart 
to deliver public 
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health initiatives 
2008 The Department of Health report 
white paper Pharmacy in 
England Building on Strengths  
Delivering the Future 
 Set out the 
government’s 
programme for a 
21st-century 
pharmaceutical 
service 
2010 The Department of Health White 
Paper Healthy lives, Healthy 
People  
 
Emphasised on the 
role of Healthy Living 
Pharmacies (HLPs) 
Outlined a radical 
shift in tackling 
public health 
challenges 
2011  The Pharmacy and 
Public Health Forum 
was established 
 
The development, 
implementation and 
evaluation of public 
health practice for 
pharmacy   
2013  Nuffield trust report Now 
Or Never Shaping pharmacy for 
The future 
A commission on 
future  
models of pharmacy 
care 
Visions for 
pharmacy, new 
models of practice, 
future role of 
pharmacy in English 
NHS 
2014 Five Year Forward View for 
NHS England  
The new models of 
health care including 
the new model of 
primary care 
Pharmacy to be 
integrated in local 
care providers’ 
networks 
2014  Nuffield trust report Now more 
Than ever.  
An independent 
assessment of 
progress made in 
implementing the 
recommendations of 
Now or Never report 
A call to integrate 
pharmacy fully into 
the models outlined 
in the ‘Five Year 
Forward View’ 
2015  The future of primary care: 
creating teams for tomorrow.  
Pharmacists to 
work in GP practices 
as well as the 
traditional role of the 
pharmacist operating 
from premises in the 
community. 
Wider use should be 
made of community 
pharmacists and 
pharmacy support 
staff in managing 
minor illness and 
advising people 
about optimising 
their medicines. 
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Identification of the role of pharmacy in public health 
 
With the introduction of NHS the workload of most community pharmacists increased.  
In 1937, 65 million doctors’ prescriptions were dispensed from 13 000 pharmacies; by 
1950, the figure had reached nearly 250 million.  Most prescriptions needed to be made 
up individually, and many pharmacists spent much of the working day dispensing, in 
contrast to, the 1930s where the pharmacists spent most of the time dealing with 
customers and providing advice (Anderson 2007), (FIP, 2012).  The Vaughan 
Intervention in 1981 addressed the possibility of the future of community pharmacy in 
public health with a focus on pharmacist role as experts in medicines.  Its draft 
advertisements carried the slogan ‘‘ask your pharmacist: you’ll get the help you need’’ 
with the recognition that community pharmaceutical services are essential part of primary 
health care (Anderson 2007).  Furthermore, in 1986 Pharmacy: a report to the Nuffield 
Foundation was published; of its 96 recommendations 26 were related to community 
pharmacy.  With a positive tone it aimed to establish full use of pharmacy contribution to 
healthcare.  The 1980’s witnessed further developments in the role of pharmacy in public 
health after the publication of the Black report and the government programme 
Promoting better health in 1987 (Anderson 2007).  Pharmacies displayed health 
education and promotion materials in addition to the distribution of health education 
leaflets (Anderson, 2007).  
 
In the 1990’s pharmacy public health roles became more defined and included public 
health areas such as smoking cessation, contraception, prevention of heart disease and 
drug abuse.  One significant development was the Barnet High Street Health Scheme in 
1991 that included structured training for pharmacists in public health and received 
publicity in both pharmaceutical and national media.  Furthermore, important 
publications were produced promoting improvements to health through pharmacy, these 
included publication of the Government’s public health white paper Our healthier nation 
in 1998 (Anderson 2007).  
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This paper defined the application of pharmaceutical public health and reports 
commissioned through the Pharmacy Health Link (PHLink) (Public Health report- NPA, 
2013).  At the beginning of the new millennium, further government support was given to 
the pharmacy’s role in public health.  In April 2005, the Department of Health published 
Choosing health through pharmacy by introducing specialists in pharmaceutical public 
health (Anderson 2007).  These specialists provided a link between pharmacy practice 
and the public.  At this stage it became important for community pharmacists to become 
part of a wider public health workforce and demonstrate that its members can become 
specialist advisors in public health (Anderson 2007).  The Department of Health report 
white paper Pharmacy in England Building on Strengths – Delivering the Future, in 2008 
set out the government’s programme for a 21st-century pharmaceutical service (Anderson 
2007).  It builds on A Vision for Pharmacy in the New NHS launched in July 2003 and 
Our health, our care, our say: a new direction for community services, published in 
January 2006 (Anderson 2007).  This paper highlighted that community pharmacies in 
the UK are easily accessible and their location in the heart of the community provides 
them with the opportunity to deliver public health initiatives.  In addition, many 
pharmacies have long opening hours to meet patients’ and consumers’ need.  Since 2005, 
over 400 new pharmacies were approved to open to the public, for at least 100 hours per 
week.   
 
Furthermore, the Department of Health report white paper Pharmacy in England Building 
on Strengths – Delivering the Future addressed the new contractual framework for 
community pharmacy that was revised in 2005 and placed services into three levels or 
tiers: essential (dispensing and repeat dispensing, healthy life style advice disposal of 
medicine), advanced (Medicines Usage Reviews (MURs) a review of patient’s medicines 
to promote adherence) and local enhanced services (smoking cessation, nicotine 
replacement therapy, supervised methadone administration, emergency hormonal 
contraception, and minor ailment schemes).  
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Several examples of pharmacy public health initiatives were presented in the Department 
of Health report white paper Pharmacy in England Building on Strengths – Delivering 
the Future (Anderson 2007); for example; Heart MOT Service in Birmingham (a NHS 
health check) in which community pharmacies were commissioned to provide 
opportunistic testing services for vascular disease. In 2010 the Department of Health 
published the white paper Healthy Lives, Healthy People. The paper outlined a radical 
shift in tackling public health challenges including smoking, drug and alcohol treatment 
services and NHS Health Checks for men and women aged 40-74.  The paper 
emphasized the potential role of Healthy Living Pharmacies (HLPs).  The HLPs were 
developed in Portsmouth to make a real difference to the health of people, initially 10 
pharmacies were awarded HLP status.  These HLP’s delivered a range of high quality 
services such as reducing smoking, weight management, emergency hormonal 
contraception, chlamydia screening, advice on alcohol and reviews of the use of 
medicines.  They proactively promoted a healthy living culture and worked closely with 
local GPs and other health and social care professionals.  In 2011 there were at least 100 
Healthy Living Pharmacies in England and by April 2013 this number has risen to 508. 
(PSNC, 2014). By May 2014 the number of HLPs across England had grown to over 800 
and attracted interest from other areas of the UK and across the world (Pharmacy and 
Public Health Forum report, 2014).   
 
In 2014 an evaluation of the Healthy Living Pharmacy concept was undertaken by Public 
Health England (Pharmacy and Public Health Forum report, 2014).  Public Health 
England conducted a survey of 1,034 members of the public. Ninety eight percent of 
people surveyed stated that they would recommend the HLP service to others and 81% 
reported that the service they received was excellent.  In addition to this survey, a 
contractor survey (Brown et al, 2014) also reported that public health services delivered 
through HLPs were effective and potentially cost effective. Ninety one percent of 
contractors said becoming an HLP was a worthwhile investment and 80% said their staff 
became more productive (Brown et al, 2014).                                                                                                                                                           
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The survey of contractors also identified several obstacles to HLP development.  These 
included managing the increased workload, raising awareness of clients and other 
healthcare professionals of the services available, and remuneration for the service.  In 
addition to public health pharmacy services delivered by Healthy Living Pharmacies, 
community pharmacists also deliver services to support medicines optimisation for 
patients with long term conditions.  
3.2- Pharmacy services and contribution areas to patient care  
 
Services that support medicines use for people with long term conditions include 
Medicines Use Reviews (MURs) and the New Medicines Service (NMS).  In this chapter 
these services were researched because of their potential to accommodate the behavioural 
intervention identified for this study.  
 
 
Medication usage review (MUR) in community pharmacy  
Medicines Use Reviews were introduced in the UK in 2005.  The purpose of a MUR is to 
improve patients’ knowledge and use of drugs.   Medicines Use Reviews aim to support 
appropriate medicines use by patients, identify side effects and drug interactions, and 
reduce waste.  A MUR service is for patients on multiple medicines for long term 
conditions and can be carried out every 12 months.  Pharmacists receive a payment of 
£28 per MUR and each pharmacy can undertake a maximum of 400 reviews per year 
(PSNC, 2015).  In England the potential annual NHS investment in the service is about 
£112 million (PSNC, 2015).  An interventional MUR can also be carried out if 
pharmacist identifies a significant problem.  A number of research projects and 
evaluations have quantified MUR activity and sought to understand factors which 
influence uptake of MURs, by both patient and pharmacist/pharmacy (Bradley et al., 
2008), (Mc Donald et al., 2010).  
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Studies evaluating targeted MUR services, focusing on a particular disease, have reported 
improved clinical outcomes (Bradley et al., 2008), (Mc Donald et al., 2010).  They have 
also highlighted the need to develop strategies to encourage uptake/delivery of MURs to 
patients who need them the most, the need for quality assurance of MURs, improving 
communication between pharmacists and GPs and improving GP enthusiasm for 
community pharmacy MUR services (Hinchliffe et al, 2011). 
 
 
Medicine Usage Reviews in the UK are usually conducted in the community pharmacy 
consultation room.  However, in some cases they can be conducted at care homes (PSNC, 
2015).  MURs are usually delivered as a face to face consultation.  Medicines use reviews 
are also carried out in several European countries. In Sweden MURs can be carried out in 
nursing homes, hospitals and some healthcare centres.  In Finland comprehensive MURs 
started in 2005 and included an interview with the patient, preferably at the patient’s 
home.  The MUR in Finland includes assessment of medication through discussion with 
the patient, the physician and the homecare nurse (PGEU Ref: 10.10.14E002). In the 
Netherlands Pharmaceutical Home Counselling and Clinical Medication review are new 
approaches that are in a developing and researching phase.  Pharmacists together with 
doctors review the medication of a patient and discuss the therapy plan with the patient.  
The pharmacist is paid 150 euros per consultation.  The consultation includes exploring 
medication related problems and exploring medication taking skills based on the patient’s 
actual use and experiences.  In Portugal the Pharmacy Association developed a model for 
a national pharmacy-based ‘brown bag’ campaign.  This campaign includes a medication 
review that targets patients aged 65 and over, in response to the health problems around a 
growing aged population, this was launched in 2007.   
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In Spain, The General Council of Pharmacists has carried out a programme of home care 
for elderly people. This included a medication review by interview with the patient and 
carer (PGEU Ref: 10.10.14E002). 
 
Table 3.2 Medication review services in different countries 
Country  Pharmacy medication review service (medication reconciliation 
and patient education) 
UK Medication Usage Reviews  
Canada  Medschecks in Ontario 
America  Medication Therapy Management  
Australia  Home Medicines Reviews  
Sweden              MURs in nursing homes, hospitals and healthcare centres 
Finland  Comprehensive MUR 
Belgium  MUR elderly patients  
Netherlands  Pharmaceutical Home Counselling and Clinical Medication review 
Portugal  Pharmacy-based brown bag campaign 
Spain  Home MUR  
 
The New Medicine Service  
Research to support the New Medicine Service development involved work at UCL 
School of Pharmacy led by Professor Nick Barber.  This included a survey (Barber et al, 
2004) which involved 258 patients above 75 years and commenced on medication for 
stroke, CHD, asthma, diabetes or rheumatoid arthritis.  The patients were followed up by 
a semi-structured telephone interview and a postal questionnaire at 10 days and 4 weeks.  
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At follow up one-third of the patients reported non-adherence to their new medicine and 
two-thirds had a medication related problem (MRP), concerns or need for further 
information.  The study (Barber et al, 2004) showed that a significant proportion of 
patients newly started on a chronic medication quickly become non-adherent, often 
intentionally. Conclusions from this study were that patients need more support when 
starting on new medication for a chronic condition and that new services may be required 
to provide this (Barber et al, 2004).   Further evidence included a randomised control trial 
(Clifford et al, 2006) which assessed the effects of pharmacists giving advice to meet 
patients’ needs after starting a new medicine for a chronic condition.  The pharmacists 
used a patient centred approach and gave advice to support patients’ individual needs.  In 
this study (Clifford et al, 2006) five hundred patients were randomised to intervention 
and control groups.  At 4-week follow-up, non-adherence was significantly lower in the 
intervention group compared to control (9% vs. 16%, P= 0.032).  The number of patients 
reporting medicine-related problems was significantly lower in the intervention group 
compared to the control (23% vs. 34%, P = 0.021).  Intervention group patients also had 
more positive beliefs about their new medicine.  Furthermore the intervention was also 
found to be cost effective (Elliot et al, 2008).  This work led to the development and 
introduction of the New Medicine Service (NMS).  
 
The NMS is a national service based in community pharmacies.  The New Medicines 
Service provides opportunities for community pharmacists to widen their professional 
activity as experts in medicine and support patients with long term conditions.  It aims to 
support patients to maximise the benefits of the medications prescribed.  The New 
Medicine Service (NMS) was implemented on the 1
st
 of October 2011 and was initially 
funded by the National Health System until 2013.  The NMS provides support with 
medicines adherence for patients being treated for four conditions/therapy areas (1) 
asthma/ chronic obstructive pulmonary disease (COPD), (2) Type 2 diabetes, (3)  
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Antiplatelet/anticoagulant therapy,(4) Hypertension.  To be eligible for the service the 
patient has to have been prescribed a medicine for one of the four conditions mentioned 
above for the first time.  The NMS provides support for adherence in the first two months 
of the medicine being prescribed.  The NMS is to support people in understanding why 
they need to take new medicines and prepare them for any adverse effects they may 
experience.  The NMS has three stages to the service: patient engagement, intervention 
and follow up.  Part of the importance of the NMS is that when a hospital initiates a new 
medicine for a patient being discharged, the hospital pharmacist can make a referral into 
the New Medicine Service.  This provides reassurance that any information they provide 
to patients is reinforced by community pharmacy colleagues.  This may improve 
therapeutic outcomes and decrease hospital readmission.  Following its implementation, 
the Department of Health commissioned an evaluation of the service in 2012, to help 
determine if it should continue to be funded by the NHS.  A research team led by the 
University of Nottingham, in collaboration with University College London, were 
awarded a grant to carry out the evaluation.  The evaluation included a randomised 
controlled trial. 
 
How the NMS trial was conducted 
Community pharmacies in the East Midlands, South Yorkshire and London were 
recruited to take part in the study.  A total of 61 pharmacies participated, although four 
withdrew after study initiation.  Pharmacists recruited patients when they presented at the 
pharmacy with a prescription for a new medicine.  After accepting the invitation to take 
part, the patients were randomised to receive either current practice (n=253) or the new 
medicines service (n=251).  Current practice was the normal supply and advice 
associated with presentation of a prescription for a new medicine for a long-term 
condition which did not exclude any patients from contacting the pharmacist or another 
healthcare professional if they wished.   
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The primary outcome of the study was patients’ adherence to their medicine.  Secondary 
outcomes included patients’ understanding of their medicines (Beliefs About Medicines 
Questionnaire (BMQ)), health status and healthcare costs. These data were gathered in 
self-completion postal questionnaires and a healthcare resource use self-completed diary 
(Elliot et al, 2015).  Qualitative research was also conducted to assess how well the 
service was received by patients and healthcare professionals.  Interviews were carried 
out with patients, pharmacists and GPs to characterise facilitators and barriers to service 
uptake, informed by individual and organisational perspectives.  Thus the qualitative 
work explored operational dimensions of NMS to deepen and explain the technology 
appraisal (The Pharmaceutical Journal, 2014) (Elliot et al, 2014). 
Findings from the randomised control trial to evaluate the NMS  
Adherence to medication was assessed after ten weeks.  Adherence to treatment was 
64.9% in the current practice group and 74.7% in the NMS group (95% confidence 
interval 1.09–2.58; P=0.018) including patients who switched medicines after advice 
from their healthcare professional. When the analysis was restricted to patients who 
continued with the same medication, 60.5% were adhering to their medicine in the 
current practice group, compared with 70.7% in the NMS group (95% CI 1.06–2.62; 
P=0.027).   An economic evaluation was conducted and suggested that in the long term, it 
is likely that NMS will deliver better outcomes at overall reduced costs.  The cost to the 
NHS is less for NMS patients because their economic model predicts that these patients 
will have fewer adverse events and so will make fewer contacts with the health service 
than patients who did not receive the service. The study was not designed to show 
differences in use of NHS services during the ten weeks that it was conducted, but rather 
to model outcomes in the future based on adherence.  However, during the ten weeks of 
the study, it was found that patients visited their GP fewer times and so delivering the 
NMS was cheaper.  
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The NMS report also recommended allowing access to patients’ records, which could 
help facilitate the advice given to patients and also suggested benefits of GPs and 
pharmacists working closely together (Elliot et al, 2014). 
Figure 3.2 New medicines service intervention 
Adapted from -Elliott R, Boyd M, Waring J et al. (2014) Understanding and appraising the new medicines 
service in the NHS in England. Available 
from: http://www.nottingham.ac.uk/~pazmjb/nms/downloads/report/files/assets/basic-
html/index.html#1 (accessed 14 August 2014) Citation: The Pharmaceutical Journal, 23/30, Vol 293, No 7824/5 
 
 
Regarding continuity of this service, the NMS is included in the recently announced 
pharmacy contract funding settlement between the Pharmaceutical Services Negotiating 
Committee (PSNC) and NHS England.  It was expected that the settlement would be a 
multi-year deal, the agreement is for 2014/2015, but the importance of the service has 
been acknowledged.  Pharmacists are paid between £20 and £28 for each completed 
NMS they provide depending on the total number of patients who receive the service in 
the month (PSNC).  Furthermore, of 11 495 community pharmacies in England, 10 553 
(91.2%) had claimed for at least one NMS episode by January 2014 (Elliot et al, 2015).  
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Other pharmacy services in the UK  
While reviewing the literature for pharmacy services in the UK several other services and 
roles were identified.  However, some of these roles are still in their early stages of 
development and may not tackle long term illnesses. Examples include community 
pharmacy management of minor illnesses and Self Care pharmacy.  These services will 
be discussed briefly.  
Community Pharmacy Management of Minor Illness 
A new campaign was approved by the Royal Pharmaceutical Society and English 
Pharmacy Board in 2014 to help with the increasing number of patients presenting in the 
A&E departments.  This involved placing pharmacists within A&E departments to assist 
people arriving with medicines supply issues, and also referring patients to community 
pharmacies to deal with common ailments.   The evidence behind this proposal included 
University of Aberdeen Minor Aliment MINA study.  This service targets four 
conditions: musculoskeletal pain, eye discomfort, upper respiratory tract-related and 
gastro-intestinal disturbance.  The MINA study showed that lower costs were associated 
with the management of these diseases in pharmacies compared with the other settings, 
and thus provides further evidence of the suitability of pharmacies to manage these 
conditions.  Moreover, health professionals and patients need to be confident in the 
ability of pharmacists and their staff to manage minor ailments.  Government policy is 
promoting community pharmacy as the preferred setting for the management of minor 
ailments.  
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There is evidence from other countries where similar policies have been introduced, that 
patient behaviour has changed and demand on high cost settings has declined (MINA 
Study, 2014). 
Self Care pharmacy 
This is not a new concept; people manage a large proportion of their ailments without 
consulting either a doctor or pharmacist.  Yet pharmacists can play a key role in helping 
people to make informed self-care choices (WHO, 1996).  In 2014, Self Care of patients 
was developed through UK community pharmacy services.  A ‘call to action’ by the 
North East London Local Pharmaceutical Committee (NELLPC) has been promoted with 
a focus on improving patient outcomes.  Definition of self care as defined by the 
Department of Health “the care taken by individuals towards their own health and well-
being-including the care extended to the family and the community”.  The conditions 
targeted by Self Care pharmacy plans are long term conditions including COPD, asthma, 
heart disease, arthritis, diabetes and bipolar disorder. The potential impact of self care 
programmes on these conditions is supported by evidence from systematic reviews.  
Potential far reaching benefits to the NHS through self care pharmacy could involve 
improved quality of consultations, reduction in number of GP visits and outpatient visits, 
reduction in the number of hospital admissions and improved medicines use.  The 
pharmacists delivering self care plans are trained in motivational interviewing and health 
coaching (which is a process that facilitates healthy, sustainable behaviour change by 
challenging clients to listen to their ‘inner wisdom’, identify their values and transform 
their goals into action).  The Self Care service has been commissioned by Newham 
Clinical Commissioning Group (CCG) and allows pharmacists and patients to develop a 
joint care plan.  Hospitals or GPs will refer patients to a participating pharmacy of their 
choice, where a self-care plan will be created.  Three follow up sessions are then arranged 
over a 12 week period to empower behaviour change in patients to improve their health 
and wellbeing outcomes.   
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Expressions of interest were obtained from pharmacy contractors who wished to 
participate in the service with the plan for the service to go live in 2015.  Self Care 
Pharmacy at NELLPC has received commissioning of £1.25 million to take the service 
forward.  A question could be raised here regarding whether the intervention designed for 
this thesis could be incorporated into Self Care pharmacy service. Although Self Care 
pharmacy service targets heart disease, patients could also be referred to this service from 
hospitals and pharmacists’ in the Self Care pharmacy programme are trained on 
behavioural skills (motivational interviewing and health coaching), Self Care pharmacy 
was in its very early stages of development when the design of the intervention for this 
study took place.  Moreover, the primary outcome to be studied in this thesis is adherence 
to cardiovascular medication. Therefore, it was concluded that the intervention of the 
study matches criteria required for the New Medicine Service and also could go under a 
MUR service.  Thus, the intervention for this study was designed to be incorporated into 
existing community pharmacy services such as the NMS and MUR service.  This will be 
further discussed in chapter four of this thesis.   
3.3-Barriers to community pharmacy services  
It was important to explore barriers to pharmacy services to increase the understanding of 
the uptake of the intervention (pharmacy service) by patients and also to identify barriers 
that could prevent pharmacies/pharmacists from delivering these clinical services if 
appointed to the study.  Community pharmacy has become recognized as an easily 
accessible source of advice in primary healthcare due to pharmacies long opening hours 
and easy access without an appointment.  Pharmacists are believed to be competent and 
well trained health professionals and there are high expectations on how community 
pharmacies can be used (Saramunee et al, 2014).  
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Nevertheless, there is evidence behind the underutilisation of novel pharmacy services 
and that international uptake of such services has been disappointing (Gidman et al, 
2012).  Several studies have aimed to further examine barriers to the uptake of pharmacy 
services and identify factors affecting service use.  
 
Barriers identified from the literature include: 
Pharmacy accommodation and the pharmacy environment 
Privacy is clearly an issue; patients could be unaware of existing consultation rooms.  In 
addition, some patients think consultation rooms in pharmacies are used only for drug 
misuse clients (Saramunee et al, 2014).  This increases the unwillingness of pharmacy 
clients to engage in private discussion regarding health without privacy.  Certain public 
health services for example health checks for screening programs and ‘flu vaccinations 
require hand washing facilities and secure internet access (Mc Naughton et al, 2011).  
Indeed 75% of community pharmacies in England are providing MUR services for which 
a consultation area is a minimum requirement, thus pharmacists may expect that the 
public would be aware of them (Saramunee et al, 2014).  However, there still remains a 
huge variability between pharmacies in the appropriateness of their accommodation.  
Pharmacy accommodation has been identified as a main barrier in other parts of the UK, 
e.g advice on prevention of HIV/hepatitis in pharmacies in Scotland and in other 
countries, e.g. in Sweden, provision of advice on health promotion.  Moreover, nearly 
two thirds of pharmacists in a survey in Canada felt that having a designated space in the 
pharmacy was very important in facilitating smoking cessation practice, whilst nearly 
half of participants in a study in Thailand (43%) thought the pharmacy setting was a 
barrier to smoking cessation counselling (Eades et al, 2011). 
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Secure internet and confidentiality  
Pharmacies need to have secure internet connections to allow them to transfer patient 
identifiable data to other health providers’ databases.  Many pharmacies in England do 
not have the full access to the NHS network which is required for the efficient and secure 
transfer of information between pharmacy and general medical practices. Confidentiality 
standards and the degree of access permitted to staff within a pharmacy team remain 
important issues (Mc Naughton et al, 2011).  The issue of confidentiality and concerns 
about other personal information remaining confidential has also been raised in other 
studies on barriers to pharmacy services use (Saramunee et al, 2014) (Gidman et al, 
2012).  This is an important aspect to be considered for the design of an intervention in 
community pharmacy, because there is a need to transfer patient discharge data from the 
hospital to community pharmacies. 
Access to patient data 
Clinical medication reviews can be optimised if pharmacists have full access to patients’ 
medical records.  When such access is not completely available this can minimise 
potential of pharmacists’ interventions to improve adherence and resolve medication 
related problems.  This barrier has been recognised and also the need to release full 
professional potential to improve patient outcomes.  In the UK initiatives such as 
Electronic Prescribing have enabled prescribers, such as GPs and practice nurses, to send 
prescriptions electronically to a pharmacy of the patient's choice.  This makes the 
prescribing and dispensing process more efficient and convenient for patients and staff.  
Moreover, recently it has been announced that community pharmacists across England 
will be given the opportunity to access patients’ Summary Care Record (SCR), with the 
patient’s consent, to support their care and treatment. This will allow pharmacists to 
support patients with better informed and tailored care. 
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Pharmacists’ time 
High dispensary work load is a barrier that is highlighted in many studies due to 
increasing prescriptions.  This has been reported to cause stress on pharmacists and even 
a desire to leave pharmacy as a profession.  This also has a negative impact on the 
interest and ability of pharmacists to deliver clinical services (Saramunee et al, 2014).  In 
a review on pharmacy services (Eades et al, 2011) lack of time was identified as a main 
barrier to providing advice on prevention of HIV/hepatitis by pharmacists and support 
staff in Scotland.  Time was also a barrier to providing smoking cessation counselling in 
the USA.  Thus time is considered a crucial barrier to service delivery.  Recent moves 
toward large dispensing factories, internet pharmacies and robotics may not be 
universally welcomed; but these together with trained accuracy checking technicians 
could free up pharmacists’ time for other services (Saramunee et al, 2014). 
 
Training 
A need for training has been identified in a number of surveys on different public health 
services.  Training is essential to develop confident and competent staff (pharmacists and 
pharmacy technicians). Training has been reported as an essential need in different 
studies; over half of pharmacists in a study in Scotland reported that attaining additional 
pharmaceutical public health knowledge was a priority for their practice and also felt that 
lack of training was a main difficulty in providing advice on prevention of diseases such 
as HIV and hepatitis.  Moreover, pharmacists in a study in New Zealand felt that training 
was a barrier to providing alcohol screening (Eades et al, 2011).  Several studies have 
also noted that pharmacists need further training in communication; counselling and 
motivational skills and that these should be included early in undergraduate pharmacy 
courses, with an aim, at improving professionalism (Saramunee et al, 2014) (Mc 
Naughton et al, 2011).  Thus, training can positively affect pharmacists’ attitudes and 
behaviours in relation to health promotion and provision of advice with medicines.  
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Therefore, it can be concluded that for an intervention to be feasible it would be 
important to offer training to the pharmacists that take part.  
 
 
Lack of General Practitioners (GPs) support 
There is evidence that GPs do not support pharmacy public health services, which has 
been an issue with MUR service (Saramunee et al, 2014).  Uptake of community 
pharmacy services is likely to improve if endorsed by GPs and integrated with other 
primary care services.  Collaboration at a primary care level is required for signposting, 
referring into existing systems, avoiding duplication and enabling individuals to select 
their preferred public health service provider (Saramunee et al, 2014).  Research in UK 
demonstrates that GPs in general favour the concept of community pharmacists helping 
patients understand their medicines, but have subsequently been disappointed with the 
MUR service.  Major problems include inappropriate clinical recommendations, 
provision to less suitable patients (example: patients with few medicines and no clear 
medicines related problems) and the MUR service not being integrated with other 
healthcare provision.  However, where therapy changes are recommended to prescribers 
following MURs, at least half appear to be implemented (Saramunee et al, 2014).  
Furthermore, evidence shows that community pharmacists often feel that their 
professional competence is underestimated by their medical colleagues.  Also community 
pharmacists and doctors very often lack opportunities to meet in person and discuss 
various aspects of patient care (PGEU Statement on Role of Pharmacist in Self-Care R: 
10.10.14E 002).  In 2015, the English Pharmacy Board launched a campaign to integrate 
community pharmacists into GP practices.  This will enable community pharmacists to 
work more closely with GPs and other healthcare professionals in primary care.  In this 
proposed role, the pharmacist would handle medicines-related issues in general practice, 
liaising with providers such as hospitals and care homes to reduce errors, review 
medication and address poly pharmacy (Robinson, 2015).    
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This took place through a new £15million scheme to fund, recruit and employ clinical 
pharmacists in GP surgeries launched by NHS England.  The scheme will involve a three 
year initiative.  This will give patients the additional support of an expert pharmacist in 
their GP surgery (NHS England, 2015).  Some of the examples of the benefits patients 
can expect from pharmacists would include extra help to manage long-term conditions, 
specific advice for those with multiple medications and better access to health checks.  
Pharmacists can be employed directly by general practices to help patients, while also 
easing GP workload and improving communication between general practice, hospitals 
and community pharmacists. The scheme will focus on areas of greatest need where GPs 
are under greatest pressure, and aims to build on the success of GP practices already 
employing pharmacists in patient-facing roles (NHS England, 2015). 
 
 
To summarise, barriers to implementing clinical services run by community pharmacists 
in the UK can be summarised into (Boyd et al, 2013):  (1) insufficient integration into 
patient pathways, (2) poorly developed relationships between GPs and pharmacists, (3) 
lack of access to information and (4) lack of willingness of pharmacists to provide the 
service.  In order to implement pharmacist-led interventions there is a need to ensure that 
pharmacists have adequate information about health of the patient and medication.  There 
is also a need to support collaboration between community pharmacists, GPs and other 
health professionals by a range of interventions, from integrated remuneration systems to 
personal contacts, solutions that promote greater mutual respect and professional trust 
(PGEU Statement on Role of Pharmacist in Self-Care R: 10.10.14E 002). 
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Remuneration for pharmacy services  
Implementation of pharmacy services are costly and time consuming.  In particular in 
smaller pharmacies and in rural areas pharmacy services may be difficult to implement 
without financial support.  It is important to ensure that pharmacists receive remuneration 
for the service and that it does not imply additional costs to pharmacy for undertaking 
these services.  A review of remunerated pharmacy clinical care services (Houle et al, 
2014) described 60 remunerable pharmacist clinical care services across North America, 
Europe, Australia and New Zealand.  Remunerated services included medication reviews, 
chronic disease management, prescription adaptations, emergency hormonal 
contraception counselling, smoking cessation counselling and minor ailment programs. 
The review (Houle et al, 2014) recommended that although lack of remuneration is a 
commonly expressed barrier preventing pharmacists from providing more clinical care 
services, the mere presence of a remuneration scheme is insufficient to ensure uptake in 
practice.  For example, some programmes report very low numbers of participating 
pharmacies and others report a high initial expression of interest but short persistence or 
very low patient enrolment over time.  Therefore, when designing and evaluating 
programs commonly reported barriers to uptake should be examined.  These include 
insufficient remuneration for services offered, burdensome paperwork and complicated 
claims submission processes.  
 
The review (Houle et al, 2014) also concluded from pharmacist opinion surveys that 
pharmacists consider the fees for their services to be insufficient considering the time 
required to provide the patient care.  Therefore, front- line pharmacists should be invited 
to payers’ discussions and processes should be piloted prior to rollout to identify 
administrative issues early.  Finally, remuneration models for clinical care services 
should consider pharmacies’ changing business models from primarily dispensing based 
revenues to a blend of dispensing and patient care reimbursement income (Houle et al, 
2014). 
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The table below lists remuneration programmes in the UK.  The intervention for our 
study can be claimed for when delivered through a MUR or NMS service.  Both these 
services are funded by the NHS as illustrated below: 
Table 3.3-Pharmacy remuneration programs in the United Kingdom (Houle et al, 2014) 
Table adapted from- Houle K. D., Grindrod K A., Chatterley T. et al. (2014) Paying pharmacists for patient 
care: A systematic review of remunerated pharmacy clinical care services Can Pharm J (Ott); 147:209-232. 
Program  Year started Location  Payer 
Starting Fresh and 
Smoke Free 
Pharmacy Services 
2008 Scotland National Health 
Service Greater 
Glasgow and Clyde 
Community 
Pharmacy Heart 
Failure Service 
2005 Scotland National Health 
Service Scotland 
Medicines Use 
Reviews 
2005-2008 Scotland, England 
and Wales 
National Health 
Service 
Discharge 
Medicines Review 
Service 
NA Wales National Health 
Service Wales 
 
Minor Ailments 
Scheme 
2005 England National Health 
Service 
 
2009 Northern Ireland  Health and Social 
Care in Northern 
Ireland 
Appliance Use 
Review 
NA England National Health 
Service 
New Medicines 
Service  
2011 England National Health 
Service 
Emergency 
hormonal 
contraception 
program 
NA Wales and Scotland  Bridgend Local 
Health Group 
 
There is also a need to understand different stakeholders’ views on services provided by 
community pharmacies: 
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3.4-Pharmacists’ and stakeholders views on pharmacy services 
It was essential to research stake holders’ views regarding pharmacy services.  This is to 
establish the feasibility and the uptake of an intervention when delivered at a community 
pharmacy level.  Below are views from the literature examining patients’ views and 
pharmacists’ views regarding community pharmacy clinical services.  
 
What are consumers’ (patients’) views? 
The UK policy and pharmacists' professional organisations have emphasised the potential 
of community pharmacists to extend their roles in patient care services.  Nevertheless, the 
general public’s views are important to be understood for the successful uptake of these 
services.  Evidence shows a generally wide satisfaction of consumers with health advice 
and services given by pharmacists (Anderson et al, 2004) (Eades et al, 2011), but a 
deeper understanding of patients’ views is advocated.   Numerous studies have examined 
patient’s views on the services provided by pharmacists and found that patients’ consider 
pharmacists to be primarily involved in medicine supply and as drug experts rather than 
experts on health and illness.  Awareness of the pharmacist’s extended role is generally 
low therefore, services may be underutilised (Gidman et al, 2012) (Anderson et al, 2004).  
Many pharmacy users do not expect to be offered clinical services by pharmacists.  Also 
patients are often reluctant to trust pharmacists to deliver unfamiliar services particularly 
those perceived to be ‘high risk’ and would rather trust pharmacists with low risk 
illnesses and OTC medicines.  Thus, confidence in pharmacists providing public health 
services is low (Eades et al, 2011). 
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Some patients perceive that trusting pharmacy services could, even seriously threaten 
their health and that high risk illness should be preferably managed by a physician 
(Gidman et al, 2012).  For example health screening results by pharmacists could not 
result in prescribed treatment or be recorded in medical records.  A concern relating to 
the commercial context and retail environment of community pharmacy also has a 
negative effect on consumers’ views, leading to doubts regarding the commercial motives 
of pharmacists in providing health services (Mc Naughton et al, 2011) (Gidman et al, 
2012).  In the UK, individuals register with one GP based in a practice.  Therefore, the 
patient becomes familiar with one GP, or a limited number of GPs.  This relationship 
between GP and patient allows rapport to develop, which leads to trust.  Pharmacists on 
the other hand take a more separated role in the dispensary hence, limiting public 
interaction.  Moreover, hierarchies in healthcare also play a role in patients’ perceptions 
of pharmacy services.  Thus GPs are viewed as established authority figures, who are 
seen to ‘tell the pharmacist what to do’ (Gidman et al, 2012).  Patients’ perceive that 
uptake of certain health services at pharmacies are a waste of time because these services 
are existent at GP surgeries and that NHS services should be free.  Finally, community 
pharmacy services need to be integrated with other primary care services.  Currently, it 
seems that role expansion gives rise to duplication of tasks because health professionals’ 
roles are not complementary, or could appear as competitive (Mc Naughton et al, 2011).  
This is likely to increase costs rather than reduce them.  Policymakers should be aware 
that, without considerable changes to systems or institutional aspects of service delivery, 
it is improbable that the public will trust pharmacists to deliver unfamiliar services 
(Gidman et al, 2012).   
 
What are pharmacists’ views? 
In order to understand and assist the behaviour changes associated with providing health 
services in community pharmacy, it is important to establish the beliefs of pharmacists  
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regarding this role.  A review of pharmacists’ perceptions of pharmacy services found 
that although pharmacists valued the health improvement role, they are more comfortable 
with medicine related health improvement work (Anderson et al, 2004).  Other studies 
show that pharmacists’ perceive their potential role in health promotion and prevention as 
very significant but recognise a wide gap between ideal and actual levels of involvement 
(Laliberté et al, 2012).  Other issues include concerns pharmacists have of being 
intrusive, and believe that they need more support to provide public health services.  
Moreover, pharmacists fear the lack of demand and expectation of a negative reaction 
from customers (Eades et al, 2011).   
 
Different qualitative studies through interviews and focus groups have demonstrated that 
most pharmacists are confident in their competence to provide health services, viewing 
their ability to deliver as being limited mainly by workload and lack of time (Saramunee 
et al, 2014), (Anderson et al, 2004).  The majority of pharmacists in a survey in Scotland 
agreed (63%) or strongly agreed (16%) that public health is important to their practice 
and a little over half agreed (48%) or strongly agreed (8%) that they were public health 
practitioners.  Pharmacists and support staff taking part in focus groups in Sweden on the 
whole welcomed their role as a health promoter.  However, it was noted that not all 
pharmacists and support staff felt this way and preferred to develop activities in areas in 
which they received their basic training (Eades et al, 2011).  In order to improve the 
health services provided in community pharmacy, training must aim to improve 
pharmacists’ confidence in providing these services.  Confident, well trained pharmacists 
could be able to offer health services more proactively which is likely to have a positive 
impact on customer attitudes and health (Eades et al, 2011). 
 
                                                 End of Chapter Three 
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The three previous chapters serve as a valid base of information to design a study. 
Chapter one confirmed the need for further research regarding management of  
cardiovascular disease. This chapter demonstrated that cardiovascular disease constitutes 
30% of all cause mortality globally and burdens from this disease are still escalating; 
unless proper measures of primary and secondary prevention strategies are addressed.  
This chapter included evidence of the effect of non adherence to medication on outcomes 
of cardiovascular diseases, showing that promoting adherence to lifesaving medicines 
after cardiac diseases, is an important area to research and remains challenging. 
Therefore, from chapter one it became apparent that a study tackling adherence to 
secondary prevention medication would be pertinent to health care needs.  Evidence from 
chapter one showed that one of the strategies to tackle non adherence to cardiac 
medication could be pharmacy care.   
 
Chapter two reviewed previous evidence and examined this strategy through a systematic 
review of forty two randomised controlled trials. The review concluded that pharmacy 
services could serve as an effective strategy to improve adherence. Twenty six out of the 
42 reviewed trials had statistically significant effects on improving adherence to 
cardiovascular medication.  Conclusions drawn from this review included; a behavioural 
intervention (motivational interviewing) to improve adherence to cardiovascular diseases 
is an area that requires further investigation and face to face and telephone pharmacist 
consultations could be effective methods in improving adherence to cardiac medication.  
The systematic review in chapter two also showed that further research to improve 
adherence to medication in patients with acute coronary syndromes is needed.  From 
chapters one and two the disease to be studied and the primary and secondary outcomes 
for the design of a new study were supported.   
Methods to deliver a pharmacy intervention were researched in chapter three that 
examined existing UK pharmacy services.  Chapter three; highlighted potential pharmacy 
services (MURs and NMS) into which an intervention could possibly be incorporated.  
Chapter three also examined issues such as the beliefs of consumers and pharmacists 
regarding community pharmacy services and roles.  Therefore, it became apparent that 
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the disease to be studied is acute coronary syndromes and also the primary outcome to be 
researched is adherence to secondary prevention medication.  In addition the strategy to 
tackle adherence would be pharmacy care and this might be achieved by designing an 
intervention incorporated into existing UK pharmacy services, conducted by community 
pharmacists, through collaborations with hospital pharmacists and GP surgeries.  Chapter 
four will discuss the methodology that led to the design and development of such an 
intervention.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
124 
 
 
 
 
 
 
 
 
 
Chapter Four 
Methodology of a Feasibility Pilot Controlled Trial 
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4.1-Field work  
Preliminary field work that led to the study design and methodology April 2012 
Preliminary field work was undertaken by the researcher.  This involved personal 
communication with relevant individuals and observations at recruitment sites.  
Discussion took place between the researchers’ at UCL School of Pharmacy (UCLSOP) 
and consultant pharmacist from the London Chest Hospital regarding the target 
population to be studied (patients with acute coronary syndromes).  The consultant 
pharmacist confirmed findings from the literature, which demonstrate that patients’ who 
stop their medications after a PCI (especially antiplatelets) risk having a re-infarction (a 
second myocardial infarction) and may need to be readmitted to the hospital.   This had 
been previously recognised by the hospital and lead to the design of an antiplatelet 
booklet by the pharmacy department.  This booklet is offered to every patient prior 
discharge.  In addition, each patient is counselled by a hospital pharmacist.  Therefore, 
designing a study to enhance adherence to these lifesaving medications would be crucial 
and of benefit for these patients.  The time to reinforce information to patients was also 
discussed.  The consultant pharmacist highlighted that information regarding the 
medication and the disease is mostly needed after discharge, once the patient is in the 
community.  Therefore, it became evident that the intervention would be best if delivered 
by community pharmacists.  Discussions also included; the competency of community 
pharmacists to uptake such an intervention and also if further training on secondary 
prevention medication after a myocardial infarction would be important.   
 
The research team at UCLSOP were also informed by the consultant pharmacist that 30% 
of patients who suffer a myocardial infarction and are admitted to the LCH are from 
ethnic minorities, in particular South Asians.  The concept ‘ethnic minority’ refers to 
many different ethnic groups of extreme heterogeneity.  This concept is used for groups 
that share minority status in their country of residence due to ethnicity, place of birth, 
language, religion, citizenship and other cultural differences.  Members of these groups 
are considered to practice different cultural norms and values from the majority culture 
126 
 
and often a different mother tongue (Scheppers et al, 2006).  The UK contains a 
culturally diverse population with ethnic minorities accounting for almost 8% of the 
population, in the 2001 census. 
 
The largest ethnic minority includes Indians, followed by 
Pakistanis, mixed ethnic backgrounds, Black Caribbean, Black Africans and 
Bangladeshis.  In addition, there is about 500,000 ethnic Middle Eastern living in the UK 
(Patient.co.uk).  Cardiovascular disease is high in all ethnic groups as well as in the 
general population.  However, it is the South Asians who have the highest prevalence of 
coronary heart disease.  South Asian refers to a heterogeneous population, with important 
differences in diet, culture, and lifestyle among different South Asian populations and 
religions.  Multiple studies of migrant South Asian populations have, however, confirmed 
a 3- to 5-fold increase in the risk for myocardial infarction and cardiovascular death as 
compared with other ethnic groups (Gupta, 2006).   In an analysis of age-standardized 
coronary heart disease (CHD) mortality in Canada over a 15-year period, South Asians 
had the highest CHD mortality compared with individuals of Chinese and European 
descent.  In addition, South Asians are prone to developing CHD at a younger age, often 
before the age of 40 years in men (Gupta, 2006).  Therefore, there is a need to look closer 
at this particular ethnic group.  In addition, very few people from ethnic minority groups 
attend cardiac rehabilitation programs.  Furthermore, there has been little research on 
cardiovascular medication compliance among ethnic minorities, despite the relatively 
high prevalence of cardiovascular conditions in these groups (Carter and Taylor, 2003) 
and a large proportion of research is performed in the UK that presently does not include 
enough ethnic minority patients, and patients from South Asian backgrounds meaning 
that results may not necessarily correlate to patients from ethnic groups (patient.co.uk).  
The LCH is located in an area with a high ethnic minority population and as discussed 
above, further research in this patient population would be essential.  This helped 
determine the decision regarding the choice of the study site. Moreover, three 
observational visits to cardiac centres were arranged for the researcher.  One to the Chest 
Hospital Barts and London NHS trust, the second to the cardiac services at the Heart 
Hospital and a third to the cardiac unit at Imperial College Healthcare NHS trust.  These 
visits were arranged to gain knowledge of hospital pharmacy system in the UK and also 
observe usual care by hospital pharmacists.  During the visit to the Heart Hospital, the 
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lead pharmacist provided contact details of other cardiac centres’ an email was sent to 
these other centres to discuss the viability of participating in the study (Guys and 
Thomas, Kings College Brompton, St. George, Imperial, Royal Free).  Response was 
received from the contacted centres.  However, it became clear that the study would need 
to commence (patient recruitment) in a single hospital site because recruitment would be 
undertaken by a single researcher and that the intervention would be more beneficial if 
conducted in community pharmacies not in the hospitals.   
 
Other discussions between the researchers at UCLSOP included the type of the 
intervention.  Background literature had revealed that a behavioural approach may be 
effective in improving adherence.  This led to a consultation with a psychologist at the 
school.  This was to further understand motivational interviewing as an approach to 
enhance adherence to medication and if motivational interviewing could be delivered by 
a community pharmacist.  Training on motivational interviewing was also considered.  At 
this time only few studies involving a pharmacist using motivational interviewing could 
be found.  This supported the idea that further research in this field would be beneficial.  
Moreover, motivational interviewing had only recently been introduced into the 
undergraduate curriculum at UCLSOP.   Discussions and background research also led to 
the idea that the intervention would be designed as a randomised control trial, where the 
intervention group would receive a consultation involving a motivational interview 
session and the control would receive usual pharmacy care both in the hospital and 
community.  However, due to the complexity of conducting a randomised control trial it 
was decided to be conducted as a feasibility/pilot study and to develop a methodology 
that can in the future be adapted to design a larger randomised control trial.  
 
After deciding the recruitment site the aim was to gain support of the community 
pharmacies and to perceive the interest to take part in the study.  A meeting was 
organised with the secretary at North East London Local Pharmaceutical Committee 
(NELLPC).  The meeting provided information regarding community pharmacies in six 
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London Boroughs (Tower Hamlets, Waltham Forest, Redbridge, Barking, Havering and 
Hackney), this included 306 pharmacies.  These pharmacies would be invited to 
participate in the study.  Further discussions involved services provided by community 
pharmacies Medication Use Reviews and The New Medicine Service, especially because 
hospital patient referral into community pharmacies could take place through the NMS.    
It was reinforced through the meeting that the intervention could be incorporated into a 
counselling session of a community pharmacist, also that this could be an opportunity to 
establish continuity of care that can extend from the hospital to the community pharmacy.   
Further discussions included reimbursement for the pharmacy services and training for 
community pharmacists.  The NELLPC agreed to support this new study.  This support 
would include; help with recruitment of pharmacies and also collaboration for the 
training sessions.  NELLPC agreed that the study and training sessions could serve as 
continuous professional development for the community pharmacists and also be an 
opportunity to introduce new counselling skills such as motivational interviewing.    
 
After approval for the intervention to be conducted in community pharmacies it became 
important to map the post codes of patients’ admitted to the London Chest Hospital.  This 
is to ascertain if the admitted patients lived in the six London Boroughs.  Mapping 
revealed that the majority of the admissions were from around the area of the hospital.  
Furthermore, to develop the research protocol that would involve motivational 
interviewing skills.  A meeting with an expert clinical psychologist from the University 
of Buckingham was arranged.  This meeting was to determine the compatibility of the 
protocol with motivational interviewing techniques.  The psychologist provided 
references and constructive input into the protocol.  Clinical observation in a UK 
community pharmacy was also arranged for the researcher to observe Medication Use 
Reviews (MURs) and the New Medicine Service (NMS).  Conclusions drawn from stake 
holders included; difficulties arise when implementing the NMS especially regarding 
patient follow up for the second consultation.  Patients do not attend the second NMS 
consultation regularly; therefore it is often conducted by telephone.  This was discussed 
with the psychologist.  This is to determine if a motivational interview session could be 
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conducted by telephone.  It was concluded from previous evidence that the intervention 
can be delivered by telephone (Teeter and Kavookjian, 2014).  Finally, a meeting took 
place with the clinical psychologist at Buckingham to discuss arrangement for 
community pharmacists training.  After the discussions above, numerous risks to the 
study should be taken into consideration, these could have an impact on the workability 
of the study.  
 
Risks and contingency  
There are several risks to the study these include recruitment risks; not achieving the 
target sample size, recruitment by hospital pharmacists could lead to loss of patients 
inside the hospital and further loss of patients during the follow up. 
Risks at community pharmacy level; not all patients attending the counselling sessions at 
the community pharmacies or the patients’ discharge letters are not forwarded to the 
community pharmacies.  Participation risks; not a sufficient number of community 
pharmacies willing to participate in the study, the number of community pharmacists 
interested in motivational interviewing training and are willing to deliver the intervention. 
Risks when delivering the intervention; motivational interviewing is a new counselling 
method; to what extent will the pharmacist follow motivational interviewing techniques?   
Therefore, issues with reliability.  Risks of data loss not all patients return the adherence 
and BMQ questionnaires.   
With these risks considered, the methodology of the study was developed as a feasibility 
study examining aspects of delivery and workability.  The study examined feasibility at a 
community pharmacy level (for both recruitment and delivery of an intervention), 
feasibility at the hospital site (for patient recruitment); feasibility at patient level (uptake 
of an intervention) and finally feasibility regarding data collection (researcher).  
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Aims and objectives of the research study 
Aim: To investigate if a pharmacy care intervention involving motivational interviews 
and referral to community pharmacy services in coronary heart disease patients could 
improve adherence to secondary prevention medication. 
Specific objectives are: 
 Establish the viability and impact of an intervention after patient’s 
discharge from hospital, on adherence to cardiovascular medication.  
 Investigate whether such an intervention is practical and feasible to deliver 
in UK community pharmacies.  
 Examine how communication between healthcare professionals’ 
community and hospital pharmacists, at the interface between primary and 
secondary care can improve medication reconciliation for patient after a 
coronary event.  
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4.2-Methodology 
Study design  
This was a feasibility study, set up as a pilot clinical trial study to examine potential 
impact of an intervention. It included an integral process evaluation to examine 
operational aspects from perspectives of all stakeholders. CONSORT guidelines are used 
widely to ensure robust reporting of clinical trials. Whilst this feasibility/ pilot study did 
not conform to all aspects of trial methodology, CONSORT can be used to illustrate the 
relevant issues in the design and methodology.      
Figure 4.1CONSORT checklist for RCT protocols: applied to this study:  
Section 
And topic  Description 
Title   Randomized control trial not in title (this would not be an accurate 
description). 
Introduction Scientific background and explanation of rationale was provided. 
Methods 
participants 
Eligibility criteria for participants and the settings and locations 
where the data were collected were all specified.   
Interventions 
Precise details of the interventions intended for each group and 
how and when they were actually administered were provided.  
Objectives Specific objectives and hypotheses were stated.  
Outcomes 
Primary outcome -self report adherence with coronary artery 
disease medication, using a validated self-report instrument 
Validated scales-Morisky scale, BMQ. 
Secondary outcomes- B.P, LDL-C, beliefs about medicines, 
measures of the feasibility study including costs and pharmacist 
time were specified. 
Sample size 
How the sample size was determined was reported, however, this 
was a feasibility pilot study so did not follow a calculation based on 
anticipated change in the primary outcome measure. 
Randomization - 
Sequence generation 
Pharmacies were randomized into intervention and control groups. 
Randomization was by using a table of random numbers.  
However, simple randomization of the entire sample was not 
possible.  
Randomization - 
Allocation concealment 
 
Concealment of randomization from the researchers until 
intervention was assigned.  
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Randomization - 
Implementation 
Randomization was by an independent statistician at UCL School 
of Pharmacy.  
Blinding (masking)  
The researcher was blinded during the data collection and analysis. 
It was not possible to blind the community pharmacists delivering 
the intervention or the hospital pharmacists and the patients due to 
the nature of the intervention.  
Statistical methods and 
analysis  
Independent T tests, Chi-square test.  
Analysis followed an intention-to-treat analysis. 
 
 
In the evaluation of health care interventions randomised control trials (RCTs) are 
considered as the “gold standard”.  Employing an experimental design with adherence to 
the RCT principles enables an evaluation in which the impact can be attributed to the 
intervention, rather than known or unknown extraneous factors (Geoffrey and Harding, 
2015).  However, while seen as a gold standard it is not always possible to achieve due to 
the fact of being expensive, especially if conducted across different locations/sites.  
However, if a smaller number of sites were to be included this could limit the 
generalizability of the findings; in addition, blinding in an RCT is not always possible 
(Geoffrey and Harding, 2015).  Other possible limitations could involve sources of bias 
such as selection bias, allocation bias, intervention bias, outcome bias and withdrawal 
bias.  This study was designed as a prospective controlled feasibility/pilot, intervention 
study.  Although the study was not designed as a RCT but as a feasibility study, it had a 
control group and methods of randomisation were employed.   
 
The key features in the design of an RCT  involves the following; two arms; intervention 
and control, to assess differences in treatment outcomes, randomisation to avoid 
systematic differences between the two arms, blinding of the research team to avoid bias 
in data collection /analysis, blinding of the participants to avoid placebo or research 
effects, assurance of the fidelity to the protocol regarding intervention delivery, choosing 
robust outcome measures and employing a systematic approach to data collection 
(Geoffrey and Harding, 2015).    
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In this study randomisation was at pharmacy level, the pharmacies, after enrolment, were 
allocated into two groups’ intervention and control to avoid contamination. 
Contamination could arise if patients in the control group attended intervention 
pharmacies. Randomisation was achieved by an independent statistician at UCLSOP 
(LW) and concealed from the research team to avoid selection bias.  Blinding procedures 
were employed. These included blinding of the researcher for data collection and 
analysis. However, it was not possible to blind community pharmacists, hospital 
pharmacists or the participants. The primary outcome measure was adherence to 
cardiovascular medication and the secondary outcomes included blood pressure and 
LDL-C.  These outcomes were selected after reviewing previous literature with a similar 
methodology to reduce outcome choice bias.  A protocol was designed and followed 
closely to reduce intervention bias.  In addition, an intention-to-treat analysis (ITT) in 
which all patients assigned to one of the treatments regardless of whether or not they 
completed or received the intervention was undertaken to avoid withdrawal bias.  
 
A systematic approach to the collection of data was used. Furthermore, measures 
regarding the feasibility of a randomised control trial were achieved through interviews 
and questionnaires with all stake holders.    It was decided by the research team that the 
intervention should be delivered at 2 points of time, 2 weeks and 3 months.  This is 
because evidence has shown that adherence to medication decreases with time and 
therefore, reinforcement of the importance of adherence to cardiac medication could be 
of benefit at these timings.  It was as also determined that follow up of patients would be 
6 months because the study is a pilot study.  Moreover, data collection would coincide 
with these timings.  Please refer to the figures 4.2, 4.3 below regarding the study design. 
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Figure 4.2 Study design  
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the feasibility of the study. 
 
Usual care   
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The diagram below (Figure 4.3) illustrates the steps of the overall methodology of the 
study.  
 
The first diagram (4.3a) outlines: 
 
1-recruitment of community pharmacies and pharmacists 
2-training of community pharmacists 
3-pharmacists deliver the intervention 
 
The second section (4.3b) illustrates: 
 
1-recruitment of patients at the LCH  
2-enrollment of patients into the study 
3-allocation to pharmacies 
4-patients receive the intervention 
 
It also outlines:  
 
1-recruitment of GPs 
2-patient follow up by research pharmacist 
3-data collection by research pharmacist and finally data analysis and results  
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Figure 4. 3a Overall methodology design  
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Figure 4.3b 
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Study population 
This included coronary heart disease patients with a discharge diagnosis of acute 
coronary syndrome (ACS). Patients discharged from the London Chest Hospital if 
eligible were enrolled into the study.   
Sampling strategy 
Study site 
The London Chest Hospital (LCH) in Bethnal Green was chosen as the study site.  The 
London Chest Hospital was selected as the study site due to the following facts (1) a large 
cardiac centre, a large number of patient admissions, a large number of pharmacy staff 
(2) the pharmacy staff are specialised in cardiovascular diseases (3) the site had 
established links with community pharmacies surrounding the hospital through the Local 
Pharmaceutical Committee (4) around 30% of patients are from an ethnic minority 
background (5) the location of the hospital is in Tower Hamlets that has the fifth highest 
premature mortality rate from CHD in the country (NHS, 2011).   The London Chest 
hospital is part of Barts and the London, one of Britain’s leading healthcare providers.  
Bethnal Green is a district in East London and is part of the London Borough of Tower 
Hamlets.  The borough has a population of 220,000 which includes one of the highest 
ethnic minority populations in the capital.  The London Chest Hospital was founded in 
1848 to offer treatment to the people of the City and east London similar to that offered 
by the Brompton Hospital (founded in 1841) to patients in west London.  Tuberculosis 
(TB) was a major endemic killing disease at that time, accounting for 20% of all deaths.  
In 1970 the hospital became one of the pioneers in the investigation and treatment of 
coronary artery disease. New drug therapy particularly streptomycin, led to a dramatic 
decline in the incidence of TB, this coincided with the development of heart valve 
surgery at the LCH.  In 2006 the London Chest Hospital launched an award-winning 
emergency Heart Attack Centre and in 2012 the London Chest Hospital became part of 
Barts Health NHS Trust.  The trust serves a population of 2.5 million in east London and 
beyond.   
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A single site was chosen because recruitment was to be undertaken by a single researcher 
and also due to lack of resources and time for a multicentre trial.  
Pharmacies                         
The primary care pharmacies were the pharmacies in North East London that are located 
around the London Chest Hospital.  These pharmacies already had established links with 
the London Chest Hospital through the NELLPC.  The links were due to their location 
around the hospital and also the hospital pharmacists at the LCH on certain occasions, 
conduct training courses for the community pharmacists by collaborating with the 
NELLPC.  Pharmacies in six London Boroughs were invited by the Local Pharmaceutical 
Committee to participate in the study.  Mapping LCH previous patients’ postcodes gave 
an indication of the area where patients normally reside and helped confirm the location 
areas for the pharmacies.  These pharmacies were invited to participate in the study.  It 
was found that the areas were located around the hospital.  
 
Patients 
The patients who were invited to participate in the study were those who had been 
admitted to the London Chest Hospital and had a coronary event.  Patients, who live in 
London, and regularly refill their prescriptions from the pharmacies recruited into the 
study.  The patients included in the study would be adults.   Most heart attack victims are 
middle-aged or older.  The average age for a first attack is 66 for men and 70 for women.  
Only 4% to 10% of all heart attacks occur before age 45 (Harvard, 2009).  The patients 
included in the study would have experienced a coronary event and been discharged on 
secondary prevention medication, the medications that the study is examining for 
adherence.  Patients were excluded if they did not live in the area where the pharmacies 
that deliver the intervention were located; this was to avoid the burden of extra travelling.   
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However, patients prior to recruitment were asked which pharmacy they normally use 
and if it was within the study area sites they would be considered for eligibility.  Patients 
with other diseases or complications were not included due to the need of extra 
management plans, surgical or medical, which were beyond the scope of this study.  
Patients living in care homes were also not included because the primary outcome is 
adherence and this could lead to bias if the patient is not in control of the medication 
routine.  Patients unable to understand English were not included because the 
intervention was to be delivered by pharmacists in English.  
 
 
4.3-Eligibility criteria  
The inclusion criteria were as follows: 
 Age > 18-yr-old. 
 Both Male/female. 
 Patients admitted for acute coronary syndromes; angina, NSTEMI/unstable 
angina, STEMI. 
 Patients included are from high risk group (hypertension, diabetes, 
hyperlipidemia), as well as patient from low risk group. 
 Patients medically treated for secondary prevention of coronary artery diseases 
and discharged on (aspirin, clopidogrel, beta-blockers, or calcium channel 
blockers, ACE-inhibitors or ARBs, and statins). 
 Patients living in /or around East London and willing to refill their prescriptions 
in the pharmacies involved in the study. 
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Exclusion criteria: 
 Congenital heart disease. 
 Complications of myocardial infarction: Arrhythmias, Severe Congestive Heart 
Failure, Tamponade/Thromboembolic disorder, Rupture (Ventricle, septum, 
papillary muscle), Aneurysm (Ventricle), Pericarditis, Infection. 
 Patients who do not live in/or around East London and do not regularly refill 
prescriptions in the pharmacies involved in the study. 
 Patients who do not live independently (living or nursing home residence). 
 Patients with less than one year survival rate. 
 Patients unable to understand oral and written English.  
 
 
 
4.4-Sample size  
Calculation of the sample size in this study did not follow a calculation based on 
anticipated change in the primary outcome measure.  Commonly calculation of a sample 
size in a randomised control trial would follow the assumption that; a RCT has two 
comparison groups and that both groups have the same size of subjects; thus sample size 
calculation will depend on the anticipated difference in the primary outcome measure.  
However, because this study was not designed as a full randomised trial but as a pilot  
feasibility study, such a calculation was not considered.   
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For this pilot study there were certain factors to be considered for the sample size 
calculation these included; the hospital patient load, the number of eligible patients, 
number of patients that could decline to participate and number of patients who do not 
understand English.  The hospital patients’ load was 1500-2000 patients per year.  When 
we apply a minimum load of 1500 patient per year; an estimated 125 patients per month 
could be recruited, if we recruit 5-6 patients per a working day.  However, since there are 
only 22 working days per calendar month and taking into account the factors mentioned 
above.  Therefore, we anticipated that if we recruit 1-2 patients per day we can achieve 
around 200 patients in 4-5 months.  Given these factors the enrolment target was set at 
200 patients, 100 patients in each group.  This sample size was considered sufficient to 
achieve the study’s objectives as a feasibility pilot study.   
 
In addition, previous literature was reviewed to determine the sample size.  For instance, 
a similar study by Obreli-Neto et al, 2011 recruited 200 patients and reported a 33 per 
cent increase in adherence with a margin error of 5 per cent and confidence interval 95 
per cent.  Furthermore, it was found that the sample size of 200 patients was in line with 
previous successful trials.  These trials aimed at enhancing adherence to cardiovascular 
medications and recruited and followed-up around 200 patients: Lee et al, 2006 increased 
adherence by 35.5%, Morgado et al, 2010 increased adherence by 22.3%, Sadik et al, 
2005 increased number of compliant patients from 33 to 85 patients and Blenkinsopp et 
al, 2000 increased adherence by 10.6%.  Thus a sample size of 200 was chosen.   
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4.5-Sampling procedures 
Study site 
The research department and the hospital pharmacists at the LCH were informed about 
the study, in order to facilitate operational aspects.  The researcher was issued with an 
honorary contract and a letter of access to enable recruitment.  Patients were recruited 
from two wards at the London Chest Hospital: CCU ward and Reviere ward.  Patients’ 
recruitment packages after being approved by ethics were printed and piloted to ensure 
that they would be easy to follow.   
 
Pharmacies 
The pharmacies approached were the pharmacies located in North East London and 
represented by NELLPC.   The study was advertised on the NELLPC website with a link 
to express interest.  The pharmacists were also informed that they could contact the 
researcher directly by email; this is if they had any queries regarding the study before 
registering interest.  After expressing interest the pharmacies were sent individual letters 
with further details explaining the study.  Pharmacists were asked to register their interest 
to take part in the study by using the link below: please use the link below to complete a 
form to express your interest.  A reminder email was sent to eligible pharmacies for 
recruitment by the link below.  
https://docs.google.com/forms/d/1YZaIoR9kbh_MCxp73qCqoXTULcnro_mEK_Nw2wI
BaYU/viewform?sid=657d857b01219bc3&token=SMgNEz4BAAA.eSvWkHQcEo5KdS
KHqaTCw.L-JwuMWDD398r2qjKO6cGA .   
Patients 
Patients were identified from the hospital admission lists and from the lists provided by 
the research department at the LCH.  There were several lists that could be reviewed by 
the research pharmacist.   
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These lists included the nurse list, the doctor list, in addition to the admission list.  
However, it was agreed with the research department at the LCH, that the research 
pharmacist would review both the research department list and the hospital admission list 
to avoid recruiting patients on more than one study simultaneously.  The research 
pharmacist then reviewed the patient’s hospital chart to outline if the patient matched the 
inclusion criteria.  The research pharmacist could approach the hospital pharmacist to 
confirm the diagnosis and also approached the patients to confirm the pharmacy used.  
The patient’s address (postcode) and general practitioner details were also identified from 
the hospital chart.   
Randomisation  
A list of the pharmacies included in the study was forwarded to an independent 
statistician at UCL-School of Pharmacy.  Randomisation was performed by using a table 
of random numbers. Randomisation was at pharmacy level to avoid contamination of the 
controls (Please refer to chapter 5 results for full details on randomisation).   
 
Blinding  
In this study the research pharmacist was blind regarding the group allocations for the 
analysis of the data.  This was to reduce bias and increase fidelity. The General 
Practitioners (GPs) clinics, from where data regarding B.P and LDL-C were collected, 
were also blind, unless referral of a patient by a community pharmacist took place. 
Blinding of the hospital pharmacists was not possible.  This is because the hospital 
pharmacists assisted the researcher with sending the discharge summary of the 
intervention patients from the hospital to the community pharmacists.  Furthermore, it 
was not possible to blind the community pharmacists delivering the intervention or the 
patients due to the nature of the intervention.  The patients attended a face to face 
intervention in the pharmacy therefore, blinding is not applicable.  
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4.6- Recruitment of Pharmacies 
Role of the research pharmacist  
The research pharmacist served as the coordinator for the study.  Duties involved liaison 
with community pharmacists, patients and GPs.  Further duties included writing the 
research protocol along with the patient invitation letters and consent forms; applying for 
ethical approval, data collection and analysis and also coordinating the training sessions 
for the pharmacists.  The researcher carried out recruitment of patients at the hospital site.  
The research pharmacist was also responsible for forwarding the intervention group 
patients’ discharge summary from the hospital to the community pharmacy that the 
patient used.  The research pharmacist contacted the community pharmacist by telephone 
and e-mail to provide the contact details of patients in the intervention group.   
 
 
Role of hospital Pharmacist  
The hospital pharmacist helped the research pharmacist by facilitating operational aspects 
of recruitment at the hospital site.  Other duties included counselling the patients before 
hospital discharge, liaison with the hospital research team and also the doctors and nurses 
on the wards.  In addition, the hospital pharmacist assisted and supported the research 
pharmacist during the recruitment process.  This was by confirming eligibility regarding 
the diagnosis of the patient, access to admission lists and patient recruitment wards.  
Other support included training on how to use the hospital computer system and help 
with baseline data collection.   
 
 
 
146 
 
Chapter Four:                                                                                                    Methodology 
 
The community pharmacies   
The community pharmacists needed to be willing to attend further training on both 
motivational interviewing and secondary prevention medication.  Also the pharmacists 
received and reviewed the patient discharge summary, contacted the patient, contacted 
the patient’s GP if needed.  The community pharmacists delivered a face to face or 
telephone consultation and also followed up patients.  As listed below in the inclusion 
criteria, the community pharmacists also had to accommodate the intervention into a 
MUR or NMS session and followed these services’ criteria and documentation.   
Pharmacies in six London Boroughs were invited to participate in the study with the 
following post codes “E1-4, E6-7, E10-18, RM1, 2, 3, 5-14, IG1-3, IG5-8, IG10, IG11, 
N1, N16, N17, N 21” (Appendix 12).  
 
Pharmacies were recruited with the following inclusion criteria: (1) pharmacies had 
pharmacists willing to counsel patients and interested in attending further training 
organised by UCL School of Pharmacy in collaboration with The University of 
Buckingham and the LPC,  (2) pharmacies have a consultation area in which patients can 
be counselled and have a telephone (land line or mobile), (3) the pharmacists were 
familiar and knowledgeable with the New Medicine Service and MUR, have contacts or 
were willing to contact general practitioners and were willing to contact patients to invite 
for a consultation in the study.   
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4.7- The intervention and intervention development 
The consultation chart (a pro forma to guide the interview consultations between the 
community pharmacists and patients) was developed by an expert psychologist trained in 
motivational interviews (KF) from Buckingham University.  The psychologist designed 
and delivered the training workshops to the community pharmacists and wrote with the 
research pharmacist the consultation road map that would be used by the community 
pharmacists.   
 
Development of the intervention  
The intervention was designed to include a behavioural intervention that involved a 
motivational interviewing session and to be integrated into existing pharmacy services 
NMS or a MUR.  The aim of the consultation was to identify the key issues that the 
pharmacist could assist the patients with and allow patients to express their concerns and 
beliefs regarding the medication.  The design of the intervention was developed based on 
conclusions from the systematic review that was written before designing the study 
(Chapter 2) and by reviewing previous literature.  The search for previous literature 
including pharmacy interventions, using motivational interviews to improve adherence to 
cardiovascular diseases resulted in finding only few studies.  These studies either had not 
published their results yet or had no significant results on adherence.  The consultation 
chart was developed by referring to a previous randomised control trial in hypertensive 
patients Ogedegbe et al, 2007, although the intervention was not delivered by 
pharmacists, but the study showed statistically significant results on adherence to 
medication and was relevant to the study’s methodology.  In Ogedegbe et al, 2007 trained 
research assistants used motivational interviewing to potentially improve adherence.  
Difference in adherence between the intervention and control group in this trial was 14% 
(P=0.027).  The motivational interviewing consultation chart included skills of “Express 
empathy, develop discrepancy, role with resistance, support self efficacy” (Bisono et al, 
2006).   
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The sessions were designed to develop a partnership between the pharmacist with the 
patient and exchange information to facilitate an informed decision.  Furthermore both 
the pharmacist and the patient would negotiate behaviour and reach an agreement.  This 
would be to access motivation and elicit commitment to change behaviour “in this case 
adherence to life saving medication”.  The key methods of a motivational interview 
include:  
 Asking open questions for example “After your Heart Attack can you tell me how 
you are managing with your medication?” 
 Using affirmations for example “Thanks for coming in today.” 
 Listening reflectively to the patient in a way that the pharmacist is still guiding the 
session but chooses what to reflect to. 
 Summary statements can be used to tie patients’ statements together, collect and 
link ideas and even sum up the consultation.   
 
The pharmacist could refer to NICE clinical guideline for myocardial infarction, during 
the consultation session if needed.  Furthermore, for adherence the pharmacist could also 
refer to the NICE 2009 guidelines strategies to support medication adherence.  The 
consultation was claimed for under the New Medicine Service (NMS) or under a 
Medicine Usage Review (MUR).  When the patient was eligible for the NMS the 
pharmacist could also refer to the NMS interview schedule or the MUR guidance if 
eligible for a MUR.  There was an overlap between communication skills for the New 
Medicine Service that involves a patient-centred approach and the motivational 
interviewing consultation.   
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In both the NMS and motivational interviewing the pharmacist starts the consultation by 
introducing himself/herself, then the pharmacist outlines the purpose of the consultation.  
In addition, the pharmacist uses open questions which are essential for the nature of the 
consultation.  In the NMS it is important to ask the right question, use open body 
language and appropriate facial expressions to allow the patient to tell their story (please 
see NMS learning programme https://www.cppe.ac.uk/programmes/l/nms-d-02). 
Regarding listening skills both the NMS and motivational interviewing recommend 
giving the patient a chance to tell what they already know before giving information. In 
the NMS the pharmacist usually summarises the key points for closing the consultation, 
while in motivational interviewing summaries should start early during the session and be 
used consistently as this is one of the a core recommendations of motivational 
interviewing, which rely on OARS (Open questions, Affirmations, Reflections, 
Summaries) technique during the session.   
 
 
For motivational interviewing patients’ motivation and confidence are assessed by scales, 
which are integral to, and influence the subsequent direction of, the consultation.  
Furthermore, ambivalence is important to be spotted by listening carefully for change in 
talk and perspectives; this should be responded to appropriately by elicit-provide-elicit 
technique (please refer to consultation chart appendix 13).  In addition, in motivational 
interviewing the pharmacist asks permission to ask questions and provide information  
Finally, in motivational interviewing the pharmacist should always mention successes 
and appreciate progress by commenting positively on attributes, for example patient 
values, desires and behaviours, this is to express hope, care and support.   
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4.8-Training for the pharmacists in the intervention group 
 
Evidence based data has shown that studies of workshops on motivational interviewing  
lasting between half a day and two days, found improvements in knowledge and skills 
that last at least for a few months (The Health Foundation, 2011).  Therefore, the sessions 
were designed to be around five hours in duration.  The sessions started at 10:00 am and 
finished at 4:00 pm.  Two five hours training sessions on motivational interviewing were 
delivered to allow pharmacists unable to attend the first session the opportunity to attend 
and also an additional two hours booster session was included in the schedule for the 
training.  Thus the training session schedule planned for the intervention group 
pharmacists included:  
 Two sessions on motivational interviews (each pharmacist only attended one 
session). 
 One booster session on motivational interviews. 
 A two hours training session on secondary prevention medication after a 
myocardial infarction.  
 
The content of the workshop was developed by the research team.  Several meetings took 
place between the psychologist at Buckingham University and the researcher at UCL 
School of Pharmacy to develop the training session materials.  These included principles 
of motivational interviewing and also case studies to fit pharmacy practice.  The training 
sessions were developed to be interactive and included different role plays.  The sessions 
were developed as continuous professional development courses which could be 
combined with practice.  The training sessions were designed based on evidence showing 
that training on motivational interviewing is best if delivered as a workshop rather than 
self guided study and could include practice sessions, role plays with ongoing supervision 
of the trainer (The Health Foundation, 2011).  
 
 
151 
 
Chapter Four:                                                                                                   Methodology 
The psychologist delivered the training on motivational interviews in interactive sessions 
with the pharmacists.  Training on secondary prevention medication was based on review 
and update of current clinical guidelines and also treatments and new medications used 
after a myocardial infarction.  The content was written and delivered by the consultant 
pharmacist from the LCH.  The research pharmacist organised the training sessions.  In 
order to ascertain the preferred days for the training and enable attendance, a survey was 
sent to the pharmacists.  This survey addressed locations and timings for the training 
sessions “Please for your kind thoughts on where you would like training session to take 
place? UCL School of Pharmacy Brunswick Square,  the County Hotel Woodford Green 
Essex or the London Chest Hospital Bethnal Green?  Also would you prefer it to be on a 
week day evening or on a Sunday morning?”  After responses were received the plan was 
for the training sessions to be conducted on Sunday mornings.  Moreover, the first 
session would take place at the County Hotel and the rest of the sessions were planned to 
take place at UCL-School of Pharmacy.  This would be feasible under the budget 
available for the training.   
 
A questionnaire was developed to assess the degree of satisfaction with the training on 
motivational interviews (please refer to results chapter 5).  This was given to the 
pharmacists at the end of each training session.  This helped provide information 
regarding the thoughts and ideas of the pharmacists on motivational interviewing as a 
new concept of counselling and communication skill.   Intervention pharmacists were 
also given the consultation chart at the final training session.  This chart was used during 
the pharmacy consultations.  The chart was laminated as a hard copy and the intervention 
pharmacists were asked to keep the laminated copy in the consultation room of the 
pharmacy please refer to (Chart in Appendix 13).   
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4.9-Delivery of the intervention 
The intervention group 
 
The intervention patients on discharge received usual care by a hospital pharmacist.  This 
consisted of a review of medications use, counselling on secondary prevention and any 
other additional prescribed medication, an antiplatelet leaflet and referral to cardiac 
rehabilitation. The researcher contacted each pharmacist to confirm that the patient’s 
details were received and if contact between the patient and pharmacist occurred.  The 
researcher also provided the patients with the pharmacist contact details along with the 
pharmacies locations.  The intervention group patients were also contacted by the 
community pharmacist to invite for a consultation in the pharmacy.  The researcher after 
each patient’s discharge forwarded the discharge summary by email to the community 
pharmacist.  This summary included the disease diagnosis, recommendations to the GPs 
for further management and the medications the patient were stabilised and discharged 
on.  Only patients in the intervention group had their discharge summaries forwarded to 
the community pharmacist.    
 
 
The intervention group consultation 
Community pharmacy consultation around 2 weeks (Consultation Chart in appendices) 
The consultation was designed to be in the pharmacy; a face to face consultation or by 
telephone for 15-20 minutes which includes: a motivational interview session, the 
pharmacists should incorporate the key motivational interview skills acquired from the 
training in their consultation and refer to the laminated copies of the consultation chart. 
Follow up after 3 months 
The second consultation was based on the same principles and had a structure similar to 
that of the first session.  However, patients were encouraged to contact their pharmacists 
before 3 months had elapsed if any further support was needed. 
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The Control Group 
 
The control patients on discharge received usual care by a hospital pharmacist. This 
consisted of a review of medications use, counselling on secondary prevention and any 
other additional prescribed medication, an antiplatelet leaflet and referral to cardiac 
rehabilitation. 
 
 
4.10-Patient recruitment  
The research pharmacist gave a presentation about the study at the LCH.  This was 
important so that other healthcare professionals (hospital pharmacists, nurses and other 
medical staff) were informed about the study, to facilitate the recruitment process.  It was 
agreed with the research department at the LCH that the research pharmacist would 
report to the department each morning for a list of patients eligible for other studies.  
These patients were not to be approached, to avoid recruiting patients on more than one 
study at the same time.  The research pharmacist received training, through an online 
training course at the LCH, regarding ethics and on how to approach/ talk to patients 
during recruitment.  Recruitment took place in two wards at the LCH “CCU ward” and 
“Riviere ward”.  The research pharmacist confirmed the patient’s eligibility.  Then the 
patient was approached by the researcher who explained the study and showed the patient 
the pharmacies’ location on a map especially designed for the study.  A recruitment 
package (this package contained information about the study and also consent forms) was 
left with the patient and the research pharmacist returned at a later time to obtain written 
consent.  If the patient was interested in taking part in the study he/she would sign a 
written consent form and be enrolled into the study.   
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The research pharmacist recorded the following from the patients’ charts; patient details 
(age, ethnicity, diagnosis) and also contact details, regular pharmacy, GP details and a 
discharge summary.  After recruitment patients were allocated into groups according to 
the primary care pharmacy that they usually refill their prescriptions from.  Patients who 
refill their prescriptions from one of the trained pharmacy sites were assigned to the 
intervention group.  Patients who regularly refill their prescription in the pharmacies that 
did not take part in the training but agreed to be control pharmacies were assigned to the 
control group. 
Figure 4.4 Patient recruitment at the hospital   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Research pharmacist assess 
eligibility of patients 
If patient eligible approached by 
pharmacist left with a 
recruitment package  
Patient agrees to take part in the 
study provides written consent  
Patient assigned to intervention 
or control group depending on 
pharmacy used  
Patient in intervention group  
Discharged from hospital 
Patient in control group  
Discharged from hospital 
 
Patient’s discharge summary 
forwarded from the hospital to 
the community pharmacy  
Patient uses control pharmacy  
Patient contacted by research 
pharmacist for data collection  
 
Patient contacted by research 
pharmacist and community 
pharmacist for consultation and 
data collection  
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4.11-Outcome Measures   
The primary outcome measure was self report adherence with coronary artery disease 
medication. The Morisky Medication Adherence Scale plus one self report question, 
adapted from Gehi et al, 2007, were used to assess adherence.  Secondary outcome 
measures were blood pressure and LDL-C.  These data were retrospectively collected at 
baseline from patients’ hospital charts and at 3 months and 6 months from GP practices 
with patient and GP consent.  Other outcomes were the Beliefs about Medicines 
Questionnaire (BMQ) to assess patients’ beliefs regarding their medicines, cost of the 
intervention and pharmacist consultation time.  Measures regarding the feasibility of the 
study were also collected.  These measures included feasibility of conducting the study, 
feasibility of the intervention and also feasibility regarding the evaluation of the study. 
These were collected by surveys, questionnaires and interviews with all stakeholders.  
 
Primary outcome measures 
The reason for selecting adherence as the primary outcome is because adherence is a 
determinant of clinical outcomes of cardiovascular diseases.  Non adherence is a growing 
concern to clinicians and healthcare systems because of mounting evidence that it is 
prevalent and associated with adverse outcomes and higher costs of care (Ho et al, 2009).  
Therefore, adherence is an area that requires further research.  Moreover, for this study 
the intervention could be incorporated into a NMS consultation, where adherence is a 
primary outcome. The reason that clinical outcomes were not selected as primary 
outcomes was because the study is designed as a pilot feasibility study and collecting 
clinical outcomes as primary outcomes would need extra resources.  
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Adherence measure - Rationale behind choosing self report questionnaires  
In a review by Garfield et al, 2012 the authors list several characteristics of a measure of 
adherence “The measure should be rooted in a theory that allows interventions to be 
tailored towards different types of non-adherence; it would also need be able to be used 
repeatedly to track patients’ adherence over time and in response to interventions; it 
should, ideally, be brief and acceptable to patients and be able to be used across a range 
of clinical conditions and it would need to be able to be completed by or in conjunction 
with carers where necessary.”  However, the authors were unable to find an adherence 
measure which met all the above criteria (Garfield et al, 2012).   Adherence in this study 
was evaluated by using two self reported measures; a scaled questionnaire the Morisky 
scale and a single self report one question.  In this research design it is not possible to use 
other adherence measures, for example direct methods cannot be used because the trial is 
not evaluating a single medication and the method can be invasive.  Pill counts were not 
chosen for this research, because the medication is not arranged in blisters but in their 
original containers and alteration by patients can occur (pill dumping).  Electronic 
medication monitors MEMS although accurate however, they are expensive and need 
return visits to download the information from medication vials and this trial did not have 
external funding to provide patients with MEMS.  Furthermore, prescription refills 
although objective and easy to perform also require a closed pharmacy system.  The trial 
has a prospective design and prescription refills could be best used for retrospective 
designs.  Therefore, the use of self report questionnaires is more suitable to measure 
adherence for this study design  The National Collaborating Centre for Primary Care 
(NCCPC) 2009 guidelines stated that self-report is the most available method for 
reporting adherence in a clinical context.  
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In looking at the advantages and disadvantages of self report in routine clinical practice 
and to recommend how it should be used by practitioners, the NCCPC guidelines have 
provided the following evidence based statements; self-reporting is the most simple and 
inexpensive method of measuring adherence, self-reporting is quick and easy to 
administer avoiding the use of sophisticated methodology or equipment, self-reporting 
methods which are validated can feasibly be used in clinical settings.  Self-reporting can 
identify those who are non adherent.  It is most likely those reporting non adherence are 
being truthful, self-reporting can gather social, situational and behavioural factors 
including revealing patterns of medicine use and what leads to non-compliance.   
In addition, there are some disadvantages of self report, as discussed in chapter 1.  Self-
reporting has the problem of over-estimating adherence; inaccurate self-reporting can be 
caused by recall bias, social desirability bias and errors in self-observation.  Taking these 
advantages and disadvantages into account self-reported adherence measurements were 
used for this study, these included: 
1- The Morisky scale 
Self reported adherence measurement the Morisky scale was used to measure adherence 
in this study.  It has been widely used in trials evaluating adherence to cardiovascular 
medication (Morgado et al, 2010, Carter et al, 2009, Calvert et al, 2012).  Morisky et al, 
1986 developed a 4-item scaled questionnaire to assess adherence with antihypertensive 
treatment.  It is composed of 4 yes/no questions about past medication use patterns and is 
thus quick and simple to use during drug history interviews.  The scale has been used for 
many different diseases such as hypertension, hyperlipidemia, asthma and HIV.  This 
version of the original scale became known as the Morisky Medication Adherence Scale 
(MMAS-4).  The MMAS-4 has been cited almost 1000 times since its publication in 
1986 and modified extensively by others.  It has also been translated and used in many 
languages.  In 2008, Morisky published an updated version the MMAS-8 which has a 
higher reliability and higher sensitivity and specificity than the MMAS-4. .  
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The MMAS-8 has also been translated into different languages.  In 2008 Morisky et al, 
examined and tested the concurrent and predictive validity of this structured, self-
reported medication adherence measure in patients with hypertension. Morisky et al, 
2008 reported that from a total of 1367 patients whom participated in the study the eight-
item medication adherence scale was reliable (α= 0.83) and significantly associated with 
blood pressure control (P<0.05).  The sensitivity of the measure for identifying low 
versus higher adherers was estimated to be 93%, and the specificity was 53%.  The 
medication adherence measure seemed to be reliable with good concurrent and predictive 
validity in primarily low income, minority patients with hypertension, and might function 
as a screening tool in outpatient settings with different patient groups (Morisky et al, 
2008). 
 
A systematic review by Garfield et al, 2011 identified 58 measures of adherence.  The 
review found that while validation data were presented in support of the vast majority of 
self reported measures (54/58) under study, data for a relatively small number of 
measures was presented for reliability (16/58) and time to complete (3/58).  The review 
also found that few of the measures were able to distinguish between different types of 
non-adherence and the authors report that this limits their ability to be used effectively in 
the continuous improvement of targeted adherence enhancing interventions.  Garfield et 
al, 2011 found that the Morisky scale is reported as having low internal reliability in half 
the papers that assessed it and as having acceptable internal reliability in the other half 
papers.  Furthermore, The Morisky 8 item scale has been previously validated in over 
1,000 patients with hypertension but not with other conditions (Garfield et al, 2012).  In 
the Morisky 8 item, six of the eight items address general adherence rather than over a 
specific time scale and items two and five address adherence over a fortnight and a day 
respectively (Garfield et al, 2012).   
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In other studies the Morisky scale has been shown not to be associated with the clinical 
outcome or sensitive to poor adherence (Dunbar-Jacob et al, 2012).  In the 8-item 
Morisky Medication Adherence Scale, the first seven items are Yes/No responses while 
the last item is a 5-point Likert response.  The additional items focus on medication-
taking behaviours, especially related to underuse, such as forgetfulness, so barriers to 
adherence can be identified more clearly.  Moreover, the MMAS ranks the degree of 
adherence instead of defining an absolute cut off for adherence (Lam and Fresco, 2015).  
Unlike analyzed scales that have a recommended cut off value; patients that took 80% or 
more of their medicines, as ascertained by an objective measure, for example, MEMS, 
are reported as adherent, and those who took less than this cut off value are reported as 
non-adherent (Lam and Fresco, 2015).  Despite the strengths and weaknesses the Morisky 
scale was chosen to be used in this study because it has been widely used and has been 
validated in a large sample.  However, because a perfect measure does not exist, for this 
research a multi-measure approach was employed.  
 
2-Self report one question  
In the Heart and Soul Study Gehi et al, 2007 followed 1015 outpatients with established 
coronary heart disease.  The patients were asked a single question “In the past month, 
how often did you take your medications as the doctor prescribed?” Non adherence was 
defined as taking medications as prescribed 75% of the time or less, (8.2%) reported non 
adherence to their medications, and 146 (14.4%) developed cardiovascular events.  Non 
adherent participants were more likely than adherent participants to develop 
cardiovascular events during 3.9 years of follow-up (22.9% vs 13.8%, P=.03).  The study 
concluded that in outpatients with stable coronary heart disease, self-reported medication 
non adherence is associated with a greater than 2-fold increased rate of subsequent 
cardiovascular events.  A single question about medication adherence may be a simple 
and effective method to identify patients at higher risk for adverse cardiovascular events.  
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The reason behind choosing this one self report question is that it was used in patients 
with coronary heart diseases, in a large population more than 1000 patients.  In addition, 
it is very simple to use.  Possible responses to this one question were: “All of the time” 
(100%), “Nearly all of the time” (90%), “Most of the time” (75%), “About half the time” 
(50%), or “Less than half the time” (<50%).  Modification to the single question used by 
Gehi et al, 2007 was used.  This was derived from a scale used to measure adherence in 
clinical trials for patients with HIV.  This modified scale has been widely used in HIV 
clinical trials, as recommended by the Outcomes Committee of the AIDS Clinical Trials 
Group (ACTG) who promotes the use of this scale in other projects (please refer to 
Appendix 14). 
 
Secondary outcome measures 
Blood pressure and LDL-C 
These outcomes were selected as secondary outcomes because both high blood pressure 
and high cholesterol level are established risk factors for coronary heart disease.  In 
addition, blood pressure (BP) and low-density lipoprotein cholesterol (LDL-C), can serve 
as biomarkers of the efficacy of pharmacotherapy to lead to optimal cardiovascular health 
outcomes.  The relationship between BP and LDL-C control and clinical outcomes has 
also been established through both epidemiological and clinical treatment trials (Lee et 
al, 2006) and also these markers have been employed in trials studying adherence to 
secondary prevention medication of a similar methodology to our study.  These outcomes 
were recorded at baseline from the patients’ hospital data and then retrospectively from 
the GP practices by the research pharmacist, by fax and telephone after obtaining patient 
consent.  It was not possible to provide patients with home blood pressure and LDL-C 
monitors or to measure these outcomes by the participating pharmacists because 
pharmacies could vary in provision of these services.   
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Blood pressure was classified before the study according to the British Hypertension 
Society guidelines 2011 into hypertension systolic blood pressure>= 140-159 mmHg and 
diastolic blood pressure of >= 90-99 mmHg. In addition the Joint British Societies 
recommend cholesterol limits for people who have, or are at risk of, coronary heart 
disease: total cholesterol - less than 4.0mmol/l and LDL cholesterol - less than 2.0mmol/l. 
 
 
The Beliefs about Medicines Questionnaire (BMQ) 
The BMQ was used to assess patient’s belief about the medication.  The BMQ could 
serve as useful tool to examine a relationship between beliefs about medications and self-
reported medication adherence.  Previous literature has shown patients’ beliefs about 
treatment influence treatment engagement and adherence (Horne et al, 2013). 
Furthermore, this relationship has been studied in previous trials (Gatti et al, 2009) 
(Sjolander et al, 2013) where patients who reported better adherence have expressed 
positive beliefs regarding the necessity of their medicines.  In this study we sought to 
examine this relationship with the hypothesis that patients’ beliefs about medicines could 
be associated with adherence.  The BMQ is a valid and reliable scale; it has been 
validated for use across a range of different diseases including renal, cardiac, diabetes, 
asthma, psychiatric and general medical illnesses (Horne and Weinman, 1999).  The scale 
comprises two main sections, the BMQ specific and BMQ general.  The BMQ specific is 
comprised of two subscales, which are BMQ necessity and BMQ concerns.  The BMQ 
general also originally comprised of two subscales which are BMQ harm and BMQ 
overuse.  A third subscale, which is BMQ benefit, was later added to BMQ general.  In 
this research only the BMQ specific will be used to assess participants’ beliefs about their 
medication.   
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The authors report moderate to high internal consistencies of BMQ specific scale (Horne 
et al, 1999).  The reported Cronbach’s alphas were; BMQ necessity= 0.55-0.86 and BMQ 
concerns = 0.63-0.80, depending on the specific diseases.  Two week test-retest of the 
BMQ among asthmatic group indicated reliability of its various subscales (BMQ 
concerns r=0.76 and BMQ necessity r= 0.77).  Discriminant and criterion validity were 
also established for the scale; correlations were obtained between BMQ concerns scores 
and self-reported medication adherence as well as between BMQ subscale scores and 
other measure of illness and medication beliefs. 
Table 4.1 The Beliefs about Medicines Questionnaire- Specific  
BMQ Specific (Necessity sub scale)  
My life would be impossible without my medicines 
Without my medicines I would be very ill 
My health at present, depends on my medicines 
My medicines protect me from becoming worse 
My health in the future will depend on my medicines 
 
BMQ Specific (Concerns subscale)  
I sometimes worry about the long term effects of my medicines 
Having to take my medicine worries me  
I sometimes worry about becoming too dependent on my medicines  
My medicine disrupts my life 
My medicines are a mystery to me  
 
Using the BMQ scale, participants are asked to rate their agreement with the specific 
statements using a 5 point likert scale (1= strongly disagree, 2= disagree, 3= uncertain, 4= 
agree and 5 =strongly agree).  The scores of each subscale are computed from the sum of 
all items within that particular subscale and range from 5-25 for both subscales BMQ 
necessity and BMQ concerns.  The necessity-concerns differential can be computed by 
subtracting the total BMQ concerns subscale score from the total BMQ necessity 
subscale score.  A positive differential score indicates that the participants perceive the 
benefits of their medication to outweigh the risks, in contrast negative differential score 
indicates that participants perceive the risk of taking their medication outweigh their 
benefits.  The differential scores range from -20 to 20.    
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Cost of the study 
There were several costs associated with conducting this feasibility study.  These 
included training of the community pharmacists on motivational interviews.  The costs of 
the training sessions including room booking, material printed, time required for the 
training, delivery of the training by a psychologist and reimbursement for the 
pharmacists’ time.  These were recorded by the research pharmacist.  Furthermore, cost 
of the community pharmacist intervention in terms of time and material spent on 
counselling patients.  The community pharmacists were asked to record the time they 
spent in contacting and counselling patients, also if they were able to fit the session under 
a NMS or MUR and how many sessions could one pharmacy manage per day, to 
establish if an intervention can be accommodated into a daily schedule of a community 
pharmacy.  
 
4.12-Liaison with the general practitioners (GPs) 
The research pharmacist used the data recorded at baseline (patient’s postcode and GP 
practice) to contact the patients’ GPs.  Each Patient’s general practitioner was sent by 
mail an individual letter by the research pharmacist, explaining briefly the study along 
with a copy of the patient’s consent form.  The GPs provided written consent on 
providing the results of blood pressure measurements and LDL-C levels during the 
timeline of the study.  The GP surgeries who did not return the consent forms were 
contacted by telephone by the research assistant and faxed a copy of the invitation letter 
and the patient’s consent form.  The GPs agreed to fax the patients’ results and be part of 
the study.  
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4.13-Process evaluation 
The process evaluation will enable an assessment of the feasibility of the intervention in 
practice and examine the types of settings, situations or circumstances in which an 
intervention is more or less likely to be effective.  If the intervention is not demonstrated 
to have a significant impact, the process evaluation may be helpful in establishing why it 
was not successful, e.g. if it is due to difficulties in implementation rather than its 
inherent inefficacy.  This will assess the implementation and operation of the 
intervention, its workability in settings and secondary or perceived impacts.   
 
For this study this will include: (1) recruitment and training of the community 
pharmacists which can be established from pharmacists’ response rates (expression of 
interest); (2) attendance at the training sessions and feedback from pharmacists regarding 
the training; (3) feasibility of the delivery of the intervention in a community pharmacy 
setting (community pharmacists’ feedback on patient contact and invitation to the 
consultation, attendance of patients to the pharmacy, patients’ receiving the consultation 
by telephone, the benefit of receiving a hospital discharge summary and  the possibility 
of incorporation of the consultation under a NMS/MUR service); (4) for GP enrolment 
the study process evaluation will include GPs’ response rate through GP letters returned, 
workability and feasibility of provision of data from GP surgeries for the secondary 
outcomes; (5) in the hospital measures such as patients’ willingness to participate in the 
study, recruitment rates will need to be established and finally; (6) patient feedback on 
the pharmacy intervention in terms of time, benefit and acceptability.  Measures 
regarding the feasibility of the study are summarised in the table below 
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Table 4.2 Measures regarding the feasibility of the study 
Measures would include: 
Hospital Pharmacists:  
1- Number of hospital pharmacists willing to take part in the trial. 
2- Time spent in sending a discharge letter to the community pharmacists 
and time spent in contacting community pharmacists. 
3- Hospital pharmacists drop out during the study. 
Community pharmacists: 
1- Number of pharmacies and pharmacist willing to take part in the study. 
2- Number of community pharmacists willing to take part in the training and 
time spent on training.  
3- Time spent by the community pharmacist in counselling patients in the two 
sessions. 
4- Time spent by community pharmacist in contacting the patient and patient 
follow up. 
5-  Community pharmacists drop out during the study. 
Patients:  
1- Number of eligible patients.  
2- Number of patients contacted by the community pharmacists. 
3- Number of patients attending the first and second visit to the community 
pharmacies. 
4- Number of patients counselled for the NMS or MUR  
 
 
 
Instruments for evaluation of the feasibility study 
Instruments for evaluation of the feasibility study involved interviews, questionnaires and 
email surveys with all stakeholders’ pharmacists and patients and also a log book and 
record of important numbers and events during the management and operation of the 
trial. This log book was kept by the researcher.   
 
 
 
166 
 
Chapter Four:                                                                                                    Methodology 
Semi structured interviews were conducted with hospital pharmacists, community 
pharmacists and patients.  A semi-structured interview is a method of research used in the 
social sciences.  While a structured interview has formalized, limited set questions, a 
semi-structured interview is flexible, allowing new questions to be brought up during the 
interview as a result of what the interviewee says.  The interviewer in a semi-structured 
interview generally has a framework of themes to be explored.  Interviews were 
conducted to evaluate operational aspects of the trial and assess workability; in addition 
to understand the stakeholders’ points of view regarding the feasibility of this study.  This 
included for the hospital pharmacists the feasibility of conducting a study in the hospital, 
for the community pharmacists all aspects of the training, the consultation and operation 
in the pharmacy and for patients’ views regarding any potential benefits and uptake of the 
intervention.    
Table 4.3 Questions for interviews with stakeholders  
Questions for hospital pharmacist 
 Please can you tell me your thoughts regarding patient recruitment and 
data collection, also regarding extra time needed for this? 
 Please can you tell me your thoughts regarding a copy of the patients 
discharge summary to be sent to the community pharmacy? Do you 
think this is vital for continuity of patient care? 
 Please can you tell me your thoughts regarding patient care services 
available in community pharmacies and how useful they are for patients? 
 
Questions for community pharmacists 
 Can you please tell me what you felt went well in the study, and what 
problems did you experience?  
Training 
 Can you kindly tell me your view of the training in regards to location, 
timing, convenience and length /duration?  
 How helpful, did you feel the training was adequate?, can you kindly 
provide any comments on particular aspects of the training, what was 
helpful, what was difficult? 
Delivery of the intervention 
 To what extent do you feel you were able to adhere to motivational 
interviewing techniques in the consultation?  
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 Can you please tell me your view on the use and value of motivational 
interviewing to support patients? 
 
Identifying patients and making arrangements for the consultation 
 Please can you inform me about how much time was required for 
identifying patients and arranging for the consultation? Did you find that 
time? 
 How much time did you need to conduct the consultation? 
 How much time did you require for arranging the second consultation? 
 How much time did you require to conduct the second consultation? 
 Please can you describe what went well? And what problems did you 
experience?  
 Can you kindly tell me what kind of impact did the consultation have on 
operation of pharmacy or other pharmacy staff or customers? 
Questions for patients: 
 What is your perceived value of the consultation, how satisfied are you with 
it? 
 Was the consultation convenient regarding the time and the pharmacy 
location? 
 So can you please describe the experience that you had with the pharmacy? 
 Was the consultation with the pharmacist helpful, can you tell me about it? 
 Was there anything that was not convenient? 
 So do you think it was beneficial in providing information about what the 
medicines are? 
 
The questions were first piloted before the conduction of the interviews to assure 
feasibility. The interviews were audio taped with the permission of the pharmacists 
and patients and notes were also taken. The interviews were then further 
transcribed, coded and analysed.   
Evaluation was conducted to demonstrate if the designed methodology of this pilot study 
could be later adapted to design a larger trial.  Also to identify weaknesses and problems 
in the operation of the study that could be avoided for future design of a larger study.  
Moreover, to highlight any strengths in the design and methodology of this pilot study 
that helped facilitate operation.   
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Assessment of the fidelity the intervention  
A scaled one question recommended by the psychologist at UCL School of Pharmacy 
was used, to assess the fidelity of the motivational interviewing techniques during the 
community pharmacy consultations.  Pharmacists were asked to quantify adherence to the 
protocol and also to what extent they used motivational interviewing, in their 
consultations with the patients.  This was part of process evaluation and was achieved by 
using the following scale question: "From a scale of 1-5 with 1 being the lowest and 5 the 
highest, how much did you adhere to the protocol and use motivational interviewing in 
your consultation?" 
 
4.14-Data collection  
Data collection for primary and secondary outcomes was carried out at the hospital and 
also at UCL School of Pharmacy by the researcher and research assistant.  The feasibility 
study was designed as a prospective study therefore; a schedule (timetable) was designed 
for the patients to be recruited and for follow up.  Patients recruited on the study would 
receive the intervention and also have their data collected at different timings depending 
on the time they were enrolled into the study.  Data in this study were collected by 
telephone and also by post.   
Data collection of self-report questionnaires  
The researcher contacted the patients by telephone to fill the Morisky questionnaire and 
also the one self-report question.  At recruitment, the researcher explained to the patients 
in the intervention group that they would be contacted by a community pharmacist for the 
intervention and by the research pharmacist for data collection to avoid confusion.  The 
research pharmacist was provided with a mobile phone dedicated for data collection.  If a 
patient did not answer, a voice message was left on the answering machine and the 
researcher would contact the patient at a more convenient time.   
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Data collection of the Belief about Medicines Questionnaire 
This included a postal questionnaire sent by the research pharmacist by mail to both 
groups of patients, to evaluate the effect of the intervention on patients’ beliefs regarding 
the medication.  A prepaid envelope was also included so that the patients could return 
their response.   
 
Data collection of secondary outcomes 
Patients’ baseline data regarding LDL-C and blood pressure were collected by the 
research pharmacist at the LCH.  The data collected at the hospital included the initial 
LDL-C and blood pressure reading on admission.  Other baseline data collected from the 
hospital included gender, age, diagnosis, ethnicity, post code and GP practice.  The 
research assistant contacted the GPs to collect data regarding LDL-C and blood pressure.  
Initially it was agreed to collect the data by telephone but the method was changed to 
faxing the data to ensure accuracy and also confidentiality of the data collected.  The 
research pharmacist employed the UCL School of Pharmacy fax form and faxed the 
patient’s consent form to the GPs.   
 
Timings of data collection  
Data was collected at baseline from the hospital, at 2 weeks for the self report 
questionnaires, at 3months for the BMQ-Scale and at 3 and 6 months for self report 
questionnaires, blood pressure and LDL-C.  
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4.15-Data processing and analysis  
Data processing 
The researcher kept a record of the study’s process.  This included number of eligible 
patients, number of patients recruited each day and number of discharge summaries sent 
to pharmacies also patient attendance to pharmacy consultations and all aspects of the 
operation of the study.  Furthermore, the researcher filed each patient’s consent form 
along with a discharge summary and data sheet.  The patient data sheet included GP 
contact details, ethnicity and patient’s address and contact details.  
 
Folders were developed for both patients in the intervention group and control group.  
Each patient was allocated a trial number.  Data regarding adherence to secondary 
prevention medication and also data including blood pressure and LDL- C were filed 
under each patient’s trial number.  This resulted in each patient’s file to include the 
following: a file number, a discharge summary, a patient data sheet, a signed consent 
form, Morisky adherence sheet at three points of time baseline, 3months, 6 months, 
Belief regarding Medicines questionnaire sheet, GP faxed results sheet at two points of 
time 3 months and 6 months.  Folders for data from interviews and questionnaires with 
stakeholders were also created by the researcher.  
 
Data analyses  
Data were analysed by using the Statistical Package for the Social Sciences (SPSS) 
version 22 for windows. In accordance with accepted practice for clinical trials an 
‘intention to treat’ approach was followed, in which all patients recruited to the study 
were included in the analyses irrespective of whether they received the full intervention 
or remained in the study until completion.  
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An independent T-test was used to compare difference in adherence between the 
intervention group and control group at baseline, 3 months and 6 months.  Significance 
was set at 5 percent level.  The independent t-test is an inferential statistical test that 
determines whether there is a statistically significant difference between the means in two 
unrelated groups. In this sample there were two groups’ intervention and control 
unrelated to each other.   In addition, an independent T-test was used to compare 
difference in blood pressure and LDL-C between the intervention group and control 
group at baseline, 3 months and 6 months, significance was set at 5 percent level.  A chi-
square test was used to test if there was a relationship between beliefs regarding the 
medicines and adherence significance was also set at 5 percent level. Furthermore, data 
from interviews and questionnaires with stakeholders were analysed by labelling and 
coding all of the data to enable identification of similarities and differences. In addition, 
content analysis was applied to make sense of the data collected and highlight important 
messages, features and findings. 
 
4.16-Ethical consideration  
Ethical approval was sought by the researchers from The National Research Ethics 
Service NRES Committee North west –Preston through the IRAS integrated research 
application process.  A favourable opinion was granted from the committee on the 28th 
of March 2013 before starting the study, R&D approval was also obtained from the Joint 
Research Management Office Queen Mary Innovation Centre at Barts Health NHS trust 
and from R&D office at University College of London. (Refer to the ethics approval 
letters in the appendices).  During recruitment the patients were informed that their 
participation would be voluntary and that they could withdraw from the study at any time 
they choose without an explanation.  The patients enrolled on the study needed to sign a 
written consent and also consent for data collection from GPs.  Eligible patients were 
provided with a recruitment package.  The package described the study and the data that 
would be collected.  
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The patients were informed how their data would be used, analyzed and that the data 
would be anonymous and unidentified.  Patients were given a trial number after 
enrolment to ensure confidentiality.  Patients were only referred to through the trial 
number.   For data protection a locked cabinet in the hospital was allocated by the 
pharmacy team to store patients’ consent forms and other data regarding GP surgery and 
contact details.  The patient’s discharge summary to the community pharmacies, was 
forwarded electronically through the secure hospital pharmacy computers.  The hospital 
computers were password protected and the passwords were changed periodically.  The 
record of the research daily activities was kept in the hospital and stored in the locked 
cabinet.  
 
 
The community pharmacists stored the information regarding the consultation with the 
patient based on MURs and NMS record keeping and data requirements.  Patient data 
was treated as strictly confidential.  In case a significant problem was identified by the 
community pharmacist conducting the intervention, the pharmacist would refer the 
patient back to the GP or the prescriber, if the referral was urgent then the referral would 
be by telephone and further documented.   
Further research data (Morisky questionnaire, BMQ questionnaire) were collected by the 
research pharmacist from the patients.  The data was stored at UCL School of Pharmacy 
in a designated cabinet and locked.  The school computers were password protected and 
only accessible to the research team, passwords were changed on a regular basis.  The 
data would be stored for more than five years and destroyed by UCL School of Pharmacy 
at the end of this period.   
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4.17-Reliability of the results  
The research pharmacist and research team followed the study protocol closely.  The 
research pharmacist conducted interviews with stakeholders by telephone and the 
interviews were audio recorded.  The research pharmacist also followed the interview 
structure closely to reduce bias.  The researcher reviewed and revisited the transcripts 
several times for new codes.  Furthermore, 10% of the interviews were checked by the 
supervisor for reliability.  The motivational interviewing consultation designed for the 
intervention was written by the psychologist from Buckingham University and was also 
reviewed by the psychologist at UCLSOP to ensure compatibility with motivational 
interviewing techniques and to increase reliability.  The community pharmacists adhered 
and tried to be consistent with the protocol of the intervention. Furthermore, the 
community pharmacists were asked to rate their use of motivational interviews with the 
patients by a scaled questionnaire designed by the psychologist to evaluate reliability.  
 
4.18-Validity of the results  
This study used Methodological triangulation which involves using more than one 
method to gather data.  Triangulation will help bring the results together and enhance the 
validity.  The study employed both interviews and questionnaires and used both 
quantitative and qualitative measures. Two quantitative measures of adherence were 
used; a validated scale for adherence measurement the Morisky scale and a one self-
report question.  This was to increase the validity of results for the primary outcome 
which is adherence to the cardiovascular medication. The study also used the BMQ 
questionnaire which is a valid and reliable scale. The BMQ has been validated across a 
range of different diseases.   
 
174 
 
Chapter Four:                                                                                                    Methodology 
 
Additionally, the study was designed with a control group and had a randomisation 
design, which could lessen external validity problems.  However, generalizability will 
still need to be tested in a larger study and with different regions and pharmacy settings.  
Furthermore, the results were reviewed and checked by the supervisor and also by an 
independent statistician at UCLSOP to ensure that the tests applied were accurate and 
relevant to the studied outcomes.  The results of the study were compared with other 
similar previous studies on cardiovascular diseases and adherence to medication as a 
check of validity.   
 
The methods of evaluation selected for this study each have their strengths and 
weaknesses for example interviews could serve as a good  measure of attitudes of 
respondents, also can provide in-depth information, allow good interpretive validity and  
have a quick turnaround for instances in telephone interviews.  However, if conducted 
face to face could be expensive and time-consuming and possibly involve reactive and 
investigator effects.  Moreover, questionnaires are considered practical and cost effective 
to use, also the results of questionnaires can be quickly and easily quantified by the 
researcher, although it is argued that questionnaires can be inadequate to understand  
some forms of information such as changes of emotions, behaviours and feelings.  
Therefore, for this study a mixed approach for evaluation was employed involving 
validated scales, interviews, questionnaires, records of study operation and conversations 
with all involved stakeholders; in order to be able to produce valid and reliable data from 
this pilot feasibility study.  
 
 
                                                     End of Chapter Four  
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This chapter will demonstrate results of the feasibility study.  It will include results on 
recruitment rates of pharmacies, GPs and patients, response rates of patients/attrition, 
characteristics of respondents and results showing comparison of intervention and 
control.  The chapter will also show results on the impact of intervention, primary and 
secondary outcomes, and measures regarding the feasibility and acceptability of the 
randomised control trial and from perspective of stake holders’ pharmacists and patients.  
 
5.1-Results on recruitment rates of pharmacies, patients and GPs 
Feasibility of recruitment of community pharmacies  
Pharmacists were contacted by North East London LPC and asked to register their 
interest to take part in the study.  Twelve pharmacies expressed initial response after one 
week.  After two weeks a further ten pharmacies showed interest.  A final email was 
forwarded to eligible pharmacies and recruitment of pharmacies by the LPC registry was 
closed on the 8
th
 of May 2013.  The total number of pharmacies who showed interest to 
participate in the project at that time was 22, these pharmacies included in total 26 
pharmacists.  Further pharmacies were invited to take part in the study, after discussions 
between the researchers raising concern that the number of pharmacies may not be 
sufficient to meet the patients’ sample size.  A talk by the researcher regarding the study 
was given during a pharmacy meeting that was also organised by the LPC.  This led to a 
further 20 pharmacies (24 pharmacists) expressing interest.  Therefore, the total number 
of pharmacies was increased from 22 to 42 and the total number of pharmacists 
expressing interest was 50.  From the 42 pharmacies that expressed interest to be part of 
the study 32 pharmacies fulfilled the inclusion criteria and were allocated into 
intervention 16 pharmacies (19 Pharmacists) and control 16 pharmacies (19 Pharmacists) 
this is discussed in the section below.  These pharmacies were marked on a map for 
North East London.   
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Allocation of pharmacies to intervention and control groups 
Simple randomisation of the entire sample was not possible because dates of training 
sessions had to be set in advance.  Thus procedures were adopted to ensure comparability 
of the intervention and control groups for this feasibility/pilot study. Pharmacy 
recruitment was all done through NELLPC.  Pharmacists informed of study by two 
different routes.  Firstly, by email 22 pharmacies responded that they wished to take part. 
These were randomised to intervention and control by an independent statistician at the 
UCL School of Pharmacy.  This process was concealed from the researcher and the 
research team and was performed at pharmacy level to avoid contamination of controls.  
To achieve sufficient numbers a second group were invited to participate during a 
professional meeting and 10 pharmacies met the inclusion criteria.  Therefore, 
pharmacists wishing to take part and able to attend the pre-determined dates of the 
training were allocated to the intervention group.  The control group was a matched 
sample drawn from remaining pharmacists who expressed a wish to take part.   
Pharmacies allocation and recruitment   
Figure 5.1 The first recruited tranche of pharmacies and their randomisation 
 
 
 
 
 
 
 
 
 
22 pharmacies expressed 
interest to participate in the 
study 
22 pharmacies  matched the 
inclusion criteria 
Randomised by an independent  
statistician 
 11 pharmacies (13 pharmacists) 
Intervention group, pharmacists 
trained on Motivational 
interviews 
 
  
 11 pharmacies (13 pharmacists)  
Control group   
Pharmacists no training  
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Figure 5.2 The second recruited tranche of pharmacies  
Further pharmacies were invited to participate in the study after a decision made by the 
research team to increase the number of pharmacies:   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3 The total number of pharmacies included in the study and their allocation 
 
 
 
 
 
 
 
  
 
 
20  pharmacies expressed 
interest to participate in the 
study 
10 pharmacies  matched the 
inclusion criteria (pharmacies able to 
attend the training on motivational 
interviews) matched with control 
pharmacies 
42 pharmacies from 6 London 
boroughs expressed interest to 
participate (50 Pharmacists)  
32 pharmacies matched the 
inclusion criteria  
(38 Pharmacists) 
Randomised 
5 pharmacies (6 pharmacists) 
Control group 
Pharmacists no training 
 
  
 
5 pharmacies (6 pharmacists) 
Intervention group   
Pharmacists trained on 
Motivational Interviewing 
 
 
 
interviews 
 
  
 
16 pharmacies 
(19 pharmacist) 
Control group (UC) 
Pharmacists no training 
 
  
 
16 pharmacies 
 (19 pharmacist) 
Intervention group (PC) 
Pharmacists Trained on 
Motivational interviews 
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Feasibility of the training of community pharmacists  
Email invitations were sent to the intervention group pharmacists to attend the training.   
The training sessions were conducted according to the schedule outlined in the 
methodology of the study these included:  
 Two sessions on motivational interviews. 
 One booster session on motivational interviews plus a training session on 
secondary prevention medication.   
Eleven pharmacists attended the training that took place on the 23
rd
 of June 2013.  A 
second training session took place at the UCL-School of Pharmacy on the 4
th
 of August 
2013, nine pharmacists attended the training.  A further training session took place on the 
8
th
 of September 2013; this included a booster training on motivational interviews along 
with training on secondary prevention medication organised by the London Chest 
Hospital.  On the 8
th
 of September 2013 10/19 pharmacists attended the booster training.  
All 19 intervention pharmacists received at least 5 hour training on motivational 
interviewing please see chart below (attendance of intervention pharmacist at the training 
sessions).  However, not all pharmacists received the booster training or the training on 
secondary prevention medication.  The given course material was sent by email and mail 
to the pharmacists unable to attend the booster session or training on secondary 
prevention medication.      
 
Locations of the training sessions 
The first training session took place at the County Hotel in North East London.  The 
second training session took place at UCL School of Pharmacy in central London.  The 
third and final session which included a booster training on motivational interviews also 
took place at UCL School of pharmacy.  Each training session was 5 hours in length 
except for the booster session that was 2 hours.  The locations were determined 
depending on the study’s available funds for room booking, training materials and 
catering and also the participants’ preference.   
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Figure 5.4 Chart Attendance of intervention pharmacist at the training sessions 
 
 
The training sessions were scheduled to be delivered on Sundays, due to work 
commitments of the pharmacists during the working days of the week.  Intervention 
group pharmacists were eager to attend and learn the new skills.  Below are some of the 
emails sent to the researcher by the intervention group pharmacists after the invitation to 
the training.  
“I am very enthusiastic about the opportunity you are creating and am pleased that it 
seems pharmacy is moving in the right direction. Well done to you. I would like to ask 
when exactly the training will take place and how and when we will be informed.” 
Regards G.S , B. Pharmacy 
 “Thanks for the invite to study. Definitely interested, would you know roughly when the   
two days training is? 
CK. W., W. Pharmacy  
• 11 intervention pharmacists attended the 
training.  
First training session on 
motivational interviews 
23rd of June 2013  
 
• 9 intervention pharmacists attended the 
training.   
Second training session on 
motivational interviews  
4th of August 2013  
• 1 intervention pharmacist dropped out of 
the study. 
•  9/19 intervention pharmacists attended 
the training. 
Third training session on 
secondary prevention 
medication plus a booster 
on  motivational interviews 
8th of September 2013  
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Certain difficulties were faced during the organisation of the training sessions.  These 
included agreement between the pharmacists on the date of the training, therefore more 
than one day was organised.  This also had an impact on the psychologist’s time, having 
to deliver the training more than once.  The location of the training had an effect on the 
number of pharmacists that could attend, due to the fact that most of the pharmacists 
worked in North East London and the preferred location was to be around this London 
area.  Not all pharmacists were keen to travel beyond this area.  Before deciding the dates 
and locations, an email survey was sent to the 13 pharmacists (first tranche of recruited 
pharmacists) in the intervention group to ask about preferred locations and days for the 
training sessions on motivational interviews.  The majority of pharmacists agreed that 
Sunday was a good day for the training.  Most pharmacists agreed that the county hotel 
would be more convenient because the pharmacies that they work at are located around 
the county hotel.  Some pharmacists still did not mind that it was at UCL School of 
Pharmacy. 
 “Yes at UCL it is convenient yea it is fine, it isn’t too difficult to get to.”   
Few pharmacists disagreed “The School of Pharmacy is time consuming.”    
Other pharmacists did not mind the location of the training. 
“I do not mind UCL or county Hotel as long as there is free parking that will be 
wonderful.” 
 
A certificate of attendance was organised by UCL School of Pharmacy for the 
pharmacists that attended the training, this was given to the pharmacists after they 
completed the training (please refer to certificate in Appendix 15).   
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Evaluation of the training 
 A questionnaire was developed to assess the degree of pharmacists’ satisfaction with the 
training on motivational interviews (please also refer to questionnaire in Appendix 16).  
This was filled by the pharmacists at the end of each training session. 
 
Figure 5.5 Evaluation of the questionnaire for the course on motivational interviews 23
rd
 
June and August 4
th
 2013 
1- How satisfied are you with the course content (range and depth)? 
 
2- How satisfied are you with the delivery and teaching methods? 
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Dissatisfied  
June 23rd 
August 4th  
0 
1 
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9 
10 
Very Satisfied  Satisfied  Neutral Dissatisfied  Very 
Dissatisfied  
June 23rd 
August 4th 
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3- Did this course succeed in enhancing your consultation skills as a health care 
practitioner? 
 
 
4- How satisfied are you with the length and time of the course?  
 
 
 
 
Results from the questionnaire above; show that the majority of intervention group 
pharmacists were either very satisfied or satisfied with the motivational interviewing 
course content, delivery, time and length and also teaching methods.  The majority of 
pharmacists also either strongly agreed or agreed that the course managed to enhance 
their consultation skills as healthcare professionals.  
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disagree 
June 23rd  
August 4th  
0 
1 
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June 23rd  
4th August 
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Below are the intervention group community pharmacists’ comments on the training. 
These results are from the evaluation questionnaire: 
 This actually should be incorporated into the pharmacy curriculum. 
 Very enlightening in new ways of improving patient outcomes through 
motivational interviews consultation. 
 Very positive learning from a specialist outside pharmacy we communicate every 
day I now know how badly we do it. 
 I plan to attend further training if possible it would be helpful to my practice.  
 Very interactive many thanks. 
 Well done, constructive, very informational. 
 Although do not like group work in this case it was very helpful. 
 Very informative thank you very much. 
 Very informative and well structured, some great new ways to motivate patients 
without putting any pressure on them and putting the ball in their court. 
 
Assessment of community pharmacists motivational interviewing skills after the training  
The psychologist evaluated the uptake of motivational interviewing skills by the 
pharmacists in the course of the training.  However, for a future larger study scales such 
as the Motivational Interviewing Treatment Integrity (MITI 3.1) scale (Moyers et al, 
2005), using recorded role-play activities that occur one week after the training has been 
received, would be recommended.  The MITI is an instrument designed to measure the 
degree to which a practitioner is interacting with a client in a way that is consistent with 
motivational interviewing.  To use the MITI, trained raters observe or listen to a 20 
minute interaction.  Validated scales such as the MITI can also provide feedback that can 
be used to increase clinical skills in the practice of motivational interviewing.  
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Interviews with community pharmacists  
The researcher invited the intervention group community pharmacists for a telephone 
interview to study their views regarding the training, the operation and delivery of the 
consultations at the pharmacy and also the use of motivational interviewing in the 
intervention.  Four pharmacists agreed and were interviewed.   
Pharmacists’ views regarding the training 
 
In the interviews some pharmacists reported that the motivational interviewing skills that 
they learned from the training sessions, needed to be applied to their practice in the 
pharmacy to be sustained as a skill.  
“Sustained application of motivational interview techniques will be the real test.” 
“Ability to mature after learning is fantastic putting the knowledge to work.” 
Other pharmacists agreed that they were able to learn the skills during the training 
sessions and could apply to practice.   
“I think during the training day I was able to learn the skills, so it was easy to learn in a 
couple of days that I went to so yes.” 
 
 
Few pharmacists thought that they needed more sessions and time to learn motivational 
interviews. “A lot to take in could be better if sessions were done over a few weeks.” “A 
refresher session will be good”  “May be a bit long but informative”.   
The pharmacists also reported that the role plays practiced during the training course 
were very helpful and enabled them to learn the skills of motivational interviewing.  
“Because we did the hand out role play that stayed in mind so you recall what you were 
doing then”   
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In addition some of the pharmacists agreed that motivational interviewing would be a 
useful skill to learn earlier at university level. 
 “I think it is a really relevant skill to have and it would be good to know about it earlier 
on, at university” 
Pharmacists’ years of graduation and thus ages differed.  This had an effect on the uptake 
of the skills some pharmacists had adopted certain techniques in counselling due to long 
experience with patients and faced difficulties in changing these techniques.   
“You have not to lose attention because you tend to go back to old practice that is hard 
isn’t it?” 
“It was all fine but I noticed during the motivational interviewing course the age range of 
the pharmacists that were there, I think I was the only one below the 30 mark and if you 
do not get it totally then I do not think there will be a right amount of change.” 
“Yes if I could have started it earlier and became more natural, than having to change a 
little bit from what I was doing.” 
It was observed and reported to the researcher by the psychologist during the training 
sessions that younger pharmacists accepted and adapted the new skills of motivational 
interviewing more easily.   
 
 
Making arrangements with patients for the consultation 
 
The intervention patients were referred from the LCH to the pharmacies for the 
consultation.  The community pharmacists reported in the interviews that they contacted 
the patient and if the patient agreed to attend the consultation a convenient time was 
agreed between both the pharmacist and the patient. 
 “We decided on a time convenient to him and me so it was on a Saturday which was 
fine.”  
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Patients who did not attend a face to face consultation were contacted by telephone and 
the pharmacists reported that they were able to engage the patient by telephone.  
“My own patients were not involved in my group, I had a patient who uses a different 
pharmacy, but I still managed to engage patient on phone”.   
Furthermore, if a patient did not respond an additional call was arranged by the 
community pharmacist.  Pharmacists also reported that contacting the patients did not 
have a negative impact on the operation of the pharmacy.  
 “Patients did not contact the pharmacy, I had to contact them.”  
“Effect on operation of pharmacy in terms of time and resources, minimal” 
“No it doesn’t have an effect on the operation of the pharmacy” 
 
Community pharmacists agreed that the integration of motivational interviews in services 
such as a MUR or NMS did not add extra timing on the consultation or the operation of 
the pharmacy.   
“I do try to keep the consultation short as possible but it has had an effect before but 
motivational interviewing has not changed that.”   
“In a busy pharmacy, coming out of a consultation can be stressful for the team.  At times 
there can be a lot of prescriptions waiting to be checked. This is regardless of which 
techniques you use.” 
“The shops floor keeps on running as it is, me being in the consultation room does not 
make any difference.”   
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The community pharmacists reported that they delivered the consultations between 15-20 
minutes. This is similar to the time pharmacists spend on a pharmacy consultation 
without using motivational interviews. 
“I try to make it about 10-15 minutes, but it depends on how many medication people are 
on.” 
“We decided, because he had a parking place so he could not be for long, so we decided 
yea 20 minutes and we stuck to that target we tried and covered everything in that time.” 
“I just need to prioritise what needs to be done first and knowing that I will be away for 
at least 10 minutes and they do not interrupt me.” 
“No the time not really it takes the same I just combine it together so it probably has not 
changed the time too much.” 
Thus the interviews show that the time to deliver the intervention with an incorporated 
motivational interview; did not differ from the time needed to deliver existing pharmacy 
sessions such as MURs and NMS.   
 
Views regarding the consultation also varied between the pharmacies depending on the 
number of available supporting staff that worked in the pharmacy and how busy the 
pharmacy usually is.   
 “The team needs to be trained up and the staff need to know what they are doing, so I do 
not have to sit physically and watch what they are doing, so they do all the dispensing 
and if they need anything they refer to me.”   
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Integration of the intervention into a MUR or NMS session 
 
The pharmacists reported that it was not always possible to fit the intervention sessions 
under a MUR or NMS.   
“I couldn’t fit under MUR or NMS I did not claim for the session” 
However, some reported that it was easier to fit under a NMS session and this was mostly 
because the patients were referred from the hospital and were on first time new 
medications such as antiplatelets.  
“Patient was on Ticagrelor as a new medicine, I put it under an NMS”,  
 Some pharmacists contacted the patients without claiming for the sessions. “Perhaps 
more details on NMS/MUR integration. I did not claim for the session” 
The pharmacists reported that such queries should have been addressed earlier during the 
protocol design and the need to provide a clear protocol supported by rules and 
regulations from the LPC. 
“I think some consultation should have been done with the LPC to see how NMS, MUR 
would impact on the intended study, and whether these would be paid.” 
 
 
Motivational interviewing in the intervention  
In the interviews the community pharmacists expressed that motivational interviews were 
important for the patients and a useful tool to enhance adherence.  
“It allows you to extract more information out of the patients, rather than directing them 
to a closed answer.”  
“Motivational interviewing works tremendously well for some patients such as the 
patients who had a life changing event.”  
“It encourages people a bit more to see what they can do and what is holding them back 
and then they can say for themselves.”   
“Motivational interviewing is a useful tool for pharmacists in motivating patients to get 
adherence and meds optimisation.” 
 
190 
 
Chapter Five:                                                                                                             Results   
One pharmacist reported that it made the patients feel that they were cared about by a 
health care professional 
 “You can feel from the patient that you are not only doing it for money but you are doing 
it because you care about them.” 
Another pharmacist reported that motivational interviewing is a useful tool but depends 
on the patient receiving the consultation.  
“Motivational interviewing will work tremendously well for some patients such as the 
patients who had a life changing event.  It will be a tool used with some patients, but it 
does depend on their desire to change.”  This statement could be related to causes of 
non-adherence that could influence the patient’s behaviour.  Causes of non-adherence 
could be internal or external.  For internal causes these could involve conscious decisions 
regarding the medicines, but could also include forgetfulness and misunderstandings 
about medicines. Other internal causes of non adherence can be related to mood and 
anxiety (Horne, 2005).  While external causes involve ease of medicine use, the dose 
regime, in addition to social factors and prescription costs (Horne, 2005).   
It was also reported by the pharmacists that motivational interviewing in their 
consultation made the consultations more structured and helped in interacting with 
patients.  
“When using motivational interviewing when you are speaking to a patient your 
consultation becomes much more structured, yes I do think it is a useful skill it does help 
you to interact with patients and get them more on board.” 
The pharmacists also expressed in interviews that motivational interviewing is a useful 
skill to learn and differs from their traditional counselling technique.  
“When using motivational interviewing a lot of information can be retrieved and it is 
different from what we were practicing traditionally.” 
“When you are using motivational interviews you realise that it is not the simple yes and 
no from the patients and it is telling the patient how you admit to help” 
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Moreover, keeping a laminated copy of the consultation chart, available in the pharmacy 
was important to use on need and pharmacists reported that they referred to it during their 
consultation. 
“I still have my cards and I can look back at them the ones you sent in the post. They are 
useful I have not used the mapping sheet but I have used all the questions” 
  “Yes it was useful to refer to the chart and refresh your way of counselling.”  
Importance of a discharge summary for the consultation 
Community pharmacists believed that the discharge summary that was sent by the 
research pharmacist from the hospital was very useful and important for the consultation. 
 “The discharge summary is vital/ paramount for discharge patients especially if new 
medications are added or medications changed on admission.”  
“Discharge summary is extremely important.  Can be hard to work out what medication 
the patient is on.  Hospitals do not refer patients to see their pharmacist.”  
 
 
 
Number of patients referred to pharmacies 
The number of patients referred to the intervention pharmacies depended on pharmacy 
location and the recruited patients’ postcodes.  Most pharmacies had either one or two 
patients.  However, one pharmacy that was closest to the hospital had 7 patients and three 
pharmacies had no patients referred to them (Please refer to Appendix 17) 
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The table below contains information recorded by the researcher summarising established 
measures regarding the feasibility of the study in regards to community pharmacies. 
Table 5.1 Established measures regarding the feasibility of the study in regards to 
community pharmacies 
Community pharmacists  
 
1-Number of pharmacies and pharmacist willing to take part in the 
study. 
 
Pharmacies     42  
 
Pharmacists    50 
 
2-Number of community pharmacists willing to take part in the 
training and time spent on training.  
 
Pharmacies     32  
Pharmacists   38 
 
Time spent on training 
5-9 hours  
3-Time spent by the community pharmacist in counselling patients 
in the two sessions. 
15-20 minute/ patient 
 
4-Time spent by community pharmacist in contacting the patient 
and patient follow up.  
15 minutes/patient 
5-Community pharmacists drop out during the study. 1 community 
pharmacist dropped 
out of the study 
Results show that from the number of community pharmacies willing to take part one can 
conclude that recruitment of community pharmacists in studies of such nature could be 
feasible.  In this study this was achieved by collaboration with NELLPC.  In addition, 
community pharmacist dropout was minimal.    
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Due to the incorporation of the consultation into existing services (MUR, NMS) extra 
time for the consultation was not needed.  A typical review MUR will take between 10 
and 20 minutes this is also usual for a NMS session.  Thus the consultation time was 
considered by pharmacists to be practical.   
 
Assessment of the delivery (fidelity) of the intervention 
Fidelity regarding the delivery of the intervention was assessed by using a scaled one 
question.  Pharmacists were asked to quantify adherence to the protocol and also to what 
extent they used motivational interviewing, in their consultations with the patients.  The 
outcome showed a positive score of 3.8 from 5.  Community pharmacists survey results 
(Scale question) "From a scale of 1-5 with 1 being the lowest and 5 the highest, how 
much did you adhere to the protocol and use motivational interviewing in your 
consultation?  How long was your consultation?”    
Table 5.2 Community pharmacists survey results                       
Pharmacist 1    Score 2               20 minutes  
Pharmacist 2    Score 3              15 minutes  
Pharmacist 3    Score 4              15 minutes  
Pharmacist 4    Score 5              10 minutes  
Pharmacist 5    Score 5              15-20 minutes   
Pharmacist 6    Score 4              15 minutes  
Pharmacist 7    Score 4              10-15 minutes 
 
This result is in line with the results from the interviews with pharmacist.  Pharmacists’ 
responses varied from using motivational interviewing quite a lot to using just small 
things taken from the motivational interviewing protocol.   
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Feasibility of the study from perspectives of hospital pharmacists’  
The researcher conducted interviews with five hospital pharmacists. These interviews 
were face to face and took place at the hospital. The interviews were to determine the 
pharmacists’ thoughts, regarding the feasibility of conducting a prospective study, patient 
recruitment at the hospital.  The interviews were also to determine the pharmacists’ views 
on continuity of care across the primary and secondary care interface and on existing 
community pharmacy services.  
Feasibility of conducting a prospective study 
Hospital pharmacists expressed that they are overloaded and conducting recruitment as a 
prospective study could be challenging in regards to time and workload.  However, 
hospital pharmacists reported that if additional staff were employed and if allowed extra 
time recruitment might be feasible.  The hospital pharmacists mentioned in the interviews 
that recruitment would depend on the nature of the study and the expected outcome. 
“Hospital pharmacists are overloaded, cannot commit 100% could do recruitment if 
given more time.”   
“Feasible, depends on the study and how involved if retrospective easier and less 
pressure prospective is different more pressure and depends on how much data and how 
long.” 
 
Pharmacists’ views on continuity of care 
The hospital pharmacists’ supported the idea of sending a discharge summary to the 
patient’s community pharmacist.  Hospital pharmacists reported that this could reduce 
medicine wastage, improve communication between primary and secondary care and 
support existing community services such as MURs and NMS.  Discharge letters in 
current practice are sent to patient’s GP by the ward clerk and also sent to community 
pharmacists on need for dosette boxes only.   
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Hospital pharmacists expressed that regular practice of sending a discharge letter with the 
patient to take to the community pharmacist is a vital recommendation and could be 
achieved.  
“Very important, decreases medication wastage, currently used for dosette boxes, can be 
sent by staff but easier to give to patients to take to community pharmacist.”  
“Definitely community pharmacists should be getting more information.  The letter could 
be sent directly from the hospital, ideal option is to give to the patient then also to post 
the letter”.  
 
Hospital pharmacists’ views on community pharmacy services 
The interviews revealed that hospital pharmacists do not have sufficient information 
regarding services offered in community pharmacies such as MURs and NMS.   The 
interviews demonstrated that hospital pharmacists need more information, especially 
regarding the NMS and also how vital this service can be to patient care and in 
supporting patients in regards to adherence.  Sufficient information regarding community 
pharmacy services, could determine patient referral into these services, after hospital 
discharge and eventually increase uptake by patients who are in essential need of support 
in primary care.  
“MUR’s are very important, for patients on long term medicines, monitoring outside the 
hospital is important, I do not know much about the NMS, I know it is a new service.” 
 “Useful at some aspects, counselling before the patient leaves the hospital should be 
enough; I do not know how good the community pharmacist could pick up stuff to be 
viewed. I do not know much about these services. 
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The table below contains information recorded by the researcher summarising established 
measures regarding the feasibility of the study in regards to hospital pharmacists.  The 
table illustrates how hospital pharmacists although had increased workload, made time to 
assist the researcher with patient recruitment, but were unable to fully undertake the 
recruitment process.  Therefore, patient recruitment took place by the researcher.   For a 
larger study it would be recommended to employ research assistants for patient 
recruitment.  Moreover, as shown in the table, time was needed to send the patient 
discharge summary to the community pharmacists.  This time would have been reduced if 
an existing system similar to sending the summary to the GPs was readily available. 
 
Table 5.3 Feasibility of the study in regards to hospital pharmacists 
Hospital pharmacists   
 
1-Number of hospital pharmacists willing to take part in the trial. 
 
 
 
 
 
 
 
 
 
 
 
Hospital pharmacists 
did not recruit patients. 
Recruitment was 
undertaken by the 
research pharmacist.  
However, number of 
hospital pharmacists 
who provided support 
and assistance to the 
research pharmacist 
was 5. 
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2-Time spent in sending a discharge letter to the community 
pharmacists and time spent in contacting community pharmacists. 
 
For each patient the 
discharge summary 
was printed at the 
hospital then scanned 
and emailed to the 
community 
pharmacist.  The 
community pharmacist 
was then contacted and 
informed.  For each 
patient 30 minutes was 
needed.  
 
Total time for 32 
intervention arm 
patients 16 hours. This 
was done on different 
days depending on 
patient discharge. 
3-Hospital pharmacists drop out during the study. This is not applicable. 
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Results on patient recruitment  
Recruitment was for 4 months.  Patient recruitment commenced on the 15
th
 of October 
2013 and was discontinued on the 10
th
 of February 2014.  Patients were recruited from 
two wards at the London Chest Hospital; CCU ward and Reviere ward.  Before 
commencing with patient recruitment, a pilot for recruitment was conducted, during the 
pilot three patients were found to be eligible from the CCU ward.  The recruitment 
package was left with the patients to read and then give their thoughts and opinions 
regarding enrolment into the study.  The three patients reported that the patient 
information sheet was easy to follow and understand.  All three patients were willing to 
take part in the study and willing to attend the consultation at the pharmacy.  These 
patients were not recruited into the study. 
 
The research pharmacist reviewed patient’s charts in the two wards where recruitment 
took place.  Once patient eligibility was confirmed the patient was approached by the 
researcher, who explained the study briefly and showed the pharmacies’ locations on a 
map.  The patients were given a recruitment package.  The research pharmacist returned 
at later time to obtain written consent from the patient.  If the patient expressed interest 
he/she was recruited into the study.  Patients differed in their response and acceptability 
to be recruited.  Some patients were keen on taking part and other patients were simply 
not interested in being part of a study.  Explaining the study as a service to be provided 
after hospital discharge and an opportunity for further follow up by a pharmacist could 
have encouraged some patients to participate.  The research pharmacist had to be cautious 
as not to disturb patients, some patients were severely tired and ill after the heart attack.  
In addition, there were certain times when patients could not be approached such as lunch 
time and protected time that is designated for patient rest. 
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Two hundred and thirty three patients were assessed for eligibility.  On average it was 
possible to recruit 2- 3 patients per day excluding the days where there were no eligible 
patients.  Recruitment was undertaken by one researcher, a sample size of 71 patients was 
reached.  The decision to stop recruitment was due to time constraints.  Patients were 
excluded if they did not meet the inclusion criteria as shown in the table and chart below. 
Table 5.4 Patients excluded from the study 
 
   
Other studies at London Chest Hospital  49 Eligible  
Lives at care home 3 Did not meet the inclusion criteria 
Other related diseases 29 Did not meet the inclusion criteria 
Refused to participate  14 Eligible but refused 
Going into surgery / operations  13 Did not meet the inclusion criteria 
Diagnosis changed  10 Did not meet the inclusion criteria 
Has mental illness/problems  11 Did not meet the inclusion criteria 
Does not speak English  13 Did not meet the inclusion criteria 
Lives outside pharmacy areas  20 Did not meet the inclusion criteria 
Patients consented to participated in the study  71 Eligible  
Total 233  
 
Thus from 233 patients, 49 were eligible, 14 refused to participate, 170 did not match 
eligibility criteria and 71 patients were eligible and enrolled into the study.  
 
Figure 5.6 Patients excluded from the study 
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Challenges at the hospital during patient recruitment 
A number of challenges occurred during the recruitment of patients; these included the 
following; (1) several research projects took place at the LCH at the same time 
recruitment was ongoing for this project.  Therefore, recruitment would not start before 
10 am until a list of patients (not to approach) was issued to prevent recruiting a patient 
into two studies at the same time, (2) protected time took place between 12:00 pm and 
2:00 pm, during this time patients could not be approached because they would have time 
to eat, rest, sleep or have a visit from a family member, (3) due to the workload at the 
LCH eligible patients’ charts were not always available (used by other health care team) 
during the time available for recruitment which could have also led to missing out some 
potential eligible patients, (4) patients after a coronary event stay for approximately two 
days in the hospital.  After leaving the recruitment package with the patient for 24 hours 
some of the patients would be discharged or transferred to other wards before making the 
decision to be enrolled in the study, (5) the research pharmacist was at the recruitment 
site 3 days per week, which is 12 days per month this sums up to approximately 48 days.  
Further challenges at the hospital included; the forwarding of the discharge summary.  
Patients in the intervention group had their discharge summaries sent to the community 
pharmacist.  It was difficult to forward the summary to the community pharmacies as 
there was no system at the hospital to forward the summary directly.  In contrast there 
was existing developed software to send the summary to the patient’s GP.   
 
 
5.2- Patients’ response rates/attrition 
Seventy one patients were enrolled in the study; 32 in the intervention group and 39 in 
the control group.  Sixty four patients completed the study, two patients died, 2 patients 
dropped out of the study 2 patients moved houses and could not be located and 1 patient 
moved to a different country.  From the 32 patients in the intervention group 30 patients 
were in contact with pharmacist and completed the study as shown in the consort diagram 
below: 
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Figure 5.7 Study recruitment  
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Assessed for eligibility (n=233) 
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Other studies at the Hospital  49 
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Other related diseases 29 
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Has mental illness/problems  11 
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(n=71) 
Allocation 
Allocated to control (n= 39) 
 Completed the study (n= 34) 
 Did not complete the study (n=3) 
  (2 patients died, 1patient dropped out 
of study) 
Allocated to intervention (n=32) 
 Received allocated intervention (n=30) 
 Did not receive allocated intervention (n= 
1) 1patient dropped out of study 
Follow-Up 
     Lost to follow-up (n= 2) 
1 patient moved house and 1 patient 
moved to a different country 
 
 
Discontinued intervention (give reasons) 
(n= 0 ) 
Lost to follow-up (n=1) 
1 patient moved house 
 
Analysis 
Analysed (n= 32) 
 Intention-to-treat, excluded from 
analysis (n= 0) 
Analysed (n= 39) 
 Intention-to-treat, excluded from 
analysis (n= 0) 
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Patients’ perceived value of the consultation 
The researcher conducted telephone interviews with coronary heart disease patients in the 
intervention group, after they received consultations from the community pharmacists. 
The patients invited to an interview were randomly selected by the researcher from the 
list of intervention patients. Four patients agreed to be interviewed regarding their 
thoughts and experiences of the community pharmacy service intervention.  Below are 
results of these interviews. 
Patient satisfaction with the consultation 
Patients reported in interviews that they were very satisfied with the consultation. They 
found it reassuring to be able to talk to a pharmacist face to face or on the telephone 
regarding their medicines and disease. 
 “Yes I was very satisfied with it, I think it is a very good idea because we could discuss 
things and problems and everything so it definitely has value.” 
“I found it reassuring, that I could talk to somebody and have any questions answered.” 
“It has been very good to have someone on the other end of the phone.” 
 
Information from the consultation 
The patients reported that being in contact with a pharmacist was very helpful after the 
heart attack. They reported in the interviews that the pharmacists were able to explain 
about the medicines and answer any questions they had.  Furthermore, the patients 
mentioned that the fact that the consultations were delivered by a pharmacist was 
beneficial, because pharmacists have knowledge about medicine and some patients faced 
problems such as side effects and adapting to a routine with the medicine after discharge, 
especially when having to take more than one medicine.  
“It was helpful because it takes a long while thinking about what the tablets are?”   
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“I was having problems with clopidogrel and that it was making me sleepy and we did 
discuss that and things like the blister pack” 
 “He explained all the medicines to me and everything and I told him how I was feeling 
because I was feeling really ill with them you know”  
Some patients also reported that the fact that the consultation was offered by a pharmacist 
was convenient, because community pharmacists are easy to reach and easier to contact. 
 “Yes to have someone who you are confident is familiar with your situation and is an 
expert in the drugs you are taking to give you that extra support.”  
“Definitely, absolutely it is advice and it is so beneficial and it does provide information, 
if there are any problems or questions I need to ask about medication or doses then I can 
ask and get that answer easily so yes.”   
 
The patients mentioned that they felt that they were able to build rapport with the 
pharmacists’ in the consultations.  
“It is not like yes let’s get this over with, no you have a nice person who has a genuine 
concern and when you feel you got empathy from a healthcare professional it makes you 
feel like you are not in the urge or on your own” 
“When it first initially happened and I got more concerned about the medication, I mean 
when it first happened this was like a welcoming sign to have someone you have seen and 
you are going through a lot and someone actually following you up so you can put the 
connection.  It helped me yes.” 
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In the interviews the patients’ expressed that the consultations saved them time, they did 
not have to book an appointment with a GP or go to another pharmacy for information, 
also some patients looked forward to the consultation with the pharmacist and could get 
problems solved. 
 “Because speaking in general if you have to go to a GP or book an appointment we do 
not have to do that.  I can talk to the pharmacist in a private situation”  
 “You see a different GP every time and the cardiologist I have seen him once.” 
 
The patients mentioned that the contact by a pharmacist helped with adherence to the 
cardiac medication.  They described the pharmacy contacts as promotes to adhere further 
to the medicines.  Also that the pharmacy consultations helped some patients get their 
medicines arranged in blisters or dosette boxes that was also useful for adherence.  
“I think it did help like when the pharmacist says are you taking your medicines? it is like 
a reminder so I keep them out there by the kettle so I see them first thing in the morning, 
so I take them, I think just that little promote you know is an additional help and keeps 
me on my toes.” 
“Things like the blister pack it helped me find a pharmacy that did it for me.” 
“You are all checking us on the medication if they have been missed and the impact of 
the medication” 
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Timing of the consultations  
Patients reported that the timings of the consultation with a pharmacist at the pharmacy or 
on the telephone were all convenient.  Patients who attended face to face appointments 
had prearranged booking times with the pharmacist and patients contacted by telephone 
also reported that the telephone timings were all convenient.   
“Well we got there and I think in the beginning he was busy, so we waited for a while but 
it wasn’t too long, then we went into a little room and my wife was with me.”  
“You have all been quite good because I have spoken three, four times now and he has 
been very polite and asked if it is ok to speak even if I am at work. It has been very very 
good I have had no problems with timings.” 
 “Yes the timings was ok it was fine”, “I am retired so the timing is ok for me it is fine” 
  
Problems and unhelpful aspects of the consultation 
The patients did not find anything inconvenient or not useful with the consultations, they 
described it as a positive experience. 
 “In what you are all doing now no I cannot see anything not useful at all, no not at all 
no.”  
“Like I said it was a positive experience, so there isn’t anything not useful” 
 
 
 
 
 
206 
 
Chapter Five:                                                                                                          Results   
Advantages from the consultations  
The patients reported that being in continuous contact with a pharmacist made them feel 
secure after a life changing event.  The patients also thought that the pharmacy 
consultation was a good service and should be offered to all patients after a heart attack. 
Patients thought that the service especially if delivered by telephone would be of benefit 
to elderly patients and carers or family members.  
“Yes it is certainly a useful service, especially for older people yes because older people 
are perhaps a little bit more confused, or for a family member if it was an older person it 
would be of assistance.” 
“I definitely think it would be great if it could be rolled out across the board really for 
every patient.” 
 “It makes you feel like you have not just been forgotten about, you know it is a major 
thing that has happened a life changing event, and you are not just forgotten and put 
aside no someone is calling following you up, asking questions, I think it is a good thing 
and idea. 
  
 One patient mentioned that it was the best thing the NHS had thought of. 
 “I think that this is one of the best ideas the NHS has come up with.”  
Another patient also mentioned that it was the only consistent service after her heart 
attack. 
“I think in the actual fact it is the only service following my heart attack that has been a 
consistent follow up.” 
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Information in the table below was recorded by the researcher and summarises 
established measures regarding the feasibility of the study in regards to patients. 
Table 5.5 Feasibility of the study in regards to patients  
Patients 
Number of eligible patients.                                    
Number of patients enrolled in the study.  
Number of patients in the intervention group and 
eligible for a pharmacy consultation.  
Number of patients contacted by the community 
pharmacists. 
Number of patients attending the first and second 
visit to the community pharmacies. 
 
 
233 patients 
71 patients 
 
32 patients 
 
30 patients 
9 patients attended 
consultations  
21 patients contacted by 
telephone 
 
The results on the number of patients willing to participate and the uptake of the 
intervention by the patients demonstrate that the intervention was workable for patients.  
The interviews also show that there was a high level of patient satisfaction with the 
consultations and that the pharmacists succeeded in engaging the patients and building 
rapport.  
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Results on liaison with the general practitioners (GPs) 
The research pharmacist used the data recorded at baseline (patient’s postcode and GP 
practice) to contact the patients’ GPs.  Patients’ general practitioners were sent by mail 
individual letters explaining briefly the study along with a copy of the patients’ consent 
forms.  The GPs provided written consent on providing the results of blood pressure 
measurements and LDL-C levels during the timeline of the study.   The number of GP 
consent letters returned to the researcher at UCL-School of Pharmacy was 50 consent 
letters from 71.  The remaining 21 GP surgeries that did not return consent letters were 
contacted by telephone and were faxed the patient’s consent letter.  Baseline data for 
blood pressure and LDL-C results were collected by the research pharmacist from the 
hospital database.  Furthermore, these results were collected from GPs at 3 months and 6 
months.   
 
 
 
Challenges with data collection from general practitioners surgeries 
Several challenges were faced during data collection from GPs these included; 
(1) Reliability of data 
Collecting patient data by telephone from receptionists was difficult.  It was apparent that 
some receptionists did not understand which tests were being asked for, particularly 
regarding LDL -C.  It was also not always clear to the receptionists when the most recent 
tests had been taken.  In some cases nurses were available to give information, but not 
always.  Therefore, a decision was made to fax the results.  Once the decision was moved 
to faxing forms for GPs to fill in; data collection improved.  However, forms were mostly 
hand written and not always easy to read.   
 
(2) Tests not performed 
Not all patients were tested either for BP or bloods at the designated times.  It was often 
reported that patients had not had any further tests.   
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(3) Late start  
Due to the delayed start and the initial issues with receptionists providing data, the first 
wave of results were not fully collected until the end of the first phase.  This meant that 
the GPs were being asked for second test results within a couple of weeks of providing 
the first results.  Obviously in some cases there was no new data and there was not a 
definitive more than 4 week period between data collection points.  It is therefore crucial 
that the data is collected in line with the data collection schedule and that in cases of 
delay the schedule is amended accordingly. 
(4) Patients stopped using regular GP 
Five patients stopped using their regular surgery and changed their surgery practice this 
was overcome by contacting the patients and enquiring regarding the address of their new 
practices.  However this had an effect on the time for data collection.  
(5) Three patients’ charts at the hospital did not have the patients’ GP contact recorded. 
(6) One GP physician wrote a letter to the research pharmacist explaining that it was 
difficult to be part of the study because of workload at the surgery (letter can be found in 
Appendix 18) and suggested to recruit a nurse at the GP practice to commit to the study 
for data collection. 
 
 
Due to all the listed obstacles above only one third of patients had full results on clinical 
outcomes blood pressure and LDL-C.  For a larger study it would be recommended that 
all tests are performed at agreed times.  It also could be better if data were to be collected 
from GPs electronically to improve accuracy.  Thus in a larger study it might be 
important to recruit nurses at GP surgeries to undertake and facilitate data collection of 
such clinical outcomes.  
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5.3-Results on outcomes  
Characteristics of respondents and comparison of intervention and control 
Seventy one patients were recruited into the study from the London Chest Hospital: 
Patients’ sex 
From 71 patients 54 patients were males and 17 patients were females: This result is 
typical with acute coronary syndrome statistics; where a man to women ratio is 
approximately 2:1 in the same age group (Mozaffarian et al., 2015). 
Diagnosis- type of acute coronary syndrome 
From 71 patients 51 patients had a ST-Elevation Myocardial Infarction (STEMI), and 20 
patients had a Non ST- Elevation Myocardial Infarction (NSTEMI). 
Age  
The majority of patients were in their sixties and seventies this result is also typical with 
acute coronary syndrome (Mozaffarian et al., 2015).  
Figure 5.8 Patient age  
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5.4- Impact of intervention results on primary and secondary outcomes 
Results on adherence to secondary prevention medication 
To evaluate adherence two measures were applied The Morisky MMAS-8 scale and a 
modified one question by Gehi et al, 2007.  The Morisky MMAS-8 scale was used to 
evaluate adherence to the secondary prevention medication. The questionnaire was 
collected at 2 weeks after hospital discharge, three months and six months, the following 
results were found using the Independent T-test.   At baseline there was no significant 
difference in adherence between the intervention group (Mean=7.45, SD=0.79) and the 
control group (Mean=7.5, SD=0.93) t (66) = -0.19 (P=0.85).  At 3 months, there was a 
statistically significant improvement in adherence in the intervention group (Mean= 7.7, 
SD=0.56) compared with the control group (Mean= 7.0, SD=1.81), on the Morisky scale 
(t (44) = 2.4, P=0.026). This corresponded to a mean difference between the groups of 
0.78 points [95% CI 0.14-1.42]. At 6 months, there was a statistically significant 
improvement in adherence in the intervention group (Mean=7.5, SD=1.47) compared 
with the control group (Mean =6.1, SD=2.09), on the Morisky scale (t (55) =2.9, 
P=0.004). This corresponded to a mean difference of 1.37 points [95% CI 0.45- 2.28] 
please refer to the graph below: 
 Figure 5.9 Result on adherence by Morisky scale 
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Measurement of adherence by Self report one Question  
Self report one question by Gehi et al, 2007 was used to measure adherence. This 
question was modified from a scale used to measure adherence in clinical trials for 
patients with HIV.  The one question was filled by patients at baseline, 3 months and at 6 
months.  At baseline there was no significant difference in adherence between the 
intervention group (M=97.4, SD=5.5) and the control group (M=97.3 SD=8.6) t (66) 
=0.023 (P=0.98), at 3 months there was no statistically significant difference in 
adherence between the intervention group (M= 98, SD=3.3) and control group (M= 93.2, 
SD=18) t (65) =1.68 (P=0.09) and no statistically significant difference at 6 months 
between the intervention group (M=95, SD=17.9) and control group (M=89.1, SD=23.7) 
t(62)= 1.22 (P=0.2).  An improvement in adherence with the one question was observed 
in the intervention group at 3 months and 6months when compared to the control group 
but did not reach statistical significance as shown in the figure below: 
Figure 5.10 Result on adherence with self report one question 
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Beliefs regarding the medication  
Forty four patients from seventy one returned by mail the BMQ specific questionnaire.  A 
chi square test was used to investigate if there was a relationship between adherence to 
secondary prevention medication and patients’ beliefs regarding their medicines.  There 
was a statistically significant relationship between the level of adherence and the beliefs 
regarding medicines, X
2 
(2, N=44) = 7.124, P=0.028.  Patients who reported better 
adherence showed positive beliefs regarding the necessity of their medicines.  Please 
refer to the chart below.  The chart demonstrates results for 44 patients in two groups’ 
adherent patients (Morisky score moderate 6-8, Morisky score high =8) and patients with 
suboptimal adherence (Morisky score < 6).  In the adherent group (28) patients perceived 
the necessity of their medication, a lesser number of patients (5) had concerns regarding 
medication taking and even a lesser number (2) their concerns were equal to the necessity 
of their medication.  In the suboptimal group a greater number of patients (5) had 
concerns regarding medication taking and a lesser number (4) perceived the necessity of 
the medications.  
Figure 5.11 Result on beliefs regarding medicine  
N=Necessity, C=Concern 
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Blood pressure results  
Blood pressure classified according to the British Hypertension Society guidelines 2011 
into hypertension systolic blood pressure>= 140-159 mmHg and diastolic blood pressure 
of >= 90-99 mmHg.   Blood pressure was measured at baseline, 3 months and 6 months.  
Around two-thirds of patients in both groups did not have a follow-up evaluation from 
their GPs. Thus at 3 and 6 months there was no statistically significant difference 
between the two groups for both systolic, diastolic blood pressure and LDL-C.  
Table 5.6 Result on systolic blood pressure in mmHg  
 Intervention  Control  P value  
Baseline  132  124 0.4 
3 months  127 121 0.3 
6 months 132 129 0.6 
An independent-samples t-test was conducted to compare the means of systolic blood 
pressure between the intervention group and the control group.   
At baseline: there was no statistically significant difference between intervention group in 
systolic blood pressure at baseline (M=132.8, SD 27) and the control group (M= 124.8, 
SD= 26) t (22) = 0.68 P=0.4. 
At 3 months: there was no statistically significant difference between the intervention 
group (M=127, SD= 20) and the control group (M= 121, SD=20) t(28) = 0.87,  P=0.3.  
At 6 months there was no statistically significant result between the intervention group 
(M=132, SD= 11) and the control group (M=129, SD= 12) t(11)=0.4, P=0.6.  
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The results show that systolic blood pressure in the intervention group at 3 months 
decreased by 5 mmHg and at 6 months returned to the same as baseline, if compared to 
the control group in which systolic blood pressure decreased by 3 mmHg at 3 months but 
increased by 5mmHg at 6 months as shown in the figure below.  
Figure 5.12 Systolic blood pressure results in mmHg 
   
Table 5.7 Result on diastolic blood pressure in mmHg 
 Intervention  Control  P value  
Baseline  74 73 0.8 
3 months  73 72 0.84 
6 months 68 75 0.2 
An independent-samples t-test was conducted to compare the means of diastolic blood 
pressure between the intervention group and the control group.  There was no statistically 
significant difference between intervention group in diastolic blood pressure at baseline 
(M= 74, SD=7.2) and the control group (M=73, SD= 11) t (20) = 0.15, P=0.8.  The study 
was not powered to show an effect on clinical outcomes; however, the difference in blood 
pressure between the intervention and control at 3 months could reflect adherence but 
would need to be tested in a further larger study.    
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 At 3 months there was no statistically significant difference between the intervention 
group (M=73, SD= 11.5) and the control group (M=72, SD= 9.9) t(24) =1.92 , P=0.84. 
 At 6 months there was no statistically significant result between the intervention group 
(M=68, SD= 11.7) and the control group (M=75, SD=4.8) t (9) =-1.26, P=0.2.   
However, at six months the diastolic blood pressure in the intervention group decreased 
by 6mmHg from baseline if compared with the control group in which diastolic blood 
pressure increased by 2 mmHg from baseline as shown in the figure below:  
 
Figure 5.13 Diastolic blood pressure results in mmHg 
 
The results on both systolic and diastolic blood pressure were not statistically significant 
but at 3 and 6 months the changes in blood pressure observed could be clinically 
important especially as controlling high blood pressure for secondary prevention is 
important for patients after a coronary event.  The reduction in blood pressure in the 
intervention group could also be an indicator of adherence to medication, because blood 
pressure can serve as a biomarker of the efficacy of pharmacotherapy. 
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Low Density Lipoprotein-Cholesterol in mmole/l  
Joint British Societies recommend cholesterol limits for people who have, or are at risk of 
coronary heart disease: total cholesterol - less than 4.0mmol/l and LDL cholesterol - less 
than 2.0mmol/l.  LDL-C was measured at baseline, 3 months and 6 months. 
Table 5.8 Result on LDL-C in mmole/l  
 Intervention  Control  P value  
Baseline  2.75 2.79 0.9 
3 months  2.65 2.67 0.9 
6 months 1.8 2.59 0.4 
An independent-samples t-test was conducted to compare the means of LDL-C between 
the intervention group and the control group.  There was no statistically significant 
difference between intervention group in LDL-C at baseline (M=2.75, SD= 1.05) and the 
control group (M=2.79, SD=1.4) t (24) = -0.079, P=0.9. 
At 3 months there was no statistically significant difference between the intervention 
group (M= 2.65, SD= 1.17) and the control group (M= 2.67, SD= 1.21) t(24) =-0.039, 
P=0.9. 
At 6 months there was no statistically significant result between the intervention group 
(M=1.8, SD=0.4) and the control group (M= 2.59, SD= 1.8) t(4) =-0.746, P=0.4.  
There was a 0.79 mmole/l difference in LDL-C at six months between the intervention 
group and control group as shown in the figure below.  The result on LDL-C should be 
addressed with caution due to the small sample size, missing data and statistical non 
significance.  However, high total cholesterol and LDL-C are established risk factors for 
myocardial infarction, NICE 2014 guideline recommends using high dose statin such as 
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atorvastatin 80 mg for treatment in people with CVD for secondary prevention.  Therapy 
should be started as soon as possible after the diagnosis and the aim is that LDL-C should 
not be above 1.8 mmol/L; with an even lower target of 1.3mmol/L.  Thus the result 
although statistically not significant could be of clinical importance to the patients. 
However, cannot be attributed to the intervention. The reduction in LDL-C in the 
intervention group could also be an indication of adherence to statins.  
Figure 5.14 Results on LDL-C in mmole/l 
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Figure 5.15 Side effects experienced by patients  
 
More patients in the control group reported that they experienced side effects than the 
patients in the intervention group; from the 71 patients’ 21 patients in the control group 
reported side effects compared to 15 patients in the intervention group.  This might have 
had an effect on medication taking behaviour and adherence in the control group 
compared to the intervention group please refer to chart below.  However, the result was 
statistically not significant P=0.56. 
 
Figure 5.16 Difference in side effects between intervention and control  
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Side effects reported by patients 36/71 patients reported side effects   
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Costs for the study 
The study was designed as a pilot feasibility study and the intervention was incorporated 
into remunerated services at community pharmacies.  Therefore, costs would be predicted 
to be minimal.  However, there were some necessary costs for the feasibility of the study.  
These included training costs on motivational interviews and also pharmacists were 
reimbursed for their time in the study.  
 
Total costs of this pilot study are listed below  
 Intervention pharmacists attended 5-7 hours of training on motivational 
interviews and 2 hour training on secondary prevention medication after a 
myocardial infarction. The cost of the training for all three sessions: 
            Psychologist training fees £1095 
            Materials £500 
            Rooms, catering £540  
 Community pharmacists (intervention group only) reimbursement for training and 
participation   £150/pharmacist paid in two instalments £75 each.  
             19 pharmacists x 150= £2850                                            
 Research assistant costs for data collection from GPs £500 
            Total for all costs = £5485. 
 
 
In addition, other costs included cost of a researcher (study coordinator), hospital 
pharmacists’ time and other non-remunerated costs.  
For a larger study these costs should be taken into consideration and funding will need to 
be secured.  For this study these costs were covered by the Harold and Marjorie Moss 
Charitable Trust scholarship.  This charity supports pharmacy research and was applied 
for and gained by the researcher at the beginning of the study.  
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The table below summarises overall conclusions regarding feasibility of the study and 
feasibility of the pharmacy intervention: 
Table 5.9 Overall conclusions regarding feasibility of the study  
Feasibility of the study  
 
Event  Conclusion  Comment  Problems  Recommendation 
for larger study  
Pharmacy 
recruitment  
Feasible  Was achieved by 
collaboration with 
LPC. 
Caused problems 
with randomisation.  
-Simple 
randomisation of 
overall sample. 
-Recruit by only 
one method. 
Training  Feasible  Pharmacists attended 
and committed to the 
study. 
-More than one 
training session had 
to be organised.  
 
-Some pharmacists 
did not attend the 
booster or training 
on secondary 
prevention 
medication. 
 
-Pharmacists not 
assessed on skills at 
the end of training. 
-Arrange more 
than one training 
session. 
 
-Ensure all 
pharmacists 
receive the full 
training sessions. 
 
-Organise online 
training. 
 
 
-Assess 
pharmacists on 
skills using valid 
scales.  
Hospital 
pharmacists  
recruitment  
Not feasible  Hospital pharmacists 
can assist with study 
but not undertake full 
commitment to study 
duties.  
Overloaded  Recruit research 
assistants to 
operate study 
including patient 
recruitment and 
administrative 
work.  
-arrange a system 
at hospital for 
communication 
between hospital 
and community 
pharmacists.  
 
Patient 
recruitment  
Feasible  Undertaken by 
researcher.  
-Other ongoing 
research projects.  
 
-Arrange study 
with research 
department at 
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-Matching patients 
with recruited 
pharmacies.  
 
-Patients not sure 
which pharmacy to 
use after discharge. 
hospital. 
- Organisation of 
recruitment time.  
-More than one 
researcher or 
research assistant 
at study site.  
- Promote study at 
site, awareness of 
study by other 
professionals 
(Doctors, nurses). 
-Review inclusion 
criteria, may be 
recruit only 
patients after first 
myocardial 
infarction.  
-Recruit a larger 
number of 
pharmacies.  
Recruitment 
of GPs 
Feasible  GPs provided consent 
to be part of study. 
Problems occurred 
with data collection 
not with GP 
recruitment.  
-Send invitation 
letter by post and 
also by telephone 
and fax. 
 
 
Research evaluation  
Data 
collection 
from 
pharmacies  
Feasible  Undertaken by 
researcher. 
-Not all pharmacists 
had time to be 
interviewed. 
- Researcher had to 
contact pharmacists 
several times due to 
workload at 
pharmacy. 
- Conduct focus 
groups not 
interviews.  
Data 
collection 
from patients 
Feasible  Undertaken by 
researcher, data 
collection by telephone 
led to a higher 
response 
Patients provided 
written consent for 
interviews.  
 
  
- Needed to contact 
patients several 
times. 
 
-Collect data by  
mixed methods  
telephone and post. 
 
 
 
Data 
collection 
from GPs 
Not feasible  Undertaken by 
research assistant. 
-Late start due to 
difficulty collecting 
data from 
receptionists. 
-Arrange tests to 
be performed at 
agreed times for 
data collection. 
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-Tests not available. 
 
-Employ nurses for 
the study to collect 
clinical outcomes. 
 
 
 
Feasibility of the pharmacy intervention  
Event  Conclusion  Comment  Problems  Recommendation 
for larger study  
Patient uptake 
and 
attendance to 
consultations  
Feasible  Patients interested in 
study. 
Patients welcomed the 
extra support from 
community 
pharmacists.  
-Patients preferred 
to receive 
intervention by 
telephone.  
- Less patients 
attended face to 
face consultations.  
Deliver the 
intervention 
entirely by 
telephone.  
Arrangement 
with 
pharmacists  
Feasible  Researcher acted as a 
link between patients 
and community 
pharmacists.  
-Pharmacists had to 
contact patients 
more than once.  
-pharmacists 
reported that mostly 
they had to contact 
patients.  
-Provide patients 
with pharmacy 
contact details on 
discharge and 
encourage patients 
to contact  
designated 
pharmacy. 
 -Provide patients 
with a referral 
letter to pharmacy. 
-Organise number 
of patients per 
pharmacy. 
Fitting session 
under MUR, 
NMS 
Not feasible  Not all sessions were 
reimbursed.  
Sessions did not fit 
under MUR, mostly 
fitted under NMS. 
-Provide clear 
reimbursement 
plans. 
- Collaborate with 
LPC on rules and 
regulations of 
pharmacy services. 
- Fit consultation 
sessions under 
NMS only.  
Use of 
motivational 
interviews 
- Pharmacy 
consultations  were not 
recorded.  
Variation between 
pharmacists on 
using motivational 
interviewing skills.  
-Record and 
review 
consultations 
between 
pharmacist and 
patient.  
-Assess 
pharmacists on 
skills early before 
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start of 
consultations.  
 
Operation and 
delivery in the 
pharmacy  
Feasible  Pharmacists reported in 
interviews that the 
consultations did not 
affect the operation of 
the pharmacy because 
incorporated in to 
existing services.  
- Time to contact 
patients and invite 
to consultation.  
-Need to ensure 
pharmacists have 
secure emails and 
internet 
connections to 
allow data transfer. 
- Explain to 
patients regarding 
pharmacy services 
during hospital 
stay and encourage  
patient to contact 
pharmacy after 
discharge 
-Incorporate 
intervention in 
existing services at 
pharmacy level 
 
 
 
 
 
End of Chapter Five 
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Chapter Six 
Interviews with South Asians in the UK and adherence to 
cardiovascular medication after Coronary Heart Disease 
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Chapter Six:                                                                           Interviews with South Asians  
This chapter describes a small study to gain some insight into South Asian patients 
regarding their medication and adherence after a coronary event.  The consultant 
pharmacist at the London Chest Hospital informed the research team that around 30% of 
admitted patients for CHD are from South Asian origin.  This was true for the patients’ 
sample recruited into the feasibility study 17/71 patients were from South Asian origin.  
Fourteen of these patients agreed to be interviewed by the researcher.   Thus a sample of 
South Asian patients’ was invited for an interview to study their adherence patterns and 
beliefs regarding the use of secondary medication after a coronary event.  
6.1-Background  
Coronary heart disease (CHD) remains the most common cause of death (and premature 
death) in the UK.  There are 94,000 deaths from CHD each year (CHD, Statistics 2010).  
South Asians living in the UK (people from India, Pakistan, Bangladesh, Sri Lanka and 
Nepal) have a higher premature death rate from CHD at a younger age, often before the 
age of 40 years in men (Gupta et al, 2006).  An explanation for excess deaths from 
coronary heart disease in South Asians is still not clear.  Several theories in previous 
literature include “migration, disadvantaged socioeconomic status, proatherogenic diet, 
lack of exercise, high levels of homocysteine and LP(a) lipoprotein, endothelial 
dysfunction, enhanced plaque and systemic inflammation (Velmurugan and Gupta, 
2005). 
 
The use of secondary prevention medication in patients after CHD is vital to maintain 
optimal heart function and to prevent mortality (Ens et al, 2013).  Adherence to 
medication in this patient group is necessary because evidence that non adherence is 
associated with adverse outcomes (Ho et al, 2009).  However, there has been little 
research on adherence to cardiovascular medication among ethnic minorities and patients 
from South Asian backgrounds, despite the relatively high prevalence of cardiovascular 
conditions in these groups.  
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 In addition, it is not known whether ethnicity plays a role in medication non adherence 
(Lai et al, 2011).  Therefore, there is a need to look closer at this particular ethnic group 
regarding adherence to medication after a coronary heart disease. 
  
6.2-Objectives 
1- Provide an insight into adherence patterns to cardiovascular medication in South 
Asians after coronary heart diseases. 
2- Identify factors that may influence adherence to cardiovascular medication. 
 
6.3-Methods 
 
Design  
Interviews with South Asian patients, discharged from a London Heart Attack Centre 
(London Chest Hospital), after a coronary heart disease event were conducted.  After 3 
months of discharge and receiving secondary prevention cardiovascular medicines, 
patients were invited to participate in a telephone interview.  This is to study their 
adherence to cardiac medication.  Ethical approval for the interviews was gained from 
National Research Ethics Service Committee North West –Preston, also from the R &D 
Joint Research Management Office Queen Mary Innovation Centre and the R&D office 
University College of London.  
 
Study setting 
 
The study was undertaken in collaboration with a London Heart Attack Centre in a 
district in East London UK.  
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Sampling and recruitment  
 
Patients, who were eligible and had signed written consent to be part of the feasibility 
study, would be approached before discharge from the hospital by the researcher.  This is 
to confirm if they would be interested in being interviewed by telephone regarding their 
medicines.  The research pharmacist reviewed the patients’ hospital charts to confirm 
eligibility for an interview.  Patients were eligible if they had a coronary event ST 
elevation myocardial infarction or non ST elevation myocardial infarction, were 
prescribed secondary prevention medication, are from South Asian origin and can 
communicate in English.  Seventeen South Asian patients before discharge from the 
centre were approached and invited to take part in the interviews, with an independent 
researcher.  Fourteen patients provided written consent and took part in the telephone 
interviews.  The three patients who did not take part were simply not interested in being 
interviewed.  South Asian ethnicity was determined from the hospital charts and further 
confirmed by the patients.   
Figure 6.1South Asian patient recruitment  
 
 
 
 
 
 
 
 
 
 
 
 
 
71 patients recruited into the pilot 
feasibility study 
During the recruitment process 17 
patients were identified by the 
researcher from the hospital charts 
to be of South Asian origin  
14 patients confirmed their 
ethnicity and agreed to be 
interviewed  
14 telephone interviews with the 
researcher  
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6.4-Data Collection  
The Interview    
Semi-structured interviews were conducted.  The questions were adapted from a previous 
study Garavalia et al, 2009.  The reason the questions were adapted from Garavalia et al, 
2009 was because the interviews in Garavalia et al, 2009 were designed to explore 
coronary heart disease patient’s adherence to secondary prevention medication.   
Garavalia et al, 2009 investigated myocardial Infarction patients’ perspectives and beliefs 
regarding their medication and designed their study with a qualitative descriptive 
methodology; patients were asked to describe their experience with the disease and 
medication.  This study also wanted to explore South Asians’ perspectives of their 
disease and medication to gain some insight regarding adherence after a coronary event.  
Previous literature has shown that factors that influence medication-taking behaviour in 
coronary artery disease include perception about coronary artery disease and about the 
medicines (Rashid et al, 2014).  In this study we further explore adherence patterns and 
factors that may influence adherence to medication.  Thus the questions were modified 
and three domains were studied: perception of disease, perception about the medication 
and factors that influence adherence.   
 
 
The semi structured interview adapted from Garavalia et al, 2009: First can you describe 
your heart attack that led to your hospitalization? Please can you tell me your beliefs 
regarding the medications that you have been prescribed and importance of the medicines 
for your heart disease? Please can you tell me if you are having problems in taking your 
medication? for example are you using a pill organiser?, are you experiencing side 
effects? Are you having any problems in forgetting to take your medicines?  Can you tell 
me what your medications are supposed to do? At this point, what do you think about 
your heart disease or do you think your heart disease is a serious matter? What changes 
have you made to your lifestyle as a result of your heart disease/attack? How do you 
think your heart disease affects your life or may change your future? 
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Instruments  
 
Apart from the interviews, quantitative measures (measures of adherence and beliefs 
about medicines) were employed.  These were already collected for the main study and 
included; the Morisky Scale and the Belief about Medicines Questionnaire Specific.  The 
self report 8-Item Morisky Medication Adherence Scale (MMAS-8) was used to assess 
adherence.  The MMAS-8 has a high reliability, sensitivity and specificity.  The Belief 
about Medicines Questionnaire Specific (BMQ-S): The BMQ-S was used to assess 
patients’ beliefs about their medication.  It is a valid and reliable scale having been 
validated for use across a range of different diseases and also cardiac illnesses (Horne and 
Weinman, 1999).  The scale comprises two main sections, the BMQ specific and BMQ 
general, the BMQ specific is comprised of two subscales, which are BMQ necessity and 
BMQ concerns.  In this research the BMQ specific was used to assess participants’ 
beliefs about their medication.  
 
6.5-Data processing and analysis   
 
All interviews were transcribed verbatim.  A framework approach to analysis was 
undertaken involving the development of an initial coding framework with each domain 
of interview schedule, informed by literature and themes that emerged from the data.  As 
analysis proceeded this was modified and refined using constant comparison techniques; 
in which all items of data assigned a particular code, were appraised for similarities and 
divergences from those already coded.  Data from the Morisky and BMQ-scale were also 
analyzed and linked with the results from the interviews.  To ensure reliability of the 
coding procedure, coding of the transcripts was undertaken by two members of the 
research team.  
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6.6-Results  
 
Fourteen interviews were carried out between January 2014 and April 2014.  The 
interviews ranged from 9 – 17 minutes in length.  Participants’ ages ranged from 32 years 
to 72 years with 7 patients in their 30’s and 40’s.  Thirteen were male and one only was a 
female, country of origin of patients included Bangladesh (N=5), Pakistan (N=3) and 
India (N=6). Themes derived from the results included: importance of medicine, 
forgetfulness, organized routine, knowledge regarding the medicines, family support, side 
effects, feeling ill or feeling healthy, rely on health care practitioner, exercise, severity of 
the disease, life style factors (Asian food and dietary intake), causes of the disease, 
fatality and socioeconomic status.   
 
Perception of disease 
 
Beliefs regarding the disease feeling ill or feeling healthy 
 
When asked to describe their experience of a heart attack, the majority of the patients 
described it as being intense unbearable pain, accompanied by tightness, sweating, 
burning, vomiting, severe indigestion pain. Very few described it as little pain, one 
patient thought that it was a chest, breathing problem. 
 “I had a breathing problem heavily too much and now I am walking no breathing 
problem”.   
The patient that thought it was a chest problem described feeling healthy after the heart 
attack and that the breathing problem was resolved.  Another patient described it as a 
vomiting problem. 
 
 “No I didn’t agree I had a heart attack I was vomiting and everything apart from that I 
didn’t have any pain”.   
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Beliefs of the acute nature of the disease in some older patients affected long term 
medicine use in patients who showed low adherence.  
“Breathing problem is not serious now, I do not know whether I should continue 
medication or not, they will tell me”.  
Patients’ who believed that the disease was acute showed a lower score on the Morisky 
scale with time.   On the other hand the majority of young patients expressed difficulty in 
acceptance of having a chronic disease and the need to use medicines on a long term 
basis.  
“I didn’t take medicine all my life and then suddenly you have 6 different medicines a day 
this is the only confusion” ,“ It is first time I am on medicines I need time to adapt to a 
routine.”   
 
 
Severity of the disease  
 
 Patients’ responses differed regarding the severity and seriousness of the heart disease.  
Some patients described it as been very serious  
“Yes of course the disease is serious you could die”  
Others thought it was serious before but currently after the event it is not serious  
“The disease is not serious at the moment”, “Mentally I do not feel it is a serious matter, 
I have been told that it is serious”, some patients were not sure “it is pretty serious isn’t 
it?”  
 Patients who believed the disease was serious scored high on the Morisky scale and had 
positive beliefs regarding the medicines on the BMQ scale with the belief that the 
medicines could prevent future cardiac events.  
 
 
 
 
233 
 
Chapter Six:                                                                            Interviews with South Asians  
 
Causes of the disease 
 
Causes of the disease were reported by most of the patients to be due to family history 
and genetics to a lesser extent due to risk factors (high cholesterol, smoking and not 
eating healthy). 
 “My family history my father died only when he was 51 and my brother when he was 
only 31 and he died he had another heart attack”.   
Other reported causes included stress, flu and a chest problem.  Two patients were not 
sure of the causes  
“I have not got a clue”, “I do not know there were no symptoms of anything; I was not 
getting tired or anything”.  
 This demonstrates that the majority of patients did not perceive the link between risk 
factors and the disease.  Mostly patients believed that the disease was inevitable and 
running in the family.   
 
 
Lifestyle factors 
 
Younger patients in this sample were more able to link the importance of healthy lifestyle 
choices such as regular exercise and healthy eating with the disease. 
“I am looking carefully at what I eat and I have cut down my alcohol”.    
However, older patients lacked understanding of the relationship between lifestyle and 
disease. 
“No before the heart attack I did not do any exercise” “Just walking nothing more 
because I am an old man”.   
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Fatality  
 
Fatalistic views were reflected in the interviews, and the idea of the will of God and not 
the individual to determine future health was often reported 
 “What can you do I mean if God gave you the life whatever he gave you have to live”.  
 In addition, worries of having another heart attack were also raised in more than half of 
the patients’ interviews.  
“I am worrying about another heart attack coming”, “Now I worry all the time, it could 
happen any time again”.   
Compliant patients believed that the medicines were important to prevent a second heart 
attack.  This was reflected in the adherence scores.  
 
Role of medications necessity verses concerns  
 
Importance of medicine  
 
When asked regarding the importance of taking medicines nearly all the patients 
responded as very important. 
“I think they are pretty important that is the reason they gave them to me.”  
Only few patients were not very sure how important the medicines were to maintain 
health  
“I do not know if they are important or not”, “If I go without my medicine I will realise if 
it is important or not but at the moment I need medicine”.   
Some patients mentioned that the number of tablets to take or the long duration to take 
was of concern “Too much medicine, is it good for you?”  
The patients who reported in the interviews that their medicines were important had 
positive BMQ scores and scored high on the Morisky adherence scale.  
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Knowledge regarding the medicines 
 
Half of the patients expressed knowledge about their medicines when asked the question 
can you please tell me what your medications are supposed to do?  On the other hand half 
reported little knowledge, mostly relying on a family member to gain the knowledge or 
on a healthcare professional or simply not interested in knowing  
“They are for cholesterol and clotting something like that, do not really know.”   
Patients who did not have knowledge regarding the medicine still reported that they were 
adherent and also had positive BMQ results.  
“Chemist explained but memory not good”, “Yes my GP told my son and at the hospital 
they told my son this is for this and this is for that, but they are important to take”, “They 
are supposed to thin your blood, no I do not know what the others are supposed to do.”   
Studies in patients with chronic diseases have previously shown that medication 
adherence can be enhanced if patients are provided with good information about their 
treatment and that adherence to medication is correlated with knowledge regarding the 
prescribed medicines (Burge et al, 2005).  This was not the case in this study.  
 
 
Factors that influenced adherence  
 
Forgetfulness 
Several patients had problems with remembering to take their medications.  The patients 
reported that this was attributed to being on medication for the first time, their young age, 
or trying to fit the medication into a habit as a daily routine. 
 “I take the medication all once a day so if I forget I forget the whole lot”, “So far no 
problem with medicine, only one problem I keep forgetting to take.”  
These patients were young patients and reported that their non adherence was 
unintentional.   They expressed a need to accept the disease and adapt to a new life style 
and routine that would include medication consumption.  
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An organized routine 
Patients were asked to describe their daily routine of taking their medications.  The 
majority of patients were able to list their medicines and how they take them every day.  
Ways to remember were reported as use of a pill box, writing on the boxes in native 
language, arranging them in a bag and making them accessible around the house.  The 
patients reported that it took time to form a habit of taking the medication everyday and 
that they were trying to organise a daily routine to help with forgetting.   
“ I remember now, before I had to get used to it but now I am in a routine” “I never had 
taken medicines before and then suddenly I start taking it in my mind I am not taking 
medicine but now no I am taking it.”  
 
Family support  
Family support varied among the patients, support was either offered as help in 
organizing the medicines, providing the knowledge about the medicines, helping with 
healthy eating and stress management.  The patients’ reported that the family support 
they received helped with their adherence to the medicines. 
 “My sister and my cousin they are trying to help me, she cooks for me.” 
“My daughter gives me the medicine and I just take so I remember.”  
 
 
Side effects 
The main side effects reported by the patients included muscle pain, coughing, cold 
extremities, bruising and lethargy.  The patients that experienced side effects reported in 
the interviews that they continued to take their medicines. 
“One tablet ramipril tablet I was coughing and the coughing comes and goes every time, 
I told my GP and now I am on a different medication and I take it every day ”, “My feet 
do feel cold then they do not stay long it is just you know, it is not a major thing I still 
take my medicine.” 
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“I am bruising very easily and it seems to stay there for a while you know the aspirin, but 
the GP said that obviously I need to take it so there hasn’t been no next steps.”   
 
Relying on health care practitioner 
More than half of the patients depended on a healthcare practitioner regarding taking 
medicines and how important they are for the disease. 
 “The doctor said they are important for my body.”, “I do not think about it if doctor says 
I need it then I need it that’s it.”, “I have the medicine regularly otherwise the doctor 
said there will be something wrong without the medicine.” 
 
 
 
Socioeconomic status 
 
Two patients reported living in low socioeconomic status (bad accommodation, large 
families, drugs and depressing environments) which affected healthy dietary choices and 
added further stress and worries to their physical and mental health.  Moreover, this was 
accompanied by depression and had a negative effect on adherence to medicines after a 
CHD. 
“I cannot sleep every night, I am worried and smoking, now I am going to sleep because 
one children is go sleeping on the floor, you know a little bit of space give it to me 
because I am worried but I am not happy I do not have enough accommodation.”, “I 
have been living in this hostel for four years and people in this place are too many they 
are always banging shouting and screaming, I cook my food and if I leave it for ten 
minutes it is gone from the cooker, I need to get out of this hole.”  
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Cardiac rehabilitation 
 
All the patients had either attended or were committed to attending cardiac rehabilitation, 
except one patient that thought that cardiac rehabilitation was additional medical 
treatment for example further injections and procedures. 
 “No I didn’t go to cardiac rehabilitation.  If they start putting injections again, I do not 
want to go through that again.” 
 The patients’ that attended cardiac rehabilitation reported that it was very useful and 
helpful.  
“Yes, I did complete cardiac rehabilitation and they are very impressed with results that 
came out.”, “Yes, I am currently doing the cardiac rehabilitation program and I am very 
happy with the progress.”, “I went to cardiac rehabilitation and I am thinking right now 
of joining a gym, I have changed the food I eat after cardiac rehabilitation”. 
 
 
Belief about Medicines Questionnaire Specific 
 
Results on the Belief about Medicines Questionnaire Specific (BMQ-S) 11 out of 14 
patients scored positive on the BMQ-S and only 3 out of 14 had a negative score.  In 
BMQ-S the fourteen patients’ had a mean (+/- SD) necessity score of 21 and a mean (SD) 
concern score of 15 (Please refer to the figure below).  This showed that more patients at 
three months believed that the benefit of their medicines outweighed their concerns.  
Patients who had positive BMQ-S scores had a score that was positively correlated with 
adherence.  
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Figure 6.2 Results on BMQ-S  
 
 
 
 
 
 
Adherence 
On the 8-Item Morisky Medication Adherence Scale (MMAS-8) at baseline the South 
Asian patients’ had a mean (SD) adherence MMAS-8 scale of 7.41 from 8 and this 
decreased with time to 7.1 and 6.8 at 3 and 6 months respectively.  A similar pattern of 
adherence to medication was observed in the patients from the pilot study that included 
71 patients, adherence to medication decreased with time as measured by the MMAS-8 
scale of 7.5 and this decreased with time to 7 and 6.1 at 3 and 6 months respectively.  
Thus there was no evident difference in adherence patterns between the South Asians’ 
and the patients in the pilot study regarding adherence to medication after an acute 
myocardial infarction as shown in the chart below: 
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BMQ-Specific  
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patients 
 
BMQ-S- Necessity sub 
scale/Concerns  
Subscale 
1 25/12  Positive score 
2 25/10 Positive score 
3 15/20 Negative score 
4 25/12 Positive score 
5 20/13 Positive score 
6 19/14 Positive score 
7 20/19 Positive score 
8 21/16 Positive score 
9 25/19 Positive score 
10 19/20 Negative score 
11 21/15 Positive score 
12 24/11 Positive score 
13 17/21 Negative score  
14 21/15 Positive score 
 21/15 Mean score 
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Figure 6.3 Patterns of adherence  
 
 
Additional factors that could influence adherence  
It was also concluded from the interviews that factors that could have influenced 
adherence in this group of patients included: forgetfulness, depression, taking medication 
for the first time, not forming a habit or routine for medication taking.  Factors such as 
knowledge and side effects did not seem to have an effect on adherence in this particular 
group of patients.  
 
 
6.7-Discussion  
The interviews highlight perspectives of members of the South Asian community 
regarding their disease and medication.  The results illustrate that there was a belief in the 
importance of the medicines after a coronary event among the interviewed South Asian 
patients.  The patients who adhered to the medicines believed that the medicines could 
prevent future cardiac events.  Older patients perceived the disease to be of an acute 
nature.  This affected long term adherence in this sample.  In addition, older patients were 
unable to correlate a link between risk factors such as exercise and diet with 
cardiovascular diseases.  
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On the other hand younger patients had difficulty in accepting the disease and this 
affected their ability to adapt to a routine for medication taking.  Coronary heart disease 
is perceived as a disease of senior citizens, as only 4% to 10% of all myocardial 
infarctions occur before age 45 (Harvard, 2009).  However, South Asian patients more 
often experience CHD before the age of 40; and in this sample half of the patients were in 
their 30’s and 40’s.  Furthermore, younger patients in this study were more able than 
older patients to correlate risk factors with cardiac disease.  Both young and old patients 
reported in the interviews that family history and genetics were the main cause of their 
disease, also that the disease was inevitable and thus early prevention and further 
treatment might not have a significant role.  Moreover, both young and old patients 
expressed strong family support with their disease and medication.  
 
 
A similar pattern of adherence to medication was observed in the South Asian group 
compared to the patients from the pilot study.  Adherence to cardiovascular medication 
reduced with time in both groups.  Thus there was no evident difference in the adherence 
pattern after a myocardial infarction.  Another finding in our study was that the patients 
rely on health care practitioners for the importance and knowledge of the medicines and 
also follow doctors’ orders and instructions with the belief that health management 
should be left to qualified health professionals.  The interviewed South Asian patients’ in 
this study expressed the importance of attending cardiac rehabilitation and had attended 
or were scheduled to attend.  Previous literature has shown that low-levels of Cardiac 
rehabilitation participation among South Asian and other ethnic minority groups have 
been reported in several English-speaking countries including the USA, Canada, the UK 
and Australia (Beswick et al. 2004).  This has been attributed to reasons such as exercise, 
culture and religion, programme access and structure and communication and language 
(Galdas et al, 2011).  The sample of patients in this study reported benefits from 
attending cardiac rehabilitation especially regarding the appropriate diet after myocardial 
infarction and the nature and amount of exercise they could uptake.   
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In the UK, the key health policy outlining the national standard for cardiac rehabilitation, 
the National Service Framework (NSF) for Coronary Heart Disease (DOH, 2000), states 
that services should be accessible and acceptable to all the people they serve regardless of 
their ethnicity.  This includes ensuring staff and services are able to meet people’s needs 
in ways that are culturally, religiously and linguistically appropriate and providing 
culturally appropriate advice about healthful lifestyles (British Heart Foundation, 2004).   
Several UK-based community health projects designed to improve CHD prevention and 
rehabilitation among South Asian individuals, such as Project Dil in Leicester (Farooqi & 
Bhavsar 2001), the BRUM study in Birmingham (Jolly et al. 2009) and the Khush Dil 
project in Edinburgh (Mathews et al, 2007), offer encouraging directions for healthcare 
professionals, in the design and delivery of culturally sensitive cardiac rehabilitation 
services (Galdas et al, 2011).  Due to the small number of participants in our study a 
larger qualitative study focusing on South Asian uptake of programmes such as cardiac 
rehabilitation would be of benefit.  
 
 
The findings in this study are preliminary however; they can provide an insight on 
adherence patterns to cardiovascular medication in a South Asian population.  The 
findings should be approached with caution due to the small sample size and the short 
length of the interviews.  Nevertheless, this study showed that increased belief regarding 
the necessity of the medicines was correlated with positive adherence scores.  This 
finding is in line with other studies with large sample sizes, for example a study that 
involved 1611 coronary heart disease patients from 35 practices in Ireland found; that a 
strong belief in the necessity of one’s medication and a lower level of concern about 
one’s medication were associated with higher levels of adherence (Byrne et al, 2005).   
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Factors that influenced adherence in our study included: forgetfulness, depression, taking 
medication for the first time and not forming a habit or routine for medication taking.  
Factors that were reported not to have an influence on adherence were side effects and 
knowledge.  The factors found in our study fall under the WHO framework for 
medication adherence that lists reasons for non adherence include younger age, 
socioeconomic factors, mental health (depression) and side effects (WHO, 2003) and can 
also be compared to results of a review (Ens et al, 2013) that concluded that medication 
side-effects, knowledge regarding the medicines, cost, forgetfulness and higher frequency 
of dosing are contributed to non-adherence.  
 
 
The main side effects reported by the patients included muscle pain, coughing, cold 
extremities, bruising and lethargy.  Although, these were reported by the patients’ a 
sample size of 14 patients is small to assign these side effects, to the general South Asian 
population.  In this study patients who reported side effects still believed that the 
medicines were important.  As mentioned in other studies (Ens et al, 2013) this area 
needs further examination.  Moreover, there are very few studies focusing on beliefs and 
adherence patterns after coronary heart disease of South Asians in the UK and due to the 
large South Asian population in the UK, larger studies of this nature are imperative.  
The patients expressed in the interviews that they follow doctors’ orders and instructions 
with the belief that health management should be left to qualified health professionals.  
This has also been concluded in other studies examining health beliefs of UK South 
Asians’ related to lifestyle diseases (Lucas et al, 2013).  In this study patients unable to 
understand and communicate in English were not included, this was a restriction to 
understanding communication barriers between South Asian patients and health care 
practitioners and how this could reflect on adherence.  Other limitations in this study 
include imbalanced gender mostly male and only one female took part in the interviews, 
thus the view might not be representative.   
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Furthermore, telephone interview has drawbacks against face-to-face interview: e.g. not 
able to build rapport with participants, people might be less likely to talk on the phone, 
which subsequently did not generate rich data.  Despite these limitations, the findings 
have shed light on the factors that influence adherence patterns to cardiovascular 
medication in a South Asian population and also the study raises awareness to the fact 
that larger studies could be beneficial in understanding culture issues around adherence to 
medication after coronary events. 
 
 
 
 
 
 
 
 
 
 
 
 
 
End of Chapter Six 
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Many new medicinal cardiovascular therapies have been introduced in the past half 
century.  There is robust evidence that when appropriately used these reduce morbidity 
and mortality rates.  However, there are continuing challenges relating to prescribing 
standards and strategies, and to the willingness and/or abilities of medicine users to take 
drugs in an optimal manner (NICE, 2009).  It has been estimated that in the order of 30-
50% of medicines prescribed for chronic conditions are not taken as recommended 
(Barber et al, 2004).  Chapters One and Two of this thesis demonstrated that medication 
taking adherence amongst individuals and populations at risk of and living with 
cardiovascular conditions remains problematic.  Although the overall human harm and 
financial cost attributable to sub-optimal CVD medicines prescribing and use is not well 
quantified (see below), addressing this issue is important. It is possible that enhanced 
health outcomes could be achieved via relatively simple measures delivered in 
community pharmacies and/or by community pharmacists and allied professionals.   
 
Examples of potentially useful interventions range from the systematic use of screening 
questions addressed to patients who have been recently discharged from hospital care (or 
who might for other reasons be at raised risk of sub-optimal vascular disease medicines 
use) through to pharmacists reviewing medication refill/repeat dispensing patterns and 
taking action to facilitate better medicines taking as and when indicated.  As 
demonstrated by the reported success of the New Medicines Service in England (Elliot et 
al, 2014), other strategies could involve follow-up telephone calls by pharmacists to 
patients who may be having problems with adherence to new (or established) therapeutic 
regimens.  Whatever the approach taken, it is important to emphasise that non-adherence 
is not solely ‘a patient problem’, and does not merely cause the physical wastage of 
medicines. It can be caused by inadequate supportive care and result in not only 
avoidable individual and family distress but also adversely impact upon the NHS and 
other health care systems by needlessly increasing overall demand for services (NICE, 
2009).   
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Against this background the research this thesis describes investigated in the context of 
post-hospital discharge MI care whether or not a pharmacy led intervention – a central 
element of which involved the use of motivational interviewing techniques – could be 
shown to result in beneficial medicines taking behaviour changes. The sections 
immediately below summarise key aspects of the analysis undertaken and offer relevant 
interpretations. Issues such as the wider role of techniques such as motivational 
interviewing in the future development of NHS primary care and the extent of the health 
gains that could be generated, together with the implications such progress could have for 
pharmacy practice and policy, are then explored. 
7.1 Key Findings  
Recruitment and training of the community pharmacists  
The project undertaken was a prospective controlled pilot study.  As indicated above, its 
central objective was to investigate the feasibility and impact of a pharmacy care 
intervention on adherence to medication in the post MI care context, and ultimately on 
coronary heart disease outcomes.  The research undertaken generated a range of positive 
findings.  Recruitment of pharmacies and training was, for example, successful. Many 
pharmacists were keen to take part, although their involvement was determined not only 
by their personal motivation but by factors such as the support staff time and financial 
resources available. Without adequate resourcing pharmacists may not be able to take 
part in training events and patient care programmes, even when well motivated to do so. 
In this study community pharmacists in the intervention group were highly committed, 
and drop-out over the period that research was undertaken was minimal (pharmacist 
dropout 1/20).  The Local Pharmaceutical Committee in North East London played a vital 
role in recruiting professional participants and in facilitating the delivery of training 
sessions by providing a venue and communicating the importance of clinical service 
provision to local community pharmacists.   
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Those who became involved in the research process reported that, after 2 days of training 
and one booster session, they felt confident in delivering the study intervention and using 
motivational interviewing skills.  However, some also said that they would have preferred 
further sessions involving patient and practitioner role playing and additional time for 
practicing their newly acquired competencies.  Such observations may raise questions 
about pharmacy education and pharmacists’ capacities to act as continuously developing 
health care professionals.  These are not explored in depth here, but it is of note that these 
findings are similar to those of other studies undertaken in the UK and elsewhere 
amongst a range of practitioner groups.  For instance, Van Eijk-Hustings et al (2011) 
worked with diabetes specialist nurses and dieticians to provide intensive training in 
motivational interviewing via a course involving 3 full days and 2 booster sessions.  They 
reported that ‘the spirit of motivational interviewing’ was present after the training 
sessions, and increased during follow-up periods.  Yet in most cases only simple 
techniques were used and the nurses and dieticians taking part in their investigation said 
that they needed more support and training in order to apply the more complex aspects of 
motivational interviewing (Van Eijk-Hustings et al, 2011).  
 
Some of the research findings contained in the available literature are not supportive of 
providing short motivational interviewing training courses. (See, for example, Efraimsson 
et al, 2011, who studied smoking cessation support given by nurses in Sweden.) Yet 
overall there is evidence that short courses can increase knowledge and change practice, 
at least for limited periods (Baer et al, 2004; Miller et al, 2004).  The Health Foundation 
(2011) has argued that the duration of training opportunities is less important than their 
quality.  The latter includes dimensions such as the clarity and effectiveness with which 
the autonomy respecting principles underpinning motivational interviewing methods are 
expressed and communicated. 
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Effective training should ideally include opportunities to practice with ‘expert patients’ or 
similar subjects, and to receive informed feedback about performance together with, 
where needed, ongoing supervision and coaching (The Health Foundation, 2011).  In the 
study reported in this thesis the training course content was delivered by a skilled 
psychologist who sought to adapt the training given to addressing the needs of post MI 
patients in the NE London social environment.   
There is also evidence that the pre-existing attitudes of professionals can impact on their 
willingness to learn and apply motivational interviewing techniques (The Health 
Foundation, 2011).  Those most willing to volunteer to take part in training may have a 
greater affinity with this ‘counselling’ (or in medical terms ‘consultation’) style than 
other professionals. Follow-up interviews undertaken with community pharmacists 
involved in this research suggested the existence of such preference variations. This 
raises some concerns about the viability of universalising the changes in pharmacy 
practice explored here. Yet against this, it is also of note that significant numbers of 
pharmacists in the control group and from the LPC who did not take part in either 
research arm requested opportunities for training in motivational interviewing. 
 
Patient recruitment and uptake of the intervention  
Recruitment is always likely to be challenging in prospective studies aimed at health 
protection rather than immediate symptom relief or curing overt disease. Recruitment 
rates can be influenced by both service user and investigator side factors (Thoma et al, 
2010).  This may be so, for instance, when patients find trial objectives difficult to 
understand, and/or fear negative outcomes. Related factors can affect investigators if 
protocol designs are complex and when, for instance, they experience difficulties in 
obtaining informed consent from patients (Thoma et al, 2010).    
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Many trials do not meet their recruitment targets (Treweek et al, 2013). A relatively 
recent study of 114 UK multicentre trials supported by two of the UK's largest research 
funding bodies (the Medical Research Council and the NIHR’s Health Technology 
Assessment Programme) found that less than a third achieved their original recruitment 
goals (n=38; 31%) and that more than half had to be extended (n=65; 53%) (McDonald et 
al, 2006).  In this study the researcher involved followed the agreed recruitment strategy 
closely, and had piloted it before the formal commencement of this phase of her research. 
Service users were in the main prepared to participate, and some specifically said that 
they agreed to take part because the intervention involved follow-up by a health care 
practitioner working in primary care.  Even so, the pilot undertaken did not reach its 
target participant patient population of 200 individuals.  This was partly due to time 
constraints and the fact that patient recruitment was undertaken by just one PhD student 
researcher.  The fact that the recruitment process took place at a single hospital site may 
have limited the generalisability of the study results to wider populations. 
 
It is in addition of note that the patient sample included not only individuals with a first 
myocardial infarction but also patients who had suffered a second or subsequent 
myocardial infarction.  Thus the subjects involved differed regarding their knowledge and 
experience regarding the use of medicines being recommended to them. Those who had 
experienced a re-infarction may, at least in some cases, have already acquired a 
negative/less than optimal approach to medicines usage.  Sample members may have also 
varied with regard to their familiarity with the community pharmacies used for repeat 
dispensing. During the study some patients ‘refilled’ their prescriptions at a pharmacy 
other than the agreed intervention pharmacy.  Uncertainty regarding which pharmacy to 
use after discharge was more common amongst patients on ‘first time’ medications than 
it was amongst those with earlier experience of taking protective post MI treatments.   
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Any future study might seek to recruit only patients recovering from a first myocardial 
infarction, in order to ensure greater consistency in the sample population. However, 
people experiencing a second or subsequent infarction may be thought to be of special 
interest in that they might be at raised risk of not using their prescribed medicines to best 
effect, perhaps because of problems such as low motivation associated with depression 
stemming from long standing illness or a lack of a sufficiently ordered approach to 
routinising protective drug use.  
 
The study intervention was successfully delivered in the context of existing pharmacy 
services. It was performed by community pharmacists via either a face-to-face contact in 
their consultation rooms or by telephone.  The pharmacists taking part reported that 
conducting consultations did not interfere with their wider pharmacy practice 
responsibilities and did not require undue amounts of time-consuming documentation 
completion. Similar findings have been generated by US and other studies in which 
motivational interviewing has been used alongside traditional pharmacy counselling 
techniques (Burke et al, 2003; Britt et al, 2004).  A meta-analysis of 72 randomised 
control trials (Rubak et al, 2005) showed that motivational interviewing can be effective 
even when applied in brief encounters of no more than 15 minutes, and that more than 
one encounter per patient leads to statistically significant increases in the observed effect 
size.  A US study by Pringle et al, 2014 – that included 218 pharmacies – also found that 
motivational interviewing could be incorporated into pharmacy workflow processes 
without affecting normal operations.  
 
Fidelity of consultation techniques  
 
The pharmacy consultations undertaken in this pilot study were not audio-recorded to 
assess their technical fidelity, albeit intervention arm pharmacists consistently reported 
that they adhered to the intervention protocol.  Fidelity was assessed at the end of the 
study via the use of a scaled question.   
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Were a full scale study to be conducted it would be recommended that fidelity should be 
assessed at an early stage, and then at different stages throughout the duration of the 
research process.  This could be achieved by community pharmacists recording (with due 
permission) all consultations and then by, say, a random 10% of each practitioner’s total 
being reviewed by researchers. 
 
In this research the community pharmacists involved in the intervention arm invited 
patients to take part in consultations.  Some NHS users were contacted more than once. 
This inevitably involved some additional work. But, as already indicated, those 
undertaking interviews reported that doing so did not have a negative impact on the 
operation of their pharmacies and their overall patterns of activity. 
 
Telephone ‘versus’ face-to-face motivational interviewing interventions 
 
Two thirds of the patients taking part in this study chose to receive the intervention by 
telephone. Differences in the time, length and nature of the intervention may have 
occurred when it was given and received by telephone rather than face-to-face.  As this 
project was designed to be a pilot feasibility study it was judged important to offer the 
intervention by both methods.  It is now apparent that telephone consultations were 
preferred by a majority of patients. Hence for any future larger study delivery via this 
route would be a recommendation.   Regarding whether or not there is a difference in the 
effectiveness of motivational interviewing delivered via alternative modes, some older 
evidence suggests that providing interventions by telephone may limit the rapport 
established and so treatment impact (Soet & Basch, 1997). This might be because 
providers and recipients are obliged to operate without non-verbal communication cues 
(Resnicow et al, 2002).   
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However, more recent evidence from reviews and meta-analyses demonstrates that 
motivational interviewing can be effectively delivered by telephone (Easthall et al, 2013; 
Teeter and Kavookjian, 2014).  Teeter and Kavookjian, for example, conducted a 
systematic review of studies of telephone-based motivational interviewing interventions 
aimed at improving medication adherence.  They included nine articles. The majority 
(five) of these found that motivational interviewing can be effective in increasing 
medication adherence when provided by telephone, albeit no studies were found that 
directly compared the two approaches (ie face-to-face versus telephone).  The conclusion 
offered here is that there is a need for more sophisticated comparative studies looking at 
possible differences in outcomes achieved through the face-to-face as opposed to 
telephone applications of motivational interviewing amongst particular sub-populations. 
However, there is at the same time already adequate evidence that the aggregate 
effectiveness of telephone based consultations is broadly comparable with that of face-to-
face interviews.  More research is also needed on the cost-effectiveness of telephone 
versus the in-person delivery of motivational interviewing (Teeter and Kavookjian, 
2014).  In relation to this present study there may be instances in which a face-to-face 
pharmacist consultation on adherence offers advantages, such as when it is useful to 
examine the consequences of what might be medicine side-effects or observe blister 
packs (Lee et al, 2006).  Nevertheless, the research that the English NMS is based upon 
involved telephone consultations which were shown to be cost effective with regard to 
enhancing adherence rates (Barber et al, 2004; Clifford et al, 2006; Elliot et al, 2014).   
 
 
The intervention offered in this study was typically incorporated into an NMS 
consultation. (The majority of all NMS interventions are delivered by telephone – see 
Elliot et al, 2014.) It is of note that more recent studies that have included assessing 
pharmacist interventions delivered by telephone also indicate that they can significantly 
improve medicines taking adherence amongst patients with long term conditions (Lyons 
et al, 2016).    
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Telephone consultations have in addition proved to be of demonstrable effectiveness 
when delivered by other health care professionals. For example, around 12% of GP 
consultations are performed over the phone.  This has been judged as useful in delivering 
many aspects of NHS primary care (Campbell et al, 2015).  The advantages of 
conducting pharmacist and other consultations via telephone (and potentially through 
other IT based routes) may, over and above their relatively modest financial cost, on 
occasions include the fact that such approaches allow service users a beneficial sense of 
anonymity and/or control (Teeter and Kavookjian, 2014).  
Telephone-provided consultations may help to increase service access for less advantaged 
populations such as those found in rural localities, and for individuals with restricted 
access to conventional health care provisions because of problems like poor mobility. 
The findings of this thesis support the view that a greater proportion of pharmacy services 
could in future desirably be offered via telephone. 
 
Pharmacists’ access to discharge summaries  
In the study reported here discharge summaries were forwarded from the hospital 
pharmacy service provider to community pharmacists in order to facilitate consultations. 
Independently located pharmacist access to patients’ hospital discharge summaries is not 
(as yet at least) usually available in the UK, or elsewhere in the world. This limits the 
potential of pharmacists’ interventions to improve adherence and resolve medication 
related problems (PGEU Statement: 10.10.14E 002).  However, NHS England has 
recently announced that it intends to facilitate community pharmacy access to Summary 
Care Records (SCRs).  This present study may be regarded as demonstrating the potential 
importance of record sharing between community and hospital care providers as a step 
towards further enhancing the support offered to patients/health service users who wish to 
better manage their conditions with the help of community pharmacists.   
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All the main stakeholders whose views were elicited during this research – including 
hospital based as well as community pharmacists, together with participating GPs and 
pharmacy service users – expressed support for the supply of discharge summaries to 
community pharmacies.  This finding is in line with evidence from the Royal 
Pharmaceutical Society (2014). The RPS recently launched a hospital referral to 
community pharmacy ‘Innovators Toolkit’. This was developed in response to the report 
“Now or Never: Shaping Pharmacy for the Future” (Smith et al, 2013).  In the Royal 
Pharmaceutical Society’s view hospital referrals to community pharmacies should be 
made electronically and could become routine practice with five years (i.e. by about 
2020).  The findings of this thesis can once again be taken to be consistent with the view 
that significant improvements in the efficiency and effectiveness pharmaceutical care 
should be possible, given appropriate pharmacy practice developments alongside wider 
health service reforms. 
 
Bridging the interface between primary and secondary care 
The observation that patients have problems with medicines taking as they move between 
primary and secondary care is by no means new.  Research in this area has been ongoing 
for well over two decades (The Pharmaceutical Journal, 2004).  Difficulties that can arise 
at this interface range from failures to ensure that hospital engendered prescription 
changes are effectively communicated to GPs and other primary care providers through 
to different brands of the same drug being prescribed and supplied. This last can, if 
uncorrected, cause patients to consume unduly high drug doses.  Improving 
communication across institutional and other service boundaries is important. The 
approach adopted in this study sought to contribute towards this goal and was in line with 
previous Royal Pharmaceutical Society recommendations, such as those of the 2012 RPS 
report “Keeping Patients Safe when they Transfer between Care Providers”.   
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The latter included a variety of guidelines intended to promote better service co-
ordination. The findings of the present study highlighted the importance of such 
recommendations, while at the same time demonstrating the continuing existence of care 
co-ordination problems.  This was in part illustrated by the fact that less than half of the 
pharmacists involved in the project did not previously have an NHS.net email address, 
and that referral at discharge into clinical services provided by community pharmacies is 
not as yet a part of standard hospital discharge care.  Following-up patients and 
optimising their medicine use through community pharmacy interventions after hospital 
discharge has the potential to improve outcomes and in this study has shown, likely to be 
welcomed by most patients.  Those receiving the pharmacy intervention described here 
reported high levels of satisfaction.  Interviewees said they found it beneficial and 
reported their appreciation of being able to ask questions about their treatment without 
the need to book and attend a GP appointment.  Service users reported that they felt well 
supported in the community by pharmacists working as (primary) health care 
professionals.   
 
Letters were sent to all the GP’s of the patients enrolled in the study.  They demonstrated 
their support by consenting to the provision of blood pressure and LDL-C test results.  
However, in practice numerous problems were encountered during the data collection 
phase of the research undertaken.  For instance, in many instances test results were not 
available at the agreed time of data collection, and practice receptionists on occasions 
appeared unfamiliar with the information needed.  For a future larger study recruitment of 
nurses working in GPs’ surgeries to help collect and provide data at the appropriate data 
collection points could help avoid such difficulties. 
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Pharmacy remuneration  
Successful community pharmacy service changes are often dependent on timely and 
otherwise adequate financial support.  This was recognised from the start of the research 
reported here.  It was intended that remuneration for the pharmacy consultation involved 
should take place via either by a MUR or an NMS payment based approach.  In the event 
a majority of the consultations undertaken were classified as NMS interventions. 
However, some counselling sessions could not be categorised as either MUR or NMS 
consultations, and so were not claimed for by the pharmacists/pharmacies who undertook 
them. Additional costs were also incurred in relation to attending the motivational 
interview training sessions.  These expenses were accommodated via the study’s small 
budget, together with support from the LPC. But the key point to stress here is that 
without transitional funding arrangements of one sort of another it is likely to prove very 
difficult – if not impossible – to achieve large scale practice changes in the community 
pharmacy context, even in the presence of a professional consensus that new ways of 
working are desirable.  
 
Use of the Beliefs About Medicine Questionnaire (BMQ) to determine pharmacy service 
users’ adherence support requirements 
The research undertaken for this thesis found a statistically significant relationship 
between self-reported adherence levels and subjects’ beliefs about medicines at 3 months 
(P=0.028).  Patients who reported better adherence displayed more positive beliefs 
regarding the necessity of taking their medicines than those with poorer adherence.  
There are some uncertainties regarding the causal links underpinning these study 
observations.  However, they are consistent with other research undertaken in the UK and 
elsewhere (Gatti et al, 2009; Sjolander et al, 2013; Horne et al, 2013).  
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For example, Horne et al’s 2013 meta-analysis of research published on the application 
of the Necessity-Concerns framework in the context of medicines taking identified 3,777 
studies, of which 94 fulfilled the inclusion criteria applied.  It was found that adherence 
rates were positively associated with positive perceptions of treatment necessity [95% CI 
(1.569-1.934), p<0.0001] and relatively few concerns about unwanted treatment 
consequences [95% CI (0.450-0.564), p<0.0001].  A cross-sectional survey by Clifford et 
al (2008) explored beliefs about medicines using the Necessity-Concerns framework as 
embodied in the BMQ.  It included patients who reported adherence, unintentional non-
adherence or intentional non-adherence. These authors found that intentional non-
adherers, compared to adherers, had relatively low belief levels regarding the 
necessity/positive value of taking their medication and relatively high levels of concern 
about taking it.  By contrast, the beliefs of unintentional non-adherers were not 
significantly different from those of adherers.  It was concluded that at the time when 
they start a new medication for a chronic condition people who become intentional non-
adherers are likely to hold beliefs that are significantly different from those of adherers 
and unintentional non-adherers (Clifford et al, 2008).  The patients involved in the study 
central to this thesis were not all on new protective medications for a first myocardial 
infarction.  Even so, Clifford et al’s work is relevant to its findings, as is the analysis 
offered by Horne and his colleagues.  Both provide evidence that perceptual factors (that 
is, medicines taking related beliefs and preferences) can influence an individual’s 
motivation to start and continue with treatment.  
 
 
This study employed a motivational interviewing based pharmacy intervention in an 
attempt to improve adherence. But not all non-adherence with agreed medicine taking 
recommendations stems from motivational problems. The evidence available indicates 
that behavioural interventions utilising motivational interviewing techniques are more 
likely to benefit individuals displaying intentional non-adherence than they are those 
classified as unintentional non-adherers (Hugtenburg et al, 2013).  
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The latter are more likely to help to use their medicines as effectively as possible by 
interventions like medicine taking reminders and allied ‘resilience’ promoting measures 
(Furniss et al, 2014).  The conclusion to be drawn here is therefore that tools such as the 
BMQ should ideally be used at a relatively early stage to determine individual needs, and 
that pharmacists should through applying comprehensive consultation and personal 
judgement skills seek to tailor the help they give in order to optimise adherence rates 
amongst all sections of the medicines using community.   
 
 
The importance of this conclusion was recently underlined by the publication of a 
descriptive prospective observational study of patients surviving myocardial infarctions. 
This found that unintentional non-adherence is normally the primary form of non-
adherence in the year following a myocardial infarction (Molloy et al, 2014). 
Unintentional and intentional non-adherence are not necessarily mutually exclusive – a 
mixture of these behaviours can exist in individuals. Yet such findings imply that 
motivational interviewing alone is unlikely to optimise medicine use and its outcomes, 
and that it should not be simplistically regarded as a non-adherence ‘cure-all’.  The view 
taken here is that acquiring motivational interviewing techniques per se ought to help 
professionals such as community pharmacists to address intentional non-adherence as 
effectively as possible.  Further, when intelligently used by comprehensively skilled and 
empathetic professional practitioners as just one aspect of their overall approach to 
communicating with patients, motivational interviewing linked interventions should also 
help people to reflect on the environmental and non-cognitive behavioural barriers to 
their taking medicines in ways that generate benefit.  A duly supportive therapeutic, 
social and physical environment may in addition motivate patients to find and implement 
ways of overcoming all such barriers to optimal medicines use, as well as adopting 
healthier life styles. 
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7.2 Motivational Interviewing and the Wider Development of NHS Primary Care 
Incorporating the above understanding into under-graduate and post-graduate pharmacy 
education might prove important for the future development of the profession.  However, 
the currently available evidence as to the value of motivational interviewing based 
pharmacy interventions remains poor (Pringle et al, 2014).  Notwithstanding the findings 
of a limited number of other investigations involving pharmacists’ use of motivational 
interviewing (Hedegaard et al, 2014) this present study adds new knowledge in that it 
demonstrates that motivational interviewing techniques can be successfully adopted, 
adapted and delivered by pharmacists in order to improve medicines taking adherence. 
There is no evidence showing that any one type of health professionals (such as doctors 
versus nurses, or pharmacists versus doctors) is inherently more effective at motivational 
interviewing than any other (The Health Foundation, 2011).  Logically there is no reason 
why this should be so except in as much that, as with other aspects of health related 
communication, the effectiveness of interventions can in any given social context be 
influenced by patient/consumer expectations relating to the competencies, authority and 
trustworthiness of the communicator.  However, such perceptions are plastic and change 
over time, as norms relating to accepted professional roles evolve.  
 
Having said this, there is presently stronger evidence that medical doctors and nurses can 
use motivational interviewing to improve adherence in medication taking than is so in the 
case of pharmacists. (See Smith et al, 1997; Kemp et al, 1998; Daley et al, 1998; 
Schmaling et al, 2001; Rosen et al, 2002; Dilorio et al, 2003; Miller, 2004; Bisono et al, 
2006; Thompson et al, 2010; and Rubak et al, 2005.)  For example, a meta-analysis by 
Easthall et al (2013) included 26 studies that evaluated the use of motivational 
interviewing and related cognition based behaviour change techniques by doctors and 
nurses to improve medication adherence.  Although the aggregated effect size the authors 
calculated is relatively modest [0.34 (0.23 to 0.46) p < 0.001] this study  
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offers robust evidence that motivational interviewing can effectively support medicines 
taking adherence in primary care.  It also found that motivational interviewing and other 
cognitive-based behaviour change techniques are flexible and adaptable to various 
primary care contexts, and suggested that informed practitioners ought to incorporate 
them into their consultation skill sets in order to facilitate medication-taking related (and 
other) behaviour changes (Easthall et al, 2013).  Despite the continuing lack of pharmacy 
specific evidence such observations may be therefore taken to justify the introduction of 
motivational interviewing into pharmacy curriculums for undergraduate and postgraduate 
pharmacists in the UK and elsewhere (Goggin et al, 2010; 
www.consultationskillsforpharmacy.com/docs/docb.pdf).  It may be argued that there is a 
need for more evidence on the effectiveness of behavioural pharmacy interventions 
before suggesting an extended formal role for them in areas such as (in England) the 
provision of the NMS and MURs.  But at the same time undue conservatism could harm 
to community pharmacy at this stage in its development. 
 
7.3 The Scale of the Health Gains Potentially Achievable  
It has already been observed that – despite the extensive interest shown in adherence 
related topics – the amount of ‘lost health gain’ due to failures to take medicines in ways 
fully consistent with the available evidence as to achieving optimal outcomes has not 
been well quantified.  This weakness in the evidence base available cannot be corrected 
here, although it is possible to offer some outline observations relating to the overall scale 
of the health gains available.  In the case of cardiovascular diseases age standardised 
death rates in England and Wales have more than halved in the last half century.  This has 
in part been due to declines in smoking rates.  But there is also good reason to believe 
that medicines have played an important part despite the fact that non-adherence in CVD 
medicines taking is common. If rates of appropriate medication usage can be enhanced 
even better outcomes should in future be achieved. 
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Evidence supporting this conclusion includes the fact that non-adherence to statins use in 
the year after hospitalisation for myocardial infarction has been linked to a 12-25% 
increased relative risk of mortality (Rasmussen et al, 2007).  Moreover, non-adherence to 
cardio protective medications (β-blockers, statins, and/or angiotensin-converting enzyme 
inhibitors) is associated with a 10-40% relative increase in the risk of (cardiovascular) 
hospitalisation and a 50-80% relative increase in mortality rates (Ho et al, 2009).   
 
 
The pilot feasibility study reported in this thesis was not powered (or of sufficient 
duration) directly to measure changes in clinical outcomes.  Instead a validated measure 
of self-reported adherence with coronary artery disease medication was employed.  Data 
were also gathered on blood pressure and LDL-C levels, along with the BMQ based 
analysis already reported.  As described earlier, after six months self-reported medication 
adherence amongst those receiving motivational support from community pharmacist 
was 17 per cent greater than that recorded by control patients.  This compares to a recent 
US study (Palacio et al, 2014) that found that a phone-based motivational interview 
improved adherence in the case of antiplatelet medicines usage by 14% (p < 0.01).  The 
effect observed during the present study was also similar in magnitude to the reported 
effect of automated text messaging used to prompt adherence to cardiovascular 
preventive treatment (Wald et al, 2014).  Some other research has failed to find similar 
benefits in relation to the treatment of people who have experienced strokes and other 
forms of vascular disease (Hedegaard et al, 2014; Ostbring et al, 2014).  Nevertheless, it 
is concluded here that there is mounting reason to believe that greater use of well-targeted 
motivational interventions by community pharmacists could prove to be of substantive 
value in today’s environment.  It is also possible if not probable that combinations of 
different types of approach to enhancing medication taking in high risk patient groups 
would have even greater effects.  
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Nevertheless, it remains true that the current evidence base relating to the utility of 
pharmacy led interventions in this field is inadequate.  Some authors have suggested that 
investing in high risk therapeutic situations like post myocardial infarction care should 
contribute cost effectively to improving  health outcomes (Peterson et al, 2004; Lee et al, 
2006; Morgado et al, 2010; Aslani et al, 2010).  Yet studies like the one reported here 
have to date failed to demonstrate statistically significant results in relation to proxy 
clinical outcomes such as reduced blood pressure and LDL-C levels (See Ho et al, 2013; 
Yunsheng et al, 2010; and Jaffray et al, 2007). A relatively recent review by Cai et al 
(2013) concluded that too few pharmacy based trials are available, and that further larger 
scale quantitative research involving CVD patients should be conducted.  The conclusion 
drawn here is in line with that analysis, albeit it is worth emphasising again that undue 
caution in relation to seeking to improve pharmaceutical care aimed at promoting better 
medicines taking could prove damaging not only for pharmacy but also to the public’s 
overall health interests.  
 
 
The extent of this last possibility is highlighted by the fact that, despite the advances 
made since the 1960s, vascular disease still causes over 150,000 deaths a year in the UK. 
Some 40,000 of these are of people aged under 75 years.  At the same time over a million 
people are at any one time living with moderate and severe disabilities caused by events 
such as MIs and strokes in England alone. Even if it were conservatively estimated that 
enhanced pharmaceutical care leading to more effective medicines use would decrease 
the incidence/consequences of such events by only 5 per cent, this could significantly 
benefit several thousand ‘new’ patients annually. 
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7.4 Implications for Pharmacy Policy and Practice  
In future, the implementation of plans stemming from the 2014 publication of NHS 
England’s ‘Five Year Forward View’ and the ongoing development of initiatives such as 
the formation of ‘Healthy Living Pharmacies’ will create more opportunities for the 
delivery via community pharmacies of interventions like the one utilised in this research. 
Even if the pilot model described and evaluated here needs further refinement, it is likely 
that over time related interventions will emerge and become widely adopted.  This is not 
least because the available evidence indicates that after a life changing event such as a 
myocardial infarction many patients welcomed the additional primary care support that 
appropriately skilled community pharmacists are capable of providing.  Dispensing and 
medicines information supply processes will over time become increasingly 
computerised. Yet simultaneously the effective provision of personal care by pharmacists 
serving as health professionals is likely to be increasingly prized. In this context the 
positive responses of GPs involved in this investigation are both welcome and 
informative.   
 
 
Some previous research studies have indicated that GPs have typically had negative 
attitudes towards extending community pharmacists’ clinical roles (Saramunee et al, 
2014).  This was, for instance, partly revealed in 2005, when the Royal College of 
General Practitioners raised concerns about extending the prescribing rights available to 
pharmacists. Yet the responses of the GPs involved in this study were more positive than 
such observations imply. Establishing clinical roles for pharmacists working in GP 
surgeries has been an English Pharmacy Board objective since 2014. It is now being 
successfully realised.  A key implication of the findings of this thesis is that there are also 
valuable opportunities for independently located community pharmacists to take play 
more active parts in clinical (including urgent as well as long term) care provision, 
working as constructive partners with GPs and primary care professionals like practice 
and community nurses. 
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Evidence such as that generated by the 2010 PINCER evaluation (Avery et al, 2010) and 
the 2012 PRACtICe study (Avery et al, 2012) has established that pharmacists can play 
critically important parts in reducing the occurrence and mitigating consequences of 
prescribing errors, and in more generally improving the quality of medication regimens. 
Yet the research findings described here also support the view that pharmacists can 
usefully act as not only experts on medicines at the pharmaceutical science and 
pharmacological levels, but as professionals skilled in understanding and facilitating 
changes in the behaviours of people who can benefit by taking medicines in optimal 
ways. 
 
 
The clinical care and patient support roles of pharmacists located in all primary care 
settings are, it can be claimed, becoming more widely recognised and accepted.  The 
findings of this research indicate that, in addition to recent measures aimed at 
encouraging the employment of pharmacists in GP surgeries, innovative approaches to 
developing community pharmacy contributions to the wellbeing of seriously ill patients 
in need of better overall care demand further investigation.  Recent Government 
announcements to the effect that pharmacists across England will, with appropriate 
patient consent, soon be able to access patients’ Summary Care Records (SCRs) can be 
taken to be an endorsement of this conclusion.  One recent report (HSCIC report, 2015) 
found that 85% of the pharmacists interviewed during its preparation agreed or strongly 
agreed that SCR access reduced the need for them to contact GPs before making 
clinically relevant decisions.  It underlined the fact that pharmacist access to SCRs can 
help doctors and their patients to avoid prescribing errors and the harm they may, if 
uncorrected, cause.   
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The Royal Pharmaceutical Society has argued that practice developments such as those 
involving motivational interviewing based intervention evaluated will help pharmacists, 
together with the people they serve, improve medicines adherence.  The RPS (2012) has 
also called for closer working between secondary and primary care, and suggested that 
good hospital pharmacy practice could beneficially include recommending community 
delivered NMS and MUR consultations during discharge processes. Although in this 
present study interviews with hospital pharmacists revealed that their knowledge 
regarding community services is often minimal, these observations can once again be 
taken to indicate that the type of intervention pioneered in this study will over time 
become incorporated into mainstream hospital and community policy and practice. 
 
A final point to note here is that during the period devoted to designing this study and its 
core interventional approach several new pharmacy development initiatives were 
identified. They ranged from the innovative Self Care Pharmacy programme being 
pioneered by the NE London LPC to the emerging the role of pharmacists in modern 
hospital A&E departments.   In addition, the Scottish ‘minor ailments scheme’ based on 
the MINA study (MINA study final report, 2014) has already been shown to reduce 
inpatient attendance rates at hospital A&E departments.  The transfer of responsibility to 
community pharmacists involved, which permits them to prescribe treatments for patients 
with a range of common non life-threatening diagnoses, has ‘given a confidence boost to 
the profession’. This service also provides value for money for the Scottish taxpayer.  
However, in England no comparable arrangements have yet been agreed.  In the case of 
the Self Care Pharmacies being established in North East London, this new scheme could 
serve to promote and facilitate the delivery of pharmacy intervention like the one 
evaluated here. It aims to enhance long term condition treatment quality, in part by 
providing participating pharmacists with training on both motivational interviewing and 
health coaching.  
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Moreover, patients can be enrolled into the Pharmacy Self Care service via hospital 
referrals.  It therefore contains many of the aspects of the intervention developed and 
piloted for this study. 
 
7.5 Study Strengths and Limitations  
 
The strengths of the research reported in this thesis include the fact that the novel 
intervention employed utilised well-validated instruments such as the Morisky Scale 
questionnaire to assess adherence and the BMQ to observe necessity and concern linked 
beliefs about taking medicines.  It is also the case that effective blinding procedures were 
put in place, and that the project was well supported by pharmacist and other participants.  
 
Its main limitations relate to the small size of the sample recruited and the fact that it was 
focused on improving care in just one area of North East London, which limits the 
confidence with which its findings can be generalised.  It would in addition be correct to 
say that using measures of adherence that do not rely on self-reported data would have 
increased the value of the findings generated, as would have been the capacity to identify 
varying rates of adherence on a medicine-by-medicine basis. However, within the 
resources available it is arguable that the approach used was the best affordable. 
 
7.6 Future Research  
Although positive, the findings of this pilot study need to be confirmed via a larger, more 
adequately powered, multicentre randomised controlled trial. A proposal for such a 
investigation was developed by the research team in partnership with an established 
Clinical Trial Unit – Priment CTU – and via a series of meetings with potential 
collaborators.  
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Institutional partners included The London Chest Hospital, University College London 
Hospital, Southampton University Hospital and Queen Alexandra Hospital Portsmouth 
together with the LPCs for North East London, Hampshire and the Isle of Wight, and 
North Central London.  Approval for the study was gained from the consultant cardiac 
pharmacists at the designated sites.  Members of the public were also involved in its 
design, including patients who had taken part in the feasibility study and other individuals 
with experience of coronary heart disease.  When finalised, the proposal was submitted to 
the NIHR, but it did not win funding.  Subsequent feedback revealed that it was not 
rejected on scientific grounds. Rather, an indication that behavioural interventions were 
not prioritised during the relevant round, which means that it might be selected for 
another call.  Details of this proposal, which should arguably be regarded as an integral 
part of the findings generated by the research reported in this thesis, are provided in 
Appendix 24. 
 
7.7 Conclusion  
Since the end of the 1950s dramatic declines in the levels of mortality caused by the 
vascular diseases have been achieved in England and the other UK nations and across the 
more affluent countries more generally.  Much of the increase in life expectancy recorded 
in Britain in the last half century has been attributable to such progress.  However, the 
acute and long term consequences of events such as myocardial infarctions together with 
strokes still account for about 30 per cent of all deaths in this country, and represent a 
dominant cause of potentially avoidable disability.  More could be done to reduce this 
burden through the facilitation of healthy life styles and the effective use of medicines 
(and other forms of health care) aimed at enhancing the primary, secondary and tertiary 
prevention of cardiovascular conditions and their sequelae. 
 
 
269 
 
 
Chapter Seven:                                                                                                     Discussion  
 
Since the 1950s there have also been major changes in pharmacy practice, in both the 
hospital and community settings.  In overall terms the main focus of the profession can be 
said to have shifted away from medicines production and supply towards areas such as 
promoting the safety and effectiveness of clinical care and achieving better health 
outcomes.  The latter commonly demands combining the skills needed for identifying the 
most effective pharmacological use of medicines with an ability to understand and 
influence the behaviours of individuals and communities seeking relief from illness and 
the preservation of good health.  The prospective controlled pilot study described in this 
thesis brings together these two over-arching themes. Specifically, the research 
undertaken demonstrates how enhanced pharmaceutical care, which in part involves 
pharmacists using motivational interviewing and allied psychological techniques to 
support changes in health determining behaviours, can help to further improve health 
outcomes relating to using medicines for (secondary) preventive care purposes amongst 
patients recovering from acute coronary events.   
 
 
Over simplified approaches, which lack due appreciation of the fact that problems such as 
failing to adhere to agreed pharmaceutical treatment programmes are complex and cannot 
be resolved only by altering patients’ motivational levels, should be avoided.  Future 
NHS pharmacists will need comprehensive consultation and service users support skills 
to match their expertise in the traditional pharmaceutical sciences.  Further, being able to 
successfully move more towards assuring the optimisation of medicines use in the 
cardiovascular and other chronic disease contexts will demand the organisation of larger 
multicentre randomised controlled trials. But the additional knowledge generated by this 
study provides evidence of the likely value of such efforts, and the design of further 
research projects could and should be informed by the findings of the work reported here. 
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As the development of increasingly effective medicines and treatment regimens for 
maintaining vascular health and stopping the progression of disabling and life threatening 
conditions continues, achieving optimal outcomes for both individuals and communities 
will require continuing investment in areas such as the promotion of adherence in 
medicines taking.  In some instances this will help limit care costs. But in the final 
analysis the most vital point to make is that pharmacy as a profession with expertise in 
not only the biological actions of drugs but in meeting the needs and influencing the 
behaviours of people who require them has the opportunity to play an even more 
important part in future individual and public health improvements than it has been able 
to fill in the past. 
 
 
 
 
The End 
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Appendices 
Appendix 1 Epidemiological transition 3 basic ages by Omran and 4 stages by Olshansky 
and Ault.  Adapted from Gaziano T.A., (2005) Cardiovascular Disease in the Developing World and Its 
Cost-Effective Management Circulation; 112: 3547-3553. 
Stage Description Life 
in years 
Dominant 
Form of 
CVD 
Percentage 
of Deaths 
Due to 
CVD 
Percentage 
of the 
World’s 
Population 
in this 
Stage 
Regions 
Affected 
Pestilence 
and famine  
Predominance of 
malnutrition and 
infectious 
diseases 
35 RHD, 
cardiomyo-
pathy due to 
infection and 
malnutrition 
5–10 11  Sub-Saharan 
Africa,parts of 
all regions 
excluding high-
income regions 
Receding 
pandemics  
Improved 
nutrition and 
public health 
leads to increase 
in chronic 
diseases, 
hypertension 
50 Rheumatic 
valvular 
disease, IHD, 
hemorrhagic 
stroke 
15–35 38 South Asia, 
southern East 
Asia and the 
Pacific, parts of 
Latin America 
and the 
Caribbean 
Degenerative 
and man-
made 
diseases 
Increased fat and 
caloric intake, 
widespread 
tobacco use, 
chronic disease 
deaths exceed 
mortality from 
infections and 
malnutrition 
60 IHD, stroke 
(ischemic and 
hemorrhagic) 
>50 35 Europe and 
Central Asia, 
northern East 
Asia 
and the Pacific, 
Latin America 
and the 
Caribbean, 
Middle East and 
North Africa, 
and urban parts 
of 
most low-
income 
regions 
(especially 
India) 
 
 
Delayed 
degenerative 
Diseases 
 
 
 
  
CVD and cancer 
are leading 
causes of 
morbidity and 
mortality; 
prevention and 
treatment avoids 
death and delays 
onset; age-
adjusted 
CVD declines 
>70 IHD, stroke 
(ischemic and 
hemorrhagic), 
CHF 
<50 15 High-income 
countries, 
parts of Latin 
America 
and the 
Caribbean 
RHD indicates rheumatic heart disease; CHF, congestive heart failure. 
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Appendix 2 Eastern Mediterranean Region -Cardiovascular Disease-Facts (Alwan, 1997), 
(Jabbour et al, 2012), (Gaziano et al, 2011).   
Country  Facts  
 
Kuwait  An increasing death rate from coronary heart 
disease and hypertension, deaths from CVDs, 
accidents and malignant neoplasms accounts for   
almost half the general mortality, age adjusted 
mortality rates 300 per 100,000 population.  
Qatar  Diseases of the circulatory system were responsible 
for 37% of deaths. 
Bahrain  Diseases of the circulatory system were reported to 
be responsible for 30% of Deaths. 
Coronary heart disease is the predominate type of 
cardiopathy and the fourth leading cause of hospital 
admission. 
Jordan  CVDs were reported as the leading cause of death in 
accounting for 44.4% of male and 34.5% of female 
mortality. 
Almost half the patients with confirmed CVDs are 
below the age of 50 yrs and 17% are above the age 
of 60 yrs.   
Cyprus, Egypt, Islamic Republic of Iran, Iraq, 
Morocco, Oman, Pakistan and Saudi Arabia.  
Hypertension (Blood Pressure > 140/90) has been 
reported to affect more than 20% of adults. 
A survey in Egypt showed that 26% of adult 
Egyptians suffer from hypertension.  
Similarly in Oman 26.3% of adults suffer from 
Hypertension. 
Egypt, Yemen and Iraq- have high rates of age-
adjusted mortality rates 500 per 100,000 population.  
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Appendix 3 Coronary heart disease/cardiovascular disease primary risk calculators and 
risk prediction charts  
ETHRISK® calculator based on Framingham data which may be appropriate for British 
black and ethnic minority groups
 
There are increasing numbers of alternative risk prediction scores, particularly focused on 
specific groups, e.g. people with diabetes, ethnic populations. 
 ASSIGN: developed in Scotland and includes an index of deprivation and also 
family history (Woodward et al, 2007).  
 Reynolds Risk Score: provides a greater accuracy for assessment of cardiovascular 
risk in women (Ridker et al, 2007). 
 UK Prospective Diabetes Study (UKPDS) Risk Engine for people with type 2 
diabetes : 
o Provides risk estimates and 95% confidence intervals, in individuals with 
type 2 diabetes not known to have heart disease, for:  
 Nonfatal and fatal coronary heart disease. 
 Nonfatal and fatal stroke. 
o These can be calculated for any given duration of type 2 diabetes based on 
current age, sex, ethnicity, smoking status, presence or absence of atrial 
fibrillation and levels of HbA1c, systolic blood pressure, total cholesterol 
and HDL cholesterol. 
 INDANA (INdividual Data ANalysis of Antihypertensive drug intervention) risk 
calculator: focuses on patients with raised blood pressure.  
 Other risk calculators include the older Sheffield Table for Primary Prevention of 
Cardiovascular Disease, the New Zealand tables and tables proposed by the 
European Society of Cardiology.  
A number of risk prediction charts are available for assessment of cardiovascular risk 
factors the charts are intended to allow the introduction of the total risk stratification 
approach for management of cardiovascular disease. 
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Examples of these charts -WHO/ISH cardiovascular risk prediction charts provides 
specific information on countries in each WHO sub region.  
The charts have been generated from the best available data, using a modelling approach 
with age, sex, smoking, blood pressure, blood cholesterol, and presence of diabetes as 
clinical entry points for overall management of cardiovascular risk. 
Separate charts have been developed for assessment of cardiovascular risk in patients 
with type 2 diabetes. There are also charts when there is absence of cholesterol 
measurement. 
-Joint British Societies’ cardiovascular disease (CVD) risk prediction chart. 
The charts exist for non diabetic and diabetic men and women. 
-The American Heart Association used Framingham risk factor data to prepare charts for 
estimating CHD risk. 
- Risk charts derived from the SCORE risk estimation system that offers direct estimation 
of total fatal cardiovascular risk in a format suited to the constraints of clinical practice. 
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Appendix 4 adapted from Osterberg, 2005 summary of measures of adherence 
Osterberg L and Blaschke T., (2005), Adherence to medication. N Engl J Med; 353: 487–497. 
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Appendix 5 Intervention setting 
   
Intervention setting  
 
The studies  Result on adherence  
Hospital (14) Lee et al,2006 , Morgado et al  , 2010 , Al 
Mazroui et al  , 2009, Sadik et al  , 2005, 
Gwadry-Sridhar et al  , 2005, Phumipamorn et 
al, 2008, Edworthy et al, 2009, Lopez et al  , 
2006, Zhao et al  , 2011, Faulkner et al  , 2000 
, Varma et al, 1999, Jarab et al, 2012, Ho etal, 
2014, Alsabbagh et al, 2012 
12 (14) Significant  
Community pharmacy 
(15) 
Bouvy et al, 2003,  Zilich et al  , 2005, 
Villeneuve et al, 2010, Murray et al  , 2007, 
Svarstad et al, 2009, Aslani et al, 2010, Lau et 
al  , 2010, Vrijens et al  , 2006, Sookaneknun 
et al  , 2004, Jaffray et al  , 2007, 
Blenkinsopp, 2000, Park et al  , 1996, Mehuys 
et al  , 2011, Planas et al  , 2009, Eussen et al  
, 2010.  
10 (15) 
Significant  
 
Both hospital and 
community pharmacy 
(1) 
Calvert et al, 2012. 1(1) 
Significant  
Clinic or primary care 
practice (9) 
Carter et al  , 2008, Hunt et al  , 2008, Taylor 
et al  , 2003 , Odegard et al  , 2005, Mehos et 
al  , 2000, Obreli-Neto et al  , 2011, Carter et 
al  , 2009, Evans et al  , 2010, Heisler et al  , 
2012.  
3 (9) 
Significant  
 
Home visit (2) Holland et al, 2007, Peterson et al, 2004.  0 (2) 
Non significant  
 
 
Appendix 6 Interventions and their mode of delivery 
 
Intervention  Trials Result on 
adherence  
1-Patient 
education by 
pharmacist 
Lee et al  , 2006,  Bouvy et al , 2003, Morgado et al  , 2010, 
Al Mazroui et al  , 2009, Sadik et al, 2005, Alsani et al  , 
2010, Murray et al, 2007, Mehuys et al, 2011, Taylor et al  , 
2003, Jaffray et al, 2007, Blenkinsopp et al  , 2000, 
Sookaneknun et al  , 2004, Phumipamorn et al, 2008 , 
Varma et al, 1999,  Odegard et al, 2005,  Park et al, 1996,  
Lopez et al, 2006,  Zhao et al  , 2011,  Planas et al, 2009 , 
Evans et al, 2010,  Eussen et al, 2010 
15(21) 
significant  
2-Telephone 
contact 
Yunsheng et al, 2010,  Faulkner et al, 2000,  Jarab et al, 
2012, Alsabbagh et al, 2012 
2(4) significant  
 
3-Use of 
electronic 
device 
 Zilich et al , 2005 (SMBP), Svarstad et al , 2009 
(pedometer, blood pressure tracker), Virijens et al, 2006 
(Beep card), Mehos et al, 2000 (SMBP) 
3(4) significant 
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4-Home visit Holland et al, 2007,  Peterson et al , 2004 
 
0 (2) non 
significant 
5-Collaborative 
care 
Carter et al  , 2008, Hunt et al  , 2008, Villeneuve et al  , 
2010, Gwadry-Sridhar et al  , 2005, Edworthy et al, 2007, 
Obreli Neto et al, 2011 , Carter et al, 2009. 
3(7) significant  
 
6-Motivational 
interviews 
Heisler et al, 2012. 1(1) non 
significant  
 
7- 
Communication 
between 
primary and 
secondary care 
Calvert et al, 2012.  1(1) significant 
 
8-Combined  
interventions 
Ho et al, 2013, Lau et al, 2010. 2(2) significant  
Appendix 7 Main Intervention 
Trial  Intervention  Trial  Intervention  Trial  Intervention  
1-Lee et 
al  , 2006 
 
FAME 
Trial 
Patient 
education  
Every 2 
months.  
and blisters 
(continued 
provision) 
 
6-Al Mazroui 
et al  , 2009      
physician 
recommendations, 
Patient education, 
Written information, 
monthly hospital visits 
11- Peterson 
et al  , 2004 
Home visits 
monthly  
Patient 
education 
 
2-Bouvy 
et al  , 
2003 
Patient 
education  
Base line 
interview, 
monthly follow 
up.  
7-Hunt et al  
, 2008   
 
Collaborative care 
pharmacist and 
physician, 
Patient education. 
12- Villeneuve 
et al  , 2010 
Collaborate 
care of 
pharmacists 
and 
physicians, 
3 visits, an 
additional 
visit if 
needed 
patient 
education   
3-
Morgado 
et al  , 
2010 
Patient 
education 3 
visits baseline, 
3 and 6 months, 
written 
material, 
recommendatio
ns 
8-Zillich et 
al  , 2005 
SBPM (Electronic),4 
visits face to face within 
3 months,  
Patient education  
physician 
recommendations  
Adherence aids 
Written material 
13-Gwadry-
Sridhar  et al  , 
2005  
 
A 
multidiscipli
-nary team 
(nurse, 
hospital 
pharmacist, 
educator) 
 2.5 hour 
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Main Intervention 
intervention 
with Four 
specific 
multifaceted 
components 
were oral, 
written, 
visual props 
and media 
videos. 
Delivered 
over 2 days  
4-
Yunshen
-g et al  , 
2010    
 
telephon
e contact  
Patient 
education at 
baseline, 
telephone calls 
2 weeks, 
1,3,6,9 months  
Written 
information 
and pillbox. 
Recommendati
ons physicians 
and nurses.  
9- Holland et 
al  , 2007 
Home visits, GP 
recommendations, 
adherence aids, written 
information  
 
 
 
14- Murray et 
al  , 2007 
In  patients 
with low 
health literacy 
and limited 
resources.    
Patient 
education 
baseline 
interview 
 verbal, 
written and 
pictures. 
Contact 
physician 
and nurses 
on need. 
 
5- Carter 
et al  , 
2008 
Collaborative 
care pharmacist 
and physician, 
baseline 
interview 4 
visits  
adherence aids, 
telephone 
contacts on 
need.  
10-Sadik et 
al  , 2005 
Patient education, 
written material, diary 
cards physician 
recommendations,  
visits for medication 
refills.  
15- Svarstad 
et al  , 2009 
Written 
material,  
Electronic 
blood 
pressure 
tracker.  
Pedometer, 
pill boxes. 
Patient 
education 
during 
regular 6 
visits 
Trial  Intervention  Trial  Intervention  Trial  Interventio
n  
16- 
Alsani 
et al  , 
2010 
Patient education and the 
use of a multi-part 
questionnaire, 4 visits.  
21-
Taylor 
et al  , 
2003 
Review of the disease 
and medication for 
MRP, patient 
educations, physician 
recommendations, 
written materials, 
24-
Edworthy 
et al  , 
2007 
 Patient 
education. A 
joint 
intensive 
program 
including 
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education on the use of 
pill boxes, glucometers.  
physicians, 
pharmacists 
and nurses. 
Videos and 
printed 
material, 
Telephone 
contacts.  
 
17- 
Lau et 
al  , 
2010   
Patient education. 
Electronic B.P home 
monitor. 
Motivational interviewing. 
Home medicine review , 
dose administration aid, 
patient medication profile,  
Refill reminders by SMS, 
telephone or mail. 
22- 
Jaffray 
et al  , 
2007 
Patient education. 
Physician 
recommendations.  
 
25- Varma 
et al, 1999. 
 
 
 
 
 
 
 
 
 
 
 
Research 
pharmacist 
Physician 
discussions 
Patient 
education in 
hospital and 
every 3 
months, 
written 
information 
(booklet), 
diary cards. 
Community 
pharmacist 
Reviewed 
patients 
cards and 
mailed to 
the 
researchers.  
 
18- 
Vrijens 
et al  , 
2006 
Review by patient and 
pharmacist of each 
patient's electronically 
compiled dosing history 
plus educational 
reminders, Beep Card.  
 
23-
Blenki-
nsopp 
et al, 
2000. 
Patient education  
(verbal, written) based 
on a guided 
questioning, 3 
interventions, 
intervention could be 
by telephone, referral to 
GPs 
26- 
Odegard et 
al  , 2005. 
Baseline 
interview to 
develop a 
diabetes 
care plan, 
weekly in 
person or 
telephone 
meetings 
19-
Phumi
p-
amorn 
et al  , 
2008 
Pharmacist patient 
education on diabetes  
accompanied by its 
pamphlet, 4 visits. 
 
20-
Sookan
e-knun 
et al  
2004 
 
Monthly face to face 
interviews with patients, 
physician 
recommendations, 
educational leaflets and a 
diary. Occasional home 
   27- Mehos 
et al  , 
2000 
 
SMBP 
Written 
material, 
pharmacist 
counseling, 
electronic 
blood 
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Main Intervention 
 visits.  pressure 
monitors, 2 
unrestricted 
visits, 
monthly 
telephone 
contacts, 
Diaries, 
physician 
recommend
ations.  
28- 
Park et 
al  , 
1996 
4 visits each 1 
month apart, a 
comprehensive 
pharmaceutical 
service. 
Physician 
recommendations 
Verbal 
counselling, 
written 
information.  
32-
Faulkn-
er et al  
, 2000 
 
 
Weekly telephone 
contact was made 
with each patient 
for 12 weeks. 
37-
Evans 
et al  , 
2010 
Interview to determine risk 
factors, booklet, telephone 
alert to patients, 
notification to physicians, 
follow up every 8 weeks 
by telephone, mail, 
electronic mail, face to 
face appointments.  
29-
Mehuy
-s et al  
, 2011 
Patient education 
and couselling at 
the start of the 
study and at each 
prescription refill.  
33-
Calvert 
et al  , 
2012 
Education on 
hospital discharge, 
pocket medication 
card, list of tips, 
pill boxes,  
communication 
between study 
pharmacist 
contacted by 
telephone 
community 
pharmacists, 
physicians, 
patients. 
38- 
Heisler 
et al  , 
2012  
Data of patients loaded 
into a data base, review 
patients electronic medical 
record, pharmacist 
contacted patients a phone 
or in person encounter, a 
welcome pack with written 
information, B.P monitors, 
motivational interviewing 
scheme, follow up 
appointments.  
30-
Obreli-
Neto 
 et al  , 
2011 
Individual follow-
ups and 
educational group 
activities, 
adherence problem 
discussions 
participation of 
patients in their 
drug treatment. 
Suggestions to 
physicians 
34-
Carter  
et al  , 
2009 
Collaborative care 
Majority 
recommendations 
to physicians, 
visits, telephone 
contact.   
39-
Eussen 
et al  , 
2010  
5 individual counseling 
sessions by a pharmacist 
during a 1-year period. 
During these sessions, 
patients received structured 
education about the 
importance of medication 
adherence. 
Lipid measurements, a 
wallet card. 
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concerning new 
drug regimens. A  
visual reminder  
 
 
31- 
Lopez 
et al  , 
2006 
Pharmacist patient 
education. 
Telephone calls 
every month for 6 
months  and then 
every 2 months for 
the remaining 6 
months.  
Written 
information 
35-
Zhao et 
al  , 
2011 
Patient education, 
supervision for side 
effects, follow up 
by telephone, 
recommendations 
to physician.  
 
 
 
 
40-
Alsabb
-agh et 
al, 
2012 
Patients were 
invited to participate in 
telephone-based cardiac 
rehab., regardless of 
participation in the formal 
program. Subjects in the 
intervention group 
were assessed by the 
pharmacist and received 
education andcounseling 
on medication adherence. 
 
  36-
Planas 
et al  , 
2009 
Patients seen on 
monthly basis, 
patient education, 
(individual plan), 
Physician 
recommendations  
41-
Jarab 
et al, 
2012 
face-to-face objective-
directed education 
from a clinical pharmacist  
and necessary lifestyle 
changes, followed by 8 
weekly telephone follow-
up calls to discuss and 
review the prescribed 
treatment plan and to 
resolve any patient 
concerns. 
42-Ho 
et al, 
2014 
(1)pharmacist-led 
medication reconciliation 
and tailoring; (2) patient 
education; (3) 
collaborative 
care between pharmacist 
and a patient’s primary 
care clinician and/or 
cardiologist; and (4) 2 
types of voice messaging 
(educational and 
medication refill reminder 
calls) 
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Appendix 8- Adherence measurement and threshold 
Trial  Adherence 
measure  
Adherence 
Threshold  
Trial  Adherence measure  Adherence 
Threshold 
1-Lee et 
al  , 2006 
Pill counts 80% 6-Al Mazroui 
et al  , 2009      
Self-reported adherence.  -------- 
2-Bouvy 
et al  , 
2003 
MEMS  Two Cutoff 
values 80% 
And 95% 
7-Hunt et al  , 
2008   
 
A Four validated patient 
self-reported questions. 
Morisky  
 
-------- 
 
3-
Morgado 
et al  , 
2010 
Morisky 
scale 5 item   
------ 8-Zillich et al  
, 2005 
Self-reported medication 
adherence was assessed 
using a validated 4-item 
questionnaire developed by 
Morisky 
 
-------- 
 
4- 
Yunsheng 
et al  , 
2010    
Prescription 
refills, The 
CMA is the 
ratio of days 
supply 
obtained to 
total days 
between refill 
records. 
The trial 
considered 
high 
adherence 
to be > 90% 
9- Holland et 
al  , 2007 
(medication adherence 
report scale or MARS; R 
Horne, personal 
communication, 2002) 
-------- 
5- Carter 
et al  , 
2008 
Pill counts  --------- 10-Sadik et al  
, 2005 
Self reported 
questionnaires 
 
 
-------- 
 
 
 
 
Trial  Adherence 
measure  
Adherence 
Threshold  
Trial  Adherence 
measure  
Adherence 
Threshold 
11- Peterson 
et al  , 2004. 
Self-reported 
questionnaire  
 
 Compliance 
was assessed 
according to 
the used 
questionnaire  
16-Aslani et al  
, 2010 
Brief Medication 
Questionnaire, 
Medication 
Adherence Report 
Scale (MARS 
Scale) 
---------- 
12-Villeneuve 
et al  , 2010 
Proportion of 
days during 
the follow up 
period with 
coverage by 
the 
medication 
dispensed  
>=80% 
 
17-Lau et al  , 
2010   
Self-reported 
Morisky score, 
Tool for Adherence 
Behaviour 
Screening (TABS), 
Medsindex score  
(refill data). 
 
< 100 
Meds refill 
data 
13-Gwadry-
Sridhar et al  , 
2005 
pharmacy  
refill data 
MEMS  
>=80% 18- Vrijens et 
al  , 2006 
MEMS -------- 
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14- Murray et 
al  , 2007 
 
Used different 
measurement 
of adherence 
Electronic 
prescription 
monitors. 
Refill 
adherence as 
the 
medication 
possession 
ratio. 
Self reported 
adherence  
 
 
 
------- 19-
Phumipamorn 
et al  , 2008 
Pill counts % 
 
-------- 
15-Svarstad et 
al  , 2009 
self-reported 
patient 
adherence 
 
prescription 
refills 
------- 20-
Sookaneknun 
et al  , 2004 
 
Adherence was 
calculated by the 
number of 
medicines taken 
divided by the 
number supplied 
multiplied by 100. 
 
>=80% 
good 
adherence  
<= 80% 
bad 
adherence. 
 
 
 
 
Trial  Adherence 
measure  
Adherence 
Threshold  
Trial  Adherence 
measure  
Adherence 
Threshold 
21- Taylor et 
al  , 2003 
Self report 
obtained by 
dividing the 
estimated 
doses taken 
by the total 
number of 
doses 
prescribed. 
<80% 24-
Edworthy 
et al  , 2007 
Patient reported 
adherence 
------ 
22-Jaffray et 
al  , 2007 
Self reported 
compliance 
---------- 25-Varma 
et al  , 1999 
 
Self reports and 
Drug use 
profiles (DUPs) 
graphic 
chronologic 
reviews 
PMRs  
continuous 
patient drug 
records.  
Below 80% under 
compliance 
More than 120% over 
compliance. 
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23-
Blenkinsopp, 
2000 
Self reported 
adherence.  
MARS 
Prescription 
refills  
 
From the 
Mars scale 
those that 
scored 34 or 
35 were 
classed as 
adherent. 
Those scoring 
33 or less as 
non-adherent. 
26- 
Odegard et 
al  , 2005 
Self-report 
medication 
adherence 
----------- 
 
 
Trial  Adherence 
measure  
Adherence 
Threshold  
Trial  Adherence measure  Adherence 
Threshold 
27- 
Mehos et 
al  ,2000 
Prescription 
refill data 
----------    
28-Park 
et al  , 
1996 
Pill counts 80% 32-Faulkner 
et al  , 2000 
 
Pill and packet 
counts and refill 
records 
80% 
29-
Mehuys 
et al  , 
2011 
Prescription 
refill data. 
Self report 
question 
----------- 33- Calvert 
et al  , 2012 
Morisky 4 item and 
prescription refills 
proportion of days 
covered (PDC).   
PDC >= 75% 
30-
Obreli-
Neto et al  
, 2011 
The morisky-
Green test 
translated into 
Portuguese. 
And 
computerized 
dispensed 
medication 
history. 
80-115% 
 
 
 
 
 
34-Carter  et 
al  , 2009 
Morisky  scale ---------- 
31- Lopez 
et al  , 
2006 
 
 
 
 
Tablet 
accountability  
 
 
 
 
95%-100% 35-Zhao et 
al  , 2012 
Morisky scale 1986, 
1983 
----------- 
Trial  Adherence 
measure  
Adherence 
Threshold  
Trial  Adherence measure  Adherence 
Threshold 
36- 
Planas et 
al  , 2009 
Prescription 
claims data 
(continuous 
measure of 
medication 
acquisition) 
----------- 40-
Alsabbagh et 
al, 2012 
Electronic filling 
records 
70% 
37- Evans Prescription 80% 41-Jarab et    Morisky scale 80% 
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et al  , 
2010 
dispensations 
(fills) 
 
al, 2012 
38- 
Heisler et 
al  , 2012 
Pharmacy 
refill data  
>20% gap 
days  
42-Ho et al, 
2014 
Prescription refills 80% 
39-Eussen 
et al  , 
2010 
Pharmacy 
dispensing 
data. 
Medication 
possession 
ratio (MPR).  
MPR of 0.9 
or more was 
defined as 
adherent 
   
 
 
Appendix 9 Effect of pharmacy care on adherence and outcomes  
Study  Trial 
length  
Effect on adherence 
 
Effect on outcomes of the diseases  
no. of 
patients  
Lee et al, 
2006  
 
 USA 
FAME 
study  
14 months  
159  
35.5%  absolute change 
in adherence  p<0.001,  
persistence was 
sustained in the 
pharmacy care group 
p<0.001 
Significant improvements in systolic BP 133.2 mmHg to 
129.9mmHg (P=.02) and LDL-C 91.7 to 86.8 mg/dl 
P=.001). 
Significant reductions in systolic BP in the pharmacy care 
group (−6.9 mm Hg; 95% CI, −10.7 to −3.1 mm Hg) vs the 
usual care group,(−1.0mmHg; 95%CI, −5.9 to 3.9mmHg; 
P=.04), but no significant between-group differences in 
LDL-C levels or reductions. 
Bouvy et 
al, 2003  
 
Nether-
land 
6 months  
152  
Intervention group did 
not use diuretics for 
140/7656 days, control 
group 337/6196 days 
(relative risk 0.33, 95% 
CI). 
There were no significant differences in rehospitalizations, 
mortality, or disease-specific quality of life between groups. 
Morgado 
et al  , 2010  
 
Portugal  
9 months  
197 
Medication adherence 
was 57.6% at baseline 
in the Intervention 
Group and 74.5% at the 
end of the study 
p=0.012. Difference in 
low adherence 22.3% 
Intervention Group vs 
43.8% Control Group  
P=0.0017 
Significant lower systolic blood pressure -6.8 mmHg (P = 
0.006) and diastolic blood pressure -2.9 mmHg  (P = 0.020) 
levels were observed in the intervention group 
Yunsheng 
et al  , 2010 
 
 
USA 
 
Sep 2000-
August 
2005. 
689 
No significant effect  
0.88 in the Pharmacy 
Intervention and 0.90 in 
the Usual Care p=0.51 
At one year, 65% in the Pharmacy Intervention condition 
and 60% in the Usual Care condition achieved an LDL-C 
level < 100 mg/dL (P = .29) the result was not statistically 
significant.  
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Carter et 
al  , 2008  
 
USA     
9 months  
179 
At baseline medication 
adherence was 
significantly better in 
the control group 89% 
vs 71% in the 
Intervention group, 
after 9 months  92% 
control and 94% 
intervention group 
p=0.396. 
The mean adjusted difference in SBP was 8.7 (95% CI: 4.4, 
12.9) mm Hg, while the difference in DBP was 5.4 (CI: 2.8, 
8.0) mm Hg. BP was controlled in 89.1% of patients in the 
intervention group and 52.9% in the control group p<0.001 
significant result  
Al 
Mazroui et 
al  , 2009  
 
UAE 
 
12 months  
240 
Non adherence was 
decreased from 48.3% 
at baseline Intervention 
Group  to 21.4%,  
49.1% in the Control 
group to 32.5%  p<0.05 
Significant reductions (P <0.001) in mean values (baseline 
vs. 12 months of HbA1c [8.5% vs. 6.9% systolic 131.4 
mmHg  vs. 127.2 mmHg and diastolic blood pressure 85.2 
mmHg vs. 76.3 mmHg were observed in  the intervention 
group; no significant changes were noted in the 
control group. 
 
 
 
 
Hunt et al, 
2008
 
 
USA 
 
12 months  
463 
 
No difference between 
the groups 67% IG vs 
69% Control Group.  A 
small non significant 
result increase from 
baseline 61% to 67%in 
the Intervention Group. 
Significantly lower systolic (p = 0.007) and diastolic (p =
0.002) blood pressures compared to control (137/75 mmHg 
vs. 143/78 mmHg). In addition, 62% of intervention subjects 
achieved target blood pressure compared to 44% of control 
subjects (p = 0.003) 
Zilich et al, 
2005
 
 
 USA 
HOME 
study  
3 months  
125 
 No significant 
differences at any time 
between the groups, 
p=0.38, significant 
increase in adherence in 
the High- Intensity 
group 61.3% at baseline 
to 87.7% end of the 
study  p=0.004. 
From baseline, SBP declined 13.4mmHg in the High-
Intensity group and 9.0mmHg in the Low- Intensity group. 
At the final visit, the difference in SBP/DBP change between 
the High-Intensity and Low -Intensity group was -4.5/-
3.2mmHg (P=.12 for SBP and P=.03 for DBP). Diastolic B.P 
significant result  
Holland et 
al, 2007 
 
 
UK 
 
 
6 months  
 
293 
 
No evident differences, 
final adherence scores 
were marginally higher 
in the intervention 
group. P=0.68. 
134 admissions occurred in the intervention group compared 
with 112 in the control group (rate ratio=1.15, 95% 
confidence interval; P=0.28), 30 intervention patients died 
compared with 24 controls (P=0.54). The difference was 
statistically non significant. 
Sadik et al 
, 2005 
 
 
UAE 
 
12 months  
 
221 
No. of patients with self 
reported compliance 
was 85 vs 35 in 
Intervention Group and 
Control Group 
respectively and at 
baseline was 33 vs 32, 
P<0.05.  
Intervention patients showed significant (P <0.05) 
improvements in a range of summary outcome measures 
exercise tolerance, forced vital capacity, health related 
quality of life.  
Peterson et 
al, 2004 
 
 
6 months  
 
94 
 
No significant result 
Self-reported patient 
compliance with 
medication did not 
change over the course 
The reduction over the course of the study in cholesterol 
levels within the intervention group was statistically 
significant (4·9 ±0·7 to 4·4 ± 0·6, P < 0·005), whereas there 
was no change within the control group (P = 0·26). The 
reduction in total cholesterol in the intervention group should 
322 
 
of the study, and total 
cholesterol levels were 
not significantly related 
to self-reported patient 
compliance either at the 
baseline (P > 0·50) or 
at follow-up 
 (P > 0·30). 
 
translate to an expected 21% reduction in cardiovascular 
mortality risk and a 16% reduction in total mortality risk – 
more than twice the risk reduction achieved in the control 
group. 
Villeneuve 
et al, 2010  
 
Canada 
 
 
12 months 
108  
 
Persistence and 
adherence at 12 months 
> 80% 
 
No significant clinical impact on lipid control in patients 
with dyslipidemia. 
 
Gwadry-
Sridhar et 
al, 2005 
 
USA 
 
12 months 
or until 
death. 
134 
 
No statistically 
significant difference in 
compliance.  
A significant effect on knowledge Health related quality of 
life The composite end points (mortality, hospital 
readmission, emergency visits) occurred in 60% control, 
67% intervention but was not statistically significant. 
Murray et 
al, 2007 
 
USA 
12 months  
314 
During the 9-month 
intervention period, 
medication adherence 
was 67.9% and 78.8% 
in the usual care and 
intervention groups, 
respectively (95% CI). 
However, these salutary 
effects dissipated in the 
3-month post 
intervention follow-up 
period.10.9% difference 
in adherence between 
the intervention and the 
control group adherence 
became 66.7% and 
70.6%difference 3.9% 
Emergency department visits and hospital admissions were 
19.4% less annual direct health care costs were lower ($–
2960)  in the intervention group.  
 
Svarstad et 
al, 2009  
 
 USA 
TEAM 
trial 
 
 
 
6 months-
one year 
576 
The intervention group 
reported lower non 
adherence (18% vs 
29%, p= 0.02). 
Had better BP control (55% vs 36%, p 0.001)  
 
Aslani et al 
, 2010
 
9 months 
142 
No significant result  Patients significantly lowered their cholesterol levels p<0.01 
5.10 mmole/l Intervention Group,4.81 CG end of study 4.63 
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Intervention Group and 4.80 Control Group 
Lau et al, 
2010  
 
 
HAPPY 
trial 
6 months 
395 
completed 
the study 
Hidden 
group 178 
It cannot be concluded 
that the intervention 
improved adherence in 
comparison to the 
control group. On the 
Morisky scale, the 
proportions of adherent 
participants in each 
group increased 
significantly over six 
months but the 
difference between 
groups was not 
statistically significant. 
Significant result in 
differences between the 
intervention and the 
control group in the 
tabs adherence score 
p=0.046, and 
significant results in the 
intervention between 
the control and the 
intervention group in 
the Medsindex score 
p=0.046. 
Significant reduction in systolic BP occurred in both groups 
(PCG: 9.97 mmHg, p<0.001; UCG: 4.61 mmHg, p<0.01) 
and was significantly greater in the PCG (p=0.02) mean 
reduction in B.P 10mmHg.  
Vrijens et 
al, 2006   
Belgium  
1 year  
392 
6.5% increase in post 
baseline adherence 
p<0.001 and 13% 
increase in persistence 
p=0.002 
 
 
 
Did not evaluate outcomes 
Phumipa-
morn et al , 
2008 
 
 
Thailand 
 
8months 
135  
diabetic  
Muslims 
The percent pill count 
was increased in the 
study group p= 0.004 
(+6.8 vs -2.8) but not in 
the control.  
No significant difference in A1c between the study and 
control group. 
P=0.56. Total cholesterol and LDL-C improvements were 
greater in the study group than the control. P=0.002 
Sookane-
knun et al, 
2004
 
 
Thailand 
6 months  
 
235 
The treatment group 
showed significantly 
better adherence 
p=0.014 Significantly 
better adherence 
increased by 58% to 
70%  
The study group had significant reduction in systolic and 
diastolic blood pressure p=0.037, 0.027, respectively.  
Taylor et 
al, 2003  
 
USA 
12months 
81 
The percentage of 
patients with 
medication compliance 
scores of 80%-100% 
increased by 15% in the 
intervention group but 
The percentage of patients responding to hypertension, 
diabetes, dyslipidemia and anticoagulation therapy increased 
significantly in the intervention group and declined in the 
control group. 
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not in the control, 
however compliance 
scores did not differ 
significantly between 
the groups.  
Jaffray et 
al  , 2007 
UK
 
 
12 Months 
1614 
 
No significant effect on 
self reported 
compliance.  
 
No statistical significant differences in outcomes. 
Blenkins-
opp, 
2000
(19) 
 
UK 
6 months 
282 
180 
completed 
the study 
At baseline the 
percentage of patients 
who were adherent was 
very similar in the two 
groups 52.3% and 51% 
in the Intervention 
Group  and Control 
Group respectively post 
study this increased to 
62.9% and 50%, 
p<0.05. 
Patients whose blood pressure was uncontrolled prior to the 
study were more likely to become controlled in the 
intervention group (P<0.05).  
Edworthy 
et al, 2007
 
 
Canada 
 
  
19 months 
 
2643 
 
 
 
Adherence in the 
intervention group was 
greater than in the 
control group only for 
beta-blockers (89% 
versus 80%; P<0.01) 
and lipid-lowering 
agents (83% versus 
78%; P<0.05). 
Total days in hospital per patient were similar (10.9 days in 
the usual care group versus 10.2 days in the intervention 
group; P not significant). Crude mortality 
was 6.2% and 5.5% in the usual care and intervention 
groups, respectively, with no significant difference (P=0.15) 
rehospitalization rates results were not significant. Post hoc 
analysis an important difference in the number of days in 
hospital might have been achieved by the program with 
considerable cost savings p<0.05)  
Varma et 
al, 1999 
 
 
 Ireland  
12months  
83 
 
No significant change 
in adherence from self 
reports, from 
computerized patient 
drug records an 
increased number of 
patients in the 
intervention group were 
compliant p=0.039. 
Group A patients showed improved  exercise capacity, 
significant improved knowledge of their drug therapy, fewer 
hospital admissions p=0.006.  
Odegard et 
al  , 2005
 
 
USA 
 
12months 
77 
Self report medication 
adherence was not 
significantly improved 
by the intervention. 
The mean HbA1c did not differ between groups p=0.61, a 
reduction in HbA1c was noted for both groups over time 
compared with baseline (p=0.001). 
Mehos et al  
, 2000 
 
 
USA 
 
6 months 
41 
Mean compliance with 
antihypertensive 
therapy was 89% in the 
control and 82% in the 
intervention group 
p=0.29. 
Reductions in systolic and diastolic pressures were 
significantly reduced from baseline in the intervention  group 
(17.0 and 10.5 mm Hg p<0.0001) but not in the control 
group (7.0 and 3.8 mmHg, p=0.12 and p=0.09) 
Park et al, 
1996 
 
 
USA 
Oct. 1993-
May1994. 
And 
Oct.1994-
Compliance for visits 2 
through 4 showed no 
difference among the 
groups , however 
Blood pressure control was significantly improved in the 
study group. 
325 
 
1995. 
64 
compliance was greater 
on visits 2, 3 compared 
with control 96.7+-4 vs 
86.0+- 20.7 p=0.025  
Mehuys et 
al, 2011
 
Belgium  
 
6 months 
288 
No evident result: 
prescription refill rates 
was very high in both 
study groups (control 
group: median = 
94.7%; intervention 
group: median = 
99.7%). Moreover, a 
substantial proportion 
of patients had 
adherence rates of more 
than 100%, even up to 
200% . Data were 
considered unsuitable 
for further analysis. 
With respect to the self-
reported adherence, 
both study groups 
declared themselves to 
be very adherent to 
their diabetes 
medication. 
 
The intervention significantly 
reduced HbA1c (between-group difference 0.5%, P = 0.009). 
 
 
 
 
 
Obreli-
Neto et al  , 
2011
 
 
Brazil 
36 Months 
 
200 
Significant 
improvement 50.5% of 
adherent patients at 
baseline vs 83.5% of 
adherent patients after 
36 months p<0.001no 
significant changes in 
the control group.  
Significant improvements in the number of patients reaching 
adequate values for their blood pressure (26.8% at baseline 
vs. 86.6% after 36-months; P< 0.001), fasting glucose 
(29.9% at baseline vs. 70.1% after, 36 months; P< 0.001), 
A1C hemoglobin (3.3% at baseline vs. 63.3% after 36 
months; P<0.001 
Lopez et 
al, 2006
 
 
 Spain 
12 months  
134 
Difference in 
compliance between the 
intervention and control 
group. 88.2% vs 60.5% 
at 2 months, 91.1% vs 
69% at 6 months and 
85% vs 73.9%.  
32.9% fewer patients in the intervention group were 
admitted again vs. the control group. The mean days of 
hospital stay per patient in 
the control group were 9.6 (SD = 18.5) vs. 5.9 (SD = 14.1) in 
the intervention group 
Faulkner 
et al, 2000 
 
 
USA 
24 months  
30  
Compliance was 
significantly better in 
the intervention group 
up to 2 years p<0.05 
63% vs 39% and 48% 
vs 23%. 
Lipid profile results were significantly better in the 
intervention group p<0.05 up to 2 years after start of therapy 
than in the control group for all parameters except high 
density lipoprotein. 
Calvert et 
al  , 2012 
 
 
USA 
6 months  
143 
Self report adherence 
no difference between 
intervention and 
control. Using 
Proportion of Days 
Covered adherence to 
both statins and beta 
Did not evaluate outcomes  
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blocker there was better 
adherence in the 
intervention vs control 
but result not 
statistically 
significant(53%-38% 
p=0.11).  
Adherence to β-
blockers was 
statistically Significant 
(p=0.03) in intervention 
versus control (71% vs 
49%, respectively.  
Carter et 
al  , 2009  
 
USA  
6 months  
402 
 
The percentage of 
patients with poor self-
reported medication 
adherence declined 
from 18.7 ± 22.0% to 
14.7 ± 20.9 in the 
control group and from 
17.3 ± 27.5 to 14.6 ± 
25.4% in the 
intervention group 
(p=0.602 and p=0.979, 
respectively). 
Mean BP decreased 
6.8/4.5 and 20.7/9.7 mm Hg in the control and intervention 
groups, respectively, (p<0.05), BP was controlled in 29.9% 
of patients in the 
control group and 63.9% in the intervention group  p<0.001) 
Zhao et al, 
2012 
 
 
China  
6 months 
278 
Significant difference in 
percentage of patients 
with low adherence  
24.8% intervention 
group  vs 41.7% control 
group p=0.0014 
BP was controlled among 
significant patients more in Intervention Group (76.4%) than 
in Control Group  (50.6%) (P = 0.0000). Significant lower 
SBP (-8.5 mmHg, P = 0.0001) and DBP (-4.7 mmHg, P = 
0.0013) levels were observed in Intervention Group. 
Planas et al  
, 2009 
 
 
USA 
9 months 
52 
Adherence increased by 
7% in the intervention 
group but the result was 
statistically not 
significant.  
The mean intervention group SBP decreased 17.32 mm Hg, 
whereas the mean control group SBP level increased 2.73 
mm Hg (P = 0.003) 
Evans et al  
, 2010 
 
 
Canada 
6 months  
176 
The proportion of 
patients exhibiting 
statin adherence of 80% 
or greater did not 
significantly differ 
between groups at study 
end (73.1%] and 80.0% 
respectively, p=0.333). 
However, 85.2% in the 
follow-up group 
continued with statin 
therapy at the end of the 
study compared with 
67.0% in the single-
contact group 
(p=0.005). 
 
Neither the mean reduction in 10-year risk (-2.68 for the 
follow-up group and -1.25 for the single-contact group, one-
tailed p=0.098) nor individual risk factors were significantly 
different between groups. 
 
 
 Heisler et 
al, 2012 
 
14 months 
4100 
More effective in 
increasing medications 
The mean SBP decrease from 6 months before to 6 months 
after the intervention period was approximately 9 mm Hg in 
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 USA  
than improving 
medication adherence.  
both arms. Mean SBPs of eligible intervention patients were 
2.4 mm Hg lower (P <0.001) immediately after the 
intervention than those achieved by control patients. 
Eussen et 
al, 2010
 
 
Nether-
lands  
12 months 
1016 
Significantly lower rate 
of discontinuation 
within 6 months after 
initiating therapy versus 
usual care (95% CI). 
No significant 
difference between 
groups was found in 
discontinuation at 12 
months (95% CI). 
Median Medication 
Possession Ratio was 
very high (>99%) in 
both groups and did not 
differ between groups. 
In the pharmaceutical care patients both mean cholesterol 
and LDL-C levels declined significantly during the study. A 
significant negative association between the Medication 
Possession Ratio and total cholesterol p=0.002 
Alsabbagh 
et al, 2012
 
Canada 
6 months  
95 
The mean adherence to 
all recently initiated 
cardiovascular 
medications combined 
was 88.8% in the 
intervention group and 
89.9% in the usual care 
group ( P = 0 .73). 
 
Did not evaluate outcomes 
 Jarab et 
al, 2012
 
 
Jordan  
6 months  
171 
The intervention group 
compared with the 
usual care group had 
small but statistically 
significant 
improvements in the 
secondary measures 
self-reported 
medication adherence, 
and self-care activities.  
Patients in the intervention group had a mean reduction of 
0.8% in A1c versus a mean increase of 0.1% from baseline 
in the usual care group (P = 0.019). Between-group 
differences in changes in the secondary measures of HDL-C 
and body mass index were not significant. 
Ho et al, 
2014
 
 
USA 
12 months  
253 
241 (95.3%) completed 
the study (122 in 
Intervention and 119 in 
Usual Care). In the 
Intervention group, 
89.3%of patients were 
adherent compared with 
73.9%in the Usual Care 
group (P = .003). Mean 
Proportion of Days 
Covered was higher in 
the Intervention group 
(0.94 vs 0.87; P< .001). 
A greater proportion of 
intervention patients 
were adherent.  
 
There were no statistically significant differences in the 
proportion of patients who achieved BP and LDL-C level 
goals. 
328 
 
Appendix 10 Strength of the evidence  
Scottish Intercollegiate Guidelines Network checklist for critical appraisal of randomised 
control trials was used to appraise the trials. The overall assessment of the paper starts by 
rating the methodological quality of the study, by using the following coding system: 
++ 
All or most of the criteria have been fulfilled. Where they have not been fulfilled the 
conclusions of the study or review are thought very unlikely to alter. 
+ 
Some of the criteria have been fulfilled. Those criteria that have not been fulfilled or 
not adequately described are thought unlikely to alter the conclusions. 
- 
Few or no criteria fulfilled. The conclusions of the study are thought likely or very 
likely to alter. 
 
Study’s 
author 
No. 
of 
pat
.  
Period  
month 
Randomise Allocation  Blindness  Intention 
To Treat 
 
Drop 
outs 
Limitation 
/quality  
1-Lee et al  , 
2006  
159 6 Computer 
generated 
random 
sequence 
Concealed Not  
Blinded 
All  
Included 
10% Confined 
population 
++ 
2-Bouvy et 
al , 2003  
152 6 Computer Not clear  Not clear  Not all 
Included 
61 
40% 
1. patient 
death 
2.Lost MEMS 
+ 
3-Morgado 
et al, 2010   
197 9 Computer  Concealed nurses  
blinded 
All 
included    
7 
3% 
Contamination  
++ 
4- 
Yunsheng et 
al  , 2010    
689 12 Statistician  Not clear  Not clear  Not all 
included 
19% Enrolled 
mostly 
Caucasians 
+ 
5- Carter et 
al  , 2008 
179 9 Table of 
random 
numbers 
Not clear  Investigat
or and 
research 
nurse  
All  
Included 
19 
10% 
Generalized to 
Clinics  
++ 
6-Al 
Mazroui et 
al  , 2009      
240 12 Restricted  Not clear  Not clear  Not clear  6 
2% 
Confined 
population 
+ 
 
 
7- Hunt et al  
, 2008   
463 12 Computer  Not clear  Single  All 
included 
41% 
 
High 
withdrawal 
+ 
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8- Zillich et 
al  , 2005 
HOME 
study 
125 3 Block 
design 
Not clear  Not 
blinded 
Not clear  8 
6% 
Selection bias 
No true control 
+ 
9-Holland et 
al, 2007 
293 6 Computer  Concealed  Not clear All 
included 
4 
1% 
No clear 
placebo 
++ 
10-Sadik et 
al  , 2005 
221 12 Minimizatio
n  
Method 
Not clear   Assessors 
Blinded  
Not  
reported 
13 
6% 
Confined 
population 
+ 
11- Peterson 
et al, 2004 
94 6 Computer  Not clear  GPs Not  
reported 
13 
13% 
Outcome 
measurements 
- 
12-
Villeneuve 
et al, 2010 
TEAM 
225 12 Cluster  
Stratified  
Block  
randomisati
on  
Not clear  Not clear   Adjusted 
results  
6% Selection bias  
External 
validity  
 
+ 
 
 
13-Gwadry-
Sridhar et 
al  , 2005  
 
134 12 Stratified  
Block  
Randomisati
on 
concealed Outcome 
assessors 
Communit
y 
pharmacis
ts and 
physicians 
All 
included  
23 
17% 
Pilot study, 
limited sample 
size. 
++ 
14-Murray 
et al  , 2007 
314 12 Computer  Concealed  Interviewe
rs  
Sensitivity 
analysis  
44 
14% 
Single 
pharmacist  
++ 
15- 
Svarstad et 
al  , 2009 
576 12 Computer  Not clear   Outcome 
assessors 
 
All 
included  
5.2% Not a 
traditional 
control group. 
++ 
16- Aslani et 
al  , 2010 
142 9 Not clear Not clear   Not clear   Not all 
included  
45 
31% 
Low 
recruitment 
High dropout 
rate 
- 
17- Lau et 
al, 2010   
395 6 Sealed 
opaque 
envelope 
technique 
Concealed  Researche
rs  
Not all 
included  
41 
10% 
Sample bias  
++ 
18-Vrijens 
et al  , 2006 
392 12 Open label 
randomised 
two districts  
------- Not 
blinded  
All 
included  
37 
9% 
Selection of 
participants  
+ 
19-Phumip- 
amorn et al  
, 2008 
135 8 Drawing a 
number 
from a 
container 
Not   
reported  
Physician 
and nurses 
Not all 
included  
5 
3% 
Confined 
population  
+ 
20-Sookane- 235 6 Simple Not clear  Not clear  All 8 Patients notes 
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knun et al  , 
2004 
randomizati
on technique 
included  3% labelled 
- 
21- Taylor 
et al  , 2003 
81 12 Not clear  Not clear  Not clear  Not all 
included 
12 
14% 
Limited 
generlizability 
- 
22-Jaffray 
et al  , 2007 
161
4 
12 Computer  Not clear Assessors 
blinded 
All 
included 
121 
7% 
selection bias 
++ 
23-Blenkin-
sopp et al, 
2000 
282 12 Cluster 
randomisati
on 
Sequentially 
for 
pharmacists 
 
 
 
Not clear 
GPs were 
blinded 
Assessors 
blinded 
Not all 
included  
20 
7% 
Patient 
recruitment  
++ 
 
 
 
 
 
 
 
 
 
24- 
Edworthy et 
al  , 2007 
264
3 
19 Coin flip Not clear  Not clear All 
included  
6% Transfer of 
care of patients 
between 
cardiologists 
+ 
25- Varma 
et al  , 1999 
83 12  Restricted 
randomisati
on 
minimisatio
n  
Method 
Not clear Not clear Not all 
included  
34 
40% 
Patient 
recruitment 
+  
26- 
Odegard et 
al  , 2005 
77 12 Blocks  
Not clear 
Not clear Not clear Intention to 
treat using 
generalised 
estimating 
equations  
11 
14% 
Randomisation 
within clinics 
+ 
27- Mehos 
et al,2000 
41 6 Deck of 
cards 
Not clear Not clear Not all 
included 
5 
12% 
Assessment of 
outcomes 
- 
28-Park et 
al, 1996 
64 4 Not clear Not clear Single 
blinded 
All 
included 
11 
17% 
Pharmacists 
aware of group 
assignment 
+ 
 
29-Mehuys 
et al  , 2011 
288 6 Randomizati
on table 
generated 
Not clear Not clear All 
included 
8 
2% 
Outcome 
measures are 
unavailable 
+ 
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30-Obreli-
Neto et al, 
2011 
200 36 Stratified 
random 
sampling 
Not clear Researche
rs 
blinded  
Not all 
included 
6 
3% 
Limited 
generliz- 
ability 
+ 
31- Lopez et 
al  , 2006 
134 12 Computer  Not clear Single  
Blinded 
Not clear 9.7% 
lost to 
follow 
up 
 
42.6% 
Lost to 
death 
High dropout 
rate 
+ 
32-Faulkner 
et al, 2000 
 
30 24 Computer  Not clear Not clear All 
included 
No 
drop- 
outs 
Small sample 
size 
- 
33- Calvert 
et al, 2012 
143 6 Computer  Concealed  Pharmacis
ts 
Blinded 
Not all 
included 
28 
19% 
Targeted 
number of 
patients was 
not achieved 
+ 
34-Carter et 
al, 2009 
402 6 Table of 
random 
numbers 
Not clear Assessors 
Blinded  
All 
included 
17% Generalized to 
Clinics 
+ 
35-Zhao et 
al  , 2012  
278 6 Computer Concealed Not clear  Not all 
included 
7.2% Pharmacist’s 
experience,  
Outcome 
measures 
+ 
36-Planas et 
al, 2009  
52 9 Computer  Not clear   Not clear  Not all 
included  
36.5% High 
withdrawal, 
Selection bias 
- 
37-Evans et 
al  , 2010 
176 6 Table of 
random 
numbers 
Concealed  Not 
blinded 
All 
included 
20 
11% 
Single centre 
+ 
38-Heisler 
et al  , 2012  
462
2 
14 Random 
number 
generator 
Concealed  Not clear  All 
included 
522 
11% 
Continued 
improvement 
in control 
group.  
Selection bias 
++ 
39-Eussen et 
al, 2010 
101
6 
12 Computer Not clear Assessors 
blinded  
Not all 
included  
117 
11% 
Contamination 
of the control 
with 
intervention 
group.  
++ 
40-Ho et al, 
2014 
253 12 Block 
randomisati
on  
Concealed  Not clear  INT 
analysis 
Less 
than 
10% 
++ 
May not be 
generalizable  
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41- 
Alsabbagh 
et al, 2012 
95 9 Block 
randomisati
on  
Not clear  Open 
labelled  
High 
withdrawal 
rate  
>20% Slow 
recruitment  
Not blinded  
+ 
42-Jaarab et 
al, 2012 
171 6 Minimisatio
n  
Not clear  Not clear  Not 
mentioned  
8% Short duration 
and 
underpowered  
- 
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Appendix 11 List of search terms used in the review 
 
 
 
 
Pubmed Search Terms 
 
("pharmacy"[MeSH Terms] OR "pharmacy"[All Fields] OR "pharmacies"[MeSH Terms] OR 
"pharmacies"[All Fields]) AND care[All Fields] AND adherence[All Fields] AND ("cardiovascular 
diseases"[MeSH Terms] OR ("cardiovascular"[All Fields] AND "diseases"[All Fields]) OR "cardiovascular 
diseases"[All Fields] OR ("cardiovascular"[All Fields] AND "disease"[All Fields]) OR "cardiovascular 
disease"[All Fields])) AND (("1990/01/01"[PDAT] : "2012/07/20"[PDAT]) AND Randomised Controlled 
Trial[ptyp]) 
adherence[All Fields] AND ("pharmacists"[MeSH Terms] OR "pharmacists"[All Fields]) AND 
("hypertension"[MeSH Terms] OR "hypertension"[All Fields])) AND (("1990/01/01"[PDAT] : 
"2012/07/20"[PDAT]) AND Randomised Controlled Trial[ptyp]) adherence[All Fields] AND 
("pharmacists"[MeSH Terms] OR "pharmacists"[All Fields]) AND ("diabetes mellitus"[MeSH Terms] OR 
("diabetes"[All Fields] AND "mellitus"[All Fields]) OR "diabetes mellitus"[All Fields] OR "diabetes"[All 
Fields] OR "diabetes insipidus"[MeSH Terms] OR ("diabetes"[All Fields] AND "insipidus"[All Fields]) OR 
"diabetes insipidus"[All Fields])) AND (("1990/01/01"[PDAT] : "2012/07/20"[PDAT]) AND Randomised 
Controlled Trial[ptyp])(adherence[All Fields] AND ("pharmacists"[MeSH Terms] OR "pharmacists"[All 
Fields]) AND ("hyperlipidaemia"[All Fields] OR "hyperlipidemias"[MeSH Terms] OR "hyperlipidemias"[All 
Fields] OR "hyperlipidemia"[All Fields] OR "Hyperlipidemia"[All Fields])) AND (("1990/01/01"[PDAT] : 
"2012/07/20"[PDAT]) AND Randomised Controlled Trial[ptyp])(adherence[All Fields] AND 
("pharmacists"[MeSH Terms] OR "pharmacists"[All Fields]) AND ("coronary disease"[MeSH Terms] OR 
("coronary"[All Fields] AND "disease"[All Fields]) OR "coronary disease"[All Fields] OR ("coronary"[All 
Fields] AND "heart"[All Fields] AND "disease"[All Fields]) OR "coronary heart disease"[All Fields] OR 
"coronary artery disease"[MeSH Terms] OR ("coronary"[All Fields] AND "artery"[All Fields] AND 
"disease"[All Fields]) OR "coronary artery disease"[All Fields] OR ("coronary"[All Fields] AND "heart"[All 
Fields] AND "disease"[All Fields]))) AND (("1990/01/01"[PDAT] : "2012/07/20"[PDAT]) AND Randomised 
Controlled Trial[ptyp])adherence[All Fields] AND ("pharmacists"[MeSH Terms] OR "pharmacists"[All 
Fields]) AND ("heart failure"[MeSH Terms] OR ("heart"[All Fields] AND "failure"[All Fields]) OR "heart 
failure"[All Fields])) AND (("1990/01/01"[PDAT] : "2012/07/20"[PDAT]) AND Randomised Controlled 
Trial[ptyp]) (("pharmacy"[MeSH Terms] OR "pharmacy"[All Fields] OR "pharmacies"[MeSH Terms] OR 
"pharmacies"[All Fields]) AND care[All Fields] AND ("patient compliance"[MeSH Terms] OR ("patient"[All 
Fields] AND "compliance"[All Fields]) OR "patient compliance"[All Fields] OR "compliance"[All Fields] OR 
"compliance"[MeSH Terms]) AND ("cardiovascular diseases"[MeSH Terms] OR ("cardiovascular"[All 
Fields] AND "diseases"[All Fields]) OR "cardiovascular diseases"[All Fields] OR ("cardiovascular"[All Fields] 
AND "disease"[All Fields]) OR "cardiovascular disease"[All Fields])) AND (("1990/01/01"[PDAT] : 
"2012/07/20"[PDAT]) AND Randomised Controlled Trial[ptyp]) ("pharmaceutical services"[MeSH Terms] 
OR ("pharmaceutical"[All Fields] AND "services"[All Fields]) OR "pharmaceutical services"[All Fields] OR 
("pharmaceutical"[All Fields] AND "care"[All Fields]) OR "pharmaceutical care"[All Fields]) AND 
adherence[All Fields] AND ("cardiovascular diseases"[MeSH Terms] OR ("cardiovascular"[All Fields] AND 
"diseases"[All Fields]) OR "cardiovascular diseases"[All Fields] OR ("cardiovascular"[All Fields] AND 
"disease"[All Fields]) OR "cardiovascular disease"[All Fields])) AND (("1990/01/01"[PDAT] : 
"2012/07/20"[PDAT]) AND "humans"[MeSH Terms] AND Randomised Controlled Trial[ptyp]) 
EMBASE search terms: Adherence, Cardiovascular, Cardiovascular disease, Care, Disease, Pharmacy, 
Pharmacy care, Adherence, RCTs. 
PsycINFO search terms: adherence, cardiovascular disease, disorders, care, disease, pharmacy, treatment 
compliance.  
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Appendix 12 Intervention pharmacies information 
 
Pharmacy Name  Location  Ownership 
type  
Consultation 
area availability 
Information 
Sources  
Pharmacists  
Qualification 
Intervention group pharmacy  
1-  
 
 
IG1 2RZ 
Ilford lane  
Independent 
chain 
pharmacy  
Yes                  BNF, Drug 
Tariff, MEP, 
Martindale, 
Internet 
sources 
 MRPharmS 
2- 
 
   
E18 2PB 
High Road 
Woodford  
Independent  Yes  NPA 
member, 
BNF, 
Martindale,  
MEP 
MRPharmS 
3- 
 
1G3 8TG 
High Road, 
Goodmayes 
Independent  Yes BNF, Drug 
Tariff, MEP, 
Martindale, 
Internet 
sources 
PhD 
MSc. 
Mpharm 
4- 
 
RM8 1YT 
Green Lane 
Dagenham 
 
Independent  Yes BNF, 
Martindale,  
MEP 
MRPharmS 
5- 
 
 
E10 7AA 
Leyton 
Waltham 
Forest 
Large Chain  Yes  BNF, Drug 
Tariff, MEP, 
Martindale, 
Internet 
sources 
MPharm 
MSc.  
6- 
 
 
RM6 6NL 
High Road 
Romford 
 
Large Chain 
 
 Mulitiple  
Yes BNF 
Medscape 
one portal  
Certificate in 
primary care 
therapeutics  
7- 
 
IG11 0LG Independent 
chain  
Yes  BNF, Drug 
Tariff, MEP, 
Martindale, 
Internet 
MPharm 
MSc. 
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sources 
8- 
 
E14 7HG Independent  Yes  BNF, Drug 
Tarrif  
MPharm  
9-  
 
E14 0EA Independent  Yes  BNF, Drug 
Tarrif  
 
MPharm  
10- 
 
E14  3BT Independent 
chain  
Yes  BNF, Drug 
Tariff, MEP, 
Martindale, 
Internet 
sources 
MPharm 
MSc. 
11- 
 
RM8 1BJ Independent  Yes    
12- 
 
 
IG3 8BS  pharmaram 
chemists 
 Yes   bnf 
martindale 
stockleys all 
other normal 
resources 
 cppe ongoing 
basis cpd and 
other numerous 
accreditation 
13- 
 
 
E7 8LQ Independent  Yes  BNF, Drug 
Tariff 
 PGDIP, 
MSc 
14-  
 
IG11  7TF Community Yes  BNF, 
Martindale, 
Internet, 
Compendium 
  
CVD, 
Anticoagulatio
n, Medicines 
Management,D
rug 
Therapeutics 
 
15-  
 
E3 5ES Independent  Yes  BNF, 
Martindale, 
Internet, 
MPharm 
16-  
 
IG11 7NN Independent  Yes  BNF Drug 
Tarrif MEP 
 MPharm 
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Appendix 13 Motivational Interviewing Chart  
Motivational Interviewing Consultation Schedule:  
Adapted from Ogedegbe et al, 2007 
1. Introductions: The pharmacist should introduce him/herself to the patient 
2. The pharmacist should briefly outline to the patient why they are in the pharmacy 
and the nature of the consultation (e.g. NMS, etc). 
 
3. Agenda Setting: Ask an open question to find out what the patient wants to get 
out of their consultation 
4. Respond to this using the core MI Skills: OARS (see techniques sheet). The 
pharmacist should use these consistently during the remainder of the consultation. 
a. Open Questions 
b. Affirmations 
c. Reflections 
d. Summaries 
 
5. Information Gathering: Elicit: What do you know about the medication that you 
are taking and how you should be taking it?  
a. The pharmacist should respond to this using MI techniques and allow the 
patient to direct discussion regarding their medication, emotions, 
behaviours, etc. 
 
6. Assess the patient’s motivation and confidence: 
a. When appropriate, ask: On a scale from 1 to 10 (with 10 being the 
highest), how motivated/interested are you in taking your medication as 
prescribed? 
b. On a scale from 1 to 10 (with 10 being the highest, how confident are you 
that you can take your heart attack medication as prescribed? 
 
7. Elicit barriers, concerns and positive self-motivational statements: depending on 
the patient’s responses to the above questions, the pharmacist can follow up with 
additional questions or OARS techniques: 
a. For high numbers: Can you tell me about why you chose X (number) 
rather than a lower number, like a 1 or a 2? (eliciting positive motivational 
statements) 
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b. For low numbers (ask as appropriate): Can you tell me about why you 
chose X (number) rather than a higher number like a 9 or 10? What would 
it take to get you to a 9 or 10? 
REMINDER: At all times, allow space for the patient to express their views and respond 
with OARS.  
 
8. Summaries: The pharmacist should draw together the discussions thus far, 
summarising the major content for the patient.  
9. Elicit: What do you think about all this? Is there something else you want to add? 
 
If necessary, provide information: 
10. Ask permission: “Would it be ok if I shared with you some information 
regarding…” 
11. Provide information: Take care to do this in short bursts and to maintain the 
balance in the consultation, so that the patient talks more than the pharmacist. 
12. Elicit: “What do you make of that information?” or similar. 
If you need to provide additional information, continue to use the ELICIT-PROVIDE-
ELICIT approach (see techniques sheet) 
 
Assess patient’s values and goals: 
13. Elicit: Can you tell me about some goals you have in life and how your health 
relates to these? 
14. Spot ambivalence: Reflect this 
15. Pharmacist should listen carefully for CHANGE TALK and respond 
appropriately using EARS: 
a. Evoking (open questions) 
b. Affirmations 
c. Reflections 
16. Action Mapping: Some patients find it is helpful to write a list about how their 
medication fits into their life, their goals and their values (offer the patient the 
Action Mapping Sheet). What do you think about completing this? 
a. If accepted, complete the action mapping sheet with the patient 
b. If rejected, discuss patient goals and values verbally. Pharmacist may offer 
to make notes for their own memory. 
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17. Summary: Pharmacist summarises the discussion about goals and values 
Next steps:  
18. Elicit: “So what do you think you will do…?” 
19. Thanks: Pharmacist to thank the patient for their participation and engagement in 
their consultation 
20. Follow-up: Pharmacist to arrange or discuss the 3-month follow-up appointment. 
Provide the patient with Pharmacy/Pharmacist contact details where appropriate. 
3-month follow-up: 
 
1. Review: In our last meeting we spoke about few issues regarding the medication 
and we highlighted some key points can remind tell me again a little of what we 
discussed? 
2. Worries: Can you tell me about any concerns you have had with your medication 
since we last met. 
a. Allow patient to outline concerns and reflect upon these. 
b. If necessary, give advice using ELICIT (permission) – INFORM – 
ELICIT formula (see Action-mapping Sheet). 
3. Solution-focused: Some patients have found it useful to review what 
approaches/solutions/techniques did or did not work for them. What would you 
think about doing this? 
a. Tell me about what approaches/solutions/techniques you have tried since 
last time. 
b. Use OARS to respond and elicit more information regarding these. 
4. Future-oriented: Having considered how you’ve taken your medication in the past 
few weeks, tell me about your plans for your medication and health in the next 
few months. 
a. If appropriate set new goals, allowing them to be patient-driven. 
b. Use action-mapping sheet if desired. 
Motivational Interviewing: Key Techniques Sheet 
 
OARS: 
 Open Questions 
o e.g. Tell me about; What do you think about, etc. 
o Avoid closed questions 
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o Take care not to ‘stack’ questions or continue questions – allow space for an 
answer 
 Affirmations 
o Mention their successes, appreciate progress, comment positively on attributes 
(e.g. patient values, desires, behaviours) 
o Express hope, caring and support 
 Reflections 
o Simple reflections: Repeat or rephrase using comparable words 
o Complex reflections: Paraphrase what you heard, reflect back the feeling, 
continue the paragraph 
o Amplified Reflections: Take what you hear, lift it, increasing intensity 
o Keep voice neutral, do not turn into a question by lifting voice 
o Avoid pre-statements (padding!) e.g. so, it seems like, etc. 
 Summaries 
o Reflect the content of the discussion over the past few minutes, joining it 
together 
o Enable deeper thinking by joining together the content of the discussion 
 
Recognise ambivalence: 
 Patients’ conflicting positive and negative thoughts on a topic 
 Reflect these back 
 Reflect their negative thoughts FIRST, then their positive thoughts 
 
Spot Change Talk 
 Reflect this back 
 Elicit more through open questions 
 Affirm 
 
Informing: ELICIT – PROVIDE - ELICIT 
 ELICIT (1): 
o Ask what the patient already knows 
o Ask what the patient thinks they should do to proceed 
 PROVIDE: 
o Ask for permission to inform 
o E.g. “would you like to know about some other approaches that some people 
have found useful?” “Would it be ok if I told you some concerns I have about 
your plan?” 
 Resistant patients: 
o Ask if they would like to hear your information now or later 
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o Prefacing: “There’s something I have to tell you, but I’d really like to know 
what you think about it.” “This may or may not concern you but…” 
 ELICIT (2): 
o Ask open questions: “What do you make of that?” “What does this mean for 
you?” 
 
 
Appendix 14 Self report questionnaires  
The Morisky 8 Items Tool (MMAS) 
 
       8.  How often do you have difficulty remembering to take all your medications?                                               
                                                                          (Please circle your response below) 
©Morisky Medication Adherence Scale (MMAS-8-Item).  
This is a generic adherence scale and the name of the health concern can be substituted in 
each question item.   You indicated that you are taking medication for your (identify 
health concern, such as “high blood pressure”).  Individuals have identified several issues 
regarding their medication-taking behaviour and we are interested in your experiences.  
There is no right or wrong answer.  Please answer each question based on your personal 
experience with your [health concern] medication.   
                                                                              (Please check your response below) 
  No=1 Yes=0 
1.  Do you sometimes forget to take your [health concern] pills?   
2.  People sometimes miss taking their medications for reasons other 
than forgetting. Thinking over the past two weeks, were there any 
days when you did not take your [health concern] medicine? 
  
 
3. Have you ever cut back or stopped taking your medication 
without telling your doctor, because you felt worse when you took 
it? 
  
4. When you travel or leave home, do you sometimes forget to bring 
along your [health concern] medication? 
 
  
5. Did you take your [health concern] medicine yesterday? 
 
  
6. When you feel like your [health concern] is under control, do you 
sometimes stop taking your medicine? 
  
 
7. Taking medication everyday is a real inconvenience for some 
people. Do you ever feel hassled about sticking to your [health 
concern] treatment plan? 
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   Never/Rarely……………………………………....4 
   Once in a while……………………………………3 
   Sometimes………………………………………....2 
   Usually…………………………………………….1 
   All the time………………………………………..0 
Coding Instructions for the ©Morisky Medication Adherence Scale (8-Item) 
You will need to reverse the code response in a positive direction for item number 5 and 
standardize the code for item 8 (0-4), resulting in a scale from low adherence to high 
adherence.  Item 8 is divided by 4 when calculating a summated score. This procedure 
standardizes the 5-point Likert scale.  The total scale has a range of 0 to 8.0.  The eight-
item compliance scale had an alpha reliability of 0.83 (n= 1367) among patients 
diagnosed with essential hypertension attending an outpatient clinic of a large teaching 
hospital.  We have used a 75% completion criterion for establishing eligibility.  The 
median value of all missing items would be substituted for the missing item for 
individuals meeting the eligibility criterion.   
 
Re-codes: 
If Item5 = 0 Item5r =  1   (high adherence) 
If Item8=4 Item8r =    1  (highest adherence) 
If Item8=3 Item8r = .75  (high adherence) 
If Item8=2 Item8r = .50 (moderate adherence) 
If Item8=1 Item8r = .25 (low adherence) 
If Item8=0 Item8r =  0   (lowest adherence) 
Adherence Level Percent 
  
Low Adherence (< 6)                                                    32.1 
Medium Adherence (6 to <8)                                        52.0 
High Adherence (= 8)                                                    15.9 
Morisky DE, Ang A, Krousel-Wood M, Ward H. Predictive Validity of a Medication 
Adherence Measure for Hypertension Control. Journal of Clinical Hypertension 2008; 
10(5):348-354 
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Krousel-Wood MA, Islam T, Webber LS, Re RS, Morisky DE, Muntner P. New 
Medication Adherence Scale Versus Pharmacy Fill Rates in Seniors With Hypertension. 
Am J Manag Care 2009;15(1):59-66. 
Morisky DE, DiMatteo MR. Improving the measurement of self-reported medication 
nonadherence: Final response. J Clin Epidemio 2011; 64:258-263. PMID:21144706 
This footnote is required on all tables or figures which present the ©MMAS-8. 
Use of the ©MMAS is protected by US copyright laws. Permission for use is required. A 
license agreement is available from: Donald E. Morisky, ScD, ScM, MSPH, Professor, 
Department of Community Health Sciences, UCLA School of Public Health, 650 Charles 
E. Young Drive South, Los Angeles, CA 90095-1772. 
Self report question adapted from Gehi et al, 2007, QOL-Adherence forms (Brief 
adherence self-report questionnaire. The AIDS Clinical Trials Group sponsored by the National 
Institute of Allergy and Infectious Diseases (NIAID). 
https//www.fstrf.org/apps/cfmr/apps/common/.../actg/…/910747pp  
Please complete the scale below. 
We understand that many people on cardiac medications find it very difficult to take them 
regularly.  We would like to know HOW MUCH of your cardiac medications you have 
taken DURING THE LAST MONTH. 
Please put a cross (x) on the line below at the point showing your best guess about how 
much of your cardiac medication you have taken in the last month. We would be 
surprised if this was 100% for most people. 
For example: 0% means you have taken none of your cardiac medication. 
50% means you have taken half your cardiac medication. 
100% means that you have taken every single dose of your cardiac medication in 
the past month. 
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Appendix 15 Certificate to community pharmacists for training on motivational 
interviewing 
 
 
UCL School of Pharmacy     
Presents 
Certificate of Attendance 
to 
Name 
For the course in Motivational Interviewing Training for use in pharmaceutical settings to 
support patient adherence  
 
Date: September 2013                                                                                                                              
Number of Hours: 6-8hours  
 
 
..........................                                                  .................................                                             
                                                                                                                                                                                                             
Dr. Katherine Finlay                                                          Felicity Smith                                                         
University of Buckingham                                      Professor of Practice and Policy                                                                                                                        
UCL-School of Pharmacy 
 
......................... 
Hemant Patel 
Mr. Hemant Patel 
Secretary,North-East London LPC 
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Appendix 16 Questionnaire to evaluate the course on motivational interviews 
Please note that the questionnaire is completely anonymous  
Tick as appropriate  
1. How satisfied are you with the course content (range and depth)? 
Very satisfied Satisfied Neutral Dissatisfied 
Very 
Dissatisfied 
     
 
2. How satisfied are you with the delivery and teaching methods? 
Very satisfied Satisfied Neutral Dissatisfied 
Very 
Dissatisfied 
     
 
3. Did this course succeed in enhancing your consultation skills as a health care 
practitioner? 
Strongly agree  Agree  Neutral disagree  
Strongly 
disagree  
     
 
4. How satisfied are you with the length and time of the course? 
Very satisfied Satisfied Neutral Dissatisfied 
Very 
Dissatisfied 
     
 
5. Do you have any further suggestions or comments regarding the course? 
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Pharmacist comments: 
 This actually should be incorporated into the pharmacy curriculum. 
 Sustained application of motivational interview techniques will be the real test. 
 A lot to take in could be better if sessions were done over a few weeks. 
 Perhaps more details on NMS/MUR integration. 
 Very enlightening in new ways of improving patient outcomes through 
motivational interviews consultation. 
 A refresher session will be good.    
 Very positive learning from a specialist outside pharmacy we communicate every 
day I now know how badly we do it. 
 I plan to attend further training if possible it would be helpful to my practice.  
 Very interactive many thanks. 
 Well done, constructive, very informational. 
 Extremely rewarding will take away and implement.  
 Ability to mature after learning is fantastic putting knowledge to work.  
 Although do not like group work in this case it was very helpful. 
 Very informative thank you very much. 
 May be a bit long but informative.  
 Very informative and well structured, some great new ways to motivate patients 
without putting any pressure on them and putting the ball in their court. 
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Appendix 17 Pharmacies and patients consultations  
Pharmacy  Number of 
patients  
Consultation  
1-  2 patients  2 contacted by telephone  
 
2-  7 patients  2 went to pharmacy 4 contacted by telephone, 
1 patient lost to follow up.   
3-  4 patients  1 went to pharmacy, 1 dropped out of study, 2 
contacted by telephone  
4-  3 patients  3 contacted by telephone  
5-  3 patients  All 3 went to the pharmacy for the 
consultation  
6-  1 patient  1Contacted by telephone  
7-  4 patients  1 went 3 contacted by telephone  
8-  2 patients  1went to pharmacy, 1 contacted by telephone  
9-  1 patient  1Went to pharmacy  
10-  1 patient 1Contacted by telephone  
11-  1 patient 1Contacted by telephone 
12-  No patients  
13-  1 patient 1Contacted by telephone 
14-  2patients  2 contacted by telephone  
15- No patients  
16-  No patients  
Total of intervention group 32 Patients, total attended consultation 9 patients and 21 
contacted by telephone, 1 patient dropped out of the study, 1 patient lost to follow 
up.   
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Appendix 18 Letter from General Practitioner  
 
 
Dr Aarron Patel MBBS 
 
Dr Aarron Patel Surgery 
Chadwell Heath Health Centre 
Ashton Gardens 
Chadwell Heath Romford 
Essex RM6 6RT 
 
Tel: 020 8918 0580      Fax: 020 8918 0582 
 
 
13 March 2014 
Zahraa Jalal 
Centre for Pharmacy Practice 
UCL School of Pharmacy 
Mezzanine Floor  
BMA House 
Tavistock Square 
London  
WC1 H 9JP 
 
Email: zahraa.ali.11.ucl.ac.uk 
 
Dear Zahraa Jalal, 
 
RE:- KD  D.O.B. 01/10/1967 ,  
 
Thank you for your letter received on 12 March 2014 requesting GP assistance with data 
collection regarding blood pressure and LDL-C testing in patients with myocardial 
infarction. 
I would wish to assist you in your valuable research but as a single handed GP with twice 
the average GP list size to manage it is extremely difficult to support research work in 
addition to my clinical workload. 
However, I am happy to allow a member of your team to collect the required data at our 
surgery including providing a consultation room for you to undertake blood pressure 
readings for my patient.  Alternatively, I can request my practice nurse to undertake 
overtime to assist you if you are agreeable to reimburse the costs of employing our 
practice nurse (at a rate of £20 per hour). 
I look forward to hearing from you 
Yours sincerely, 
Dr Aarron Patel 
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Appendix 19 Enquiries from pharmacists who expressed interest to take part in the study  
 
   Dear Zahraa, 
   Thank you for your email in relation to the two days of MUR and NMS training. 
As a pharmacist myself who would be taking part, I would be grateful if you could 
confirm the following:  
1. Who will be paying for the two days training? 
2. At what amount is the payment for? 
I look forward to hearing from you shortly, and thank you for your assistance in 
advance. 
 
Kind Regards, | Director | Britannia Pharmacy  
Head Office 
21 - 23 Horns Road 
Ilford, Essex, IG2 6BN  
www.britanniapharmacy.com 
 
Hi Zahraa 
I am very enthusiastic about the opportunity you are creating and am pleased that it 
seems Pharmacy is moving in the right direction. Well done to you. I would like to ask 
when exactly the training will take place and how and when we will be informed? 
Regards 
G.S 
Britannia Pharmacy 
 
Hi Zahraa 
   My names is C. P., and I am one of the pharmacists from Britannia Pharmacy, in 
relation to the two training days, any ideas of when it will take place? 
   Kind Regards 
   C. P  
   Britannia Pharmacy 
   
 
     Dear zahraa. Thanks for the invite to study. Definitely interested, would you know   
roughly when the two days training is? 
    CK Wan 
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Appendix 20 Recruitment letters  
General practitioners consent letter  Title of research: Feasibility and Potential Impact of 
Community Pharmacy Care including Motivational Interviews on Adherence to 
Secondary Prevention Medication in patients with Coronary Heart Diseases  
Chief investigator:  Professor Felicity Smith                   Researcher:  Zahraa SMA Jalal 
(PhD student), Principal investigator :  Sotiris Antoniou   
Dear Doctor,  
I am Zahraa SMA Jalal, a PhD student at the UCL-School of Pharmacy.   I would like to 
request your assistance with a study that aims to investigate the potential impact of a 
pharmacy care intervention involving motivational interviews and referral to the New 
Medicine Service in coronary heart disease patients on adherence to secondary 
prevention medication and on outcomes of coronary heart disease.  
Despite the importance of secondary prevention, non-adherence rates for myocardial 
infarction patients are still low for prescribed, evidence-based medicines and the main 
concern is not with compliance alone but with patients that discontinue medications that 
can lead to serious consequences.   Medications like aspirin and clopidogrel if stopped 
early can lead to short term consequences for instance rehospitalisation and even 
increased risk of death. 
The intervention aims to increase patients’ understanding of their medication by 
motivating the patients to use their medication to achieve optimal outcomes.  This is a 
pharmacy based study and eligible patients will be identified at discharge from The 
London Chest Hospital.  There will be two groups of patients’ intervention group and 
control group.  The intervention will be delivered by community pharmacists and will 
include two counselling sessions incorporating motivational interviews for which 
pharmacists will have received training.  
To evaluate the outcomes, I would like to ask your assistance and permission to obtain 
both LDL-C and blood pressure data of patients included in this study.   Patients’ will 
have given their consent for this information to be collected a copy of the patient consent 
form is attached to this letter.  For each surgery we estimate that there will be only a 
small number of patients.  The research pharmacist will contact the surgery by telephone 
or email to ask for the data, the patients’ information will be treated as strictly 
confidential.  If you are happy to assist, please sign the consent form and return in the 
pre-paid envelope provided to the researcher’s address below or alternatively if you 
prefer further information, you can email or phone the researcher.Thank you for your 
time and I look forward to hearing from you.  If you need further information please do 
not hesitate to contact me: 
Zahraa SMA Jalal   
Department of Practice and Policy  
UCL School of Pharmacy 
Mezzanine Floor, Entrance A, BMA House , Tavistock Square, London WC1H 9JP. 
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General practitioners consent form 
Patient Identification Number for this trial: 
CONSENT FORM 
Title of Project: Feasibility and Potential Impact of Community Pharmacy Care including 
Motivational Interviews on Adherence to Secondary Prevention Medication in patients 
with Coronary Heart Diseases 
 
Chief investigator:  Professor Felicity Smith                   Researcher:  Zahraa SMA Jalal 
(PhD student) 
Principal Investigator Sotiris Antoniou  
                                                                                                                                      
Please initial all boxes  
I confirm that I have read and understand the General Practitioners consent letter dated 
31/01/2013 (version 2) for the above study.  
I agree to provide assistance and permission to obtain both LDL-C and blood pressure 
data of patients included in this study.   Patients’ will have given their consent for this 
information to be collected. 
            
 
Name of General Practitioner                Date               Signature  
Please return to researcher’s address 
Zahraa SMA Jalal  
Department of Practice and Policy  
UCL School of Pharmacy 
Mezzanine Floor, Entrance A, BMA House  
Tavistock Square, London WC1H 9JP  
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Patient invitation letter 
Title of research: Feasibility and Potential Impact of Community Pharmacy Care 
including Motivational Interviews on Adherence to Secondary Prevention Medication in 
patients with Coronary Heart Diseases 
Dear Sir or Madam, 
I would like to invite you to participate in a research study that aims to enhance patients’ 
knowledge regarding their disease and medication and as a result their compliance to 
secondary prevention medication after a heart attack. 
Before you decide to take part in the study, it is important that you understand why this 
study is being done and what it will involve.  Thus, please read the Patient Information 
Sheet carefully and discuss it with others if you wish.  
If you are interested to take part in the study, please inform the hospital 
pharmacist/research pharmacist. If you prefer further information, you can email or 
phone the researcher or chief investigator. 
 
 
Kind regards 
Researcher (PhD-student) 
Zahraa SMA Jalal                                                                              
Centre for Pharmacy Practice, 
UCL- School of Pharmacy, 
Mezzanine Floor, BMA House, 
Tavistock Square, London WC1H 9JP 
 
Chief Investigator 
Professor Felicity Smith  
Professor of Practice and Policy 
UCL-School of Pharmacy 
Department of Practice and Policy 
29-39 Brunswick Square, London WC1N 
1AX 
 
 
Principal Investigator  
Sotiris Antoniou  
Consultant Pharmacist  
Pharmacy Department  
London Chest Hospital 
Barts Heath NHS Trust 
Bonner Road 
London E2 9JX 
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Patient Information Sheet 
 
Title of research: Feasibility and Potential Impact of Community Pharmacy Care 
including Motivational Interviews on Adherence to Secondary Prevention Medication in 
patients with Coronary Heart Diseases 
Who Am I? 
                                                                                               
I am Zahraa SMA Jalal a PhD student  
at the UCL-School of Pharmacy. 
 
What is the purpose of this study?  
 
The study is testing a new way for local 
pharmacists to help patients who have had a 
heart attack with their medicines.  It is a way of 
consulting with patients to identify problems, 
and help achieve the best outcomes.  We want 
to see if this new service is better than what 
happens at present.   
 
Why have I been chosen? 
 
You are being invited to take part in this study 
because you live in East London, have had a 
heart attack that has been treated at the London 
Chest Hospital and you obtain your medicines 
from one of the pharmacies taking part in the 
study.  
 
 
What will I be asked to do if I take part? 
In this study there are two groups of pharmacies.  
In one group (intervention), the pharmacists have 
been trained in a new way of supporting patients 
who have had a heart attack to take their 
medicines.  The other group (control) will 
provide their services as usual.  Pharmacies have 
chosen to be intervention or control pharmacies 
by chance.  If you collect your medicines from 
one of the intervention group pharmacies, when 
you leave hospital you will be given a letter for 
your local pharmacist, who will then invite you to 
have a consultation about your medicines on two 
occasions, the first about 2 weeks after you leave 
hospital and the second about 3 months later, the 
consultation will take approximately 20 minutes.  
If you collect your medicines from a pharmacy in 
the control group, you will receive care as usual 
from the hospital and community pharmacy.   
 
To help us evaluate the intervention participants 
in both groups will be asked to complete 2 
questionnaires about the services and using 
medicines that will take a total of around 10 
minutes to complete.  The researcher may also 
call you to ask about how helpful the consultation 
was.   
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Do I have to take part? 
 
No, it is up to you to decide. The research 
pharmacist will go through this leaflet with 
you, which you can keep.  If you agree to take 
part you will be asked to sign a consent form. 
You are free to withdraw from the study at any 
time without giving a reason.   
 
 
 
 
 
 
 
What are the possible disadvantages of 
participating in this study? 
 
There should be no disadvantages to taking 
part. Whichever group you are in, your 
pharmacist will provide usual services for you.  
 
 
Is the study confidential and what will happen 
to the results of this study? 
 
 All the information that you will provide or 
any other information we may obtain about 
your medication from your hospital records 
will be treated strictly confidential.  The 
A small number of participants will also be 
contacted by the researcher for a brief interview, 
which will take between 10 and 30 minutes, if 
you are agreeable this will be audio-recorded.  
The researcher will use anonymised verbatim 
quotes and the participant is allowed to stop, edit 
and delete audio recording.  
With your permission to help us evaluate the 
intervention we will also ask your GP for some 
routine information on your blood pressure and 
cholesterol, a copy of your consent form will be 
sent to your GP.  
What are the possible advantages of taking part? 
 
We cannot promise that the study will help you, 
but we hope it will provide information to help us 
plan services in the future.   
 
What if something goes wrong? 
 
If you have a concern about any aspect of the 
study, you should ask to speak to the researcher [ 
Zahraa SMA Jalal], project supervisor [Professor 
Felicity Smith] or consultant pharmacist at The 
London Chest Hospital [Sotiris Antoniou].  They 
will do their best to answer your questions.  If 
you remain unhappy and wish to complain, or 
have any concerns about any aspect of the way 
you have been approached or treated by members 
of staff you may have experienced due to your 
participation in the research, National Health 
Service or UCL complaints mechanisms are 
available to you.  Please ask your research doctor 
if you would like more information on this.  In 
the unlikely event that you are harmed by taking 
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information you provide will be made 
anonymous by removing your personal details.  
That means that you will not be identified in 
any report or publication that is produced about 
the study.  The results of the study will be 
reported as a part of a thesis and may be 
published in professional journals.  If you 
would like a copy of the report or papers, 
please ask the researcher, Zahraa SMA Jalal. 
part in this study, compensation may be available.  
If you suspect that the harm is the result of the 
Sponsor’s (University College London) or the 
hospital's negligence then you may be able to 
claim compensation.  After discussing with your 
research doctor, please make the claim in writing 
to the [Professor Felicity Smith] who is the Chief 
Investigator for the research and is based at [The 
UCL-School of Pharmacy, Department of 
Practice and Policy29-39 Brunswick Square, 
London WC1N 1AX 
Tel: 0207753 5800 Email : f.j.smith@ucl.ac.uk] .  
The Chief Investigator will then pass the claim to 
the Sponsor’s Insurers, via the Sponsor’s office. 
You may have to bear the costs of the legal action 
initially, and you should consult a lawyer about 
this. 
Further information and contact details 
If you would like to know more about this study, 
please contact the researcher  Zahraa SMA Jalal  
Centre for Pharmacy Practice, UCL- School of 
Pharmacy, Mezzanine Floor, BMA House, 
Tavistock Square, London WC1H 9JP.   
Email:zahraa.ali.11@ucl.ac.uk 
 Thank you for reading this – please ask any 
questions if you need to. 
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CONSENT FORM                                      Patient Identification Number for this trial:    
Title of Project: Feasibility and Potential Impact of Community Pharmacy Care including 
Motivational Interviews on Adherence to Secondary Prevention Medication in patients 
with Coronary Heart Diseases 
Chief investigator:  Professor Felicity Smith       Researcher:  Zahraa SMA Jalal (PhD 
student) Principal investigator:  Sotiris Antoniou   
Please initial all boxes  
1. I confirm that I have read and understand the patient information sheet dated 
31/01/2013 (version 1) for the above study.  I have had the opportunity to 
consider the information, ask questions and have had these answered 
satisfactorily. 
   
2. I understand that my participation is voluntary and that I am free to withdraw 
at any time without giving any reason, without my medical care or legal 
rights being affected. 
 
3. I give permission to the community pharmacist to contact me and/or to refer 
me to the GP in case of need. 
 
4. I understand that the study will involve the collection of data regarding my 
blood pressure and cholesterol results from my GP to help evaluate the 
intervention. 
 
5. I am aware that I might be contacted by phone by the research pharmacist for 
an interview and that a request maybe made to audio-record but this is not a 
requirement.  
 
6. I understand that the researcher will use anonymised verbatim quotes and the 
participant is allowed to stop, edit and delete audio recording. 
 
7. I am aware that I will be asked to complete 2 questionnaires about the 
services and using medicines. 
 
8. I agree to take part in the above study. 
               
Name of Participant             Date             Signature 
 
            
Name of Person taking consent             Date  
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Appendix 21 BMQ and Adherence results for South Asians sample  
Patient 
No. 
Control  Intervention  Result on BMQ Adherence  
Baseline, 3months 
6months  
2 RN BMQ 25/10  B/R   Positive  8 8 8 
40 HG BMQ 25/19  B/R   Positive 8 8 8 
1MH  BMQ 25/12 B/R   Positive  6.75 8 7 
10MB  BMQ 25/12 B/R   Positive  7.5 8 7.5 
16MP  BMQ 21/15 B/R   Positive  8 8 8 
42ZQ  BMQ 24/11 B/R   Positive  8 8 8 
45MV  BMQ 17/21 R/B  Negative  5.75 5.75 5.75 
57IR  BMQ 20/19 B/R   Positive 8 8 8 
55MB  BMQ 21/15 B/R   Positive 8 8 8 
7SA   R/B Negative  5.75 0.7 0 
39FM BMQ 19/10  R/B Negative  7 7 8 
15MS  BMQ 19/14 B/R   Positive  7 6.75 7 
12NB BMQ 20/13  B/R   Positive  8 8 5.5 
32NM BMQ 21/16  B/R   Positive  8 8 6.75 
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Appendix 22 Coding, themes and analysis  
 Forgetting Sufficient 
knowledge 
Insufficient 
knowledge  
Family 
support 
Side effects  Feeling ill  Feeling 
healthy 
1 32    32 muscle 
pain  
32 
indigestion 
 
2   39  39 vomiting   
3 40  40  40 coughing  40 
vomiting 
and 
sweating 
 
4   2 2 2 cold feet 2 sweating  
5   55  No side 
effects  
55   
6 7  7   7 tightness  
7 12 12   Bruising  12 tightness  
8 1 1   No side 
effects 
1 chest pain  
9  10  10 No side 
effects 
10 burning 
pain 
 
10 42    No side 
effects 
42 
vomiting 
42 
 
11   15 15 relies 
on son 
 15 
breathing 
problem 
 
12  16   Cold 
extremities 
16 body 
pain 
 
13  45    45 sweating   
14   57 57 relies 
on 
daughter  
No side 
effects 
  
 
 
 
 
 
 
 
 
358 
 
 Relying on 
healthcare 
practitioners  
Cardiac 
rehabilitation  
Asian 
food 
Exercising 
Before 
heart 
attack  
Not 
exercising 
Before heart 
attack 
Severity of 
the disease 
Non 
severity 
of the 
disease 
1  32 yes went ot 
rehab. 
 32   32 
2 39 if doctor 
says I have to 
take it then I 
have to 
39 Yes going     39  
3 40 doctor say 
take regular 
40 yes went to 
rehab.  
spicy 
and ghee 
40 walking    
4 2 2 yes   2   
5 55 if 
prescribed  
Yes 55 Curries 55 walking  55 not sure   
6  No 7  7 7 7 yes  
7 12 12 yes   12 little    
8  1yes 1 greasy   1 no  1 yes   
9  10 yes  10 
walking 
    
10   42  42  42 you can 
die 
 
11 15 relies on 
GP 
15 yes 15 junk   15  15 
12 16 relies on 
healthcare 
practitioner  
16yes 16  16   
13  45 yes 45 45   45 
14  57 yes 57 57   57 
 
 Importance 
of the 
medicine 
Problems 
taking the 
medicine 
Organising 
the 
medicine 
Not 
organising 
the 
medicine 
Taking 
medication 
for the first 
time  
Family 
history 
of the 
disease  
Eating 
healthy 
Diet 
1 32 important    32 32 32 32 
2 39 important       
3 40 not sure       
4 2 important  2 organise      
5 55 not sure   55 organise     Not sure 
6  7 not 
taking  
 7    
7 12 important       12 
8 1 important   1 once a day     
9 10 v. 
important 
 10     
10 42 v.  42     
359 
 
important  
11 15 v. 
important 
      
12 16 not sure       
13 45 not sure   45     
14   57     
 
 Not 
eating a 
healthy 
diet  
Causes of 
the disease 
Use of pill 
box 
Worries 
of 
another 
heart 
attack 
Fatality 
and 
God 
Depression  Socio-
economic 
status  
1  32 family 
history 
     
2 39 39 eating 
junk food 
and 
cholesterol 
     
3  40 family 
history 
brother, 
father  
 40     
4  2 stress  2    
5  55 not sure  Uses pill 
box  
 
    
6  No clue  7    
7 45 
alcohol  
Stress, 
family, 
genetics, 
high 
cholesterol   
 12    
8  1 junk food   1 1   
9 10 before 
attack 
Diet 10 yes  10  10 10 
10  Flu 42 42 yes      
11  15 chest 
problem  
  15   
12 16 
smoked  
  16    
13    45    
14 Smoker  Smoking    57  57 lack of 
rest  
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Appendix 24 
This proposal was informed by a feasibility/ pilot study that has been undertaken by the 
applicants: 
 
Title of the research proposal  
A multicentre randomised controlled trial to evaluate the impact of a motivational interviewing-
based community pharmacy intervention to enhance clinical outcomes (LDL-C) to secondary 
prevention medication in patients with coronary heart disease. 
 
The aim  
The aim of the study will be to evaluate the impact of a community pharmacy intervention 
involving motivational interviews with coronary heart disease patients on adherence to secondary 
preventive medication and clinical outcomes.  The study will also include an integral process 
evaluation of the feasibility and acceptability across different locations, patient populations and 
pharmacy settings.     
 
Design  
Multi-centre prospective randomised controlled trial of a community pharmacy based 
intervention for patients discharged from hospital following an acute coronary syndrome (ACS). 
 
Sites and setting 
The study will be undertaken in 4 areas in the south of England two parts of London, Portsmouth 
and Southampton.  Involvement of these locations will enable participating of patients from urban 
and rural areas of differing socio-economic backgrounds. It will involve a number of hospital 
sites and community pharmacies, so that differences in the organisation and delivery of services 
and different types of pharmacy can be taken into account.  
 
Target population  
Patients discharged from 4 cardiac centres with a first diagnosis of ACS, randomised to 
intervention and control arms.  
 
Inclusion criteria patients above 18yrs, admitted with ACS, discharged on secondary prevention 
medication, consent to participation.  
 
Exclusion criteria congenital heart disease, complications of myocardial infarction, do not live  
independently (nursing or care home), terminal illness, unable to understand English. 
 
Duration 
Total duration of trial 4 years (48 months) 
Recruitment of pharmacies and training 6 months  
Recruitment of patients 10 months  
Duration of follow up of patients 12 months  
Data collection, follow up, process evaluation, writing reports, dissemination 20 months   
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The intervention 
Patients discharged from four cardiac centres after a first coronary event will receive a telephone 
consultation involving a motivational interview delivered by a community pharmacist 2 weeks 
post-discharge and again at 3 and 6 months.   The patient’s discharge summary will be forwarded 
from the hospital, by the research assistant, to the community pharmacist. The patient will also be 
given a copy of the discharge letter.  The patients will receive a motivational interviewing 
consultation of 15-20 minutes, Pharmacists will be provided with a laminated copy of the 
consultation to use during their consultation with the patient.  The community pharmacist should 
claim the consultation through the New Medicine Service (NMS) (part of their NHS contractual 
framework). Although the service will be paid for through the NMS, pharmacists will be 
reimbursed for their time and for taking part in the intervention (Training time and contacting the 
patients to invite to the intervention).  
 
 
The consultation  
Communication is integral to any practitioner-patient interaction. Motivational interviewing is a 
patient-centred counselling technique, which aims to evoke behaviour change through the 
exploration and resolution of ambivalence (Rubak et al, 2005; Miller & Rollnick, 2002). 
Motivational interviewing aims to facilitate and enhance the patient's intrinsic motivation to 
change or uptake a behaviour (such as medication adherence) by engaging the patient in an 
empathetically supportive, collaborative but strategically directed conversation.  The consultation 
will involve a motivational interview session, the pharmacist will incorporate the key 
motivational interview skills that they learned from the training in their consultation and refer to 
the consultation chart. Typically, those trained in motivational interviewing use a variety of 
techniques that can be divided into microskills, strategies and behaviour change techniques of 
“Express empathy, develop discrepancy, role with resistance, support self efficacy” (Bisono et al, 
2006).  The sessions will aim to develop a partnership between the pharmacist with the patient 
and exchange information to facilitate an informed decision.  Furthermore both the pharmacist 
and the patient will negotiate behaviour and reach an agreement.  The goal is to access motivation 
and elicit commitment to change behaviour “in this case would be adherence to life saving 
medication” 
 
Training for pharmacists  
Intervention pharmacies will be invited by UCL School of Pharmacy for training on motivational 
interviewing and the delivery of the intervention.  The training will include a two day workshop 
on motivational interviews and one day training on secondary prevention medication.  Training 
on motivational interviewing will be delivered by an expert psychologist from UCL School of 
Pharmacy. Training on secondary prevention medication will be delivered by an expert consultant 
pharmacist from the London Chest Hospital. Trained pharmacists will undergo assessment after 
completing the training. The pharmacists will be assessed through role plays of the intervention to 
assure fidelity of motivational interviewing techniques. To test for the success of the training and 
ensure that the pharmacists who undergo the training have sufficient skills to deliver the 
intervention, the Motivational Interviewing Treatment Integrity (MITI 3.1) scale will be used 
(Moyers et al, 2005) using recorded role-play activities that occur one week after the training has 
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been received.  The MITI is an instrument designed to measure the degree to which a practitioner 
is interacting with a client in a way that is consistent with motivational interviewing. To use the 
MITI, trained raters observe or listen to a 20 minute interaction.  Pharmacists will also be asked 
to complete a self-report instrument to assess their knowledge and confidence in their new skills.   
  
Training venue and facilitators 
Training will take place at all the cardiac centres’ areas at the following locations UCL-School of 
Pharmacy, University of Portsmouth and University of Southampton. The universities will be 
contacted in advance to arrange the training location and convenient times. The training will run 
for two months every 2 weeks at a different location, it is estimated that each training session will 
accommodate around no more than 20 pharmacists per group. It will be delivered by a registered 
psychologist and trainer in motivational interviewing with over a decade of experience and 
facilitated by collaborators at the relevant sites.  Two training sessions will be held in the London 
area.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
 
Sampling strategy and procedures 
The design of the study will follow CONSORT guidelines for randomised control trials 
www.consort-statement.org and analysis will follow an intention to treat.   Randomisation will 
be performed by an independent statistician at UCL School of Pharmacy.  Patient randomisation: 
patients will be randomly allocated by using a table of random numbers into intervention and 
control arms.  The randomisation will be concealed from the research team.  Pharmacies in the 
intervention areas London, Portsmouth and Southampton will be allocated to intervention and 
control according to their postcode area and then invited to the training.  Analysis will be 
conducted by an independent researcher. The researcher and the research assistants will be blind 
to the patients’ allocation, it is not possible to blind the patients or the pharmacists delivering the 
intervention due to the nature of the intervention.  
 
Sample size  
To detect a clinically important difference in LDL-C of 0.4mmol/L, and assuming standard 
deviation of 1.25mmol/L and correlation between baseline and follow up measurements of 0.48 
(from feasibility work) the total sample size required is 316 (90% power, 5% significance). 
Inflating this for clustering by pharmacist: assumed ICC=0.05, average of 3 patients per 
pharmacist (2 after drop out), 166 pharmacist clusters of 3 patients (total=498 patients) will be 
required.   
 
Pharmacies 
There are around 1282 pharmacies in central and east London, 132 pharmacies in Portsmouth,  
114 in Southampton this sum up to a total 1582 Pharmacies 
An invitation letter for the study will be sent to the pharmacies through the local Pharmaceutical 
Committees (LPC).  Pharmacies will register their interest online by an online register set up by 
the LPC’s for the trial. It is estimated depending on previous data from pharmacy recruitment in 
the pilot study, invitations sent to 360 pharmacies resulted in a response rate of 50 pharmacies. 
Therefore, it could be possible to recruit around 220 pharmacies in this trial. The pharmacies will 
be allocated to 110 pharmacies intervention and 110 pharmacies control; this will depend on 
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pharmacy response rate.  Approximately each pharmacy will deliver the intervention to 1-2 
patient’s depending on the sample size.  The number of pharmacies and patients included in the 
study will vary according to the area and city location, it would be anticipated that more 
pharmacies and patients from the London area will be recruited.  
 
 
Recruitment procedures  
There will be three stages of recruitment: 
Recruitment of hospitals:  An invitation letter will be sent from UCL School of Pharmacy to the 
cardiac centres which already been approached and expressed a willingness to participate, and/or 
are already on-board. The letter will explain the protocol and what is expected to occur during 
patient recruitment. The letter will also explain the role of the research assistants that will 
undertake the recruitment and what is needed from the hospital pharmacists to facilitate the 
process. The hospitals’ will sign an agreement contract for the trial with UCL School of 
Pharmacy and also help arrange honorary contracts for the researchers.   
Recruitment of pharmacies/pharmacists: Pharmacies that express interest to take part in the study 
will be mailed individual letters explaining the study. The pharmacies will be informed that the 
pharmacy will be allocated to either intervention or control by chance. Invitation to the training 
will be after randomisation, only intervention pharmacists will be invited to the training.  The 
control group pharmacists will be offered the training after the completion of the intervention.  
Recruitment of patients: Recruitment of patients will be by the research assistants. A research 
assistant will be allocated in each of the cardiac centres.  The research assistant will review the 
patient’s hospital chart to assess patient eligibility and postcode. Patients with a first coronary 
event will then be approached, explained about the trial and then left with a recruitment package 
to read. The assistant will return at a later time to answer any queries the patient has and a consent 
form will be signed, if the patient expresses interest to be part of the study. Patients enrolled on 
other studies will not be included.  
  
Instruments and outcome measures for evaluation of the intervention 
Primary outcome: LDL-C and blood pressure (from hospital charts at baseline and from GPs 
during patient follow up) 
 
Secondary measures 
1- Adherence to secondary prevention cardiovascular medications (Antiplatelets, betablockers, 
ACE inhibitors or ARBs, calcium channel blockers and statins) 
2-Rehospitalisation, re-infarction (from hospital charts) 
 3-Beleif Medicines Questionnaire-Specific (mailed to patients)  
4-Concept on subjective wellbeing SWLS scale and PANAS (mailed to patients) 
Measures of adherence will be robust (use multiple measures):  
- Self-report on a validated scale Morisky self report questionnaire MMAS-8 this will be 
collected by mail and telephone. 
- Prescription refill data from the pharmacies this will enable detection of adherence for the 
different medicines. A letter will be sent to both control and intervention pharmacies 
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explaining the study and pharmacies will have to provide consent for collection of refill 
data that will be collected by the research assistants.  
- Repeat prescription requests from GPs, a letter will be sent to both control and 
intervention patients’ GPs explaining the study and the GPs will provide consent for 
collection of patients’ prescription data. 
Costs  
An economist from Priment CTU will evaluate costs of delivery and costs impact (improved 
adherence, less morbidity, hosp admissions avoided).  The economic evaluation will report the 
cost-effectiveness of the intervention compared to treatment as usual over 12 months.  Life-time 
costs and quality adjusted life years (QALYs) will be calculated from a previously developed 
CVD model. 
Data collection 
Data will be collected by the research team. The research assistants will collect data from 
participating pharmacists, pharmacies, GPs and patients in control and intervention groups.  Data 
will be collected from the hospitals at baseline and at 6 months and 12 months. 
Process evaluation 
An integral process evaluation will assess operational aspects with patients, pharmacists, GPs and 
hospitals, to identify circumstances required for successful implementation.  The integral process 
evaluation will employ quantitative and qualitative methods to ensure a comprehensive 
evaluation of feasibility, acceptability, perceived impact across all sites and from all perspectives. 
This will include assessment of:  
 No. of eligible patients and response rates 
 No. placed with a participating pharmacy 
 Measures of uptake by pharmacists 
 Attrition rates pharmacists and patients in contact following discharge, successful 
arrangement of consultation, successful completion of intervention 
 The effectiveness of training and fidelity to intervention, especially the employment of 
motivational interviewing techniques in the delivery of the intervention. 
  
The acceptability/ workability in all and perceived impact from the perspective of all stakeholders 
which will be examined in semi-structured interviews with representatives of all stakeholders  
 
Operational aspects in the pharmacy 
Adherence to protocol; the pharmacists will keep a copy of the consultation in the pharmacy, in 
the consultation room to refer to during their consultation. The pharmacist will conduct the 
consultation by telephone in the consultation room.  The intervention should aim not to affect the 
workflow of the pharmacy because it is designed to fit under the New Medicine Service 
consultation. Interviews with patients that complete the intervention will be conducted to evaluate 
the perceived value of the consultation.  Treatment fidelity to intervention; this will be measured 
by asking the pharmacists to audio record their consultations with the patients after both patient 
and pharmacist consent. Pharmacists will conduct consultations with the use of audio equipment 
and 20 minutes of each consultation will be assessed using the MITI to calculate how 
motivational interviewing congruent the session was.  
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Acceptability and perceived impact from all stakeholders: interviews will be conducted with a 
sample of hospital and community pharmacists, patients (intervention and control).  
 
PPI- public patient involvement -Patients and pharmacists that were part of the pilot study were 
involved in writing the full protocol for this main study. 
 
Dissemination plan  A dissemination strategy for the project will be developed to allow uptake 
and success of the project. 
Stakeholders in this project will include: 
 The hospitals (the cardiac centres), Presentations on the project will be given in each 
cardiac centre to the healthcare professionals to raise the awareness of the project and its 
objectives this will facilitate recruitment. Leaflets will be designed and included in the 
patient recruitment package to be given to eligible patients.  
 
 The Local Pharmaceutical Committees (LPC) in each area, attendance at LPC meetings 
by the researchers 
 
 The pharmacies (Pharmacists) 
 
 The patients  
 
A website for the project will be developed to allow all stake holders to be informed. 
The trial protocol will be presented in conference presentations and posters. 
The trial will be registered on Clinicaltrials.gov. 
 
Costs and justification of costs 
 Psychologist and consultant pharmacist training fees for all training sessions  
 Materials for the training and training certificates 
 Room bookings and catering  
 Research team and research assistants’ Salaries 
 Postdoctoral project manager (Full time employment) 
 Research assistants (Full time employment) 
 Collaborators  
 Economist 
 Advisory group expenses 
 Travel expenses to sites 
 Telephone costs  
 Documentation  
 Patient Public Involvement costs (travel) 
 Community pharmacists (intervention group only) reimbursement for training and 
participation  
 Community pharmacists (control group only) training   
 GPs costs nurses to provide patient data at surgeries 
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Flow chart for the multicentre trial proposal  
 
 
 
 
 
 
 
 
 
 
 
   
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BMQ: Beliefs Medication Questionnaire SWL: Satisfaction With Life scale, PANAS: positive and negative affect 
scale, RPR: Repeat prescription requests. http://internal.psychology.illinois.edu/~ediener/SWLS.html, 
http://www.google.co.uk/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=0CCgQFjAA&url=http%3A%2F%2F
www.cnbc.pt%2Fjpmatos%2F28.Watson.pdf&ei=QU6QVJn4DI2LaMGLgvgH&usg=AFQjCNE1zfLunrDdxVxR8cZ
L7hSf4wtDiQ&sig2=Jc_1rZOuaFnT-HPPNEf_Ug&bvm=bv.81828268,d.d2s 
Four cardiac centres 
4 areas in the south of England 
All community pharmacies invited to participate 
– randomised to receive training in motivational 
interviewing (and offer intervention) or control 
(offer care as usual) 
Participants recruited following 
admission for first ACS from 4 
cardiac centres and randomised 
into intervention and control arms 
  Intervention group (PC) 
patients  
 
Meet inclusion criteria provide 
informed consent. 
 Control group (UC) 
patients 
 
  
 
Consultation at 2 weeks 
face to face or 
telephone (motivational 
interviewing) 
 
Consultation at 3 months by 
telephone (motivational 
interviewing) 
 
        Usual care   
 Baseline patients data LDL-C, 
B.P after two weeks Self report 
adherence measures & BMQ, 
SWLS scale, PANAS. 
   
 
Patients on Secondary 
prophylactic medication for 
Coronary Heart Disease 
 
 
6 months follow up LDL-C, B.P Self 
report adherence measures, 
pharmacy refill data &RPR, BMQ 
rehospitalisation, re-infarction 
from hospital charts and SWLS, 
PANAS to both groups. 
 
 
Consultation at 6 months by 
telephone (motivational 
interviewing) 
 
12 months follow up LDL-C, B.P 
Self report adherence 
measures, pharmacy refill data 
&RPR, BMQ, rehospitalisation, 
re-infarction from hospital 
charts SWLS, PANAS to both 
groups. 
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The End 
